"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,AU,B2,AU 2004/277375 B2,104-727-929-662-766,2010-12-02,2010,AU 2004/277375 A,2004-08-03,US 63540203 A;;US 2004/0022304 W,2003-08-06,"Tricalcium phosphates, their composites, implants incorporating them, and methods for their production",,ANGSTROM MEDICA INC,AHN EDWARD,,https://lens.org/104-727-929-662-766,Granted Patent,no,2,0,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61K33/42;;A61K6/838;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42,,0,0,,,,INACTIVE
2,AU,A1,AU 2004/277375 A1,088-339-126-475-665,2005-04-14,2005,AU 2004/277375 A,2004-08-03,US 63540203 A;;US 2004/0022304 W,2003-08-06,"Tricalcium phosphates, their composites, implants incorporating them, and methods for their production",,ANGSTROM MEDICA INC,AHN EDWARD,,https://lens.org/088-339-126-475-665,Patent Application,no,0,0,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61K33/42;;A61K6/838;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42,,0,0,,,,INACTIVE
3,WO,A2,WO 2005/032456 A2,163-617-059-854-862,2005-04-14,2005,US 2004/0022304 W,2004-08-03,US 63540203 A,2003-08-06,"TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",ANGSTROM MEDICA INC;;AHN EDWARD,AHN EDWARD,,https://lens.org/163-617-059-854-862,Patent Application,yes,1,13,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42,,3,1,031-831-463-451-097,10.1016/s0955-2219(02)00263-7,"S. KWON ET AL., JOURNAL OF THE EUROPEAN CERAMIC SOCIETY, vol. 23, 2003, pages 1039 - 1045;;I. KONDOH ET AL., JOURNAL OF THE CERAMIC SOCIETY OF JAPAN, vol. 97, 1989, pages 90 - 91;;See also references of EP 1660036A4",PENDING
4,WO,A3,WO 2005/032456 A3,170-427-422-124-693,2006-09-08,2006,US 2004/0022304 W,2004-08-03,US 63540203 A,2003-08-06,"TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",ANGSTROM MEDICA INC;;AHN EDWARD,AHN EDWARD,,https://lens.org/170-427-422-124-693,Search Report,no,1,0,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61F2/02;;A61K6/083;;A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42,,1,0,,,See also references of EP 1660036A4,PENDING
5,EP,A2,EP 1660036 A2,161-049-034-038-097,2006-05-31,2006,EP 04809488 A,2004-08-03,US 2004/0022304 W;;US 63540203 A,2003-08-06,"TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION",,ANGSTROM MEDICA INC,AHN EDWARD,,https://lens.org/161-049-034-038-097,Patent Application,yes,0,0,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61L27/12;;A61F2/02;;A61K6/083;;A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/42,,0,0,,,,DISCONTINUED
6,CA,A1,CA 2535085 A1,132-533-286-684-792,2005-04-14,2005,CA 2535085 A,2004-08-03,US 63540203 A;;US 2004/0022304 W,2003-08-06,"TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",ANGSTROM MEDICA INC,AHN EDWARD,,https://lens.org/132-533-286-684-792,Patent Application,no,0,0,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61K33/42;;A61K6/838;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/26;;A61L27/28;;A61L27/42;;A61L27/54,,0,0,,,,DISCONTINUED
7,EP,A4,EP 1660036 A4,189-655-163-045-601,2010-09-08,2010,EP 04809488 A,2004-08-03,US 2004/0022304 W;;US 63540203 A,2003-08-06,"TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION",,ANGSTROM MEDICA INC,AHN EDWARD,,https://lens.org/189-655-163-045-601,Search Report,no,2,0,16,16,0,A61K33/42;;A61K38/1816;;A61K45/06;;A61L27/12;;A61L27/425;;C01B25/32;;A61P19/08;;A61K33/42;;A61K38/1816;;A61K45/06;;A61L27/12;;A61L27/425;;A61L31/148;;A61L31/16;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61L27/12;;A61F2/02;;A61K6/083;;A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/42,,3,1,031-831-463-451-097,10.1016/s0955-2219(02)00263-7,"KWON S-H ET AL: ""Synthesis and dissolution behavior of beta-TCP and HA/beta-TCP composite powders"", JOURNAL OF THE EUROPEAN CERAMIC SOCIETY, ELSEVIER SCIENCE PUBLISHERS, BARKING, ESSEX, GB LNKD- DOI:10.1016/S0955-2219(02)00263-7, vol. 23, no. 7, 1 June 2003 (2003-06-01), pages 1039 - 1045, XP004409215, ISSN: 0955-2219;;ISAO KONDOH ET AL: ""SINTERING OF TRICALCIUM PHOSPHATE BY HIP"", JOURNAL OF THE CERAMIC SOCIETY OF JAPAN, INTERNATIONAL EDITION, FUJI TECHNOLOGY PRESS, TOKYO, JP, vol. 97, no. 9, 1 September 1989 (1989-09-01), pages 90/91, XP000103696, ISSN: 0912-9200;;See also references of WO 2005032456A2",DISCONTINUED
8,US,B2,US 8029755 B2,041-611-271-351-68X,2011-10-04,2011,US 63540203 A,2003-08-06,US 63540203 A,2003-08-06,"Tricalcium phosphates, their composites, implants incorporating them, and methods for their production","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",ANGSTROM MEDICA,AHN EDWARD S,ANGSTROM ACQUISITION CORP. II (2007-10-23);;ANGSTROM MEDICA (2003-09-08);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/041-611-271-351-68X,Granted Patent,yes,35,14,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,C01B15/16;;A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42,423/311;;423/305;;423/308;;423/309,43,30,043-089-258-531-516;;009-950-071-269-434;;076-703-888-880-926;;017-162-822-047-705;;055-518-492-905-991;;062-072-155-353-276;;059-423-131-390-076;;050-615-037-103-623;;002-238-459-220-166;;183-625-779-188-736;;031-831-463-451-097;;094-786-226-957-41X;;045-682-605-366-675;;132-132-218-339-500;;049-634-994-801-472;;020-285-596-578-943;;012-934-366-578-216;;101-181-238-750-07X;;060-367-557-637-322;;061-694-882-893-092;;169-823-447-868-719;;021-812-309-424-14X;;117-990-278-694-499;;118-627-534-558-972;;156-891-593-478-105;;053-619-816-111-830;;030-022-846-308-347;;024-885-681-386-182;;169-436-925-645-377;;073-876-640-911-887,10.1002/crat.2170310519;;10.2109/jcersj1950.95.1103_741;;10.2109/jcersj.96.837;;10.2109/jcersj.97.554;;10.2109/jcersj.98.404;;10.2109/jcersj.98.1054;;10.1016/0955-2219(95)00123-9;;10.2109/jcersj.99.150;;10.2109/jcersj.99.211;;10.2109/jcersj.100.602;;10.1016/s0955-2219(02)00263-7;;10.2109/jcersj.97.965;;10.1007/bf01117352;;10.1111/j.1151-2916.1998.tb02618.x;;10.1016/s0142-9612(02)00193-x;;12322969;;10.1016/s0142-9612(02)00196-5;;12322972;;11791909;;10.1016/s0142-9612(01)00218-6;;11791911;;10.1016/s0142-9612(01)00220-4;;10.1016/s0924-0136(01)00611-2;;10.1016/s0142-9612(01)00119-3;;11761160;;10.1201/9780203751367-26;;10.1021/la990590i;;11396875;;10.1016/s0142-9612(00)00332-x;;10.1002/1097-4636(20010615)55:4<566::aid-jbm1050>3.0.co;2-f;;11288085;;10.1016/s0142-9612(98)00193-8;;10204990;;10.6028/jres.106.054;;27500063;;pmc4865300;;10.1007/bf00591468;;15348776;;10.1023/a:1018506800033;;10.1361/105996300770349827;;10.1016/s0142-9612(02)00327-7;;12423592,"Ahn, ""Nanostructured Apatites as Orthopedic Biomaterials,"" (Ph.D. Dissertation, Massachusetts Institute of Technology) 1-93 (Jun. 2001).;;Kawamoto et al., The Ceramic Society of Japan, 99(1): 19-22 (1991).;;Krajewski et al., Cryst. Res. Technol., 31(5): 637-646 (1996).;;Toriyama et al., The Ceramic Society of Japan, 94(9): 78-82 (1986).;;Toriyama et al., The Ceramic Society of Japan, 95(4): 92-94 (1987).;;Toriyama et al., The Ceramic Society of Japan, 95(7): 741-745 (1987).;;Toriyama et al., The Ceramic Society of Japan, 95(8): 68-70 (1987).;;Toriyama et al., The Ceramic Society of Japan 96(8): 837-841 (1988).;;Toriyama et al., The Ceramic Society of Japan 97(5): 554-558 (1989).;;Toriyama et al., The Ceramic Society of Japan, 98(4): 404-407 (1990).;;Toriyama et al., The Ceramic Society of Japan, 98(9): 1054-1057 (1990).;;Toriyama et al., Journal of the European Ceramic Society, 16: 429-436 (1996).;;Yokogawa et al., The Ceramic Society of Japan, 99(2): 150-152 (1991).;;Yokogawa et al., The Ceramic Society of Japan, 99(3): 211-214 (1991).;;Yokogawa et al., The Ceramic Society of Japan, 100(4): 602-604 (1992).;;Kwon et al., ""Synthesis and dissolution behavior of beta-TCP and HA/beta-TCP composite powders,"" Journal of the European Ceramic Society, 23(7): 1039-1045 (Jun. 1, 2003).;;Kondoh et al., ""Sintering of Tricalcium Phosphate by HIP,"" Journal of the Ceramic Society of Japan, 97(9): 965-967 (1989).;;Lange et al., ""Effects of attrition milling and post-sintering heat treatment on fabrication, microstructure and properties of transformation toughened ZrO2,"" Journal of Materials Science 21: 768-774 (1986).;;Kivrak, N., et al., ""Synthesis of Calcium Hydroxyapatite-Tricalcium Phosphate (HA-TCP) Composite Bioceramic Powders and Their Sintering Behavior,"" J. Am. Ceram. Soc. 81, 2245-52 (1998).;;Victoria, E., et al., ""Synthesis and Characterisation of Biphasic Calcium Phosphate,"" Tends Biomater. Artif. Organs 16, 12-14 (2002).;;Dong, J., et al., ""Promotion of Bone Formation Using Highly Pure Porous Beta-TCP Combined With Bone Marrow-Derived Osteoprogenitor Cells,"" Biomaterials 23, 4493-4502 (2002).;;Fini, M., et al., ""A Bone Substitute Composed of Polymethylmethacrylate and Alpha-Tricalcium Phosphate: Results in Terms of Osteoblast Function and Bone Tissue Formation,"" Biomaterials 23, 4523-4531 (2002).;;Raynaud, S., et al., ""Calcium Phosphate Apatites With Variable Ca/P Atomic Ratio I: Synthesis, Characterization and Thermal Stability of Powders,"" Biomaterials 23, 1065-1072 (2002).;;Raynaud, S., et al., ""Calcium Phosphate Apatites With Variable Ca/P Atomic Ratio III: Mechanical Properties and Degradation in Solution of Hot Pressed Ceramics,"" Biomaterials 23 1081-1089 (2002).;;Kumar, R., et al., ""RF Plasma Processing of Ultra-Fine Hydroxyapatite Powders,"" Journal of Materials Processing Technology 113, 456-462 (2001).;;Kurashina, K., et al., ""Ectopic Osteogenesis With Biphasic Ceramics of Hydroxyapatite and Tricalcuim Phosphate in Rabbits,"" Biomaterials 23, 407-412 (2002).;;Traplis, C., et al., ""Calcium hydroxyapatite Formation by Sol-Gel Route,"" Chimica Chronica New Series, 23, 205-208 (1994).;;Deputa, A., et al., ""Preparation of Calcium Phosphate Powders by Water Extraction Variant of Sol-Gel process,"" CRC Press: Hydroxyapatite and Related Materials, 263-268 (1994).;;Takahashi, H., et al., ""Synthesis of Stoichiometric Hydroxyapatite by a ""Gel"" Route From the Aqueous Solution of Citric and Phosphonoacetic Acids,"" Eur. J. Solid State lnorg. Chem.. 32, 829-835 (1995).;;Hirai, T., et al., ""The Preparation of Spherical Calcium Phosphate Fine Particles Using an Emulsion Liquid Membrance System,"" Langmuir, 16, 955-960 (2000).;;Liu, D., et al., ""Water-Based Sol-Gel Synthesis of Hydroxyapatite: Process Development,"" Biomaterials 22, 1721-1730 (2001).;;Serraj, S., et al., ""Effect on Composition of Dry Mechanical Grinding of Calcium Phosphate Mixtures,"" J. Biomed. Mater. Res. 55, 566-575, (2001).;;Slosarczyk, A., et al., ""Calcium Phosphate Materials Prepared from Precipitates With Various Calcium: Phosphate Molar Ratios,"" J. Am. Ceram. Soc., 79, 2539-44, (1996).;;Lin, F., et al., ""Preparation of Biphasic Porous Bioceramics by Heating Bovine Cancellous Bone With Na2P2O7*10H2O Addition,"" Biomaterials 20, 475-484, (1999).;;Tenhuisen, K., et al., ""Phase Evolution During the Formation of Alpha-Tricalcium Phosphate,"" J. Am. Ceram., Soc. 82, 2813-2818, (1999).;;Mathew, M., et al., ""Structures of Biological Minerals in Dental Research,"" J. Re. Natl. Inst. Stand. Technol. 106, 1035-1044, (2001).;;Akao, M., et al., ""Dense Polycrystalline Beta-Tricalcium Phosphate for Prosthetic Applications,"" J. Mater. Sci., 17, 343-346, (1982).;;Cuneyt-Tas, A., et al., ""An Investigation of the Chemical Synthesis and High-Temperature Sintering Behavior of Calcium Hydroxyapatite (HA) and Tricalcium Phosphate (TCP) Bioceramics,"" J. Mater. Sci. Mater. Med. 8, 91-96, (1997).;;Prevey, P., ""X-Ray Diffraction Characterization of Crystallinity and Phase Composition in Plasma-Sprayed Hydroxylapatite Coatings,"" J. Thermal Spray Technol. 9, 369-376, (2000).;;Sayer, M., et al., Structure and Composition of Silicon-Stabilized Tricalcium Phosphate, Biomaterials 24, 369-382, (2003).;;Kurokawa, ""Preparation of Fine Powder of Calcium Phosphate by using Vacuum Freeze-Drying Processing,"" The Report of Government Industrial Research Institute, 34(7): 210-216 (Jul. 1985).;;Toriyama et al., ""High Strength beta-Tricalcium Phosphate Ceramics I. Mechanochemical Synthesis of beta-Tricalcium Phosphate,"" The Report of Government Industrial Research Institute, 39(5): 217-223 (May 1990).;;Toriyama et al., ""High Strength beta-Tricalcium Phosphate Ceramics II. Sintering Behavior of beta-Tricalcium Phosphate,"" The Report of Government Industrial Research Institute, 39(5): 224-228 (May 1990).",INACTIVE
9,US,B2,US 8597604 B2,141-396-127-079-710,2013-12-03,2013,US 201113228216 A,2011-09-08,US 201113228216 A;;US 63540203 A,2003-08-06,"Tricalcium phosphates, their composites, implants incorporating them, and methods for their production","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",AHN EDWARD S;;PIONEER SURGICAL TECH INC,AHN EDWARD S,ANGSTROM ACQUISITION CORP. II (2007-10-23);;ANGSTROM MEDICA INC (2003-09-08);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/141-396-127-079-710,Granted Patent,yes,36,7,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,C01B15/16;;A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42,423/311;;423/305;;423/308;;423/309;;424/423;;623/26,43,31,030-022-846-308-347;;024-885-681-386-182;;169-823-447-868-719;;049-634-994-801-472;;020-285-596-578-943;;021-812-309-424-14X;;028-184-224-567-061;;132-132-218-339-500;;094-786-226-957-41X;;043-089-258-531-516;;060-367-557-637-322;;061-694-882-893-092;;031-831-463-451-097;;045-682-605-366-675;;156-891-593-478-105;;117-990-278-694-499;;053-619-816-111-830;;169-436-925-645-377;;012-934-366-578-216;;101-181-238-750-07X;;073-876-640-911-887;;118-627-534-558-972;;059-423-131-390-076;;076-703-888-880-926;;017-162-822-047-705;;009-950-071-269-434;;055-518-492-905-991;;062-072-155-353-276;;183-625-779-188-736;;050-615-037-103-623;;002-238-459-220-166,10.1007/bf00591468;;15348776;;10.1023/a:1018506800033;;10.1201/9780203751367-26;;10.1016/s0142-9612(02)00193-x;;12322969;;10.1016/s0142-9612(02)00196-5;;12322972;;10.1021/la990590i;;10.2109/jcersj.99.19;;10.1111/j.1151-2916.1998.tb02618.x;;10.2109/jcersj.97.965;;10.1002/crat.2170310519;;10.1016/s0924-0136(01)00611-2;;10.1016/s0142-9612(01)00119-3;;11761160;;10.1016/s0955-2219(02)00263-7;;10.1007/bf01117352;;10.1016/s0142-9612(98)00193-8;;10204990;;11396875;;10.1016/s0142-9612(00)00332-x;;10.6028/jres.106.054;;27500063;;pmc4865300;;10.1361/105996300770349827;;11791909;;10.1016/s0142-9612(01)00218-6;;11791911;;10.1016/s0142-9612(01)00220-4;;10.1016/s0142-9612(02)00327-7;;12423592;;10.1002/1097-4636(20010615)55:4<566::aid-jbm1050>3.0.co;2-f;;11288085;;10.1016/0955-2219(95)00123-9;;10.2109/jcersj.96.837;;10.2109/jcersj.97.554;;10.2109/jcersj1950.95.1103_741;;10.2109/jcersj.98.404;;10.2109/jcersj.98.1054;;10.2109/jcersj.100.602;;10.2109/jcersj.99.150;;10.2109/jcersj.99.211,"Ahn, ""Nanostructured Apatites as Orthopedic Biomaterials,"" (Ph.D. Dissertation, Massachusetts Institute of Technology) 1-93 (Jun. 2001).;;Akao, M., et al., ""Dense Polycrystalline Beta-Tricalcium Phosphate for Prosthetic Applications,"" J. Mater. Sci., 17: 343-346, (1982).;;Cuneyt-Tas, A., et al., ""An Investigation of the Chemical Synthesis and High-Temperature Sintering Behavior of Calcium Hydroxyapatite (HA) and Tricalcium Phosphate (TCP) Bioceramics,"" J. Mater. Sci. Mater. Med., 8: 91-96, (1997).;;Deputa, A., et al., ""Preparation of Calcium Phosphate Powders by Water Extraction Variant of Sol-Gel process,"" CRC Press: Hydroxyapatite and Related Materials, 263-268 (1994).;;Dong, J., et al., ""Promotion of Bone Formation Using Highly Pure Porous Beta-TCP Combined With Bone Marrow-Derived Osteoprogenitor Cells,"" Biomaterials, 23: 4493-4502 (2002).;;Fini, M., et al., ""A Bone Substitute Composed of Polymethylmethacrylate and Alpha-Tricalcium Phosphate: Results in Terms of Osteoblast Function and Bone Tissue Formation,"" Biomaterials, 23: 4523-4531 (2002).;;Hirai, T., et al., ""The Preparation of Spherical Calcium Phosphate Fine Particles Using an Emulsion Liquid Membrance System,"" Langmuir, 16: 955-960 (2000).;;Kawamoto et al., ""Coating of beta-Tricalcium Phosphate on Yttria-Partially Stabilized Zirconia Using Magnesium Metaphosphate as an Interlayer,"" The Ceramic Society of Japan, 99(1): 19-22 (1991).;;Kivrak, N., et al., ""Synthesis of Calcium Hydroxyapatite-Tricalcium Phosphate (HA-TCP) Composite Bioceramic Powders and Their Sintering Behavior,"" J. Am. Ceram. Soc., 81: 2245-52 (1998).;;Kondoh et al., ""Sintering of Tricalcium Phosphate by HIP,"" Journal of the Ceramic Society of Japan, 97(9): 965-967 (1989).;;Krajewski et al., ""Spectrometric Study of the Thermal Evolution of Mechanochemically Prepared Hydroxyapatite-based Powders,"" Cryst. Res. Technol., 31(5): 637-646 (1996).;;Kumar, R., et al., ""RF Plasma Processing of Ultra-Fine Hydroxyapatite Powders,"" Journal of Materials Processing Technology, 113: 456-462 (2001).;;Kurashina, K., et al., ""Ectopic Osteogenesis With Biphasic Ceramics of Hydroxyapatite and Tricalcuim Phosphate in Rabbits,"" Biomaterials, 23: 407-412 (2002).;;Kurokawa, ""Preparation of Fine Powder of Calcium Phosphate by using Vacuum Freeze-Drying Processing,"" The Report of Government Industrial Research Institute, 34(7): 210-216 (Jul. 1985).;;Kwon et al., ""Synthesis and dissolution behavior of beta-TCP and HA/beta-TCP composite powders,"" Journal of the European Ceramic Society, 23(7): 1039-1045 (Jun. 1, 2003).;;Lange et al., ""Effects of attrition milling and post-sintering heat treatment on fabrication, microstructure and properties of transformation toughened ZrO2,"" Journal of Materials Science, 21: 768-774 (1986).;;Lin, F., et al., ""Preparation of Biphasic Porous Bioceramics by Heating Bovine Cancellous Bone With Na2P2O7*10H2O Addition,"" Biomaterials, 20: 475-484, (1999).;;Liu, D., et al., ""Water-Based Sol-Gel Synthesis of Hydroxyapatite: Process Development,"" Biomaterials, 22: 1721-1730 (2001).;;Mathew, M., et al., ""Structures of Biological Minerals in Dental Research,"" J. Re. Natl. Inst. Stand. Technol., 106: 1035-1044, (2001).;;Prevey, P., ""X-Ray Diffraction Characterization of Crystallinity and Phase Composition in Plasma-Sprayed Hydroxylapatite Coatings,"" J. Thermal Spray Techn., 9: 369-376, (2000).;;Raynaud, S., et al., ""Calcium Phosphate Apatites With Variable Ca/P Atomic Ratio I: Synthesis, Characterization and Thermal Stability of Powders,"" Biomaterials, 23: 1065-1072 (2002).;;Raynaud, S., et al., ""Calcium Phosphate Apatites With Variable Ca/P Atomic Ratio III: Mechanical Properties and Degradation in Solution of Hot Pressed Ceramics,"" Biomaterials, 23: 1081-1089 (2002).;;Sayer, M., et al., Structure and Composition of Silicon-Stabilized Tricalcium Phosphate, Biomaterials, 24: 369-382, (2003).;;Serraj, S., et al., ""Effect on Composition of Dry Mechanical Grinding of Calcium Phosphate Mixtures,"" J. Biomed. Mater. Res., 55: 566-575, (2001).;;Slosarczyk, A., et al., ""Calcium Phosphate Materials Prepared from Precipitates With Various Calcium: Phosphate Molar Ratios,"" J. Am. Ceram. Soc., 79: 2539-44, (1996).;;Takahashi, H., et al., ""Synthesis of Stoichiometric Hydroxyapatite by a ""Gel"" Route From the Aqueous Solution of Citric and Phosphonoacetic Acids,"" Eur. J. Solid State Inorg. Chem., 32: 829-835 (1995).;;Tenhuisen, K., et al., ""Phase Evolution During the Formation of Alpha-Tricalcium Phosphate,"" J. Am. Ceram. Soc., 82: 2813-2818, (1999).;;Toriyama et al., ""High Strength beta-Tricalcium Phosphate Ceramics I. Mechanochemical Synthesis of beta-Tricalcium Phosphate,"" The Report of Government Industrial Research Institute, 39(5): 217-223 (May 1990);;Toriyama et al., ""High Strength beta-Tricalcium Phosphate Ceramics II. Sintering Behavior of beta-Tricalcium Phosphate,"" The Report of Government Industrial Research Institute, 39(5): 224-228 (May 1990).;;Toriyama et al., ""Synthesis of Hydroxyapatite-Based Powders by Mechano-Chemical Method and their Sintering,"" Journal of the European Ceramic Society, 16: 429-436 (1996).;;Toriyama et al., ""Effect of Mixed Addition of Al2O3 and SiO2 on Mechanical Strength of Sintered beta-Tricalcium Phosphate,"" The Ceramic Society of Japan, 96(8): 837-841 (1988).;;Toriyama et al., ""Thermal Change of Calcium Deficient Apatite Obtained by Mechanochemical Treatment,"" The Ceramic Society of Japan, 97(5): 554-558 (1989).;;Toriyama et al., ""Synthesis of beta-Tricalcium Phosphate by Use of Wet Milling,"" The Ceramic Society of Japan, 94(9): 78-82 (1986).;;Toriyama et al., ""Bending Strength of Hydroxyapatite Ceramics Containing alpha-Tricalcium Phosphate,"" The Ceramic Society of Japan, 95(4): 92-94 (1987).;;Toriyama et al., ""Sinterable Powder of Mechanochemically Synthetic beta-Tricalcium Phosphate,"" The Ceramic Society of Japan, 95(7): 741-745 (1987).;;Toriyama et al., ""Effect of MgO Addition on Bending Strength of Sintered beta-Tricalcium Phosphate Prepared by Mechanochemical Synthesis,"" The Ceramic Society of Japan, 95(8): 68-70 (1987).;;Toriyama et al., ""Estimation of Biocompatibility of High Strength beta-Tricalcium Phosphate Ceramics by a Tissue Culture Method,"" The Ceramic Society of Japan, 98(4): 404-407 (1990).;;Toriyama et al., ""beta-Tricalcium Phosphate Coating on Alumina Ceramic,"" The Ceramic Society of Japan, 98(9): 1054-1057 (1990).;;Traplis, C., et al., ""Calcium hydroxyapatite Formation by Sol-Gel Route,"" Chimica Chronica New Series, 23: 205-208 (1994).;;Victoria, E., et al., ""Synthesis and Characterisation of Biphasic Calcium Phosphate,"" Tends Biomater. Artif. Organs, 16: 12-14 (2002).;;Yokogawa et al., ""Apatite Coating on Yttria Doped Partially Stabilized Zirconia Plate in the Presence of Water Vaper,"" The Ceramic Society of Japan, 100(4): 602-604 (1992).;;Yokogawa et al., ""Preparation of Trimagnesium Phosphate by Mechanochemical Reaction,"" The Ceramic Society of Japan, 99(2): 150-152 (1991).;;Yokogawa et al., ""Tricalsium Phosphate Coating on Zirconia by Using Calcium Metaphosphate and Tetracalcium Phosphate,"" The Ceramic Society of Japan, 99(3): 211-214 (1991).",EXPIRED
10,US,A1,US 2017/0050849 A1,089-593-519-337-108,2017-02-23,2017,US 201615345155 A,2016-11-07,US 201615345155 A;;US 201314070122 A;;US 201113228216 A;;US 63540203 A,2003-08-06,"TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",PIONEER SURGICAL TECH INC,AHN EDWARD S,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;ANGSTROM ACQUISITION CORP. II (2007-10-23);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;ANGSTROM MEDICA INC (2003-09-08);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/089-593-519-337-108,Patent Application,yes,0,0,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,C01B25/32;;A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42,,0,0,,,,ACTIVE
11,US,A1,US 2014/0056950 A1,035-604-736-010-541,2014-02-27,2014,US 201314070122 A,2013-11-01,US 201314070122 A;;US 201113228216 A;;US 63540203 A,2003-08-06,"TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",PIONEER SURGICAL TECH INC,AHN EDWARD S,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;ANGSTROM ACQUISITION CORP. II (2007-10-23);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;ANGSTROM MEDICA INC (2003-09-08);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/035-604-736-010-541,Patent Application,yes,0,4,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61L31/14;;A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42;;A61L31/16,424/400;;424/602,0,0,,,,EXPIRED
12,US,A1,US 2011/0318402 A1,177-913-159-805-069,2011-12-29,2011,US 201113228216 A,2011-09-08,US 201113228216 A;;US 63540203 A,2003-08-06,"TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",AHN EDWARD S;;ANGSTROM MEDICA,AHN EDWARD S,ANGSTROM ACQUISITION CORP. II (2007-10-23);;ANGSTROM MEDICA INC (2003-09-08);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/177-913-159-805-069,Patent Application,yes,2,8,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61K33/42;;A61K6/838;;A61K9/00;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42;;A61P19/08;;B32B9/00;;C01B25/32,424/423;;423/311;;424/602;;428/220,0,0,,,,EXPIRED
13,US,B2,US 9517293 B2,014-228-599-592-750,2016-12-13,2016,US 201314070122 A,2013-11-01,US 201314070122 A;;US 201113228216 A;;US 63540203 A,2003-08-06,"Tricalcium phosphates, their composites, implants incorporating them, and methods for their production","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",PIONEER SURGICAL TECH INC,AHN EDWARD S,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;ANGSTROM ACQUISITION CORP. II (2007-10-23);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;ANGSTROM MEDICA INC (2003-09-08);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/014-228-599-592-750,Granted Patent,yes,36,0,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61L31/14;;A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42;;A61L31/16,,45,31,030-022-846-308-347;;024-885-681-386-182;;169-823-447-868-719;;049-634-994-801-472;;020-285-596-578-943;;021-812-309-424-14X;;028-184-224-567-061;;132-132-218-339-500;;094-786-226-957-41X;;043-089-258-531-516;;060-367-557-637-322;;061-694-882-893-092;;031-831-463-451-097;;045-682-605-366-675;;156-891-593-478-105;;117-990-278-694-499;;053-619-816-111-830;;169-436-925-645-377;;012-934-366-578-216;;101-181-238-750-07X;;073-876-640-911-887;;118-627-534-558-972;;059-423-131-390-076;;076-703-888-880-926;;017-162-822-047-705;;009-950-071-269-434;;055-518-492-905-991;;062-072-155-353-276;;183-625-779-188-736;;050-615-037-103-623;;002-238-459-220-166,10.1007/bf00591468;;15348776;;10.1023/a:1018506800033;;10.1201/9780203751367-26;;10.1016/s0142-9612(02)00193-x;;12322969;;10.1016/s0142-9612(02)00196-5;;12322972;;10.1021/la990590i;;10.2109/jcersj.99.19;;10.1111/j.1151-2916.1998.tb02618.x;;10.2109/jcersj.97.965;;10.1002/crat.2170310519;;10.1016/s0924-0136(01)00611-2;;10.1016/s0142-9612(01)00119-3;;11761160;;10.1016/s0955-2219(02)00263-7;;10.1007/bf01117352;;10.1016/s0142-9612(98)00193-8;;10204990;;11396875;;10.1016/s0142-9612(00)00332-x;;10.6028/jres.106.054;;27500063;;pmc4865300;;10.1361/105996300770349827;;11791909;;10.1016/s0142-9612(01)00218-6;;11791911;;10.1016/s0142-9612(01)00220-4;;10.1016/s0142-9612(02)00327-7;;12423592;;10.1002/1097-4636(20010615)55:4<566::aid-jbm1050>3.0.co;2-f;;11288085;;10.1016/0955-2219(95)00123-9;;10.2109/jcersj.96.837;;10.2109/jcersj.97.554;;10.2109/jcersj1950.95.1103_741;;10.2109/jcersj.98.404;;10.2109/jcersj.98.1054;;10.2109/jcersj.100.602;;10.2109/jcersj.99.150;;10.2109/jcersj.99.211,"Ahn, ""Nanostructured Apatites as Orthopedic Biomaterials,"" (Ph.D. Dissertation, Massachusetts Institute of Technology) 1-93 (Jun. 2001).;;Akao, M., et al., ""Dense Polycrystalline Beta-Tricalcium Phosphate for Prosthetic Applications,"" J. Mater. Sci., 17: 343-346, (1982).;;Cuneyt-Tas, A., et al., ""An Investigation of the Chemical Synthesis and High-Temperature Sintering Behavior of Calcium Hydroxyapatite (HA) and Tricalcium Phosphate (TCP) Bioceramics,"" J. Mater. Sci. Mater. Med., 8: 91-96, (1997).;;Deputa, A., et al., ""Preparation of Calcium Phosphate Powders by Water Extraction Variant of Sol-Gel process,"" CRC Press: Hydroxyapatite and Related Materials, 263-268 (1994).;;Dong, J., et al., ""Promotion of Bone Formation Using Highly Pure Porous Beta-TCP Combined With Bone Marrow-Derived Osteoprogenitor Cells,"" Biomaterials, 23: 4493-4502 (2002).;;Fini, M., et al., ""A Bone Substitute Composed of Polymethylmethacrylate and Alpha-Tricalcium Phosphate: Results in Terms of Osteoblast Function and Bone Tissue Formation,"" Biomaterials, 23: 4523-4531 (2002).;;Hirai, T., et al., ""The Preparation of Spherical Calcium Phosphate Fine Particles Using an Emulsion Liquid Membrance System,"" Langmuir, 16: 955-960 (2000).;;Kawamoto et al., ""Coating of beta-Tricalcium Phosphate on Yttria-Partially Stabilized Zirconia Using Magnesium Metaphosphate as an Interlayer,"" The Ceramic Society of Japan, 99(1): 19-22 (1991).;;Kivrak, N., et al., ""Synthesis of Calcium Hydroxyapatite-Tricalcium Phosphate (HA-TCP) Composite Bioceramic Powders and Their Sintering Behavior,"" J. Am. Ceram. Soc., 81: 2245-52 (1998).;;Kondoh et al., ""Sintering of Tricalcium Phosphate by HIP,"" Journal of the Ceramic Society of Japan, 97(9): 965-967 (1989).;;Krajewski et al., ""Spectrometric Study of the Thermal Evolution of Mechanochemically Prepared Hydroxyapatite-based Powders,"" Cryst. Res. Technol., 31(5): 637-646 (1996).;;Kumar, R., et al., ""RF Plasma Processing of Ultra-Fine Hydroxyapatite Powders,"" Journal of Materials Processing Technology, 113: 456-462 (2001).;;Kurashina, K., et al., ""Ectopic Osteogenesis With Biphasic Ceramics of Hydroxyapatite and Tricalcuim Phosphate in Rabbits,"" Biomaterials, 23: 407-412 (2002).;;Kurokawa, ""Preparation of Fine Powder of Calcium Phosphate by using Vacuum Freeze-Drying Processing,"" The Report of Government Industrial Research Institute, 34(7): 210-216 (Jul. 1985).;;Kwon et al., ""Synthesis and dissolution behavior of beta-TCP and HA/beta-TCP composite powders,"" Journal of the European Ceramic Society, 23(7): 1039-1045 (Jun. 1, 2003).;;Lange et al., ""Effects of attrition milling and post-sintering heat treatment on fabrication, microstructure and properties of transformation toughened ZrO2,"" Journal of Materials Science, 21: 768-774 (1986).;;Lin, F., et al., ""Preparation of Biphasic Porous Bioceramics by Heating Bovine Cancellous Bone With Na2P2O7*10H2O Addition,"" Biomaterials, 20: 475-484, (1999).;;Liu, D., et al., ""Water-Based Sol-Gel Synthesis of Hydroxyapatite: Process Development,"" Biomaterials, 22: 1721-1730 (2001).;;Mathew, M., et al., ""Structures of Biological Minerals in Dental Research,"" J. Re. Natl. Inst. Stand. Technol., 106: 1035-1044, (2001).;;Prevey, P., ""X-Ray Diffraction Characterization of Crystallinity and Phase Composition in Plasma-Sprayed Hydroxylapatite Coatings,"" J. Thermal Spray Techn., 9: 369-376, (2000).;;Raynaud, S., et al., ""Calcium Phosphate Apatites With Variable Ca/P Atomic Ratio I: Synthesis, Characterization and Thermal Stability of Powders,"" Biomaterials, 23: 1065-1072 (2002).;;Raynaud, S., et al., ""Calcium Phosphate Apatites With Variable Ca/P Atomic Ratio III: Mechanical Properties and Degradation in Solution of Hot Pressed Ceramics,"" Biomaterials, 23: 1081-1089 (2002).;;Sayer, M., et al., Structure and Composition of Silicon-Stabilized Tricalcium Phosphate, Biomaterials, 24: 369-382, (2003).;;Serraj, S., et al., ""Effect on Composition of Dry Mechanical Grinding of Calcium Phosphate Mixtures,"" J. Biomed. Mater. Res., 55: 566-575, (2001).;;Slosarczyk, A., et al., ""Calcium Phosphate Materials Prepared from Precipitates With Various Calcium: Phosphate Molar Ratios,"" J. Am. Ceram. Soc., 79: 2539-44, (1996).;;Takahashi, H., et al., ""Synthesis of Stoichiometric Hydroxyapatite by a ""Gel"" Route From the Aqueous Solution of Citric and Phosphonoacetic Acids,"" Eur. J. Solid State Inorg. Chem., 32: 829-835 (1995).;;Tenhuisen, K., et al., ""Phase Evolution During the Formation of Alpha-Tricalcium Phosphate,"" J. Am. Ceram. Soc., 82: 2813-2818, (1999).;;Toriyama et al., ""High Strength beta-Tricalcium Phosphate Ceramics I. Mechanochemical Synthesis of beta-Tricalcium Phosphate,"" The Report of Government Industrial Research Institute, 39(5): 217-223 (May 1990).;;Toriyama et al., ""High Strength beta-Tricalcium Phosphate Ceramics II. Sintering Behavior of beta-Tricalcium Phosphate,"" The Report of Government Industrial Research Institute, 39(5): 224-228 (May 1990).;;Toriyama et al., ""Synthesis of Hydroxyapatite-Based Powders by Mechano-Chemical Method and their Sintering,"" Journal of the European Ceramic Society, 16: 429-436 (1996).;;Toriyama et al., ""Effect of Mixed Addition of Al2 O3 and SiO2 on Mechanical Strength of Sintered beta-Tricalcium Phosphate,"" The Ceramic Society of Japan, 96(8): 837-841 (1988).;;Toriyama et al., ""Thermal Change of Calcium Deficient Apatite Obtained by Mechanochemical Treatment,"" The Ceramic Society of Japan, 97(5): 554-558 (1989).;;Toriyama et al., ""Synthesis of beta-Tricalcium Phosphate by Use of Wet Milling,"" The Ceramic Society of Japan, 94(9): 78-82 (1986).;;Toriyama et al., ""Bending Strength of Hydroxyapatite Ceramics Containing alpha-Tricalcium Phosphate,"" The Ceramic Society of Japan, 95(4): 92-94 (1987).;;Toriyama et al., ""Sinterable Powder of Mechanochemically Synthetic beta-Tricalcium Phosphate,"" The Ceramic Society of Japan, 95(7): 741-745 (1987).;;Toriyama et al., ""Effect of MgO Addition on Bending Strength of Sintered beta-Tricalcium Phosphate Prepared by Mechanochemical Synthesis,"" The Ceramic Society of Japan, 95(8): 68-70 (1987).;;Toriyama et al., ""Estimation of Biocompatibility of High Strength beta-Tricalcium Phosphate Ceramics by a Tissue Culture Method,"" The Ceramic Society of Japan, 98(4): 404-407 (1990).;;Toriyama et al., ""beta-Tricalcium Phosphate Coating on Alumina Ceramic,"" The Ceramic Society of Japan, 98(9): 1054-1057 (1990).;;Traplis, C., et al., ""Calcium hydroxyapatite Formation by Sol-Gel Route,"" Chimica Chronica New Series, 23: 205-208 (1994).;;Victoria, E., et al., ""Synthesis and Characterisation of Biphasic Calcium Phosphate,"" Tends Biomater. Artif. Organs, 16: 12-14 (2002).;;Yokogawa et al., ""Apatite Coating on Yttria Doped Partially Stabilized Zirconia Plate in the Presence of Water Vaper,"" The Ceramic Society of Japan, 100(4): 602-604 (1992).;;Yokogawa et al., ""Preparation of Trimagnesium Phosphate by Mechanochemical Reaction,"" The Ceramic Society of Japan, 99(2): 150-152 (1991).;;Yokogawa et al., ""Tricalsium Phosphate Coating on Zirconia by Using Calcium Metaphosphate and Tetracalcium Phosphate,"" The Ceramic Society of Japan, 99(3): 211-214 (1991).;;U.S. Appl. No. 10/635,402, filed Aug. 6, 2003.;;U.S. Appl. No. 13/228,216, filed Sep. 8, 2011.",ACTIVE
14,US,B2,US 10011486 B2,126-967-823-496-406,2018-07-03,2018,US 201615345155 A,2016-11-07,US 201615345155 A;;US 201314070122 A;;US 201113228216 A;;US 63540203 A,2003-08-06,"Tricalcium phosphates, their composites, implants incorporating them, and methods for their production","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",PIONEER SURGICAL TECH INC,AHN EDWARD S,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;ANGSTROM ACQUISITION CORP. II (2007-10-23);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;ANGSTROM MEDICA INC (2003-09-08);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/126-967-823-496-406,Granted Patent,yes,36,0,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61K33/42;;A61K6/838;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42;;A61L31/14;;A61L31/16;;C01B25/32,,46,25,030-022-846-308-347;;024-885-681-386-182;;169-823-447-868-719;;049-634-994-801-472;;020-285-596-578-943;;021-812-309-424-14X;;132-132-218-339-500;;094-786-226-957-41X;;043-089-258-531-516;;060-367-557-637-322;;061-694-882-893-092;;045-682-605-366-675;;156-891-593-478-105;;117-990-278-694-499;;053-619-816-111-830;;169-436-925-645-377;;012-934-366-578-216;;101-181-238-750-07X;;073-876-640-911-887;;118-627-534-558-972;;059-423-131-390-076;;017-162-822-047-705;;183-625-779-188-736;;050-615-037-103-623;;002-238-459-220-166,10.1007/bf00591468;;15348776;;10.1023/a:1018506800033;;10.1201/9780203751367-26;;10.1016/s0142-9612(02)00193-x;;12322969;;10.1016/s0142-9612(02)00196-5;;12322972;;10.1021/la990590i;;10.1111/j.1151-2916.1998.tb02618.x;;10.2109/jcersj.97.965;;10.1002/crat.2170310519;;10.1016/s0924-0136(01)00611-2;;10.1016/s0142-9612(01)00119-3;;11761160;;10.1007/bf01117352;;10.1016/s0142-9612(98)00193-8;;10204990;;11396875;;10.1016/s0142-9612(00)00332-x;;10.6028/jres.106.054;;27500063;;pmc4865300;;10.1361/105996300770349827;;11791909;;10.1016/s0142-9612(01)00218-6;;11791911;;10.1016/s0142-9612(01)00220-4;;10.1016/s0142-9612(02)00327-7;;12423592;;10.1002/1097-4636(20010615)55:4<566::aid-jbm1050>3.0.co;2-f;;11288085;;10.1016/0955-2219(95)00123-9;;10.2109/jcersj.97.554;;10.2109/jcersj.100.602;;10.2109/jcersj.99.150;;10.2109/jcersj.99.211,"Ahn, “Nanostructures Apatites as Orthopedic Biomaterials,” (Ph.D. Dissertation, Massachusetts Institute of Technology) 1-93 (Jun. 2001).;;Akao, M., et al., “Dense Polycrystalline Beta-Tricalcium Phosphate for Prosthetic Applications,” J. Mater. Sci., 17: 343-346, (1982).;;Cuneyt-Tas, A., et al., “An Investigation of The Chemical Synthesis and High-Temperature Sintering Behavior of Calcium Hydroxyapatite (HA) and Tricalcium Phosphate (TCP) Bioceramics,” J. Mater. Sci. Mater. Med., 8: 91-96, (1997).;;Deputa, A., et al., “Preparation of Calcium Phosphate Powders by Water Extraction Variant of Sol-Gel process,” CRC Press: Hydroxyapatite and Related Materials, 263-268 (1994).;;Dong, J., et al., “Promotion of Bone Formation Using Highly Pure Porous Beta-TCP Combined With Bone Marrow-Derived Osteoprogenitor Cells,” Biomaterials, 23: 4493-4502 (2002).;;Fini, M., et al., “A Bone Substitute Composed of Polymethylmethacrylate and Alpha-Tricalcium Phosphate: Results in Terms of Osteoblast Function and Bone Tissue Formation,” Biomaterials, 23: 4523-4531 (2002).;;Hirai, T., et al., “The Preparation of Spherical Calcium Phosphate Fine Particles Using an Emulsion Liquid Membrance System,” Langmuir, 16: 955-960 (2000).;;Kawamoto et al., “Coating of β-Tricalcium Phosphate on Yttria-Partially Stabilized Zirconia Using Magnesium Metaphosphate as an Interlayer,” The Ceramic Society of Japan, 99(1): 19-22 (1991).;;Kivrak, N., et al., “Synthesis of Calcium Hydroxyapatite-Tricalcium Phosphate (HA-TCP) Composite Bioceramic Powders and Their Sintering Behavior,” J. Am. Ceram. Soc., 81: 2245-52 (1998).;;Kondoh et al., “Sintering of Tricalcium Phosphate by HIP,” Journal of the Ceramic Society of Japan, 97(9): 965-967 (1989).;;Krajewski et al., “Spectrometric Study of the Thermal Evolution of Mechanochemically Prepared Hydroxyapatite-based Powders,” Cryst. Res. Technol., 31(5): 637-646 (1996).;;Kumar, R., et al., “RF Plasma Processing of Ultra-Fine Hydroxyapatite Powders,” Journal of Materials Processing Technology, 113: 456-462 (2001).;;Kurashina, K., et al., “Ectopic Osteogenesis With Biphasic Ceramics of Hydroxyapatite and Tricalcuim Phosphate in Rabbits,” Biomaterials, 23: 407-412 (2002).;;Kurokawa, “Preparation of Fine Powder of Calcium Phosphate by using Vacuum Freeze-Drying Processing,” The Report of Government Industrial Research Institute, 34(7): 210-216 (Jul. 1985).;;Kwon et al., “Synthesis and dissolution behavior of β-TCP and HA/β-TCP composite powders,” Journal of the European Ceramic Society, 23(7): 1039-1045 (Jun. 1, 2003).;;Lange et al., “Effects of attrition milling and post-sintering heat treatment on fabrication, microstructure and properties of transformation toughened ZrO2.” Journal of Materials Science, 21: 763-774 (1986).;;Lin, F., et al., “Preparation of Biphasic Porous Bioceramics by Heating-Bovine Cancellous Bone With Na2P2O7*10H2O Addition,” Biomaterials, 20: 475-484, (1999).;;Liu, D., et al., “Water-Based Sol-Gel Synthesis of Hydroxyapatite: Process Development,” Biomaterials, 22: 1721-1730 (2001).;;Mathew, M., et al., “Structures of Biological Minerals in Dental Research,” J. Re. Natl. Inst. Stand. Technol., 106: 1035-1044, (2001).;;Prevey, P., “X-Ray Diffraction Characterization of Crystallinity and Phase Composition in Plasma-Sprayed Hydroxylapatite Coatings,” J. Thermal Spray Techn., 9: 369-376, (2000).;;Raynaud, S., et al., “Calcium Phosphate Apatites With Variable Ca/P Atomic Ratio I: Synthesis, Characterization and Thermal Stability of Powders,” Biomaterials, 23: 1065-1072 (2002).;;Raynaud, S., et al., “Calcium Phosphate Apatites With Variable Ca/P Atomic Ratio III: Mechanical Properties and Degradation in Solution of Hot Pressed Ceramics,” Biomaterials, 23: 1081-1089 (2002).;;Sayer, M., et al., Structure and Composition of Silicon-Stabilized Tricalcium Phosphate, Biomaterials, 24: 369-362, (2003).;;Serraj, S., et al., “Effect on Composition of Dry Mechanical Grinding of Calcium Phosphate Mixtures,” J. Biomed Mater. Res., 55: 566-575, (2001).;;Slosarczyk, A., et al., “Calcium Phosphate Materials Prepared from Precipitates With Various Calcium: Phosphate Molar Ratios,” J. Am. Ceram. Soc., 79: 2539-44, (1996).;;Takahashi, H., et al., “Synthesis of Stoichiometric Hydroxyapatite by a “Gel” Route From the Aqueous Solution of Citric and Phosphonoacetic Acids,” Eur. J. Solid State Inorg. Chem., 32: 829-835 (1995).;;Tenhuisen, K., et al., “Phase Evolution During The Formation of Alpha-Tricalcium Phosphate,” J. Am. Ceram. Soc., 82: 2813-2818, (1999).;;Toriyama et al., “High Strength β-Tricalcium Phosphate Ceramics I. Mechanochemical Synthesis of β-Tricalcium Phosphate,” The Report of Government Industrial Research Institute, 39(5): 217-223 (May 1990).;;Toriyama et al., “High Strength β-Tricalcium Phosphate Ceramics II. Sintering Behavior of β-Tricalcium Phosphate,” The Report of Government Industrial Research Institute, 39(5): 224-228 (May 1990).;;Toriyama et al., “Synthesis of Hydroxyapatite-Based Powders by Mechano-Chemical Method and their Sintering,” Journal of the European Ceramic Society, 16: 429-436 (1996).;;Toriyama et al., “Effect of Mixed Addition of Al2O3 and SiO2 on Mechanical Strength of Sintered β-Tricalcium Phosphate,” The Ceramic Society of Japan, 96(8): 837-841 (1988).;;Toriyama et al., “Thermal Change of Calcium Deficient Apatite Obtained by Mechanochemical Treatment,” The Ceramic Society of Japan, 97(5): 554-558 (1989).;;Toriyama et al., “Synthesis of β-Tricalcium Phosphate by Use of Wet Milling,” The Ceramic Society of Japan, 94(9): 78-82 (1986).;;Toriyama et al., “Bending Strength of Hydroxyapatite Ceramics Containing α-Tricalcium Phosphate,” The Ceramic Society of Japan, 95(4): 92-94 (1987).;;Toriyama et al., “Sinterable Powder of Mechanochemically Synthetic β-Tricalcium Phosphate,” The Ceramic Society of Japan, 95(7): 741-745 (1987).;;Toriyama et al., “Effect of MgO Addition on Bending Strength of Sintered β-Tricalcium Phosphate Prepared by Mechanochemical Synthesis,” The Ceramic Society of Japan, 95(8): 68-70 (1987).;;Toriyama et al., “Estimation of Biocompatibility of High Strength β-Tricalcium Phosphate Ceramics by a Tissue Culture Method,” The Ceramic Society of Japan, 98(4): 404-407 (1990).;;Toriyama et al., “β-Tricalcium Phosphate Coating on Alumina Ceramic,” The Ceramic Society of Japan, 98(9): 1054-1057 (1990).;;Traplis, C., et al., “Calcium hydroxyapatite Formation by Sol-Gel Route,” Chimica Chronica New Series, 23: 205-208 (1994).;;Victoria, E., et al., “Synthesis and Characterisation of Biphasic Calcium Phosphate,” Tends Biomater. Artif. Organs, 16: 12-14 (2002).;;Yokogawa et al., “Apatite Coating on Yttria Doped Partially Stabilized Zirconia Plate in the Presence of Water Vaper,” The Ceramic Society of Japan, 100(4): 602-604 (1992).;;Yokogawa et al., “Preparation of Trimagnesium Phosphate by Mechanochemical Reaction,” The Ceramic Society of Japan, 99(2): 150-152 (1991).;;Yokogawa et al., “Tricalsium Phosphate Coating on Zirconia by Using Calcium Metaphosphate and Tetracalcium Phosphate,” The Ceramic Society of Japan, 99(3): 211-214 (1991).;;U.S. Appl. No. 10/635,402, filed Aug. 6, 2003.;;U.S. Appl. No. 13/228,216, filed Sep. 8, 2011.;;U.S. Appl. No. 14/070,122, filed Nov. 1, 2013.",ACTIVE
15,US,A1,US 2005/0031704 A1,135-400-193-293-223,2005-02-10,2005,US 63540203 A,2003-08-06,US 63540203 A,2003-08-06,"Tricalcium phosphates, their composites, implants incorporating them, and methods for their production","Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",ANGSTROM MEDICA,AHN EDWARD S,ANGSTROM ACQUISITION CORP. II (2007-10-23);;ANGSTROM MEDICA (2003-09-08);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/135-400-193-293-223,Patent Application,yes,30,161,16,16,0,A61K33/42;;A61K33/42;;A61K38/1816;;A61K38/1816;;A61K45/06;;A61K45/06;;A61L27/12;;A61L27/12;;A61L27/425;;A61L27/425;;A61L31/148;;A61L31/16;;A61P19/08;;C01B25/32;;C01B25/32;;C01P2002/60;;C01P2004/61;;C01P2006/10;;C01P2006/60,A61K6/838;;A61K33/42;;A61K38/18;;A61K45/06;;A61L27/12;;A61L27/42,424/602;;424/617,0,0,,,,EXPIRED
16,CN,A,CN 101114517 A,076-056-045-958-053,2008-01-30,2008,CN 200710107351 A,2007-05-29,US 80963606 P,2006-05-30,System and method for performing dynamic trimming,,NVIDIA CORP,ERIC MASSON;;EDWARD AHN,,https://lens.org/076-056-045-958-053,Patent Application,no,0,4,2,8,0,,G11C7/22;;H03L7/00,,0,0,,,,ACTIVE
17,KR,A,KR 20070115692 A,143-033-555-757-725,2007-12-06,2007,KR 20070052271 A,2007-05-29,US 78426807 A;;US 80963606 P,2006-05-30,SYSTEM AND METHOD FOR PERFORMING DYNAMIC TRIMMING,"A system and a method for performing dynamic trimming are provided to implement low power operation by operating a low power dynamic trimming circuit with a frequency randomly decreased from a frequency of a data clock signal of a DDR memory. A system for performing dynamic trimming includes a clock(210), a counter(220), a phase length detector(230) and a conversion module(240). The clock generates a reference clock signal, and the reference clock signal includes a first frequency, a factor of a second frequency of the signal. The counter is connected to the clock, and generates a plurality of clock pulses on the basis of pulses of the reference clock signal. The plurality of clock pulses is generated to have a slower frequency from the first frequency. The phase length detector is connected to the counter, and includes a trimmer chain detecting at least one average length of the plurality of clock pulses. The conversion module is connected to the phase length detector, and converts the length into phase delay applied to the signal.",NVIDIA CORP,MASSON ERIC;;AHN EDWARD,,https://lens.org/143-033-555-757-725,Patent Application,no,0,0,6,8,0,G11C7/1072;;G11C7/1072;;G11C11/4076;;G11C7/222;;G11C7/222;;G11C11/407;;G11C29/023;;G11C29/028;;G11C2029/0409;;G11C2207/2254;;G11C2207/2254;;H03L7/091;;H03L7/091,G11C11/407,,0,0,,,,ACTIVE
18,CN,C,CN 100583289 C,153-469-321-357-550,2010-01-20,2010,CN 200710107351 A,2007-05-29,US 80963606 P,2006-05-30,System for performing dynamic trimming,"A system and method for performing dynamic trimming. Specifically, the system comprises a clock for generating a reference clock signal. The reference clock signal comprises a first frequency that is a factor of a second frequency of a signal (e.g., data clock signal from DDR memory). A counter is coupled to the clock and generates a plurality of clock pulses based on pulses of the reference clock signal. The plurality of clock pulses is generated at a slower frequency from the first frequency for low power operation. A phase length detector is coupled to the counter and comprises a trimmer chain for detecting an average length of at least one of the generated plurality of clock pulses. A transformation module is coupled to the phase length detector for transforming the average length to a phase delay of the signal.",NVIDIA CORP,ERIC MASSON;;EDWARD AHN,,https://lens.org/153-469-321-357-550,Granted Patent,no,0,0,2,8,0,,G11C7/22;;H03L7/00,,0,0,,,,ACTIVE
19,US,A1,US 2011/0004307 A1,093-150-115-072-061,2011-01-06,2011,US 44593607 A,2007-10-16,US 44593607 A;;US 85197206 P;;US 2007/0081559 W,2006-10-16,"FUSION DEVICE, SYSTEMS AND METHODS THEREOF","The spinal fusion device ( 100 ) of the invention is implanted within an intervertebral space between adjacent upper and lower vertebrae and secured to the vertebrae with cement. The fusion device includes upper and lower endplate facing surfaces ( 150, 160 ) each having at least one opening ( 120 ) for delivering cement material to adjacent contact surfaces of the vertebrae above and below the implant. Utilizing quick-setting cement compositions with the device <:an allow for almost immediate fusion of the vertebrae, thus, reducing or eliminating the need for adjuvant fixation devices such as screws, plates, and/or rods, while also simultaneously providing precise delivery of cement to contact surfaces between the fusion device and vertebrae.",AHN EDWARD S;;CVINAR JOHN,AHN EDWARD S;;CVINAR JOHN,PIONEER SURGICAL TECHNOLOGY INC (2010-09-22),https://lens.org/093-150-115-072-061,Patent Application,yes,2,88,7,7,0,A61F2/441;;A61F2/441;;A61B17/7098;;A61B17/7098;;A61F2/28;;A61F2/28;;A61F2/4455;;A61F2/4455;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30062;;A61F2002/30062;;A61F2002/302;;A61F2002/302;;A61F2002/30225;;A61F2002/30225;;A61F2002/30579;;A61F2002/30579;;A61F2002/30583;;A61F2002/30583;;A61F2002/30586;;A61F2002/30586;;A61F2002/30772;;A61F2002/30772;;A61F2002/30904;;A61F2002/30904;;A61F2002/4495;;A61F2002/4495;;A61F2002/4631;;A61F2002/4631;;A61F2210/0004;;A61F2210/0004;;A61F2210/0085;;A61F2210/0085;;A61F2230/0065;;A61F2230/0065;;A61F2230/0069;;A61F2230/0069;;A61F2310/00011;;A61F2310/00011;;A61F2310/00179;;A61F2310/00179;;A61F2310/00293;;A61F2310/00293;;A61F2310/00353;;A61F2310/00353,A61F2/44,623/17.12;;606/279;;206/570,0,0,,,,INACTIVE
20,WO,A3,WO 2008/140551 A3,106-599-844-881-192,2008-12-31,2008,US 2007/0081559 W,2007-10-16,US 85197206 P,2006-10-16,FUSION DEVICE,"The spinal fusion device (100) of the invention is implanted within an intervertebral space between adjacent upper and lower vertebrae and secured to the vertebrae with cement. The fusion device includes upper and lower endplate facing surfaces (150, 160) each having at least one opening (120) for delivering cement material to adjacent contact surfaces of the vertebrae above and below the implant. Utilizing quick-setting cement compositions with the device <:an allow for almost immediate fusion of the vertebrae, thus, reducing or eliminating the need for adjuvant fixation devices such as screws, plates, and/or rods, while also simultaneously providing precise delivery of cement to contact surfaces between the fusion device and vertebrae.",ANGSTROM MEDICA INC;;AHN EDWARD S;;CVINAR JOHN,AHN EDWARD S;;CVINAR JOHN,,https://lens.org/106-599-844-881-192,Search Report,yes,6,0,7,7,0,A61F2/441;;A61F2/441;;A61B17/7098;;A61B17/7098;;A61F2/28;;A61F2/28;;A61F2/4455;;A61F2/4455;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30062;;A61F2002/30062;;A61F2002/302;;A61F2002/302;;A61F2002/30225;;A61F2002/30225;;A61F2002/30579;;A61F2002/30579;;A61F2002/30583;;A61F2002/30583;;A61F2002/30586;;A61F2002/30586;;A61F2002/30772;;A61F2002/30772;;A61F2002/30904;;A61F2002/30904;;A61F2002/4495;;A61F2002/4495;;A61F2002/4631;;A61F2002/4631;;A61F2210/0004;;A61F2210/0004;;A61F2210/0085;;A61F2210/0085;;A61F2230/0065;;A61F2230/0065;;A61F2230/0069;;A61F2230/0069;;A61F2310/00011;;A61F2310/00011;;A61F2310/00179;;A61F2310/00179;;A61F2310/00293;;A61F2310/00293;;A61F2310/00353;;A61F2310/00353,A61F2/44,,0,0,,,,PENDING
21,CN,A,CN 101616642 A,136-567-759-402-283,2009-12-30,2009,CN 200780043392 A,2007-10-16,US 85197206 P,2006-10-16,Fusion device,"The spinal fusion device (100) of the invention is implanted within an intervertebral space between adjacent upper and lower vertebrae and secured to the vertebrae with cement. The fusion device includes upper and lower endplate facing surfaces (150, 160) each having at least one opening (120) for delivering cement material to adjacent contact surfaces of the vertebrae above and below the implant. Utilizing quick-setting cement compositions with the device <:an allow for almost immediate fusion of the vertebrae, thus, reducing or eliminating the need for adjuvant fixation devices such as screws, plates, and/or rods, while also simultaneously providing precise delivery of cement to contact surfaces between the fusion device and vertebrae.",ANGSTROM MEDICA INC,AHN EDWARD S;;JOHN CVINAR,,https://lens.org/136-567-759-402-283,Patent Application,no,0,6,7,7,0,A61F2/441;;A61F2/441;;A61B17/7098;;A61B17/7098;;A61F2/28;;A61F2/28;;A61F2/4455;;A61F2/4455;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30062;;A61F2002/30062;;A61F2002/302;;A61F2002/302;;A61F2002/30225;;A61F2002/30225;;A61F2002/30579;;A61F2002/30579;;A61F2002/30583;;A61F2002/30583;;A61F2002/30586;;A61F2002/30586;;A61F2002/30772;;A61F2002/30772;;A61F2002/30904;;A61F2002/30904;;A61F2002/4495;;A61F2002/4495;;A61F2002/4631;;A61F2002/4631;;A61F2210/0004;;A61F2210/0004;;A61F2210/0085;;A61F2210/0085;;A61F2230/0065;;A61F2230/0065;;A61F2230/0069;;A61F2230/0069;;A61F2310/00011;;A61F2310/00011;;A61F2310/00179;;A61F2310/00179;;A61F2310/00293;;A61F2310/00293;;A61F2310/00353;;A61F2310/00353,A61F2/44,,0,0,,,,DISCONTINUED
22,US,B2,US 9089437 B2,031-989-098-828-908,2015-07-28,2015,US 44593607 A,2007-10-16,US 44593607 A;;US 85197206 P;;US 2007/0081559 W,2006-10-16,"Fusion device, systems and methods thereof",The invention provides a fusion device for use in spinal fusion procedures. The invention also provides systems and methods that include filling the fusion device with a cement composition.,AHN EDWARD S;;CVINAR JOHN;;PIONEER SURGICAL TECH INC,AHN EDWARD S;;CVINAR JOHN,PIONEER SURGICAL TECHNOLOGY INC (2010-09-22),https://lens.org/031-989-098-828-908,Granted Patent,yes,8,4,7,7,0,A61F2/441;;A61F2/441;;A61B17/7098;;A61B17/7098;;A61F2/28;;A61F2/28;;A61F2/4455;;A61F2/4455;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30062;;A61F2002/30062;;A61F2002/302;;A61F2002/302;;A61F2002/30225;;A61F2002/30225;;A61F2002/30579;;A61F2002/30579;;A61F2002/30583;;A61F2002/30583;;A61F2002/30586;;A61F2002/30586;;A61F2002/30772;;A61F2002/30772;;A61F2002/30904;;A61F2002/30904;;A61F2002/4495;;A61F2002/4495;;A61F2002/4631;;A61F2002/4631;;A61F2210/0004;;A61F2210/0004;;A61F2210/0085;;A61F2210/0085;;A61F2230/0065;;A61F2230/0065;;A61F2230/0069;;A61F2230/0069;;A61F2310/00011;;A61F2310/00011;;A61F2310/00179;;A61F2310/00179;;A61F2310/00293;;A61F2310/00293;;A61F2310/00353;;A61F2310/00353,A61F2/44;;A61B17/70;;A61F2/28;;A61F2/30;;A61F2/46,,0,0,,,,INACTIVE
23,WO,A2,WO 2008/140551 A2,195-066-239-685-560,2008-11-20,2008,US 2007/0081559 W,2007-10-16,US 85197206 P,2006-10-16,"FUSION DEVICE, SYSTEMS AND METHODS THEREOF",The invention provides a fusion device for use in spinal fusion procedures. The invention also provides systems and methods that include filling the fusion device with a cement composition.,ANGSTROM MEDICA INC;;AHN EDWARD S;;CVINAR JOHN,AHN EDWARD S;;CVINAR JOHN,,https://lens.org/195-066-239-685-560,Patent Application,yes,12,11,7,7,0,A61F2/441;;A61F2/441;;A61B17/7098;;A61B17/7098;;A61F2/28;;A61F2/28;;A61F2/4455;;A61F2/4455;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30062;;A61F2002/30062;;A61F2002/302;;A61F2002/302;;A61F2002/30225;;A61F2002/30225;;A61F2002/30579;;A61F2002/30579;;A61F2002/30583;;A61F2002/30583;;A61F2002/30586;;A61F2002/30586;;A61F2002/30772;;A61F2002/30772;;A61F2002/30904;;A61F2002/30904;;A61F2002/4495;;A61F2002/4495;;A61F2002/4631;;A61F2002/4631;;A61F2210/0004;;A61F2210/0004;;A61F2210/0085;;A61F2210/0085;;A61F2230/0065;;A61F2230/0065;;A61F2230/0069;;A61F2230/0069;;A61F2310/00011;;A61F2310/00011;;A61F2310/00179;;A61F2310/00179;;A61F2310/00293;;A61F2310/00293;;A61F2310/00353;;A61F2310/00353,A61F2/44,,0,0,,,,PENDING
24,EP,A2,EP 2083760 A2,021-713-632-719-083,2009-08-05,2009,EP 07874220 A,2007-10-16,US 2007/0081559 W;;US 85197206 P,2006-10-16,FUSION DEVICE and SYSTEMS,,PIONEER SURGICAL TECH INC,AHN EDWARD S;;CVINAR JOHN,,https://lens.org/021-713-632-719-083,Patent Application,yes,0,0,7,7,0,A61F2/441;;A61F2/441;;A61B17/7098;;A61B17/7098;;A61F2/28;;A61F2/28;;A61F2/4455;;A61F2/4455;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30062;;A61F2002/30062;;A61F2002/302;;A61F2002/302;;A61F2002/30225;;A61F2002/30225;;A61F2002/30579;;A61F2002/30579;;A61F2002/30583;;A61F2002/30583;;A61F2002/30586;;A61F2002/30586;;A61F2002/30772;;A61F2002/30772;;A61F2002/30904;;A61F2002/30904;;A61F2002/4495;;A61F2002/4495;;A61F2002/4631;;A61F2002/4631;;A61F2210/0004;;A61F2210/0004;;A61F2210/0085;;A61F2210/0085;;A61F2230/0065;;A61F2230/0065;;A61F2230/0069;;A61F2230/0069;;A61F2310/00011;;A61F2310/00011;;A61F2310/00179;;A61F2310/00179;;A61F2310/00293;;A61F2310/00293;;A61F2310/00353;;A61F2310/00353,A61F2/44,,1,0,,,See references of WO 2008140551A2,ACTIVE
25,EP,B1,EP 2083760 B1,013-304-997-578-837,2014-01-15,2014,EP 07874220 A,2007-10-16,US 2007/0081559 W;;US 85197206 P,2006-10-16,FUSION DEVICE and SYSTEMS,,PIONEER SURGICAL TECH INC,AHN EDWARD S;;CVINAR JOHN,,https://lens.org/013-304-997-578-837,Granted Patent,yes,6,3,7,7,0,A61F2/441;;A61F2/441;;A61B17/7098;;A61B17/7098;;A61F2/28;;A61F2/28;;A61F2/4455;;A61F2/4455;;A61F2/4465;;A61F2/4465;;A61F2/447;;A61F2/447;;A61F2002/2817;;A61F2002/2817;;A61F2002/2835;;A61F2002/2835;;A61F2002/30062;;A61F2002/30062;;A61F2002/302;;A61F2002/302;;A61F2002/30225;;A61F2002/30225;;A61F2002/30579;;A61F2002/30579;;A61F2002/30583;;A61F2002/30583;;A61F2002/30586;;A61F2002/30586;;A61F2002/30772;;A61F2002/30772;;A61F2002/30904;;A61F2002/30904;;A61F2002/4495;;A61F2002/4495;;A61F2002/4631;;A61F2002/4631;;A61F2210/0004;;A61F2210/0004;;A61F2210/0085;;A61F2210/0085;;A61F2230/0065;;A61F2230/0065;;A61F2230/0069;;A61F2230/0069;;A61F2310/00011;;A61F2310/00011;;A61F2310/00179;;A61F2310/00179;;A61F2310/00293;;A61F2310/00293;;A61F2310/00353;;A61F2310/00353,A61F2/44,,0,0,,,,ACTIVE
26,DE,D1,DE 3060701 D1,119-105-301-773-469,1982-09-16,1982,DE 3060701 T,1980-04-25,US 5348879 A,1979-06-29,A DRY METHOD OF ETCHING AND AN APPARATUS USING SOLID MASKING MATERIALS FOR ETCH RATE MODIFICATION,,IBM,AHN KIE YEUNG;;COX DANIEL EDWARD,,https://lens.org/119-105-301-773-469,Granted Patent,no,0,0,6,6,0,C23F1/12;;H01L21/3065;;H01L21/31116;;H01L21/32136;;H01L21/32137;;C23F1/12;;H01L21/32136;;H01L21/32137;;H01L21/3065;;H01L21/31116,C23F4/00;;C23F1/12;;H01L21/3065;;H01L21/311;;H01L21/3213,,0,0,,,,EXPIRED
27,US,B2,US 7966509 B2,127-224-713-723-339,2011-06-21,2011,US 78426807 A,2007-04-06,US 78426807 A;;US 80963606 P,2006-05-30,System and method for performing low power dynamic trimming,"A system and method for performing dynamic trimming. Specifically, the system comprises a clock for generating a reference clock signal. The reference clock signal comprises a first frequency that is a factor of a second frequency of a signal (e.g., data clock signal from DDR memory). A counter is coupled to the clock and generates a plurality of clock pulses based on pulses of the reference clock signal. The plurality of clock pulses is generated at a slower frequency from the first frequency for low power operation. A phase length detector is coupled to the counter and comprises a trimmer chain for detecting an average length of at least one of the generated plurality of clock pulses. A transformation module is coupled to the phase length detector for transforming the average length to a phase delay of the signal.",NVIDIA CORP,MASSON ERIC L;;AHN EDWARD S,NVIDIA CORPORATION (2007-03-29),https://lens.org/127-224-713-723-339,Granted Patent,yes,13,1,6,8,0,G11C7/1072;;G11C7/1072;;G11C11/4076;;G11C7/222;;G11C7/222;;G11C11/407;;G11C29/023;;G11C29/028;;G11C2029/0409;;G11C2207/2254;;G11C2207/2254;;H03L7/091;;H03L7/091,G06F1/04,713/500;;713/503,1,1,034-919-501-866-775,10.1109/asap.2002.1030705,"Arnold, ""Reduced Power Consumption for MPEG Decoding With LNS"", 2002, IEEE Proceedings of the IEEE International Conference on Application-Specific Systems, Architectures, and Processors, pp. 1-11.",ACTIVE
28,AU,A1,AU 2021/324976 A1,125-923-064-394-482,2023-03-16,2023,AU 2021/324976 A,2021-08-13,US 202063064975 P;;US 2021/0046001 W,2020-08-13,Motorized injection system and methods of use,"System and methods for injection into a cavity are provided. In some embodiments, an injection system includes an injection assembly comprising a syringe barrel defining a lumen between proximal and distal ends and a second sealing element moveably disposed within the lumen to dispense an injection agent from an injection chamber defined in the syringe barrel. A puncture element delivers the injection agent into a space in a tissue. The tissue is less permeable to the injection agent than the space. The injection system also includes a support platform to support the injection assembly and anchor it relative to a site of injection, a drive assembly to operate the injection assembly, one or more sensors to monitor one or more forces on the injection assembly, and a controller in communication with the one o more sensors to receive information about the one or more forces on the injection system.",MEIRAGTX UK II LTD,LAULICHT BRYAN;;CHITNIS GIRISH;;AHN EDWARD,,https://lens.org/125-923-064-394-482,Patent Application,no,0,0,9,9,0,A61M5/46;;A61M5/20;;A61M5/1456;;A61M2205/50;;A61M2205/332;;A61F9/0017;;A61F9/0026;;A61M5/20;;A61M2205/332;;A61M5/1456;;A61M5/46;;A61F9/0017;;A61M2205/50;;A61F9/0026;;A61F9/0026;;A61F9/0017;;A61M5/20;;A61M5/1456;;A61M2205/332;;A61M2205/50,A61M5/46;;A61F9/007;;A61M5/00;;A61M5/315,,0,0,,,,PENDING
29,WO,A3,WO 2009/029734 A3,168-601-331-233-332,2011-07-28,2011,US 2008/0074700 W,2008-08-28,US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH-) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECHNOLOGY INC;;LIN JUCHUI RAY;;AHN EDWARD S,LIN JUCHUI RAY;;AHN EDWARD S,,https://lens.org/168-601-331-233-332,Search Report,yes,5,1,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61K6/838;;A61K6/884;;A61L24/04,,0,0,,,,PENDING
30,NZ,A,NZ 747413 A,013-623-353-838-54X,2020-09-25,2020,NZ 74741317 A,2017-04-26,US 2017/0029635 W;;US 201662367377 P;;US 201662328396 P,2016-04-27,Compositions for use in treating tendon degeneration,"Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication. Said composition is administered via intra-osteotendinous injection at zone one, zone two, zone three, or zone four of the osteotendinous junction.",ANIKA THERAPEUTICS INC,WHITE COLIN;;AHN EDWARD;;NOEL SEKONI,,https://lens.org/013-623-353-838-54X,Patent Application,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,PENDING
31,EP,A2,EP 2744575 A2,030-043-725-045-897,2014-06-25,2014,EP 12754150 A,2012-08-17,US 201161525391 P;;US 2012/0051441 W,2011-08-19,INJECTABLE FILLERS FOR AESTHETIC MEDICAL ENHANCEMENT AND FOR THERAPEUTIC APPLICATIONS,,PIONEER SURGICAL TECH INC,CAPISTRON STEPHEN M;;AHN EDWARD S,,https://lens.org/030-043-725-045-897,Patent Application,yes,1,1,6,6,0,A61K8/0279;;A61K8/0279;;A61K8/042;;A61K8/042;;A61K8/24;;A61K8/24;;A61K8/73;;A61K8/73;;A61K8/90;;A61K8/90;;A61K2800/594;;A61K2800/594;;A61K2800/91;;A61K2800/91;;A61Q19/08;;A61Q19/08;;C01B25/327;;C01B25/327;;C01B25/32;;C01B25/32;;C01P2004/61;;C01P2004/61;;C01P2006/12;;C01P2006/12,A61Q19/08;;A61K8/04;;A61K8/24;;C01B25/32,,1,0,,,See also references of WO 2013028551A2,DISCONTINUED
32,KR,A,KR 20230088339 A,142-182-836-784-941,2023-06-19,2023,KR 20237008641 A,2021-08-13,US 202063064975 P;;US 2021/0046001 W,2020-08-13,전동식 주사 시스템 및 그 사용방법,"공동으로의 주입을 하기 위한 시스템 및 방법이 제공된다. 일부 실시예에서, 주사 시스템은 근위 단부와 원위 단부 사이에 루멘을 정의하는 주사기 배럴 및 주사기 배럴 내에 정의된 주입 챔버로부터 주사제를 분배하기 위해 루멘 내에 이동 가능하게 배치된 제2 밀봉 요소를 구비하는 주사 어셈블리를 포함한다. 천자 요소는 주사제를 조직의 공간으로 전달한다. 조직은 공간보다 주사제에 대한 투과성이 낮다. 주사 시스템은 또한 주사 조립체를 지지하고 주사 부위에 대해 주사 조립체를 고정시키는 지지 플랫폼, 주사 조립체를 작동시키는 구동 조립체, 주사 조립체 상의 하나 이상의 힘을 모니터링하는 하나 이상의 센서, 및 하나 이상의 센서와 통신하여 주사 시스템 상의 하나 이상의 힘에 관한 정보를 수신하는 제어기를 포함한다. 제어기는 상기 정보에 기초하여 천자 요소가 주입 챔버와 공간을 유체 연결할 때까지 주사제가 주입 챔버 내에 유지되도록 조직을 통해 공간을 향한 방향으로 천자 요소를 진행하도록 구동 조립체를 조작하도록 구성된다.",MEIRAGTX UK II LTD,LAULICHT BRYAN;;CHITNIS GIRISH;;AHN EDWARD,,https://lens.org/142-182-836-784-941,Patent Application,no,0,0,9,9,0,A61M5/46;;A61M5/20;;A61M5/1456;;A61M2205/50;;A61M2205/332;;A61F9/0017;;A61F9/0026;;A61M5/20;;A61M2205/332;;A61M5/1456;;A61M5/46;;A61F9/0017;;A61M2205/50;;A61F9/0026;;A61F9/0026;;A61F9/0017;;A61M5/20;;A61M5/1456;;A61M2205/332;;A61M2205/50,A61F9/00;;A61M5/145;;A61M5/20,,0,0,,,,PENDING
33,KR,A,KR 20010062839 A,162-355-342-662-766,2001-07-07,2001,KR 20000085306 A,2000-12-29,US 47472899 A,1999-12-29,VARIABLE DISPLACEMENT COMPRESSOR HAVING PISTON ANTI-ROTATION STRUCTURE,"PURPOSE: A variable displacement swash plate type compressor having a structure for preventing the rotation of a piston is provided to be received in a small crank case for reducing the whole diameter of the crank case. CONSTITUTION: A variable displacement swash plate type compressor(10) having a structure for preventing the rotation of a piston includes a cylinder block(12) formed with a plurality of cylinders(14) inside, a crank case(18) mounted at an end of the cylinder block for sealing the cylinder block and having an inner wall formed with longitudinal depressed portions(24) between bearing surfaces(22), and a plurality of pistons(52) mounted in the respective cylinders slidably, wherein each of the piston has a structure(60) for preventing the rotation to be aligned at a position corresponding to the depressed portion with a clearance in a radial direction, and the rotation preventing structure includes a pair of facing shoulder parts and an outer surface(73) extended between the shoulder parts.",HALLA CLIMATE CONTROL CORP;;VISTEON GLOBAL TECH INC,AHN HU NAM;;GANSTER PETER EDWARD,,https://lens.org/162-355-342-662-766,Patent Application,no,0,0,6,6,0,F04B27/08;;F04B27/0878;;F04B27/0878,F04B27/10;;F04B27/08,,0,0,,,,EXPIRED
34,WO,A9,WO 2017/189723 A9,184-663-440-453-24X,2018-06-28,2018,US 2017/0029635 W,2017-04-26,US 201662328396 P;;US 201662367377 P,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN;;AHN EDWARD;;NOEL SEKONI,,https://lens.org/184-663-440-453-24X,Search Report,yes,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,PENDING
35,US,A1,US 2009/0270527 A1,197-210-364-993-42X,2009-10-29,2009,US 20091808 A,2008-08-28,US 20091808 A;;US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",ANGSTROM MEDICA,LIN JUCHUI RAY;;AHN EDWARD S,PIONEER SURGICAL TECHNOLOGY INC (2010-10-29),https://lens.org/197-210-364-993-42X,Patent Application,yes,56,47,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/04;;A61K6/838;;A61K6/884,523/116,0,0,,,,INACTIVE
36,CA,A1,CA 2845838 A1,025-412-944-344-678,2013-02-28,2013,CA 2845838 A,2012-08-17,US 201161525391 P;;US 2012/0051441 W,2011-08-19,INJECTABLE FILLERS FOR AESTHETIC MEDICAL ENHANCEMENT AND FOR THERAPEUTIC APPLICATIONS,"The present invention relates to a biocompatible injectable filler composition comprising calcium phosphate particles having a porosity of about 10% to about 90%, a BET surface area of about 1 m2/g to about 100 m2/g, and a mean particle size of about 1 micron to about 30 microns, a thermoreversible hydrophilic gelling agent, a carrier comprising water and an optional persistence enhancer and/or volumizing agent, and methods of its use to restore tissue volume and/or to smooth out tissue defects as in soft tissue or deep tissue augmentation.",PIONEER SURGICAL TECHNOLOGY,CAPISTRON STEPHEN M;;AHN EDWARD S,,https://lens.org/025-412-944-344-678,Patent Application,no,0,0,6,6,0,A61K8/0279;;A61K8/0279;;A61K8/042;;A61K8/042;;A61K8/24;;A61K8/24;;A61K8/73;;A61K8/73;;A61K8/90;;A61K8/90;;A61K2800/594;;A61K2800/594;;A61K2800/91;;A61K2800/91;;A61Q19/08;;A61Q19/08;;C01B25/327;;C01B25/327;;C01B25/32;;C01B25/32;;C01P2004/61;;C01P2004/61;;C01P2006/12;;C01P2006/12,A61K8/24;;A61Q19/08;;C01B25/32,,0,0,,,,DISCONTINUED
37,US,B2,US 9561961 B2,109-264-137-173-458,2017-02-07,2017,US 201213588809 A,2012-08-17,US 201213588809 A;;US 201161525391 P,2011-08-19,Injectable fillers for aesthetic medical enhancement and for therapeutic applications,"The present invention relates to a biocompatible injectable filler composition comprising calcium phosphate particles having a porosity of about 10% to about 90%, a BET surface area of about 1 m 2 /g to about 100 m 2 /g, and a mean particle size of about 1 micron to about 30 microns, a thermoreversible hydrophilic gelling agent, a carrier comprising water and an optional persistence enhancer and/or volumizing agent, and methods of its use to restore tissue volume and/or to smooth out tissue defects as in soft tissue or deep tissue augmentation.",CAPISTRON STEPHEN M;;AHN EDWARD S;;PIONEER SURGICAL TECH INC,CAPISTRON STEPHEN M;;AHN EDWARD S,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;PIONEER SURGICAL TECHNOLOGY (2012-11-05);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2013-11-14),https://lens.org/109-264-137-173-458,Granted Patent,yes,18,3,6,6,0,A61K8/0279;;A61K8/0279;;A61K8/042;;A61K8/042;;A61K8/24;;A61K8/24;;A61K8/73;;A61K8/73;;A61K8/90;;A61K8/90;;A61K2800/594;;A61K2800/594;;A61K2800/91;;A61K2800/91;;A61Q19/08;;A61Q19/08;;C01B25/327;;C01B25/327;;C01B25/32;;C01B25/32;;C01P2004/61;;C01P2004/61;;C01P2006/12;;C01P2006/12,C08K3/32;;A61K8/02;;A61K8/04;;A61K8/24;;A61K8/73;;A61K8/90;;A61M5/00;;A61Q19/08;;B44C1/22;;C01B25/32;;C08K5/06;;C08L5/02,,6,3,019-083-970-999-000;;019-669-628-676-984;;057-242-935-944-278,10.1002/jbm.a.10444;;12734812;;10.1002/ar.1115;;11500810;;10.1016/j.actbio.2011.03.019;;21440094,"Li et a., ""Injectable drug-delivery systems based on supramolecular hydrogels formed by poly(ethylene oxide)s and alpha-cyclodextrin"", Journal of Biomedical Materials Research Part A, 65A(2), 2003, pp. 196-202.;;Gutowska et al., ""Injectable Gels for Tissue Engineering,"" The Anatomical Record, 263(4): 342-349 (Jan. 1, 2001).;;Zhou et al., ""Nanoscale hydroxyapatite particles for bone tissue engineering,"" Acta Biomaterialia, 7(7): 2769-2781 (Mar. 16, 2011).;;European Patent Office, International Search Report in International Patent Application No. PCT/US2012/051441 (Mar. 6, 2013).;;International Bureau of WIPO, International Preliminary Report on Patentability in International Patent Application No. PCT/US2012/051441 (Feb. 25, 2014).;;European Patent Office, Examination Report in European Patent Application No. 12754150.6 (Mar. 6, 2015).",ACTIVE
38,EP,A1,EP 4196196 A1,037-113-624-209-528,2023-06-21,2023,EP 21856817 A,2021-08-13,US 202063064975 P;;US 2021/0046001 W,2020-08-13,MOTORIZED INJECTION SYSTEM AND METHODS OF USE,,MEIRAGTX UK II LTD,LAULICHT BRYAN;;CHITNIS GIRISH;;AHN EDWARD,,https://lens.org/037-113-624-209-528,Patent Application,yes,0,0,9,9,0,A61M5/46;;A61M5/20;;A61M5/1456;;A61M2205/50;;A61M2205/332;;A61F9/0017;;A61F9/0026;;A61M5/20;;A61M2205/332;;A61M5/1456;;A61M5/46;;A61F9/0017;;A61M2205/50;;A61F9/0026;;A61F9/0026;;A61F9/0017;;A61M5/20;;A61M5/1456;;A61M2205/332;;A61M2205/50,A61M5/46;;A61F9/007;;A61M5/00;;A61M5/315,,0,0,,,,PENDING
39,WO,A3,WO 2013/028551 A3,189-213-074-458-465,2013-05-02,2013,US 2012/0051441 W,2012-08-17,US 201161525391 P,2011-08-19,INJECTABLE FILLERS FOR AESTHETIC MEDICAL ENHANCEMENT AND FOR THERAPEUTIC APPLICATIONS,"The present invention relates to a biocompatible injectable filler composition comprising calcium phosphate particles having a porosity of about 10% to about 90%, a BET surface area of about 1 m 2 /g to about 100 m 2 /g, and a mean particle size of about 1 micron to about 30 microns, a thermoreversible hydrophilic gelling agent, a carrier comprising water and an optional persistence enhancer and/or volumizing agent, and methods of its use to restore tissue volume and/or to smooth out tissue defects as in soft tissue or deep tissue augmentation.",PIONEER SURIGICAL TECHNOLOGY;;CAPISTRON STEPHEN M;;AHN EDWARD S,CAPISTRON STEPHEN M;;AHN EDWARD S,,https://lens.org/189-213-074-458-465,Search Report,yes,8,0,6,6,0,A61K8/0279;;A61K8/0279;;A61K8/042;;A61K8/042;;A61K8/24;;A61K8/24;;A61K8/73;;A61K8/73;;A61K8/90;;A61K8/90;;A61K2800/594;;A61K2800/594;;A61K2800/91;;A61K2800/91;;A61Q19/08;;A61Q19/08;;C01B25/327;;C01B25/327;;C01B25/32;;C01B25/32;;C01P2004/61;;C01P2004/61;;C01P2006/12;;C01P2006/12,A61Q19/08;;A61K8/04;;A61K8/24;;C01B25/32,,3,2,019-669-628-676-984;;057-242-935-944-278,10.1002/ar.1115;;11500810;;10.1016/j.actbio.2011.03.019;;21440094,"ANNA GUTOWSKA ET AL: ""Injectable gels for tissue engineering"", THE ANATOMICAL RECORD, vol. 263, no. 4, 1 January 2001 (2001-01-01), pages 342 - 349, XP055051708, ISSN: 0003-276X, DOI: 10.1002/ar.1115;;HONGJIAN ZHOU ET AL: ""Nanoscale hydroxyapatite particles for bone tissue engineering"", ACTA BIOMATERIALIA, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 7, 16 March 2011 (2011-03-16), pages 2769 - 2781, XP028095821, ISSN: 1742-7061, [retrieved on 20110324], DOI: 10.1016/J.ACTBIO.2011.03.019;;See also references of EP 2744575A2",PENDING
40,US,A1,US 2013/0060230 A1,026-141-937-443-71X,2013-03-07,2013,US 201213588809 A,2012-08-17,US 201213588809 A;;US 201161525391 P,2011-08-19,INJECTABLE FILLERS FOR AESTHETIC MEDICAL ENHANCEMENT AND FOR THERAPEUTIC APPLICATIONS,"The present invention relates to a biocompatible injectable filler composition comprising calcium phosphate particles having a porosity of about 10% to about 90%, a BET surface area of about 1 m 2 /g to about 100 m 2 /g, and a mean particle size of about 1 micron to about 30 microns, a thermoreversible hydrophilic gelling agent, a carrier comprising water and an optional persistence enhancer and/or volumizing agent, and methods of its use to restore tissue volume and/or to smooth out tissue defects as in soft tissue or deep tissue augmentation.",CAPISTRON STEPHEN M;;AHN EDWARD S;;PIONEER SURGICAL TECHNOLOGY,CAPISTRON STEPHEN M;;AHN EDWARD S,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;PIONEER SURGICAL TECHNOLOGY (2012-11-05);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2013-11-14),https://lens.org/026-141-937-443-71X,Patent Application,yes,4,40,6,6,0,A61K8/0279;;A61K8/0279;;A61K8/042;;A61K8/042;;A61K8/24;;A61K8/24;;A61K8/73;;A61K8/73;;A61K8/90;;A61K8/90;;A61K2800/594;;A61K2800/594;;A61K2800/91;;A61K2800/91;;A61Q19/08;;A61Q19/08;;C01B25/327;;C01B25/327;;C01B25/32;;C01B25/32;;C01P2004/61;;C01P2004/61;;C01P2006/12;;C01P2006/12,C08K3/32;;A61M5/00;;B44C1/22;;C08K5/06;;C08L5/02,604/506;;106/462;;604/500;;216/108,1,1,019-083-970-999-000,10.1002/jbm.a.10444;;12734812,"Li et a., ""Injectable drug-delivery systems based on supramolecular hydrogels formed by poly(ethylene oxide)s and alpha-cyclodextrin"", Journal of Biomedical Materials Research Part A, 65A(2), 2003, pp. 196-202.",ACTIVE
41,CA,A1,CA 3189210 A1,176-906-309-360-340,2022-02-17,2022,CA 3189210 A,2021-08-13,US 202063064975 P;;US 2021/0046001 W,2020-08-13,MOTORIZED INJECTION SYSTEM AND METHODS OF USE,"System and methods for injection into a cavity are provided. In some embodiments, an injection system includes an injection assembly comprising a syringe barrel defining a lumen between proximal and distal ends and a second sealing element moveably disposed within the lumen to dispense an injection agent from an injection chamber defined in the syringe barrel. A puncture element delivers the injection agent into a space in a tissue. The tissue is less permeable to the injection agent than the space. The injection system also includes a support platform to support the injection assembly and anchor it relative to a site of injection, a drive assembly to operate the injection assembly, one or more sensors to monitor one or more forces on the injection assembly, and a controller in communication with the one o more sensors to receive information about the one or more forces on the injection system.",MEIRAGTX UK II LTD,LAULICHT BRYAN;;CHITNIS GIRISH;;AHN EDWARD,,https://lens.org/176-906-309-360-340,Patent Application,no,0,0,9,9,0,A61M5/46;;A61M5/20;;A61M5/1456;;A61M2205/50;;A61M2205/332;;A61F9/0017;;A61F9/0026;;A61M5/20;;A61M2205/332;;A61M5/1456;;A61M5/46;;A61F9/0017;;A61M2205/50;;A61F9/0026;;A61F9/0026;;A61F9/0017;;A61M5/20;;A61M5/1456;;A61M2205/332;;A61M2205/50,A61F9/007;;A61M5/00;;A61M5/315;;A61M5/46,,0,0,,,,PENDING
42,TW,B,TW I336891 B,051-567-803-685-670,2011-02-01,2011,TW 96119166 A,2007-05-29,US 80963606 P;;US 78426807 A,2006-05-30,System and method for performing dynamic trimming,,NVIDIA CORP,MASSON ERIC L;;AHN EDWARD S,,https://lens.org/051-567-803-685-670,Granted Patent,no,0,0,6,8,0,G11C7/1072;;G11C7/1072;;G11C11/4076;;G11C7/222;;G11C7/222;;G11C11/407;;G11C29/023;;G11C29/028;;G11C2029/0409;;G11C2207/2254;;G11C2207/2254;;H03L7/091;;H03L7/091,,,0,0,,,,ACTIVE
43,TW,A,TW 200807441 A,083-809-407-067-846,2008-02-01,2008,TW 96119166 A,2007-05-29,US 80963606 P;;US 78426807 A,2006-05-30,System and method for performing dynamic trimming,"A system and method for performing dynamic trimming. Specifically, the system comprises a clock for generating a reference clock signal. The reference clock signal comprises a first frequency that is a factor of a second frequency of a signal (e.g., data clock signal from DDR memory). A counter may be coupled to the clock and may generate a plurality of clock pulses based on pulses of the reference clock signal. The plurality of clock pulses may be generated at a slower frequency from the first frequency for low power operation. A phase length detector may be coupled to the counter and may comprise a trimmer chain for detecting an average length of at least one of the generated plurality of clock pulses. A transformation module may be coupled to the phase length detector for transforming the average length to a phase delay of the signal.",NVIDIA CORP,MASSON ERIC L;;AHN EDWARD S,,https://lens.org/083-809-407-067-846,Patent of Addition,no,0,1,6,8,0,G11C7/1072;;G11C7/1072;;G11C11/4076;;G11C7/222;;G11C7/222;;G11C11/407;;G11C29/023;;G11C29/028;;G11C2029/0409;;G11C2207/2254;;G11C2207/2254;;H03L7/091;;H03L7/091,G11C8/18,,0,0,,,,ACTIVE
44,SG,A,SG 10201913342U A,083-027-420-138-85X,2020-03-30,2020,SG 10201913342U A,2017-04-26,US 201662328396 P;;US 201662367377 P,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,,ANIKA THERAPEUTICS INC,WHITE COLIN;;AHN EDWARD;;NOEL SEKONI,,https://lens.org/083-027-420-138-85X,Unknown,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,,,0,0,,,,PENDING
45,SG,A,SG 11201809197X A,118-753-000-839-400,2018-11-29,2018,SG 11201809197X A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,,ANIKA THERAPEUTICS INC,WHITE COLIN;;AHN EDWARD;;NOEL SEKONI,,https://lens.org/118-753-000-839-400,Unknown,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,PENDING
46,WO,A1,WO 2022/036256 A1,105-642-555-176-352,2022-02-17,2022,US 2021/0046001 W,2021-08-13,US 202063064975 P,2020-08-13,MOTORIZED INJECTION SYSTEM AND METHODS OF USE,"System and methods for injection into a cavity are provided. In some embodiments, an injection system includes an injection assembly comprising a syringe barrel defining a lumen between proximal and distal ends and a second sealing element moveably disposed within the lumen to dispense an injection agent from an injection chamber defined in the syringe barrel. A puncture element delivers the injection agent into a space in a tissue. The tissue is less permeable to the injection agent than the space. The injection system also includes a support platform to support the injection assembly and anchor it relative to a site of injection, a drive assembly to operate the injection assembly, one or more sensors to monitor one or more forces on the injection assembly, and a controller in communication with the one o more sensors to receive information about the one or more forces on the injection system.",BULLSEYE THERAPEUTICS INC,LAULICHT BRYAN;;CHITNIS GIRISH;;AHN EDWARD,,https://lens.org/105-642-555-176-352,Patent Application,yes,5,0,9,9,0,A61M5/46;;A61M5/20;;A61M5/1456;;A61M2205/50;;A61M2205/332;;A61F9/0017;;A61F9/0026;;A61M5/20;;A61M2205/332;;A61M5/1456;;A61M5/46;;A61F9/0017;;A61M2205/50;;A61F9/0026;;A61F9/0026;;A61F9/0017;;A61M5/20;;A61M5/1456;;A61M2205/332;;A61M2205/50,A61M5/46;;A61F9/007;;A61M5/00;;A61M5/315,,0,0,,,,PENDING
47,WO,A2,WO 2009/029734 A2,112-887-183-012-080,2009-03-05,2009,US 2008/0074700 W,2008-08-28,US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH-) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC;;LIN JUCHUI RAY;;AHN EDWARD S,LIN JUCHUI RAY;;AHN EDWARD S,,https://lens.org/112-887-183-012-080,Patent Application,yes,0,18,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61K6/838;;A61K6/884;;A61L24/04,,0,0,,,,PENDING
48,EP,A1,EP 0020935 A1,134-605-148-889-370,1981-01-07,1981,EP 80102245 A,1980-04-25,US 5348879 A,1979-06-29,A dry method of etching and an apparatus using solid masking materials for etch rate modification.,"A method for etching materials in which a solid (26), located in the vicinity of the substrate (24), is used to provide reactive species (32) for etching the substrate. In contrast with prior art etching techniques, an ion beam (30) is provided which strikes a solid source (26) located in the vicinity of the substrate. Reactive gas species (32) are given off by the solid source when it is hit by the ion beam and these species etch the substrate (24). Etch rates can be enhanced or retarded depending upon the composition of the solid mask (26). The process has particular utility in etching generally active metals such as Ti, Nb, Ta, NiFe, etc. which undergo a large change in etch rate when mixed gases, such as argon plus O2, CF 4 , CO, or CO 2  (singularly or in combination) are used. As an example, solid TEFLON (a trademark of E.I. Du Pont de Nemours) can be used to surround the substrate during etching in order to generate active species, such as C and F, for etching of materials such as Ti, Si, NiFe, etc. Conductors and dielectrics can also be etched by this technique.",IBM,AHN KIE YEUNG;;COX DANIEL EDWARD,,https://lens.org/134-605-148-889-370,Patent Application,yes,3,9,6,6,0,C23F1/12;;H01L21/3065;;H01L21/31116;;H01L21/32136;;H01L21/32137;;C23F1/12;;H01L21/32136;;H01L21/32137;;H01L21/3065;;H01L21/31116,C23F4/00;;C23F1/12;;H01L21/3065;;H01L21/311;;H01L21/3213,,2,0,,,"IBM TECHNICAL DISCLOSURE BULLETIN, Vol. 7, No. 9, February 1965, A. REISMAN et al.: ""A low temperature technique for selective area etching of semiconductor materials"", page 733.;;PHILIPS TECHNICAL REVUE, Vol. 38, No. 7/8, 1978/79, H. KALTER et al.: ""Plasma etching in IC technology"", pages 200-210.",EXPIRED
49,BR,A2,BR 112023002649 A2,114-382-715-161-810,2023-05-02,2023,BR 112023002649 A,2021-08-13,US 2021/0046001 W;;US 202063064975 P,2020-08-13,SISTEMA DE INJEÇÃO MOTORIZADO E MÉTODOS DE USO,"SISTEMA DE INJEÇÃO MOTORIZADO E MÉTODOS DE USO. Sistema e métodos para injeção em uma cavidade são providos. Em algumas modalidades, um sistema de injeção inclui um conjunto de injeção compreendendo um cilindro de seringa definindo um lúmen entre as extremidades proximal e distal e um segundo elemento de vedação disposto de forma móvel dentro do lúmen para dispensar um agente de injeção de uma câmara de injeção definida no cilindro de seringa. Um elemento de punção dispensa o agente de injeção em um espaço em um tecido. O tecido é menos permeável ao agente de injeção do que o espaço. O sistema de injeção também inclui uma plataforma de suporte para suportar o conjunto de injeção e ancorá-lo em relação a um local de injeção, um conjunto de acionamento para operar o conjunto de injeção, um ou mais sensores para monitorar uma ou mais forças no conjunto de injeção e um controlador em comunicação com um ou mais sensores para receber informações sobre uma ou mais forças no sistema de injeção. O controlador é configurado, com base nas informações, para operar o conjunto de acionamento para avançar o elemento de punção através do tecido em direção ao espaço, de modo que o agente de injeção permaneça na câmara de injeção até que o elemento de punção conecte de maneira fluida a câmara de injeção ao espaço.",MEIRAGTX UK II LTD,BRYAN LAULICHT;;GIRISH CHITNIS;;EDWARD AHN,,https://lens.org/114-382-715-161-810,Patent Application,no,0,0,9,9,0,A61M5/46;;A61M5/20;;A61M5/1456;;A61M2205/50;;A61M2205/332;;A61F9/0017;;A61F9/0026;;A61M5/20;;A61M2205/332;;A61M5/1456;;A61M5/46;;A61F9/0017;;A61M2205/50;;A61F9/0026;;A61F9/0026;;A61F9/0017;;A61M5/20;;A61M5/1456;;A61M2205/332;;A61M2205/50,A61M5/46;;A61F9/007;;A61M5/00;;A61M5/315,,0,0,,,,PENDING
50,EP,B1,EP 0020935 B1,149-310-860-278-481,1982-07-28,1982,EP 80102245 A,1980-04-25,US 5348879 A,1979-06-29,A DRY METHOD OF ETCHING AND AN APPARATUS USING SOLID MASKING MATERIALS FOR ETCH RATE MODIFICATION,,INTERNATIONAL BUSINESS MACHINES CORPORATION,"AHN, KIE YEUNG;;COX, DANIEL EDWARD",,https://lens.org/149-310-860-278-481,Granted Patent,yes,0,0,6,6,0,C23F1/12;;H01L21/3065;;H01L21/31116;;H01L21/32136;;H01L21/32137;;C23F1/12;;H01L21/32136;;H01L21/32137;;H01L21/3065;;H01L21/31116,C23F4/00;;C23F1/12;;H01L21/3065;;H01L21/311;;H01L21/3213,,0,0,,,,EXPIRED
51,US,A1,US 2007/0280034 A1,146-510-920-577-895,2007-12-06,2007,US 78426807 A,2007-04-06,US 78426807 A;;US 80963606 P,2006-05-30,System and method for performing low power dynamic trimming,"A system and method for performing dynamic trimming. Specifically, the system comprises a clock for generating a reference clock signal. The reference clock signal comprises a first frequency that is a factor of a second frequency of a signal (e.g., data clock signal from DDR memory). A counter is coupled to the clock and generates a plurality of clock pulses based on pulses of the reference clock signal. The plurality of clock pulses is generated at a slower frequency from the first frequency for low power operation. A phase length detector is coupled to the counter and comprises a trimmer chain for detecting an average length of at least one of the generated plurality of clock pulses. A transformation module is coupled to the phase length detector for transforming the average length to a phase delay of the signal.",MASSON ERIC L;;AHN EDWARD S,MASSON ERIC L;;AHN EDWARD S,NVIDIA CORPORATION (2007-03-29),https://lens.org/146-510-920-577-895,Patent Application,yes,13,4,6,8,0,G11C7/1072;;G11C7/1072;;G11C11/4076;;G11C7/222;;G11C7/222;;G11C11/407;;G11C29/023;;G11C29/028;;G11C2029/0409;;G11C2207/2254;;G11C2207/2254;;H03L7/091;;H03L7/091,G11C8/00,365/233,0,0,,,,ACTIVE
52,WO,A2,WO 2013/028551 A2,196-104-248-092-418,2013-02-28,2013,US 2012/0051441 W,2012-08-17,US 201161525391 P,2011-08-19,INJECTABLE FILLERS FOR AESTHETIC MEDICAL ENHANCEMENT AND FOR THERAPEUTIC APPLICATIONS,"The present invention relates to a biocompatible injectable filler composition comprising calcium phosphate particles having a porosity of about 10% to about 90%, a BET surface area of about 1 m 2 /g to about 100 m 2 /g, and a mean particle size of about 1 micron to about 30 microns, a thermoreversible hydrophilic gelling agent, a carrier comprising water and an optional persistence enhancer and/or volumizing agent, and methods of its use to restore tissue volume and/or to smooth out tissue defects as in soft tissue or deep tissue augmentation.",PIONEER SURIGICAL TECHNOLOGY;;CAPISTRON STEPHEN M;;AHN EDWARD S,CAPISTRON STEPHEN M;;AHN EDWARD S,,https://lens.org/196-104-248-092-418,Patent Application,yes,3,2,6,6,0,A61K8/0279;;A61K8/0279;;A61K8/042;;A61K8/042;;A61K8/24;;A61K8/24;;A61K8/73;;A61K8/73;;A61K8/90;;A61K8/90;;A61K2800/594;;A61K2800/594;;A61K2800/91;;A61K2800/91;;A61Q19/08;;A61Q19/08;;C01B25/327;;C01B25/327;;C01B25/32;;C01B25/32;;C01P2004/61;;C01P2004/61;;C01P2006/12;;C01P2006/12,A61Q19/08,,1,0,,,See also references of EP 2744575A2,PENDING
53,SG,A,SG 10201913379R A,156-398-354-242-673,2020-02-27,2020,SG 10201913379R A,2017-04-26,US 201662328313 P,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,,ANIKA THERAPEUTICS INC,AHN EDWARD;;LIN CHIA-EN;;WHITE COLIN,,https://lens.org/156-398-354-242-673,Unknown,no,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,,,0,0,,,,PENDING
54,ES,T3,ES 2958507 T3,049-870-930-695-177,2024-02-09,2024,ES 17722590 T,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,Procedimientos y composiciones para el tratamiento del hueso degenerado,"La presente divulgación se refiere a métodos y composiciones para el tratamiento del hueso degenerado en un paciente. En algunas realizaciones, los métodos y composiciones divulgados en el presente documento son útiles en el tratamiento, la prevención o el retraso de la progresión de una enfermedad ósea relacionada con la degeneración ósea, como la osteoartritis (""OA""), la artritis reumatoide y la necrosis vascular. (Traducción automática con Google Translate, sin valor legal)",ANIKA THERAPEUTICS INC,AHN EDWARD;;LIN CHIA-EN;;WHITE COLIN,,https://lens.org/049-870-930-695-177,Granted Patent,no,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58;;A61P19/02;;A61P19/08,,0,0,,,,ACTIVE
55,US,S,US D0663833 S,154-420-783-851-309,2012-07-17,2012,US 37894110 F,2010-11-11,US 37894110 F,2010-11-11,Mixing syringe,,AHN EDWARD S;;CAPISTRON STEPHEN;;SCHLOSSBERG BRIAN;;PIONEER SURGICAL TECH INC,AHN EDWARD S;;CAPISTRON STEPHEN;;SCHLOSSBERG BRIAN,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2011-10-18),https://lens.org/154-420-783-851-309,Design Right,no,0,3,1,1,0,,,2402;;D24/114,0,0,,,,ACTIVE
56,SG,A,SG 11201809202X A,056-532-911-068-671,2018-11-29,2018,SG 11201809202X A,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,,ANIKA THERAPEUTICS INC,AHN EDWARD;;LIN CHIA-EN;;WHITE COLIN,,https://lens.org/056-532-911-068-671,Unknown,no,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,PENDING
57,EP,A2,EP 2192886 A2,046-041-435-113-638,2010-06-09,2010,EP 08828365 A,2008-08-28,US 2008/0074700 W;;US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,,PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN,,https://lens.org/046-041-435-113-638,Patent Application,yes,0,0,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61K6/838;;A61K6/884;;A61L24/04,,0,0,,,,ACTIVE
58,CA,A1,CA 3151700 A1,042-061-699-255-659,2021-03-25,2021,CA 3151700 A,2020-09-20,US 201962903406 P;;US 202063052518 P;;US 2020/0051702 W,2019-09-20,INJECTION SYSTEMS AND METHODS OF THEIR USE,"An injection system comprising a syringe barrel; a first sealing element and a second sealing element moveably disposed in the syringe barrel; an injection chamber between them; a puncture element extending from the first sealing element to deliver an injection agent from the injection chamber into a biological space, wherein one or more of the syringe barrel, the first or the second sealing element are configured to prevent proximal movement of the first sealing element past a pre-selected location, while allowing the second sealing element to come in contact with the first sealing element, the system is configured such that, when a force is applied on the second sealing element in a distal direction, in response to a first opposing force, the puncture element advances and in response to a second opposing force, the puncture element remains stationary and the injection agent is conveyed through the puncture element.",MEIRAGTX THERAPEUTICS INC,CHITNIS GIRISH;;KARP JEFF;;AHN EDWARD;;LAULICHT BRYAN,,https://lens.org/042-061-699-255-659,Patent Application,no,0,0,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61M5/46,,0,0,,,,PENDING
59,US,E,US RE039196 E,172-710-312-250-003,2006-07-18,2006,US 4480102 A,2002-01-11,US 4480102 A;;US 86386304 A;;US 74929910 A;;US 201213536924 A;;US 201414196317 A;;US 793098 A;;US 3553597 P,1997-01-16,"Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production","Methods for synthesis of nanocyrstalline apatites are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the recovered product. Particulate apatite compositions having aveage crystal size of less than 150 nm are provided. Products also can have a surface area of at least 40 m 2 /g and can be of high density. Hydroxyapatite material is investigated in particular detail. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",MASSACHUSETTS INST TECHNOLOGY,YING JACKIE Y;;AHN EDWARD S;;NAKAHIRA ATSUSHI,,https://lens.org/172-710-312-250-003,Amended Patent,yes,33,58,6,6,0,A61F2/30767;;A61F2310/00239;;A61F2310/00293;;A61F2310/00796;;A61L27/12;;A61L27/32;;A61L2400/12;;C03C4/0007;;C03C14/00;;C04B35/117;;C04B35/447;;C04B35/46;;C04B35/488;;C04B35/6262;;C04B35/62675;;C04B35/645;;C04B2235/3212;;C04B2235/3217;;C04B2235/3225;;C04B2235/3232;;C04B2235/3244;;C04B2235/3246;;C04B2235/5409;;C04B2235/5445;;C04B2235/5454;;C04B2235/549;;C04B2235/608;;C04B2235/656;;C04B2235/6562;;C04B2235/6567;;C04B2235/668;;C04B2235/785;;C04B2235/80;;C04B2235/96;;C04B2235/9653;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;F16C2240/64;;A61L27/12;;C04B2235/6567;;C04B35/6262;;C04B2235/3217;;C04B35/645;;C04B2235/3212;;A61L2400/12;;C04B2235/608;;C04B2235/6562;;C04B2235/656;;C03C14/00;;A61F2310/00293;;C04B35/488;;C04B2235/5409;;A61F2/30767;;A61L27/32;;C04B2235/668;;C04B2235/96;;C04B2235/3244;;C04B2235/80;;C04B35/447;;C04B35/62675;;C03C4/0007;;C04B2235/3232;;C04B35/117;;A61F2310/00796;;C04B2235/9653;;C04B2235/3246;;C04B2235/3225;;C04B2235/5454;;C04B35/46;;C04B2235/5445;;C04B2235/785;;A61F2310/00239;;C04B2235/549;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;C03C4/0021,A61F2/00;;A61F2/00;;A61F2/30;;A61L27/12;;A61L27/32;;C04B35/00;;C04B35/447,501/1;;623/23.56;;106/35;;424/423;;424/422;;428/689;;428/704,15,8,110-663-797-689-867;;002-289-136-138-168;;030-022-846-308-347;;044-980-089-580-198;;124-291-658-751-089;;027-679-405-535-454;;052-533-823-201-03X;;043-674-907-736-237,10.1111/j.1151-2916.1991.tb07132.x;;10.1142/9789814317351_0001;;10.1007/bf00591468;;10.1016/0167-577x(95)00016-x;;10.1111/j.1151-2916.1989.tb07680.x;;10.1021/nl0055299;;10.1016/s0142-9612(00)00075-2;;10905463;;10.1016/s0142-9612(99)00020-4;;10395391,"R.W. Siegel, ""Recent Progress in Nanophase Materials"", Processing and Properties of Nanocrystalline Materials, C. Survanaravana, J. Singh and E.H. Froes, Eds. The Minerals, Metals and Materials Society, 1996.;;L.L. Hench, ""Bioceramics: From Concept to Clinic"", American Ceramic Society Bulletin, vol. 72, No. 4, pp. 93-98 (Apr. 1993).;;L.L. Hench, ""Bioceramics: From Concept to Clinic"", J. Am. Ceram., Soc. 74[7], pp. 1487-1510 (1991).;;L.L. Hench and J. Wilson, An Introduction to Bioceramics, Chapter 1 ""Introduction"" pp. 1-24, L.L. Hench and J. Wilson, Eds., 1993.;;J.D. deBruin et al., ""Biological Responses to Calcium Phosphate Ceramics"", Bone-Bonding-Reed Healthcare Communications, Ducheyne, Kokubo & Van Blitterswijk, Eds., pp. 57-72, 1992.;;M. Akao et al., ""Dense Polycrystalline beta-Tricalcium Phosphate for Prosthetic Applications,"" J. of Materials Science, 17, pp. 343-346, 1982.;;K. Niihara et al., ""New Nanocomposite Structural Ceramics"", Nanophase and Nanocomposite Materials, S. Komarneni, J.C. Parker, G.J. Thomas, Eds. Mat. Res. Soc. Symp. Proc. vol. 286, pp. 405-412, (1993).;;M. Jarcho, et al., ""Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form"", J. of Materials Science, 11, pp. 2027-2035 (1976), no month.;;M. Akao et al., ""Mechanical Properties of Sintered Hydroxyapatite for Prosthetic Applications"", J. of Materials Science, 16, pp. 809-812 (1981), no month.;;M. Jarcho, et al., ""Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form"", J. of Materials Science, 16, pp. 809-812 (1981).;;Fang et al., ""Fabrication of Transparent Hydroxyapatite Ceramics by Ambient-Pressure Sintering,"" Materials Letters, 1995, 23, 147-151.;;Uematsu et al., ""Transparent Hydroxyapatite Prepared by Hot Isotactic Pressing of Filter Cake,"" J. Am. Ceram. Soc., 1989, 72(8), 1476-1478.;;Ahn, E.S., et al., ""Nanostructure Processing of Hydroxyapatite-based Bioceramics,"" Nano Letters, 1(3), (2001), pp. 149-153.;;Webster, Thomas J., ""Enhanced Functions of Osteoblasts on Nanophas Ceramics,"" Biomaterials 21 (2000) 1803-1810.;;Webster, Thomas J., ""Osteoblast Adhesion on Nonophase Ceramics,"" Biomaterials 20 (1999) 1221-1227.",PENDING
60,US,A,US 6013591 A,061-348-767-867-268,2000-01-11,2000,US 793098 A,1998-01-16,US 793098 A;;US 3553597 P,1997-01-16,"Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production","Methods for synthesis of nanocrystalline apatites are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the recovered product. Particulate apatite compositions having average crystal size of less than 150 nm are provided. Products also can have a surface area of at least 40 m.sup.2 /g and can be of high density. Hydroxyapatite material is investigated in particular detail. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",MASSACHUSETTS INST TECHNOLOGY,YING JACKIE Y;;AHN EDWARD S;;NAKAHIRA ATSUSHI,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1998-08-26),https://lens.org/061-348-767-867-268,Granted Patent,yes,15,432,6,6,0,A61F2/30767;;A61F2310/00239;;A61F2310/00293;;A61F2310/00796;;A61L27/12;;A61L27/32;;A61L2400/12;;C03C4/0007;;C03C14/00;;C04B35/117;;C04B35/447;;C04B35/46;;C04B35/488;;C04B35/6262;;C04B35/62675;;C04B35/645;;C04B2235/3212;;C04B2235/3217;;C04B2235/3225;;C04B2235/3232;;C04B2235/3244;;C04B2235/3246;;C04B2235/5409;;C04B2235/5445;;C04B2235/5454;;C04B2235/549;;C04B2235/608;;C04B2235/656;;C04B2235/6562;;C04B2235/6567;;C04B2235/668;;C04B2235/785;;C04B2235/80;;C04B2235/96;;C04B2235/9653;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;F16C2240/64;;A61L27/12;;C04B2235/6567;;C04B35/6262;;C04B2235/3217;;C04B35/645;;C04B2235/3212;;A61L2400/12;;C04B2235/608;;C04B2235/6562;;C04B2235/656;;C03C14/00;;A61F2310/00293;;C04B35/488;;C04B2235/5409;;A61F2/30767;;A61L27/32;;C04B2235/668;;C04B2235/96;;C04B2235/3244;;C04B2235/80;;C04B35/447;;C04B35/62675;;C03C4/0007;;C04B2235/3232;;C04B35/117;;A61F2310/00796;;C04B2235/9653;;C04B2235/3246;;C04B2235/3225;;C04B2235/5454;;C04B35/46;;C04B2235/5445;;C04B2235/785;;A61F2310/00239;;C04B2235/549;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;C03C4/0021,A61F2/00;;A61F2/30;;A61L27/12;;A61L27/32;;C04B35/447,501/1;;106/35;;423/308;;423/311;;428/689;;428/704;;623/11;;623/12;;427/2.27;;424/423;;424/422,9,3,110-663-797-689-867;;002-289-136-138-168;;030-022-846-308-347,10.1111/j.1151-2916.1991.tb07132.x;;10.1142/9789814317351_0001;;10.1007/bf00591468,"R.W. Siegel, Recent Progress in Nanophase Materials , Processing and Properties of Nanocrystalline Materials, C.Suryanarayana, J.Singh and F.H.Froes, Eds., The Minerals, Metals & Materials Society, 1996, no month.;;L.L. Hench, Bioceramics: From Concept to Clinic , American Ceramic Society Bulletin, vol. 72, No. 4, pp. 93 98 (Apr. 1993).;;L.L. Hench, Bioceramics: From Concept to Clinic , J. Am. Ceram. Soc. 74 7 , pp. 1487 1510 (1991), no month.;;L.L. Hench and J. Wilson, An Introduction to Bioceramics, Chapter 1 Introduction , pp. 124, L.L. Hench and J. Wilson, Eds., 1993. no month.;;J.D. deBruijn et al., Biological Responses to Calcium Phosphate Ceramics , Bone Bonding Reed Healthcare Communications, Ducheyne, Kokubo & Van Blitterswijk, Eds., pp. 57 72, 1992, no month.;;M. Akao, et al., Dense Polycrystalline Tricalcium Phosphate For Prosthetic Applications, J. of Materials Science, 17, pp. 343 346, 1982, no month.;;M. Jarcho, et al., Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form , J. of Materials Science, 11, pp. 2027 2035 (1976), no month.;;M. Akao et al., Mechanical Properties of Sintered Hydroxyapatite for Prosthetic Applications , J. of Materials Science, 16, pp. 809 812 (1981), no month.;;K. Niihara, et al., New Nanocomposite Structural Ceramics , Nanophase and Nanocomposite Materials, S. Komarneni, J.C. Parker, G.J. Thomas, Eds., Mat. Res. Soc. Symp Proc., vol. 286, pp. 405 412 (1993), no month.",EXPIRED
61,EP,B1,EP 2192886 B1,047-307-622-959-227,2017-12-20,2017,EP 08828365 A,2008-08-28,US 2008/0074700 W;;US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,,PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN,,https://lens.org/047-307-622-959-227,Granted Patent,yes,5,0,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/02;;A61K6/083;;A61K6/838;;A61K6/884;;A61L24/04;;A61L24/06,,0,0,,,,ACTIVE
62,KR,A,KR 20220083712 A,061-839-239-159-600,2022-06-20,2022,KR 20227013322 A,2020-09-20,US 201962903406 P;;US 202063052518 P;;US 2020/0051702 W,2019-09-20,주입 시스템 및 사용 방법,"주입 시스템은 주입기 베럴; 상기 주입기 베럴에 이동 가능하게 배치된 제 1 밀봉 요소 및 제 2 밀봉 요소; 그들 사이의 주입 챔버; 주입 챔버로부터 생물학적 공간으로 주입제를 전달하기 위해 제 1 밀봉 요소로부터 연장되는 천자 요소를 포함하고, 상기 주입기 배럴, 제 1 또는 제 2 밀봉 요소 중 하나 이상은 제 1 밀봉 요소의 근위 이동을 방지하도록 구성됨 미리 선택된 위치를 지나고, 제 2 밀봉 요소가 제 1 밀봉 요소와 접촉하게 하는 동안, 시스템은 힘이 원위 방향으로 제 2 밀봉 요소에 가해질 때, 제 1 밀봉 요소에 응답하여 구성된다. 반대 힘이 가해지면 천자 요소가 전진하고 제 2 반대 힘에 응답하여 천자 요소는 정지 상태를 유지하고 주입제는 천자 요소를 통해 전달된다.",MEIRAGTX THERAPEUTICS INC,CHITNIS GIRISH;;KARP JEFF;;AHN EDWARD;;LAULICHT BRYAN,,https://lens.org/061-839-239-159-600,Patent Application,no,0,0,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61M5/46;;A61F9/00;;A61J1/20;;A61M5/315;;A61M5/32;;A61M5/50,,0,0,,,,PENDING
63,MX,A,MX 2022003405 A,122-858-899-719-065,2022-08-22,2022,MX 2022003405 A,2020-09-20,US 201962903406 P;;US 202063052518 P;;US 2020/0051702 W,2019-09-20,INJECTION SYSTEMS AND METHODS OF THEIR USE.,"An injection system comprising a syringe barrel; a first sealing element and a second sealing element moveably disposed in the syringe barrel; an injection chamber between them; a puncture element extending from the first sealing element to deliver an injection agent from the injection chamber into a biological space, wherein one or more of the syringe barrel, the first or the second sealing element are configured to prevent proximal movement of the first sealing element past a pre-selected location, while allowing the second sealing element to come in contact with the first sealing element, the system is configured such that, when a force is applied on the second sealing element in a distal direction, in response to a first opposing force, the puncture element advances and in response to a second opposing force, the puncture element remains stationary and the injection agent is conveyed through the puncture element.",MEIRAGTX THERAPEUTICS INC,AHN EDWARD;;LAULICHT BRYAN;;CHITNIS GIRISH;;KARP JEFF,,https://lens.org/122-858-899-719-065,Patent Application,no,0,0,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61M5/46;;A61F9/007;;A61M5/00;;A61M5/178;;A61M5/315;;A61M5/32,,0,0,,,,PENDING
64,US,A1,US 2022/0379044 A1,001-627-844-730-325,2022-12-01,2022,US 202017761481 A,2020-09-20,US 202017761481 A;;US 202063052518 P;;US 201962903406 P;;US 2020/0051702 W,2019-09-20,Injection Systems and Methods of Their Use,"An injection system comprising a syringe barrel; a first sealing element and a second sealing element moveably disposed in the syringe barrel; an injection chamber between them; a puncture element extending from the first sealing element to deliver an injection agent from the injection chamber into a biological space, wherein one or more of the syringe barrel, the first or the second sealing element are configured to prevent proximal movement of the first sealing element past a pre-selected location, while allowing the second sealing element to come in contact with the first sealing element, the system is configured such that, when a force is applied on the second sealing element in a distal direction, in response to a first opposing force, the puncture element advances and in response to a second opposing force, the puncture element remains stationary and the injection agent is conveyed through the puncture element.",MEIRAGTX THERAPEUTICS INC,CHITNIS GIRISH;;KARP JEFF;;AHN EDWARD;;LAULICHT BRYAN,BULLSEYE THERAPEUTICS INC (2020-12-28);;MEIRAGTX THERAPEUTICS INC (2021-10-04),https://lens.org/001-627-844-730-325,Patent Application,yes,0,0,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61M5/46;;A61F9/00;;A61J1/20;;A61M5/315;;A61M5/32,,0,0,,,,PENDING
65,US,E,US RE041584 E,055-767-162-156-702,2010-08-24,2010,US 86386304 A,2004-06-07,US 86386304 A;;US 793098 A;;US 4480102 A;;US 74929910 A;;US 201414196317 A;;US 201213536924 A;;US 3553597 P,1997-01-16,"Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production","Methods for synthesis of nanocrystalline apatites are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the recovered product. Particulate apatite compositions having average crystal size of less than 150 nm are provided. Products also can have a surface area of at least 40 m 2 /g and can be of high density. Hydroxyapatite material is investigated in particular detail. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",MASSACHUSETTS INST TECHNOLOGY,YING JACKIE Y;;AHN EDWARD S;;NAKAHIRA ATSUSHI,,https://lens.org/055-767-162-156-702,Amended Patent,yes,34,16,6,6,0,A61F2/30767;;A61F2310/00239;;A61F2310/00293;;A61F2310/00796;;A61L27/12;;A61L27/32;;A61L2400/12;;C03C4/0007;;C03C14/00;;C04B35/117;;C04B35/447;;C04B35/46;;C04B35/488;;C04B35/6262;;C04B35/62675;;C04B35/645;;C04B2235/3212;;C04B2235/3217;;C04B2235/3225;;C04B2235/3232;;C04B2235/3244;;C04B2235/3246;;C04B2235/5409;;C04B2235/5445;;C04B2235/5454;;C04B2235/549;;C04B2235/608;;C04B2235/656;;C04B2235/6562;;C04B2235/6567;;C04B2235/668;;C04B2235/785;;C04B2235/80;;C04B2235/96;;C04B2235/9653;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;F16C2240/64;;A61L27/12;;C04B2235/6567;;C04B35/6262;;C04B2235/3217;;C04B35/645;;C04B2235/3212;;A61L2400/12;;C04B2235/608;;C04B2235/6562;;C04B2235/656;;C03C14/00;;A61F2310/00293;;C04B35/488;;C04B2235/5409;;A61F2/30767;;A61L27/32;;C04B2235/668;;C04B2235/96;;C04B2235/3244;;C04B2235/80;;C04B35/447;;C04B35/62675;;C03C4/0007;;C04B2235/3232;;C04B35/117;;A61F2310/00796;;C04B2235/9653;;C04B2235/3246;;C04B2235/3225;;C04B2235/5454;;C04B35/46;;C04B2235/5445;;C04B2235/785;;A61F2310/00239;;C04B2235/549;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;C03C4/0021,C01B15/16;;A61F2/00;;A61F2/30;;A61L27/12;;A61L27/32;;C04B35/01;;C04B35/447,501/1;;106/35;;423/308;;423/311;;424/423;;424/422,29,17,059-423-131-390-076;;043-089-258-531-516;;028-184-224-567-061;;009-950-071-269-434;;017-162-822-047-705;;062-072-155-353-276;;050-615-037-103-623;;002-238-459-220-166;;183-625-779-188-736;;027-679-405-535-454;;030-022-846-308-347;;044-980-089-580-198;;110-663-797-689-867;;002-289-136-138-168;;124-291-658-751-089;;043-674-907-736-237;;052-533-823-201-03X,10.1016/0955-2219(95)00123-9;;10.1002/crat.2170310519;;10.2109/jcersj.99.19;;10.2109/jcersj1950.95.1103_741;;10.2109/jcersj.97.554;;10.2109/jcersj.98.1054;;10.2109/jcersj.99.150;;10.2109/jcersj.99.211;;10.2109/jcersj.100.602;;10.1021/nl0055299;;10.1007/bf00591468;;10.1016/0167-577x(95)00016-x;;10.1111/j.1151-2916.1991.tb07132.x;;10.1142/9789814317351_0001;;10.1111/j.1151-2916.1989.tb07680.x;;10.1016/s0142-9612(99)00020-4;;10395391;;10.1016/s0142-9612(00)00075-2;;10905463,"Toriyama et al, ""Synthesis of Hydroxyapatite-Based Powders by Mechano-Chemical Method and their Sintering"", Journal of the European Ceramic Society, 16, 1996, pp. 429-436.;;Krajewski et al, ""Spectrometric Study of the Thermal Evolution of Mechanochemically Prepared Hydroxyapatite-based Powders"", Cry. Res. Technol., 31(5), pp. 637-646, 1996.;;M. Jarcho, et al., ""Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form"", J. of Materials Science, 11, pp. 2027-2035 (1976), no month.;;M. Akao, et al., ""Mechanical Properties of Sintered Hydroxyapatite for Prosthetic Applications,"" J. of Materials Science, 16, pp. 809-812, (1981), no month.;;Kawamoto et al., ""Coating of beta-Tricalcium Phosphate on Yttria-Partially Stabilized Zirconia Using Magnesium Metaphosphate as an Interlayer"", The Ceramic Society of Japan, 99(1): 19-22 (1991), Abstract.;;Toriyama et al., ""Synthesis of beta-Tricalcium Phosphate by Use of Wet Milling"" The Ceramic Society of Japan, 94(9): 78-82 (1986), Abstract.;;Toriyama et al., ""Bending Strength of Hydroxyapatite Ceramics Containing alpha-Tricalcium Phosphate"" The Ceramic Society of Japan, 95(4): 92-94 (1987), Abstract.;;Toriyama et al., ""Sinterable Powder of Mechanochemically Synthetic beta-Tricalcium Phosphate"" The Ceramic Society of Japan, 95(7): 741-745 (1987), Abstract.;;Toriyama et al., ""Effect of MgO Addition on Bending Strength of Sintered beta-Tricalcium Phosphate Prepare by Mechanochemical Synthesis"" The Ceramic Society of Japan, 95(8): 68-71 (1987), Abstract.;;Toriyama et al., ""Effect of Mixed Addition of A1203 and Si02 on Mechanical Strength of Sintered beta-Tricalcuim Phosphate"" The Ceramic Society of Japan, 96(8): 837-841 (1988), Abstract.;;Toriyama et al., ""Thermal Change of Calcuim Deficient Apatite Obtained by Mechanochemical Treatment"" The Ceramic Society of Japan, 97(5): 554-558 (1989), Abstract.;;Toriyama et al., ""Estimation of Biocompatibility of High Strength beta-Tricalcuim Phosphate Ceramics by a Tissue Culture Method"" The Ceramic Society of Japan, 98(4): 404-407 (1990), Abstract.;;Toriyama et al., ""beta-Tricalcium Phosphate Coating on Alumina Ceramic"" The Ceramic Society of Japan, 98(9): 1054-1057 (1990), Abstract.;;Yokogawa et al., ""Preparation of Trimagnesium Phosphate by Mechanochmical Reaction"" The Ceramic Society of Japan, 99(2): 150-152 (1991), Abstract.;;Yokogawa et al., ""Tricalsium Phosphate Coating on Zirconia by Using Calcium Metaphosphate and Tetracalcium Phosphate"" The Ceramic Society of Japan, 99(3): 211-214 (1991), Abstract.;;Yokogawa et al., ""Apatite Coating on Yttria Doped Partially Stablized Zirconia Plate in the Presence of Water Vapor"" The Ceramic Society of Japan, 100(4): 602-604 (1992), Abstract.;;Ahn, E.S., et al., ""Nanostructure Processing of Hydroxyapatite-based Bioceramics,"" Nano Letters, 1(3), (2001), pp. 149-153.;;Akao, M., et al., ""Dense Polycrystalline beta-Tricalcium Phosphate for Prosthetic Applications,"" J. of Materials Science, 17, pp. 343-346, 1982.;;deBruin, J.D., et al., ""Biological Responses to Calcium Phosphate Ceramics"", Bone-Bonding-Reed Healthcare Communications, Ducheyne, Kokubo & Van Blitterswijk, Eds., pp. 57-72, 1992.;;Fang, et al., ""Fabrication of Transparent Hydroxyapatite Ceramics by Ambient-Pressure Sintering,"" Materials Letters, 1995, 23, 147-151.;;Hench, L.L., ""Bioceramics: From Concept to Clinic"", J. American Ceramic, Society 74 [7], pp. 1487-1510 (1991).;;Hench, L.L., ""Bioceramics: From Concept to Clinic"", J. American Ceramic Society Bulletin, vol. 72, No. 4, pp. 93-98 (Apr. 1993).;;Hench, L.L., and J. Wilson, An Introduction to Bioceramics, Chapter 1 ""Introduction"", pp. 1-24, L.L. Hench and J. Wilson, Eds., 1993.;;Jarcho, M., et al., ""Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form"", J. of Materials Science, 16., pp. 809-812 (1981).;;Niihara K., et al., ""New Nanocomposite Structural Ceramics"", Nanophase and Nanocomposite Materials, S. Komarneni, J.C. Parker, G.J. Thomas, Eds. Mat. Res. Soc. Symp. Proc. vol. 286, pp. 405-412, (1993).;;Siegel, R.W., ""Recent Progress in Nanophase Materials"", Processing and Properties of Nanocrystalline Materials, C. Survanaravana, J. Singh and E.H. Froes, Eds. The Minerals, Metals and Materials Society, 1996.;;Uematsu, et al., ""Transparent Hydroxyapatite Prepared by Hot Isotactic Pressing of Filter Cake,"" J. American Ceramic Society, 1989, 72 (8), 1476-1478.;;Webster, T.J., ""Osteoblast Adhesion on Nonophase Ceramics,"" Biomaterials 20 (1999) 1221-1227.;;Webster, T.J., ""Enhanced Functions of Osteoblasts on Nanophas Ceramics,"" Biomaterials 21 (2000) 1803-1810.",PENDING
66,BR,A2,BR 112022005148 A2,078-864-428-670-100,2023-02-23,2023,BR 112022005148 A,2020-09-20,US 2020/0051702 W;;US 202063052518 P;;US 201962903406 P,2019-09-20,SISTEMAS DE INJEÇÃO E MÉTODOS DE USO DOS MESMOS,"SISTEMAS DE INJEÇÃO E MÉTODOS DE USO DOS MESMOS. Um sistema de injeção compreendendo um cilindro de seringa; um primeiro elemento de vedação e um segundo elemento de vedação disposto de forma móvel no cilindro de seringa; uma câmara de injeção entre eles; um elemento de punção que se estende do primeiro elemento de vedação para fornecer um agente de injeção da câmara de injeção para um espaço biológico, em que um ou mais do cilindro de seringa, o primeiro ou o segundo elemento de vedação são configurados para impedir o movimento proximal do primeiro elemento de vedação após um local pré-selecionado, enquanto permite que o segundo elemento de vedação entre em contato com o primeiro elemento de vedação, o sistema é configurado de modo que, quando uma força é aplicada no segundo elemento de vedação em uma direção distal, em resposta a uma primeira força oposta, o elemento de punção avança e em resposta a uma segunda força oposta, o elemento de punção permanece estacionário e o agente de injeção é transportado através do elemento de punção.",MEIRAGTX THERAPEUTICS INC,GIRISH CHITNIS;;JEFF KARP;;EDWARD AHN;;BRYAN LAULICHT,,https://lens.org/078-864-428-670-100,Patent Application,no,0,0,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61M5/46;;A61F9/007;;A61M5/00;;A61M5/178;;A61M5/315;;A61M5/32,,0,0,,,,PENDING
67,EP,A4,EP 4031214 A4,088-327-294-706-33X,2023-11-08,2023,EP 20866654 A,2020-09-20,US 201962903406 P;;US 202063052518 P;;US 2020/0051702 W,2019-09-20,INJECTION SYSTEMS AND METHODS OF THEIR USE,,MEIRAGTX THERAPEUTICS INC,CHITNIS GIRISH;;KARP JEFF;;AHN EDWARD;;LAULICHT BRYAN,"MEIRAGTX THERAPEUTICS, INC. (2022-08-17)",https://lens.org/088-327-294-706-33X,Search Report,no,4,0,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61F9/00;;A61M5/315;;A61M5/32;;A61M5/46,,0,0,,,,PENDING
68,US,E,US RE046275 E,147-925-082-952-14X,2017-01-17,2017,US 201414196317 A,2014-03-04,US 201414196317 A;;US 793098 A;;US 201213536924 A;;US 74929910 A;;US 86386304 A;;US 4480102 A;;US 3553597 P,1997-01-16,"Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production","Methods for synthesis of nanocrystalline apatites are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the recovered product. Particulate apatite compositions having average crystal size of less than 150 nm are provided. Products also can have a surface area of at least 40 m 2 /g and can be of high density. Hydroxyapatite material is investigated in particular detail. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",MASSACHUSETTS INST TECHNOLOGY,YING JACKIE Y;;AHN EDWARD S;;NAKAHIRA ATSUSHI,,https://lens.org/147-925-082-952-14X,Amended Patent,yes,45,2,6,6,0,A61F2/30767;;A61F2310/00239;;A61F2310/00293;;A61F2310/00796;;A61L27/12;;A61L27/32;;A61L2400/12;;C03C4/0007;;C03C14/00;;C04B35/117;;C04B35/447;;C04B35/46;;C04B35/488;;C04B35/6262;;C04B35/62675;;C04B35/645;;C04B2235/3212;;C04B2235/3217;;C04B2235/3225;;C04B2235/3232;;C04B2235/3244;;C04B2235/3246;;C04B2235/5409;;C04B2235/5445;;C04B2235/5454;;C04B2235/549;;C04B2235/608;;C04B2235/656;;C04B2235/6562;;C04B2235/6567;;C04B2235/668;;C04B2235/785;;C04B2235/80;;C04B2235/96;;C04B2235/9653;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;F16C2240/64;;A61L27/12;;C04B2235/6567;;C04B35/6262;;C04B2235/3217;;C04B35/645;;C04B2235/3212;;A61L2400/12;;C04B2235/608;;C04B2235/6562;;C04B2235/656;;C03C14/00;;A61F2310/00293;;C04B35/488;;C04B2235/5409;;A61F2/30767;;A61L27/32;;C04B2235/668;;C04B2235/96;;C04B2235/3244;;C04B2235/80;;C04B35/447;;C04B35/62675;;C03C4/0007;;C04B2235/3232;;C04B35/117;;A61F2310/00796;;C04B2235/9653;;C04B2235/3246;;C04B2235/3225;;C04B2235/5454;;C04B35/46;;C04B2235/5445;;C04B2235/785;;A61F2310/00239;;C04B2235/549;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;C03C4/0021,A61F2/00;;A61L27/12;;A61F2/30;;A61L27/32;;B82Y30/00;;C01B25/32;;C03C4/00;;C03C14/00;;C04B35/447;;C04B35/46;;C04B35/488;;C04B35/626;;C04B35/645,,30,20,027-679-405-535-454;;030-022-846-308-347;;044-980-089-580-198;;002-289-136-138-168;;110-663-797-689-867;;028-184-224-567-061;;043-089-258-531-516;;076-703-888-880-926;;055-518-492-905-991;;009-950-071-269-434;;017-162-822-047-705;;062-072-155-353-276;;059-423-131-390-076;;124-291-658-751-089;;052-533-823-201-03X;;043-674-907-736-237;;183-625-779-188-736;;002-238-459-220-166;;050-615-037-103-623;;094-544-572-690-939,10.1021/nl0055299;;10.1007/bf00591468;;10.1016/0167-577x(95)00016-x;;10.1142/9789814317351_0001;;10.1111/j.1151-2916.1991.tb07132.x;;10.2109/jcersj.99.19;;10.1002/crat.2170310519;;10.2109/jcersj.96.837;;10.2109/jcersj.98.404;;10.2109/jcersj1950.95.1103_741;;10.2109/jcersj.97.554;;10.2109/jcersj.98.1054;;10.1016/0955-2219(95)00123-9;;10.1111/j.1151-2916.1989.tb07680.x;;10.1016/s0142-9612(00)00075-2;;10905463;;10.1016/s0142-9612(99)00020-4;;10395391;;10.2109/jcersj.100.602;;10.2109/jcersj.99.211;;10.2109/jcersj.99.150;;10.1103/physreve.72.011605;;16089977,"Ahn, E.S., et al., ""Nanostructure Processing of Hydroxyapatite-based Bioceramics,"" Nano Letters, 1(3), (2001), pp. 149-153.;;Akao, M., et al., ""Dense Polycrystalline beta-Tricalcium Phosphate for Prosthetic Applications,"" J. of Materials Science, 17, pp. 343-346, 1982.;;deBruin, J.D., et al., ""Biological Responses to Calcium Phosphate Ceramics"", Bone-Bonding-Reed Healthcare Communications, Ducheyne, Kokubo & Van Blitterswijk, Eds., pp. 57-72, 1992.;;Fang, et al., ""Fabrication of Transparent Hydroxyapatite Ceramics by Ambient-Pressure Sintering,"" Materials Letters, 1995, 23, 147-151.;;Hench, L.L. and J. Wilson, An Introduction to Bioceramics, Chapter 1 ""Introduction"" pp. 1-24, L.L. Hench and J. Wilson, Eds., 1993.;;Hench, L.L., ""Bioceramics: From Concept to Clinic"", J. American Ceramic, Society 74 [7], pp. 1487-1510 (1991).;;Hench, L.L., ""Bioceramics: From Concept to Clinic"", J. American Ceramic Society Bulletin, vol. 72, No. 4, pp. 93-98 (Apr. 1993).;;Jarcho, M., et al., ""Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form"", J. of Materials Science, 16., pp. 809-812 (1981).;;Kawamoto et al., ""Coating of beta-Tricalcium Phosphate on Yttria-Partially Stabilized Zirconia Using Magnesium Metaphosphate as an Interlayer"", The Ceramic Society of Japan, 99(1): 19-22 (1991).;;Krajewski et al., ""Spectrometric Study of the Thermal Evolution of Mechanochemically Prepared Hydroxyapatite-based Powders,"" Cryst. Res. Technol., 31(5): 637-646 (1996).;;Niihara K., et al., ""New Nanocomposite Structural Ceramics"", Nanophase and Nanocomposite Materials, S. Komarneni, J.C. Parker, G.J. Thomas, Eds. Mat. Res. Soc. Symp. Proc. vol. 286, pp. 405-412, (1993).;;Siegel, R.W., ""Recent Progress in Nanophase Materials"", Processing and Properties of Nanocrystalline Materials, C. Survanaravana, J. Singh and E.H. Froes, Eds. The Minerals, Metals and Materials Society, 1996.;;Toriyama et al., ""Bending Strength of Hydroxyapatite Ceramics Containing alpha-Tricalcium Phosphate"" The Ceramic Society of Japan, 95(4): 92-94 (1987).;;Toriyama et al., ""Effect of MgO Addition on Bending Strength of Sintered beta-Tricalcium Phosphate Prepare by Mechanochemical Synthesis"" The Ceramic Society of Japan, 95(8): 68-70 (1987).;;Toriyama et al., ""Effect of Mixed Addition of Al2O3 and SiO2 on Mechanical Strength of Sintered beta-Tricalcium Phosphate"" The Ceramic Society of Japan, 96(8): 837-841 (1988).;;Toriyama et al., ""Estimation of Biocompatibility of High Strength beta-Tricalcium Phosphate Ceramics by a Tissue Culture Method"" The Ceramic Society of Japan, 98(4): 404-407 (1990).;;Toriyama et al., ""Sinterable Powder of Mechanochemically Synthetic beta-Tricalcium Phosphate"" The Ceramic Society of Japan, 95(7): 741-745 (1987).;;Toriyama et al., ""Thernal Change of Calcium Deficient Apatite Obtained by Mechanochemical Treatment"" The Ceramic Society of Japan, 97(5): 554-558 (1989).;;Toriyama et al., ""beta-Tricalcium Phosphate Coating on Alumina Ceramic"" The Ceramic Society of Japan, 98(9): 1054-1057 (1990).;;Toriyama et al., ""Synthesis of Hydroxyapatite-Based Powders by Mechano-Chemical Method and Their Sintering,"" Journal of the European Ceramic Society, 16: 429-436 (1996).;;Uematsu, et al., ""Transparent Hydroxyapatite Prepared by Hot Isotactic Pressing of Filter Cake,"" J. American Ceramic Society, 1989, 72 (8), 1476-1478.;;Webster, T.J., ""Enhanced Functions of Osteoblasts on Nanophas Ceramics,"" Biomaterials 21 (2000) 1803-1810.;;Webster, T.J., ""Osteoblast Adhesion on Nonophase Ceramics,"" Biomaterials 20 (1999) 1221-1227.;;Yokogawa et al., ""Apatite Coating on Yttria Doped Partially Stablized Zirconia Plate in the Presence of Water Vapor"" The Ceramic Society of Japan, 100(4): 602-604 (1992).;;Yokogawa et al., ""Tricalsium Phosphate Coating on Zirconia by Using Calcium Metaphosphate and Tetracalcium Phosphate"" The Ceramic Society of Japan, 99(3): 211-214 (1991).;;Yokogawa et al., ""Preparation of Trimagnesium Phosphate by Mechanochmical Reaction"" The Ceramic Society of Japan, 99(2): 150-152 (1991).;;[No Author Listed] Definition of ""acicular"" from The American Geological Institute. Dictionary of Geological Terms. Published 1984. 3rd Edition: p. 4.;;Gránásy et al., Growth and form spherulites. American Physical Society. Physical Review E. Jul. 19, 2005. 72 (011605):1-15. DOI: 10.1103/PhysRevE.72.011605.;;M. Jarcho, et al., ""Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form"", J. of Materials Science, 11, pp. 2027-2035 (1976), no month.;;M. Akao et al., ""Mechanical Properties of Sintered Hydroxyapatite for Prosthetic Applications"", J. of Materials Science, 16, pp. 809-812 (1981), no month.",PENDING
69,US,E,US RE043661 E,118-424-254-105-653,2012-09-18,2012,US 74929910 A,2010-03-29,US 74929910 A;;US 793098 A;;US 86386304 A;;US 4480102 A;;US 53692412 A;;US 201414196317 A;;US 3553597 P,1997-01-16,"Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production","Methods for synthesis of nanocrystalline apatites are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the recovered product. Particulate apatite compositions having average crystal size of less than 150 nm are provided. Products also can have a surface area of at least 40 m 2 /g and can be of high density. Hydroxy apatite material is investigated in particular detail. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",YING JACKIE Y;;AHN EDWARD S;;NAKAHIRA ATSUSKI;;MASSACHUSETTS INST TECHNOLOGY,YING JACKIE Y;;AHN EDWARD S;;NAKAHIRA ATSUSKI,,https://lens.org/118-424-254-105-653,Amended Patent,yes,39,5,6,6,0,A61F2/30767;;A61F2310/00239;;A61F2310/00293;;A61F2310/00796;;A61L27/12;;A61L27/32;;A61L2400/12;;C03C4/0007;;C03C14/00;;C04B35/117;;C04B35/447;;C04B35/46;;C04B35/488;;C04B35/6262;;C04B35/62675;;C04B35/645;;C04B2235/3212;;C04B2235/3217;;C04B2235/3225;;C04B2235/3232;;C04B2235/3244;;C04B2235/3246;;C04B2235/5409;;C04B2235/5445;;C04B2235/5454;;C04B2235/549;;C04B2235/608;;C04B2235/656;;C04B2235/6562;;C04B2235/6567;;C04B2235/668;;C04B2235/785;;C04B2235/80;;C04B2235/96;;C04B2235/9653;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;F16C2240/64;;A61L27/12;;C04B2235/6567;;C04B35/6262;;C04B2235/3217;;C04B35/645;;C04B2235/3212;;A61L2400/12;;C04B2235/608;;C04B2235/6562;;C04B2235/656;;C03C14/00;;A61F2310/00293;;C04B35/488;;C04B2235/5409;;A61F2/30767;;A61L27/32;;C04B2235/668;;C04B2235/96;;C04B2235/3244;;C04B2235/80;;C04B35/447;;C04B35/62675;;C03C4/0007;;C04B2235/3232;;C04B35/117;;A61F2310/00796;;C04B2235/9653;;C04B2235/3246;;C04B2235/3225;;C04B2235/5454;;C04B35/46;;C04B2235/5445;;C04B2235/785;;A61F2310/00239;;C04B2235/549;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;C03C4/0021,A61F2/28;;A61F2/00;;A61F2/30;;A61L27/12;;A61L27/32;;C01B15/16;;C04B35/01;;C04B35/447,106/35;;501/123;;423/308;;423/309,29,19,075-308-502-291-736;;027-679-405-535-454;;030-022-846-308-347;;044-980-089-580-198;;002-289-136-138-168;;110-663-797-689-867;;028-184-224-567-061;;043-089-258-531-516;;055-518-492-905-991;;009-950-071-269-434;;017-162-822-047-705;;062-072-155-353-276;;059-423-131-390-076;;124-291-658-751-089;;052-533-823-201-03X;;043-674-907-736-237;;183-625-779-188-736;;002-238-459-220-166;;050-615-037-103-623,10.1007/bf00552220;;10.1021/nl0055299;;10.1007/bf00591468;;10.1016/0167-577x(95)00016-x;;10.1142/9789814317351_0001;;10.1111/j.1151-2916.1991.tb07132.x;;10.2109/jcersj.99.19;;10.1002/crat.2170310519;;10.2109/jcersj.98.404;;10.2109/jcersj1950.95.1103_741;;10.2109/jcersj.97.554;;10.2109/jcersj.98.1054;;10.1016/0955-2219(95)00123-9;;10.1111/j.1151-2916.1989.tb07680.x;;10.1016/s0142-9612(00)00075-2;;10905463;;10.1016/s0142-9612(99)00020-4;;10395391;;10.2109/jcersj.100.602;;10.2109/jcersj.99.211;;10.2109/jcersj.99.150,"Jarcho et al. ""Hydroxyapatite Synthesis and Charcterization in Dense Polycrsytalline Form"", J. of Materials Science, 11, pp. 2027-2035, (no month)1976.;;Akao et al. ""Mechanical properties of Sintered Hydroxyapatite for Prosthetic Applications"", J. of Materials Science, 16, pp. 809-812, (no month) 1981.;;Ahn, E.S., et al., ""Nanostructure Processing of Hydroxyapatite-based Bioceramics,"" Nano Letters, 1(3), (2001), pp. 149-153.;;Akao, M., et al., ""Dense Polycrystalline beta-Tricalcium Phosphate for Prosthetic Applications,"" J. of Materials Science, 17, pp. 343-346, 1982.;;deBruin, J.D., et al., ""Biological Responses to Calcium Phosphate Ceramics"", Bone-Bonding-Reed Healthcare Communications, Ducheyne, Kokubo & Van Blitterswijk, Eds., pp. 57-72, 1992.;;Fang, et al., ""Fabrication of Transparent Hydroxyapatite Ceramics by Ambient-Pressure Sintering,"" Materials Letters, 1995, 23, 147-151.;;Hench, L.L. and J. Wilson, An Introduction to Bioceramics, Chapter 1 ""Introduction"" pp. 1-24, L.L. Hench and J. Wilson, Eds., 1993.;;Hench, L.L., ""Bioceramics: From Concept to Clinic"", J. American Ceramic, Society 74 [7], pp. 1487-1510 (1991).;;Hench, L.L., ""Bioceramics: From Concept to Clinic"", J. American Ceramic Society Bulletin, vol. 72, No. 4, pp. 93-98 (Apr. 1993).;;Jarcho, M., et al., ""Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form"", J. of Materials Science, 16., pp. 809-812 (1981).;;Kawamoto et al., ""Coating of beta-Tricalcium Phosphate on Yttria-Partially Stabilized Zirconia Using Magnesium Metaphosphate as an Interlayer"", The Ceramic Society of Japan, 99(1): 19-22 (1991), Abstract.;;Krajewski et al., ""Spectrometric Study of the Thermal Evolution of Mechanochemically Prepared Hydroxyapatite-based Powders,"" Cryst. Res. Technol., 31(5): 637-646 (1996).;;Niihara K., et al., ""New Nanocomposite Structural Ceramics"", Nanophase and Nanocomposite Materials, S. Komarneni, J.C. Parker, G.J. Thomas, Eds. Mat. Res. Soc. Symp. Proc. vol. 286, pp. 405-412, (1993).;;Siegel, R.W., ""Recent Progress in Nanophase Materials"", Processing and Properties of Nanocrystalline Materials, C. Survanaravana, J. Singh and E.H. Froes, Eds. The Minerals, Metals and Materials Society, 1996.;;Toriyama et al., ""Bending Strength of Hydroxyapatite Ceramics Containing alpha-Tricalcium Phosphate"" The Ceramic Society of Japan, 95(4): 92-94 (1987), Abstract.;;Toriyama et al., ""Effect of MgO Addition on Bending Strength of Sintered beta-Tricalcium Phosphate Prepare by Mechanochemical Synthesis"" The Ceramic Society of Japan, 95(8): 68-70 (1987), Abstract.;;Toriyama et al., ""Effect of Mixed Addition of Al203 and Si02 on Mechanical Strength of Sintered beta-Tricalcium Phosphate"" The Ceramic Society of Japan, 96(8): 837-841 (1988), Abstract.;;Toriyama et al., ""Estimation of Biocompatibility of High Strength beta-Tricalcium Phosphate Ceramics by a Tissue Culture Method"" The Ceramic Society of Japan, 98(4): 404-407 (1990), Abstract.;;Toriyama et al., ""Sinterable Powder of Mechanochemically Synthetic beta-Tricalcium Phosphate"" The Ceramic Society of Japan, 95(7): 741-745 (1987), Abstract.;;Toriyama et al., ""Thernal Change of Calcium Deficient Apatite Obtained by Mechanochemical Treatment"" The Ceramic Society of Japan, 97(5): 554-558 (1989), Abstract.;;Toriyama et al., ""beta-Tricalcium Phosphate Coating on Alumina Ceramic"" The Ceramic Society of Japan, 98(9): 1054-1057 (1990), Abstract.;;Toriyama et al., ""Synthesis of Hydroxyapatite-Based Powders by Mechano-Chemical Method and Their Sintering,"" Journal of the European Ceramic Society, 16: 429-436 (1996).;;Uematsu, et al., ""Transparent Hydroxyapatite Prepared by Hot Isotactic Pressing of Filter Cake,"" J. American Ceramic Society, 1989, 72 (8), 1476-1478.;;Webster, T.J., ""Enhanced Functions of Osteoblasts on Nanophas Ceramics,"" Biomaterials 21 (2000) 1803-1810.;;Webster, T.J., ""Osteoblast Adhesion on Nonophase Ceramics,"" Biomaterials 20 (1999) 1221-1227.;;Yokogawa et al., ""Apatite Coating on Yttria Doped Partially Stablized Zirconia Plate in the Presence of Water Vapor"" The Ceramic Society of Japan, 100(4): 602-604 (1992), Abstract.;;Yokogawa et al., ""Tricalsium Phosphate Coating on Zirconia by Using Calcium Metaphosphate and Tetracalcium Phosphate"" The Ceramic Society of Japan, 99(3): 211-214 (1991), Abstract.;;Yokogawa et al., ""Preparation of Trimagnesium Phosphate by Mechanochmical Reaction"" The Ceramic Society of Japan, 99(2): 150-152 (1991), Abstract.;;R.W. Siegel, ""Recent Progress in Nanophase Materials"", Processing and Properties of Nanocrystalline Materials, C.Suryanarayana, J.Singh and F.H.Froes, Eds., The Minerals, Metals & Materials Society, 1996, no month.",PENDING
70,AU,A1,AU 2020/349562 A1,022-088-279-872-188,2022-05-12,2022,AU 2020/349562 A,2020-09-20,US 201962903406 P;;US 202063052518 P;;US 2020/0051702 W,2019-09-20,Injection systems and methods of their use,"An injection system comprising a syringe barrel; a first sealing element and a second sealing element moveably disposed in the syringe barrel; an injection chamber between them; a puncture element extending from the first sealing element to deliver an injection agent from the injection chamber into a biological space, wherein one or more of the syringe barrel, the first or the second sealing element are configured to prevent proximal movement of the first sealing element past a pre-selected location, while allowing the second sealing element to come in contact with the first sealing element, the system is configured such that, when a force is applied on the second sealing element in a distal direction, in response to a first opposing force, the puncture element advances and in response to a second opposing force, the puncture element remains stationary and the injection agent is conveyed through the puncture element.",MEIRAGTX THERAPEUTICS INC,CHITNIS GIRISH;;KARP JEFF;;AHN EDWARD;;LAULICHT BRYAN,"MEIRAGTX THERAPEUTICS, INC. (2023-05-18)",https://lens.org/022-088-279-872-188,Patent Application,no,0,0,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61M5/46;;A61F9/007;;A61M5/00;;A61M5/178;;A61M5/315;;A61M5/32,,0,0,,,,PENDING
71,EP,A1,EP 4031214 A1,065-090-076-077-021,2022-07-27,2022,EP 20866654 A,2020-09-20,US 201962903406 P;;US 202063052518 P;;US 2020/0051702 W,2019-09-20,INJECTION SYSTEMS AND METHODS OF THEIR USE,,BULLSEYE THERAPEUTICS INC,CHITNIS GIRISH;;KARP JEFF;;AHN EDWARD;;LAULICHT BRYAN,"MEIRAGTX THERAPEUTICS, INC. (2022-08-17)",https://lens.org/065-090-076-077-021,Patent Application,yes,0,0,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61M5/46;;A61F9/007;;A61M5/00;;A61M5/178;;A61M5/315;;A61M5/32,,0,0,,,,PENDING
72,AT,T1,AT E486560 T1,102-504-402-643-947,2010-11-15,2010,AT 06800903 T,2006-08-08,US 70647305 P;;US 2006/0030764 W,2005-08-08,ZEMENTPRODUKTE SOWIE VERFAHREN ZU DEREN HERSTELLUNG UND VERWENDUNG,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA INC,LIN JUCHUI;;AHN EDWARD;;YUAN HANSEN;;MRAZ PAUL,,https://lens.org/102-504-402-643-947,Granted Patent,no,0,0,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K6/884;;A61K6/891,,0,0,,,,INACTIVE
73,WO,A1,WO 2021/055906 A1,112-527-038-935-461,2021-03-25,2021,US 2020/0051702 W,2020-09-20,US 201962903406 P;;US 202063052518 P,2019-09-20,INJECTION SYSTEMS AND METHODS OF THEIR USE,"An injection system comprising a syringe barrel; a first sealing element and a second sealing element moveably disposed in the syringe barrel; an injection chamber between them; a puncture element extending from the first sealing element to deliver an injection agent from the injection chamber into a biological space, wherein one or more of the syringe barrel, the first or the second sealing element are configured to prevent proximal movement of the first sealing element past a pre-selected location, while allowing the second sealing element to come in contact with the first sealing element, the system is configured such that, when a force is applied on the second sealing element in a distal direction, in response to a first opposing force, the puncture element advances and in response to a second opposing force, the puncture element remains stationary and the injection agent is conveyed through the puncture element.",BULLSEYE THERAPEUTICS INC,CHITNIS GIRISH;;KARP JEFF;;AHN EDWARD;;LAULICHT BRYAN,,https://lens.org/112-527-038-935-461,Patent Application,yes,10,3,12,12,0,A61M5/46;;A61M2210/0612;;A61J1/2096;;A61M5/329;;A61M2005/323;;A61M5/31505;;A61M2005/31516;;A61M2005/5026;;A61M2005/5033;;A61F9/0017;;A61F9/0008;;A61M2210/0612;;A61M5/329;;A61M2005/323;;A61M2005/31516;;A61M2005/5033;;A61M2005/5026;;A61M5/46;;A61M5/31505;;A61J1/2096;;A61M5/46;;A61M5/31505;;A61M5/31511;;A61M5/3221;;A61M5/502;;A61M5/329;;A61J1/2096;;A61F9/0008;;A61M2005/31516;;A61M2005/323;;A61M2005/5026;;A61M2005/5033;;A61M2210/0612;;A61F9/0008;;A61J1/2096;;A61M5/31505;;A61M5/3221;;A61M5/46;;A61M2210/0612,A61F9/007;;A61M5/46;;A61M5/00;;A61M5/178;;A61M5/315;;A61M5/32,,0,0,,,,PENDING
74,US,E,US RE044820 E,090-335-446-566-666,2014-04-01,2014,US 201213536924 A,2012-06-28,US 201213536924 A;;US 793098 A;;US 74929910 A;;US 86386304 A;;US 4480102 A;;US 3553597 P,1997-01-16,"Nanocrystalline apatites and composites, prostheses incorporating them, and methods of their production","Methods for synthesis of nanocrystalline apatites are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the recovered product. Particulate apatite compositions having average crystal size of less than 150 nm are provided. Products also can have a surface area of at least 40 m 2 /g and can be of high density. Hydroxyapatite material is investigated in particular detail. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.",YING JACKIE Y;;AHN EDWARD S;;NAKAHIRA ATSUSKI;;MASSACHUSETTS INST TECHNOLOGY,YING JACKIE Y;;AHN EDWARD S;;NAKAHIRA ATSUSKI,,https://lens.org/090-335-446-566-666,Amended Patent,yes,42,6,6,6,0,A61F2/30767;;A61F2310/00239;;A61F2310/00293;;A61F2310/00796;;A61L27/12;;A61L27/32;;A61L2400/12;;C03C4/0007;;C03C14/00;;C04B35/117;;C04B35/447;;C04B35/46;;C04B35/488;;C04B35/6262;;C04B35/62675;;C04B35/645;;C04B2235/3212;;C04B2235/3217;;C04B2235/3225;;C04B2235/3232;;C04B2235/3244;;C04B2235/3246;;C04B2235/5409;;C04B2235/5445;;C04B2235/5454;;C04B2235/549;;C04B2235/608;;C04B2235/656;;C04B2235/6562;;C04B2235/6567;;C04B2235/668;;C04B2235/785;;C04B2235/80;;C04B2235/96;;C04B2235/9653;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;F16C2240/64;;A61L27/12;;C04B2235/6567;;C04B35/6262;;C04B2235/3217;;C04B35/645;;C04B2235/3212;;A61L2400/12;;C04B2235/608;;C04B2235/6562;;C04B2235/656;;C03C14/00;;A61F2310/00293;;C04B35/488;;C04B2235/5409;;A61F2/30767;;A61L27/32;;C04B2235/668;;C04B2235/96;;C04B2235/3244;;C04B2235/80;;C04B35/447;;C04B35/62675;;C03C4/0007;;C04B2235/3232;;C04B35/117;;A61F2310/00796;;C04B2235/9653;;C04B2235/3246;;C04B2235/3225;;C04B2235/5454;;C04B35/46;;C04B2235/5445;;C04B2235/785;;A61F2310/00239;;C04B2235/549;;Y10S977/776;;C01B25/32;;B82Y30/00;;C04B2235/77;;C03C4/0021,A61F2/28;;A61F2/00;;A61F2/30;;A61L27/12;;A61L27/32;;C01B15/16;;C04B35/447,106/35;;424/423;;424/422,27,19,027-679-405-535-454;;030-022-846-308-347;;044-980-089-580-198;;002-289-136-138-168;;110-663-797-689-867;;028-184-224-567-061;;043-089-258-531-516;;076-703-888-880-926;;055-518-492-905-991;;009-950-071-269-434;;017-162-822-047-705;;062-072-155-353-276;;059-423-131-390-076;;124-291-658-751-089;;052-533-823-201-03X;;043-674-907-736-237;;183-625-779-188-736;;002-238-459-220-166;;050-615-037-103-623,10.1021/nl0055299;;10.1007/bf00591468;;10.1016/0167-577x(95)00016-x;;10.1142/9789814317351_0001;;10.1111/j.1151-2916.1991.tb07132.x;;10.2109/jcersj.99.19;;10.1002/crat.2170310519;;10.2109/jcersj.96.837;;10.2109/jcersj.98.404;;10.2109/jcersj1950.95.1103_741;;10.2109/jcersj.97.554;;10.2109/jcersj.98.1054;;10.1016/0955-2219(95)00123-9;;10.1111/j.1151-2916.1989.tb07680.x;;10.1016/s0142-9612(00)00075-2;;10905463;;10.1016/s0142-9612(99)00020-4;;10395391;;10.2109/jcersj.100.602;;10.2109/jcersj.99.211;;10.2109/jcersj.99.150,"Ahn, E.S., et al., ""Nanostructure Processing of Hydroxyapatite-based Bioceramics,"" Nano Letters, 1(3), (2001), pp. 149-153.;;Akao, M., et al., ""Dense Polycrystalline beta-Tricalcium Phosphate for Prosthetic Applications,"" J. of Materials Science, 17, pp. 343-346, 1982.;;deBruin, J.D., et al., ""Biological Responses to Calcium Phosphate Ceramics"", Bone-Bonding-Reed Healthcare Communications, Ducheyne, Kokubo & Van Blitterswijk, Eds., pp. 57-72, 1992.;;Fang, et al., ""Fabrication of Transparent Hydroxyapatite Ceramics by Ambient-Pressure Sintering,"" Materials Letters, 1995, 23, 147-151.;;Hench, L.L. and J. Wilson, An Introduction to Bioceramics, Chapter 1 ""Introduction"" pp. 1-24, L.L. Hench and J. Wilson, Eds., 1993.;;Hench, L.L., ""Bioceramics: From Concept to Clinic"", J. American Ceramic, Society 74 [7], pp. 1487-1510 (1991).;;Hench, L.L., ""Bioceramics: From Concept to Clinic"", J. American Ceramic Society Bulletin, vol. 72, No. 4, pp. 93-98 (Apr. 1993).;;Jarcho, M., et al., ""Hydroxylapatite Synthesis and Characterization in Dense Polycrystalline Form"", J. of Materials Science, 16., pp. 809-812 (1981).;;Kawamoto et al., ""Coating of beta-Tricalcium Phosphate on Yttria-Partially Stabilized Zirconia Using Magnesium Metaphosphate as an Interlayer"", The Ceramic Society of Japan, 99(1): 19-22 (1991), Abstract.;;Krajewski et al., ""Spectrometric Study of the Thermal Evolution of Mechanochemically Prepared Hydroxyapatite-based Powders,"" Cryst. Res. Technol., 31(5): 637-646 (1996).;;Niihara K., et al., ""New Nanocomposite Structural Ceramics"", Nanophase and Nanocomposite Materials, S. Komarneni, J.C. Parker, G.J. Thomas, Eds. Mat. Res. Soc. Symp. Proc. vol. 286, pp. 405-412, (1993).;;Siegel, R.W., ""Recent Progress in Nanophase Materials"", Processing and Properties of Nanocrystalline Materials, C. Survanaravana, J. Singh and E.H. Froes, Eds. The Minerals, Metals and Materials Society, 1996.;;Toriyama et al., ""Bending Strength of Hydroxyapatite Ceramics Containing alpha-Tricalcium Phosphate"" The Ceramic Society of Japan, 95(4): 92-94 (1987), Abstract.;;Toriyama et al., ""Effect of MgO Addition on Bending Strength of Sintered beta-Tricalcium Phosphate Prepare by Mechanochemical Synthesis"" The Ceramic Society of Japan, 95(8): 68-70 (1987), Abstract.;;Toriyama et al., ""Effect of Mixed Addition of Al2O3 and SiO2 on Mechanical Strength of Sintered beta-Tricalcium Phosphate"" The Ceramic Society of Japan, 96(8): 837-841 (1988), Abstract.;;Toriyama et al., ""Estimation of Biocompatibility of High Strength beta-Tricalcium Phosphate Ceramics by a Tissue Culture Method"" The Ceramic Society of Japan, 98(4): 404-407 (1990), Abstract.;;Toriyama et al., ""Sinterable Powder of Mechanochemically Synthetic beta-Tricalcium Phosphate"" The Ceramic Society of Japan, 95(7): 741-745 (1987), Abstract.;;Toriyama et al., ""Thernal Change of Calcium Deficient Apatite Obtained by Mechanochemical Treatment"" The Ceramic Society of Japan, 97(5): 554-558 (1989), Abstract.;;Toriyama et al., ""beta-Tricalcium Phosphate Coating on Alumina Ceramic"" The Ceramic Society of Japan, 98(9): 1054-1057 (1990), Abstract.;;Toriyama et al., ""Synthesis of Hydroxyapatite-Based Powders by Mechano-Chemical Method and Their Sintering,"" Journal of the European Ceramic Society, 16: 429-436 (1996).;;Uematsu, et al., ""Transparent Hydroxyapatite Prepared by Hot Isotactic Pressing of Filter Cake,"" J. American Ceramic Society, 1989, 72 (8), 1476-1478.;;Webster, T.J., ""Enhanced Functions of Osteoblasts on Nanophas Ceramics,"" Biomaterials 21 (2000) 1803-1810.;;Webster, T.J., ""Osteoblast Adhesion on Nonophase Ceramics,"" Biomaterials 20 (1999) 1221-1227.;;Yokogawa et al., ""Apatite Coating on Yttria Doped Partially Stablized Zirconia Plate in the Presence of Water Vapor"" The Ceramic Society of Japan, 100(4): 602-604 (1992), Abstract.;;Yokogawa et al., ""Tricalsium Phosphate Coating on Zirconia by Using Calcium Metaphosphate and Tetracalcium Phosphate"" The Ceramic Society of Japan, 99(3): 211-214 (1991), Abstract.;;Yokogawa et al., ""Preparation of Trimagnesium Phosphate by Mechanochmical Reaction"" The Ceramic Society of Japan, 99(2): 150-152 (1991), Abstract.;;M. Akao et al., ""Mechanical Properties of Sintered Hydroxyapatite for Prosthetic Applications"", J. of Materials Science, 16, pp. 809-812 (1981), no month.",PENDING
75,ZA,B,ZA 201807136 B,038-494-894-059-644,2021-05-26,2021,ZA 201807136 A,2018-10-25,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/038-494-894-059-644,Granted Patent,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,,,0,0,,,,ACTIVE
76,EP,A3,EP 4223328 A3,111-612-409-075-924,2023-10-04,2023,EP 23164800 A,2017-04-26,US 201662328313 P;;EP 17722590 A;;US 2017/0029651 W,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and avascular necrosis.",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/111-612-409-075-924,Search Report,yes,3,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,1,1,050-805-324-699-893,10.1179/1743676111y.0000000019,"S AHMADZADEH-ASL ET AL: ""Preparation and characterisation of calcium phosphate-hyaluronic acid nanocomposite bone cement"", ADVANCES IN APPLIED CERAMICS: STRUCTURAL, FUNCTIONAL ANDBIOCERAMICS, vol. 110, no. 6, 1 August 2011 (2011-08-01), GB, pages 340 - 345, XP055393882, ISSN: 1743-6753, DOI: 10.1179/1743676111Y.0000000019",PENDING
77,WO,A1,WO 2017/189723 A1,074-621-744-195-16X,2017-11-02,2017,US 2017/0029635 W,2017-04-26,US 201662328396 P;;US 201662367377 P,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC;;WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/074-621-744-195-16X,Patent Application,yes,34,1,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,3,2,028-229-697-241-092;;017-401-471-856-820,20205851;;pmc2825499;;10.1186/1758-2555-2-4;;25253243;;10.1007/s00776-014-0650-z,"PETRELLA ROBERT J ET AL: ""Management of Tennis Elbow with sodium hyaluronate periarticular injections"", SPORTS MEDICINE, ARTHROSCOPY, REHABILITATION, THERAPY & TECHNOLOGY, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. 1, 2 February 2010 (2010-02-02), pages 4, XP021070550, ISSN: 1758-2555;;YOSHIDA MAMORU ET AL: ""Therapeutic effects of high molecular weight hyaluronan injections for tendinopathy in a rat model"", JOURNAL OF ORTHOPAEDIC SCIENCE, SPRINGER VERLAG. TOKYO, JP, vol. 20, no. 1, 25 September 2014 (2014-09-25), pages 186 - 195, XP035431765, ISSN: 0949-2658, [retrieved on 20140925], DOI: 10.1007/S00776-014-0650-Z;;""Remington's Pharmaceutical Sciences"", 1995, MACK PUBLISHING COMPANY",PENDING
78,US,B2,US 8815973 B2,147-507-113-351-100,2014-08-26,2014,US 20091808 A,2008-08-28,US 20091808 A;;US 96846207 P,2007-08-28,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M;;PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY INC (2010-10-29),https://lens.org/147-507-113-351-100,Granted Patent,yes,61,10,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/04;;A61F2/28;;A61K6/838;;A61K6/884,523/116;;523/113;;623/23.61;;623/23.62;;424/423,26,18,038-399-707-220-522;;058-009-416-650-791;;081-991-165-119-818;;142-308-826-149-38X;;174-928-735-004-634;;065-082-320-859-616;;044-329-228-978-129;;024-150-338-971-192;;116-522-166-790-802;;069-164-232-245-440;;038-941-767-748-705;;017-281-044-576-345;;036-529-121-020-291;;007-154-985-080-232;;021-926-143-771-429;;008-779-797-892-977;;002-974-894-406-198;;015-989-772-543-489,12866105;;10.1002/anie.200351244;;15520369;;10.1073/pnas.0407218101;;pmc528737;;10.1016/j.biomaterials.2006.09.028;;17034844;;10458268;;10.1016/s8756-3282(99)00127-1;;10.1016/s1381-5148(98)00054-6;;10.1002/1097-4628(20000919)77:12<2711::aid-app190>3.0.co;2-t;;10.1016/j.biomaterials.2005.10.023;;16313954;;10.1016/s0142-9612(02)00370-8;;12485798;;17079046;;10.1016/j.jconrel.2006.09.009;;10.1021/bc060200l;;17226966;;10.1016/s0142-9612(96)00082-8;;9003891;;14963178;;10.1097/01.rvi.0000109394.74740.56;;pmc7976525;;15313726;;10.1023/a:1003822131632;;10.1016/j.biomaterials.2007.01.037;;17367850;;16081184;;10.1016/j.jconrel.2005.06.022;;10.2136/sssaj2005.0158;;10.1007/978-1-4020-4728-2_4,"3M ESPE, ""Z100(TM) MP Brochure,"" (1-5) Retrieved from the internet on Jul. 28, 2005 from www.matweb.com/search/SpecifiedMaterialPrint.asp?bassnum= PMMM02.;;""Standard Specification for Acrylic Bone Cement,"" Annual Book of ASTM Standards; Medical Devices, F 451-99a: 56-62 (1999).;;Anderson et al., Angew. Chem. Int. Ed., 42: 3153-3158 (2003).;;Anderson et al., Proceedings of the National Academy of Sciences of the United States of America, 101(45):16028-16033 (Nov. 1, 2004).;;Arote et al., Biomaterials, 28: 735-744 (2007).;;Brown, ""Solubilities of Phosphates and Other Sparingly Soluble Compounds,"" Environmental Phosphorus Handbook, (Griffith et al., eds.), 203-239 (John Wiley & Sons, New York, NY, 1973).;;Burton et al Huntsman Corporation Brochure, 1-105 (Apr. 27, 2005).;;Deramond et al., Bone, 25(2 Supplemental): 17S-21S (Aug. 1999).;;Jagur-Grodzinski et al., Reactive & Functional Polymers, 39: 99-138 (1999).;;Jean et al., J. Applied Polymer Science, 77: 2711-2717 (2000).;;Kim et al. Biomaterials, 27: 2292-2301 (2006).;;Kincaid, ""Epoxy Polyacrylate Hybrids . . . A Continuing Study,"" Resolution Performance Products LLC tech paper, 1-15 (Nov. 2001).;;Kweon et al., Biomaterials, 24: 801-808 (2003).;;Lin et al., Journal of Controlled Release, 116 (2): 130-137 (Nov. 28, 2006).;;Lin et al., Bioconjugate Chemistry, 18 (1): 138-145 (Jan./Feb. 2007).;;Liso et al., Biomaterials, 18(1): 15-20 (1997).;;Liu et al., Chemistry Communication, (20): 2630-26301 (Oct. 21, 2003).;;Nussbaum et al., J. Vasc. Interv. Radiol. 15(2): 121-126 (Feb. 2004).;;Pressly, ""Complications Related to the Use of Bone Cement and Bone Void Fillers in Treating Compression Fractures of the Spine"", FDA Public Health Web Notification, 1-3 (May 7, 2004).;;Provenzano et al., American Journal of Neuroradiology, 25(7): 1286-1290 (Aug. 2004).;;Serbetci et al. Turk. J. Med. Sci., 30: 543-549 (2000).;;Srinivasachari et al., Biomaterials, 28: 2885-2898 (2007).;;Zhong et al., Journal of Controlled Release, 109 (1-3): 317-329 (Dec. 5, 2005).;;International Search Report with respect to PCT/US2008/074700 (Jun. 8, 2011).;;Farenhorst, ""Importance of Soil Organic Matter Fractions in Soil-Landscape and Regional Assessments of Pesticide Sorption and Leaching in Soil,"" Soil Sci. Soc. Am. J. 70: 1005-1012 (May-Jun. 2006).;;Loffredo et al., ""The Role of Humic Substances in the Fate of Anthropogenic Organic Pollutants in Soil with Emphasis on Endocrine Disruptor Compounds,"" Soil and Water Pollution Monitoring, Protection and Remediation, 3(23): 69-92 (2006).",INACTIVE
79,US,A1,US 2019/0358362 A1,026-362-156-879-560,2019-11-28,2019,US 201916532799 A,2019-08-06,US 201916532799 A;;US 201815982686 A;;US 201715670284 A;;US 201615149986 A;;US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-07-16),https://lens.org/026-362-156-879-560,Patent Application,yes,0,0,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/06;;A61K6/083;;A61K6/838;;A61K6/884;;A61L24/02;;A61L24/04,,0,0,,,,ACTIVE
80,US,A1,US 2014/0357754 A1,070-112-291-587-986,2014-12-04,2014,US 201414461138 A,2014-08-15,US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-07-16),https://lens.org/070-112-291-587-986,Patent Application,yes,2,5,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/04;;A61K6/838;;A61K6/884;;A61L24/02,523/116;;528/341,0,0,,,,ACTIVE
81,KR,A,KR 20190010565 A,050-181-732-064-085,2019-01-30,2019,KR 20187033902 A,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,퇴행한 골의 치료를 위한 방법 및 조성물,"본 개시내용은 환자에서의 퇴행한 골의 치료를 위한 방법 및 조성물에 관한 것이다. 일부 실시양태에서, 본원에 개시된 방법 및 조성물은 골 퇴행과 연관된 골 질환, 예를 들면, 골관절염(""OA""), 류마티스 관절염, 및 무혈관 괴사의 치료, 예방, 또는 진행의 지연에 유용하다.",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA EN;;WHITE COLIN D,,https://lens.org/050-181-732-064-085,Patent Application,no,5,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61B17/00;;A61B17/34;;A61B17/88;;A61L24/00;;A61L27/12;;A61L27/20;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,ACTIVE
82,AU,A1,AU 2017/257966 A1,056-649-909-362-555,2018-11-15,2018,AU 2017/257966 A,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,Methods and compositions for the treatment of degenerate bone,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and a vascular necrosis",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/056-649-909-362-555,Patent Application,no,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,DISCONTINUED
83,CA,A1,CA 3021765 A1,151-818-140-271-731,2017-11-02,2017,CA 3021765 A,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and a vascular necrosis",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/151-818-140-271-731,Patent Application,no,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,PENDING
84,US,A1,US 2018/0264165 A1,040-641-393-216-698,2018-09-20,2018,US 201815982686 A,2018-05-17,US 201815982686 A;;US 201715670284 A;;US 201615149986 A;;US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-07-16),https://lens.org/040-641-393-216-698,Patent Application,yes,11,1,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/06;;A61K6/083;;A61K6/838;;A61K6/884;;A61L24/02;;A61L24/04,,0,0,,,,ACTIVE
85,TW,A,TW 202114712 A,130-062-613-410-780,2021-04-16,2021,TW 109130386 A,2017-04-27,US 201662328396 P;;US 201662367377 P,2016-04-27,Use of composition for preparing drug for treating injured tendon in animal or human and kit,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/130-062-613-410-780,Patent of Addition,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61K31/728;;A61P19/00,,0,0,,,,PENDING
86,EP,A1,EP 3448394 A1,174-756-518-777-51X,2019-03-06,2019,EP 17723815 A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/174-756-518-777-51X,Patent Application,yes,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,ACTIVE
87,AU,B2,AU 2017/257956 B2,194-969-543-678-024,2019-11-07,2019,AU 2017/257956 A,2017-04-26,US 201662367377 P;;US 201662328396 P;;US 2017/0029635 W,2016-04-27,Compositions for use in treating tendon degeneration,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/194-969-543-678-024,Granted Patent,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,ACTIVE
88,US,B2,US 9358319 B2,126-247-020-329-676,2016-06-07,2016,US 201414461138 A,2014-08-15,US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-07-16),https://lens.org/126-247-020-329-676,Granted Patent,yes,62,4,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61K6/083;;A61K6/838;;A61K6/884;;A61L24/02;;A61L24/04;;A61L24/06,,26,18,038-399-707-220-522;;058-009-416-650-791;;081-991-165-119-818;;142-308-826-149-38X;;002-974-894-406-198;;174-928-735-004-634;;065-082-320-859-616;;044-329-228-978-129;;024-150-338-971-192;;069-164-232-245-440;;116-522-166-790-802;;038-941-767-748-705;;017-684-871-981-930;;015-989-772-543-489;;017-281-044-576-345;;036-529-121-020-291;;021-926-143-771-429;;008-779-797-892-977,12866105;;10.1002/anie.200351244;;15520369;;10.1073/pnas.0407218101;;pmc528737;;10.1016/j.biomaterials.2006.09.028;;17034844;;10458268;;10.1016/s8756-3282(99)00127-1;;10.2136/sssaj2005.0158;;10.1016/s1381-5148(98)00054-6;;10.1002/1097-4628(20000919)77:12<2711::aid-app190>3.0.co;2-t;;10.1016/j.biomaterials.2005.10.023;;16313954;;10.1016/s0142-9612(02)00370-8;;12485798;;10.1021/bc060200l;;17226966;;17079046;;10.1016/j.jconrel.2006.09.009;;10.1016/s0142-9612(96)00082-8;;9003891;;10.1039/b309487a;;14594315;;10.1007/978-1-4020-4728-2_4;;14963178;;10.1097/01.rvi.0000109394.74740.56;;pmc7976525;;15313726;;10.1016/j.biomaterials.2007.01.037;;17367850;;16081184;;10.1016/j.jconrel.2005.06.022,"""Standard Specification for Acrylic Bone Cement,"" Annual Book of ASTM Standards; Medical Devices, F 451-99a: 56-62 (1999).;;3M ESPE, ""Z100(TM) MP Brochure,"" (1-5) Retrieved from the internet on Jul. 28, 2005 from www.matweb.com/search/SpecifiedMaterialPrint.asp?bassnum= PMMM02.;;Anderson et al., ""Semi-Automated Synthesis and Screening of a Large Library of Degradable Cationic Polymers for Gene Delivery,"" Angew. Chem. Int. Ed., 42: 3153-3158 (2003).;;Anderson et al., ""A polymer library approach to suicide gene therapy for cancer,"" Proceedings of the National Academy of Sciences of the United States of America, 101(45):16028-16033 (Nov. 1, 2004).;;Arote et al., ""A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier,"" Biomaterials, 28: 735-744 (2007).;;Brown, ""Solubilities of Phosphates and Other Sparingly Soluble Compounds,"" Environmental Phosphorus Handbook, (Griffith et al., eds.), 203-239 (John Wiley & Sons, New York, NY, 1973).;;Burton et al Huntsman Corporation Brochure, 1-105 (Apr. 27, 2005).;;Deramond et al., ""Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty,"" Bone, 25(2 Supplemental): 17S-21S (Aug. 1999).;;Farenhorst, ""Importance of Soil Organic Matter Fractions in Soil-Landscape and Regional Assessments of Pesticide Sorption and Leaching in Soil,"" Soil Sci. Soc. Am. J. 70: 1005-1012 (May-Jun. 2006).;;International Search Report with respect to PCT/US2008/074700 (Jun. 8, 2011).;;Jagur-Grodzinski et al., ""Biomedical application of functional polymers,"" Reactive & Functional Polymers, 39: 99-138 (1999).;;Jean et al., ""Polyurethane Acrylate/Epoxy-Amine Acrylate Hybrid Polymer Networks,"" J. Applied Polymer Science, 77: 2711-2717 (2000).;;Kim et al., ""Highly effective and slow-biodegradable network-type cationic gene delivery polymer: Small library-like approach synthesis and characterization,"" Biomaterials, 27: 2292-2301 (2006).;;Kincaid, ""Epoxy Polyacrylate Hybrids . . . A Continuing Study,"" Resolution Performance Products LLC tech paper, 1-15 (Nov. 2001).;;Kweon et al., ""A novel degradable polycaprolactone networks for tissue engineering,"" Biomaterials, 24: 801-808 (2003).;;Lin et al., ""Novel Bioreducible Poly(amido amine)s for Highly Efficient Gene Delivery,"" Bioconjugate Chemistry, 18 (1): 138-145 (Jan./Feb. 2007).;;Lin et al., ""Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: Synthesis and in vitro gene transfer properties,"" Journal of Controlled Release, 116 (2): 130-137 (Nov. 28, 2006).;;Liso et al., ""Analysis of the leaching and toxicity of new amine activators for the curing of acrylic bone cements and composites,"" Biomaterials, 18(1): 15-20 (1997).;;Liu et al., ""Novel poly(amino ester)s obtained from Michael addition polymerizations of trifunctional amine monomers with diacrylates: safe and efficient DNA carriers,"" Chemistry Communication, (20): 2630-26301 (Oct. 21, 2003).;;Loffredo et al., ""The Role of Humic Substances in the Fate of Anthropogenic Organic Pollutants in Soil with Emphasis on Endocrine Disruptor Compounds,"" Soil and Water Pollution Monitoring, Protection and Remediation, 3(23): 69-92 (2006).;;Nussbaum et al., ""The Chemistry of Acrylic Bone Cements and Implications for Clinical Use in Image-guided Therapy,"" J. Vasc. lnterv. Radiol. 15(2): 121-126 (Feb. 2004).;;Pressly, ""Complications Related to the Use of Bone Cement and Bone Void Fillers in Treating Compression Fractures of the Spine"", FDA Public Health Web Notification, 1-3 (May 7, 2004).;;Provenzano et al., ""Bone Cements: Review of Their Physiochemical and Biochemical Properties in Percutaneous Vertebroplasty,"" American Journal of Neuroradiology, 25(7): 1286-1290 (Aug. 2004).;;Serbetci et al., ""Mechanical and Thermal Properties of Hydroxyapatite-Impregnated Bone Cement,"" Turk. J. Med. Sci., 30: 543-549 (2000).;;Srinivasachari et al., ""Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy,"" Biomaterials, 28: 2885-2898 (2007).;;Zhong et al., ""A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s,"" Journal of Controlled Release, 109 (1-3): 317-329 (Dec. 5, 2005).",ACTIVE
89,EP,B1,EP 3448447 B1,143-929-840-392-86X,2023-05-03,2023,EP 17722590 A,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,,ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,"ANIKA THERAPEUTICS, INC. (2019-10-09)",https://lens.org/143-929-840-392-86X,Granted Patent,yes,3,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58;;A61P19/02;;A61P19/08,,1,0,,,"S AHMADZADEH-ASL ET AL: ""Preparation and characterisation of calcium phosphate-hyaluronic acid nanocomposite bone cement"", ADVANCES IN APPLIED CERAMICS: STRUCTURAL, FUNCTIONAL ANDBIOCERAMICS, vol. 110, no. 6, 1 August 2011 (2011-08-01), pages 340-345, XP055393882, GB ISSN: 1743-6753, DOI: 10.1179/1743676111Y.0000000019",ACTIVE
90,EP,A2,EP 4223328 A2,001-103-390-528-618,2023-08-09,2023,EP 23164800 A,2017-04-26,US 201662328313 P;;EP 17722590 A;;US 2017/0029651 W,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and avascular necrosis.",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/001-103-390-528-618,Patent Application,yes,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58;;A61P19/02;;A61P19/08,,21,12,079-917-155-143-075;;006-837-341-882-455;;044-676-914-321-692;;030-624-550-011-358;;009-826-017-364-520;;137-899-486-143-649;;089-498-557-882-208;;067-853-870-646-274;;021-069-836-946-558;;012-323-936-818-339;;036-529-943-767-423;;071-886-453-351-761,23365809;;11774307;;10.1002/jbm.1263;;10.1007/s11999-015-4311-0;;pmc4457753;;25917421;;pmc4128718;;25111138;;10.1371/journal.pone.0104603;;10.3390/ma10040334;;28772697;;pmc5506916;;19027947;;10.1016/j.biomaterials.2008.10.053;;2277045;;10.1016/0021-9290(90)90003-l;;10.1002/jor.1100020106;;6491796;;10.1902/jop.2008.070038;;18251643;;10.1039/b811953h;;10.1080/0014013032000121660;;14668173;;10.1186/1471-2474-9-137;;pmc2575212;;18844988,"SHARKEY, P. F ET AL., AM. J. ORTHOP. (BELLE MEAD NJ), vol. 41, no. 9, 2012, pages 413 - 17;;HISATOME, T. ET AL., J. BIOMED. MATER. RES, vol. 59, no. 3, 2002, pages 490 - 98;;CHATTERJEE, D. ET AL., CLIN. ORTHOP. RELAT. RES, vol. 473, no. 1, 2015, pages 2334 - 42;;NISHIZUKA, T. ET AL., PLOS ONE, vol. 9, no. 8, 2014, pages e104603;;SUBCHONDROPLASTY® PROCEDURE ACCUFILL® BONE SUBSTITUTE MATERIAL (BSM, 18 April 2017 (2017-04-18), Retrieved from the Internet <URL:http://subchondroplasty.com/healthcare-professionals-bsm.html>;;TOFIGHI, A ET AL., J. BIOMIMETICS BIOMAT. TISSUE ENG'G, vol. 2, 2009, pages 39 - 28;;FARR, J.;COHEN, S. B, OPER. TECH. SPORTS MED, vol. 27, no. 2, 2013, pages 138 - 43;;ELIAZ, NMETOKI, N., MATERIALS, vol. 10, 2017, pages 334;;PEK, Y. S ET AL., BIOMAT, vol. 30, 2009, pages 822 - 28;;AHMADZADEH-ASL, S. ET AL., ADV. APPLIED CERAMICS, vol. 110, no. 6, 2011, pages 340 - 45;;CHOI, K ET AL.: ""23"", J. BIOMECH, no. 11, 1990, pages 1103 - 13;;BROWN, T. DVRAHAS, M. S. J, ORTHOPED. RES, vol. 2, no. 1, 1984, pages 32 - 38;;MENTE, P. LLEWIS, J. L. J, ORTHOPED. RES, vol. 72, no. 5, 1994, pages 637 - 47;;WEBB, P.: ""An introduction to the physical characterization of materials by mercury intrusion porosimetry with emphasis on reduction and presentation of experimental data"", MICROMERITICS INSTRUMENT CORP, 2001;;NEIVA, R. F. ET AL., J. PERIODONTOL, vol. 79, no. 2, 2008, pages 291 - 99;;BOHNER, M. ET AL., J. MATER. CHEM, vol. 18, 2008, pages 5669 - 75;;DIDOMENICO, ANUSSBAUM, M. A, ERGONOMICS, vol. 46, no. 15, 2003, pages 1531 - 1548;;BONE-CEMENT DELIVERY SYSTEM (P-SYSTEM), 20 April 2017 (2017-04-20), Retrieved from the Internet <URL:http://www.medmix.ch/portofolio-item/bone-cement-delivery-system-p-system>;;COLLINS, N. J ET AL., ARTHRITIS CARE RES. (HOBOKEN, vol. 63, no. 011, 2011, pages S208 - 228;;PATEL, P. S. D. ET AL., BMC MUSCULOSKELETAL DISORDERS, vol. 9, 2008, pages 137;;TRANSWELL® PERMEABLE SUPPORTS SELECTION AND USE GUIDE, 24 April 2017 (2017-04-24), Retrieved from the Internet <URL:http://csmedia2.corning.com/LifeSciences/Media/pdf/transwell_guide.pelf>",PENDING
91,US,A1,US 2017/0312385 A1,018-858-466-118-352,2017-11-02,2017,US 201715497720 A,2017-04-26,US 201715497720 A;;US 201662328313 P,2016-04-27,Methods and Compositions For The Treatment of Degenerate Bone,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (“OA”), rheumatoid arthritis, and avascular necrosis.",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,ANIKA THERAPEUTICS INC (2017-05-24),https://lens.org/018-858-466-118-352,Patent Application,yes,0,5,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/20;;A61B17/00;;A61B17/34;;A61B17/88;;A61L27/02;;A61L27/12;;A61L27/50,,0,0,,,,DISCONTINUED
92,US,B2,US 10799610 B2,025-066-504-196-828,2020-10-13,2020,US 201916532799 A,2019-08-06,US 201916532799 A;;US 201815982686 A;;US 201715670284 A;;US 201615149986 A;;US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-07-16),https://lens.org/025-066-504-196-828,Granted Patent,yes,69,0,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/06;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/04,,31,18,038-399-707-220-522;;058-009-416-650-791;;081-991-165-119-818;;142-308-826-149-38X;;002-974-894-406-198;;174-928-735-004-634;;065-082-320-859-616;;044-329-228-978-129;;024-150-338-971-192;;069-164-232-245-440;;116-522-166-790-802;;038-941-767-748-705;;017-684-871-981-930;;015-989-772-543-489;;017-281-044-576-345;;036-529-121-020-291;;021-926-143-771-429;;008-779-797-892-977,12866105;;10.1002/anie.200351244;;15520369;;10.1073/pnas.0407218101;;pmc528737;;10.1016/j.biomaterials.2006.09.028;;17034844;;10458268;;10.1016/s8756-3282(99)00127-1;;10.2136/sssaj2005.0158;;10.1016/s1381-5148(98)00054-6;;10.1002/1097-4628(20000919)77:12<2711::aid-app190>3.0.co;2-t;;10.1016/j.biomaterials.2005.10.023;;16313954;;10.1016/s0142-9612(02)00370-8;;12485798;;10.1021/bc060200l;;17226966;;17079046;;10.1016/j.jconrel.2006.09.009;;10.1016/s0142-9612(96)00082-8;;9003891;;10.1039/b309487a;;14594315;;10.1007/978-1-4020-4728-2_4;;14963178;;10.1097/01.rvi.0000109394.74740.56;;pmc7976525;;15313726;;10.1016/j.biomaterials.2007.01.037;;17367850;;16081184;;10.1016/j.jconrel.2005.06.022,"U.S. Appl. No. 12/200,918, filed Aug. 28, 2008.;;U.S. Appl. No. 14/461,138, filed Aug. 15, 2014.;;U.S. Appl. No. 15/149,986, filed May 9, 2016.;;U.S. Appl. No. 15/670,284, filed Aug. 7, 2017.;;U.S. Appl. No. 15/982,686, filed May 17, 2018.;;“Standard Specification for Acrylic Bone Cement,” Annual Book of ASTM Standards; Medical Devices, F 451-99a: 56-62 (1999).;;3M ESPE, “Z100™ MP Brochure,” (1-5) Retrieved from the internet on Jul. 28, 2005 from www.matweb.com/search/SpecifiedMaterialPrint.asp?bassnum= PMMM02.;;Anderson et al., “Semi-Automated Synthesis and Screening of a Large Library of Degradable Cationic Polymers for Gene Delivery,” Angew. Chem. Int. Ed., 42: 3153-3158 (2003).;;Anderson et al., “A polymer library approach to suicide gene therapy for cancer,” Proceedings of the National Academy of Sciences of the United States of America, 101(45):16028-16033 (Nov. 1, 2004).;;Arote et al., “A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier,” Biomaterials, 28: 735-744 (2007).;;Brown, “Solubilities of Phosphates and Other Sparingly Soluble Compounds,” Environmental Phosphorus Handbook, (Griffith et al., eds.), 203-239 (John Wiley & Sons, New York, NY, 1973).;;Burton et al. Huntsman Corporation Brochure, 1-105 (Apr. 27, 2005).;;Deramond et al., “Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty,” Bone, 25(2 Supplemental): 17S-21S (Aug. 1999).;;Farenhorst, “Importance of Soil Organic Matter Fractions in Soil-Landscape and Regional Assessments of Pesticide Sorption and Leaching in Soil,” Soil Sci. Soc. Am. J. 70: 1005-1012 (May-Jun. 2006).;;International Search Report with respect to PCT/US2008/074700 (dated Jun. 8, 2011).;;Jagur-Grodzinski et al., “Biomedical application of functional polymers,” Reactive & Functional Polymers, 39: 99-138 (1999).;;Jean et al., “Polyurethane Acrylate/Epoxy-Amine Acrylate Hybrid Polymer Networks,” J. Applied Polymer Science, 77: 2711-2717 (2000).;;Kim et al., “Highly effective and slow-biodegradable network-type cationic gene delivery polymer: Small library-like approach synthesis and characterization,” Biomaterials, 27: 2292-2301 (2006).;;Kincaid, “Epoxy Polyacrylate Hybrids. . . A Continuing Study,” Resolution Performance Products LLC tech paper, 1-15 (Nov. 2001).;;Kweon et al., “A novel degradable polycaprolactone networks for tissue engineering,” Biomaterials, 24: 801-808 (2003).;;Lin et al., “Novel Bioreducible Poly(amido amine)s for Highly Efficient Gene Delivery,” Bioconjugate Chemistry, 18 (1): 138-145 (Jan./Feb. 2007).;;Lin et al., “Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: Synthesis and in vitro gene transfer properties,” Journal of Controlled Release, 116 (2): 130-137 (Nov. 28, 2006).;;Liso et al., “Analysis of the leaching and toxicity of new amine activators for the curing of acrylic bone cements and composites,” Biomaterials, 18(1): 15-20 (1997).;;Liu et al., “Novel poly(amino ester)s obtained from Michael addition polymerizations of trifunctional amine monomers with diacrylates: safe and efficient DNA carriers,” Chemistry Communication, (20): 2630-26301 (Oct. 21, 2003).;;Loffredo et al., “The Role of Humic Substances in the Fate of Anthropogenic Organic Pollutants in Soil with Emphasis on Endocrine Disruptor Compounds,” Soil and Water Pollution Monitoring, Protection and Remediation, 3(23): 69-92 (2006).;;Nussbaum et al., “The Chemistry of Acrylic Bone Cements and Implications for Clinical Use in Image-guided Therapy,” J. Vasc. Interv. Radiol. 15(2): 121-126 (Feb. 2004).;;Pressly, “Complications Related to the Use of Bone Cement and Bone Void Fillers in Treating Compression Fractures of the Spine”, FDA Public Health Web Notification, 1-3 (May 7, 2004).;;Provenzano et al., “Bone Cements: Review of Their Physiochemical and Biochemical Properties in Percutaneous Vertebroplasty,” American Journal of Neuroradiology, 25(7): 1286-1290 (Aug. 2004).;;Serbetci et al., “Mechanical and Thermal Properties of Hydroxyapatite-Impregnated Bone Cement,” Turk. J. Med. Sci., 30: 543-549 (2000).;;Srinivasachari et al., “Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy,” Biomaterials, 28: 2885-2898 (2007).;;Zhong et al., “A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s,” Journal of Controlled Release, 109 (1-3): 317-329 (Dec. 5, 2005).",ACTIVE
93,US,B2,US 10441677 B2,073-885-460-793-347,2019-10-15,2019,US 201715497577 A,2017-04-26,US 201715497577 A;;US 201662367377 P;;US 201662328396 P,2016-04-27,Methods and compositions for treating tendon degeneration,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,ANIKA THERAPEUTICS INC (2017-05-24),https://lens.org/073-885-460-793-347,Granted Patent,yes,49,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61L27/20;;A61K31/715;;A61L27/38;;A61L27/50,,34,22,050-805-324-699-893;;020-666-611-918-854;;013-618-913-604-199;;058-744-542-822-452;;187-392-748-207-800;;018-675-689-501-664;;069-390-664-020-670;;009-964-623-420-153;;063-289-326-449-55X;;017-401-471-856-820;;025-777-935-487-53X;;028-229-697-241-092;;102-300-340-093-016;;000-710-134-311-581;;150-223-761-167-372;;020-208-282-425-697;;039-694-486-841-744;;009-853-787-596-313;;014-573-258-791-687;;002-840-987-822-285;;115-829-659-643-43X;;074-739-237-164-91X,10.1179/1743676111y.0000000019;;10.1002/art.22290;;17195226;;pmc2100202;;10.1111/j.1469-7580.2006.00540.x;;16637873;;10.1007/s11999-009-1206-y;;pmc2865621;;20049569;;10.4172/2379-1764.1000130;;10.1034/j.1600-0838.2000.010006312.x;;11085557;;23294647;;pmc3625943;;10.1016/j.jhsa.2012.11.012;;10204932;;10.2106/00004623-199902000-00014;;10.1302/0301-620x.81b2.9154;;10.1302/0301-620x.81b2.0810259;;10073590;;24321104;;10.1186/ar4405;;pmc4061721;;25253243;;10.1007/s00776-014-0650-z;;15330037;;10.1302/0301-620x.86b6.14329;;20205851;;pmc2825499;;10.1186/1758-2555-2-4;;10.2106/00004623-200501000-00030;;15634833;;10.2106/jbjs.d.01850;;21508358;;10.1007/1-84628-050-8_9;;28828182;;pmc5549180;;10.1302/2058-5241.2.160075;;10.9790/0853-150754953;;10.1111/j.1600-0838.2009.00986.x;;19706001;;16787448;;10.1111/j.1600-0838.2006.00522.x;;10.1186/s12891-015-0785-x;;pmc4596363;;26444018;;26537858;;10.1186/s12891-015-0735-7;;pmc4634145;;10.1177/03635465030310062901;;14623657;;10.1007/s11552-014-9642-x;;pmc4235906;;25414603,"Glossary of medical education terms, Institute of International Medical Education. http://www.iime.org/glossary.htm Accessed in Mar. 2013. (Year: 2013).;;Pereira et al. Chapter 6 Hyaluronic Acid. Advances in Experimental Medicine and Biology 1059, J. M. Oliveira et al. (eds.), Osteochondral Tissue Engineering, Springer International Publishing AG, part of Springer Nature 2018. https://doi.org/10.1007/978-3-319-76735-2_6 (Year: 2018).;;Abrams, et al., “Subchondral Bone Treatment,” in Biologic Knee Reconstruction: A Surgeon's Guide, Cole BJ, Harris JD, eds.; Ch. 12, pp. 83-89 (2015) (7 pages).;;Ahmadzadeh-Asl, S., et al., “Preparation and characterisation of calcium phosphate-hyaluronic acid nanocomposite bone cement”, Advances in Applied Ceramics: Structural, Functional and Bioceramics, 110:6, 340-345, Aug. 1, 2011 (7 pages).;;Anika Therapeutics, Inc., “Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow),” ClinicalTrials.gov identifier: NCT02861183; Downloaded from https://clinicaltrials.gov/ct2/show/NCT02861183 on Aug. 17, 2016 (4 pgs.).;;Benjamin, M. et al, “Microdamage and Altered Vascularity at the Enthesis-Bone Interface Provides an Anatomic Explanation for Bone Involvement in the HLA-B27-Associated Spondylarthritides and Allied Disorders”, Arthritis & Rheumatism, 56(1):224-233, Jan. 2007 (10 pages).;;Benjamin, M. et al., “Where tendons and ligaments meet bone: attachment sites (‘entheses’) in relation to exercise and/or mechanical load”, J. Anat., 208:471-490, 2006 (20 pages).;;Dourte, L. et al., “Tendon Properties Remain Altered in a Chronic Rat Rotator Cuff Model”, Clin. Orthop. Relat. Res., 468:1485-1492, Jun. 2010 (8 pages).;;Gorelick, L. et al., “Lateral Epicondylitis Injection Therapy: A Safety and Efficacy Analysis of Hyaluronate versus Corticosteroid Injections,” Adv. Tech. Biol. Med., vol. 3, No. 2, (2015) (4 pages).;;International Search Report and Written Opinion issued by the European Patent Office as International Searching Authority in PCT/US2017/029635, dated Sep. 5, 2017 (23 pages).;;Kannus, P., “Structure of the tendon connective tissue”, Scand J Med Sci Sports, 10:312-320, 2000 (9 pages).;;Kolodzinskyi, M. et al., “The Effects of Hylan G-F 20 Surface Modification on Gliding of Extrasynovial Canine Tendon Grafts In Vitro,” J. Hand Surg. Am., vol. 38A, pp. 231-236, Feb. 2013 (6 pages).;;Kraushaar, B. et al., “Current Concepts Review Tendinosis of the Elbow (Tennis Elbow): Clinical Features and Findings of Histological, Immunohistochemical, and Electron Microscopy Studies”, The Journal of Bone and Joint Surgery, Incorporated, 81-A(2):259-278, Feb. 1999 (20 pages).;;Li, et al., “Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes,” Arthritis Research & Therapy, vol. 15, (2013) (12 pages).;;Yoshida, M., et al., “Therapeutic effects of high molecular weight hyaluronan injections for tendinopathy in a rat model”, Journal of Orthop Sci, 20(1):186-195, Sep. 25, 2014 (10 pages).;;Nishida, J. et al., “Effect of hyaluronic acid on the excursion resistance of tendon grafts” Journal of Bone & Joint Surgery (Br.), 86-6:918-924, Aug. 2004 (7 pages).;;Petrella, R.J. et al., “Management of Tennis Elbow with sodium hyaluronate periarticular injections”, Sports Medicine, Arthroscopy, Rehabilitation, Therapy & Technology, vol. 2, No. 4 (2010) (6 pages).;;Sharma, P. et al., “Tendon Injury and Tendinopahty: Healing and Repair”, Journal of Bone & Joint Surgery,87:187-202, Jan. 2005 (17 pages).;;Yu, Y. et al., “Ras/Raf/MEK/ERK Pathway Is Associated with Lung Metastasis of Osteosarcoma in an Orthotopic Mouse Model”, Anticancer Research, vol. 31: 1147-1152 (2011) (6 pages).;;Best, et al., “Chapter 4: Skeletal Muscle and Tendon” in Practical Orthopaedic Sports Medicine and Arthroscopy, Johnson and Pedowitz Eds., Wolters Kluwer Health, Philadelphia, Pennsylvania, pp. 37-50, 2007 (20 pages).;;Ho, et al., “Chapter 9: Tendon Injuries”, In Essentials in Elbow Surgery, Antuna and Barco Eds., Springer-Verlag, London, pp. 141-159, 2014 (21 pages).;;Renstrom, et al., “Chapter 9: Insertional Tendinopathy in Sports”, in Tendon Injuries: Basic Science and Clinical Medicine, Maffulli, et al., Eds., Springer-Verlag, London, pp. 70-85, 2005 (19 pages).;;Walsh, et al., “Chapter 67: Injection Procedures”, in DeLisa's Physical Medicine & Rehabilitation: Principles and Practice, vol. 1, Fifth Edition, Frontera, et al., Eds., Wolters Kluwer, Philadelphia, Pennsylvania, pp. 1815-1873, 2010 (64 pages).;;Wu, et al., “Tendon injuries: basic science and new repair proposals”, EFORT Open Reviews, 2:332-342, Jul. 2017 (11 pages).;;International Preliminary Report on Patentability for Application No. PCT/US2017/029635 dated Nov. 8, 2018.;;Jose et al., A Comparative Study on the Efficacy of Local Infiltration of Autologous Blood versus Local Corticosteroid Infiltration for the Treatment of Chronic Lateral Epicondylitis Elbow. IOSR Journal of Dental and Medical Sciences. Jul. 2016;15(6):49-53.;;Kjaer et al., From mechanical loading to collagen synthesis, structural changes and function in human tendon. Scand J Med Sci Sports. Aug. 2009;19(4):500-10. doi: 10.1111/j.1600-0838.2009.00986.x.;;Langberg et al., Eccentric rehabilitation exercise increases peritendinous type I collagen synthesis in humans with Achilles tendinosis. Scand J Med Sci Sports. Feb. 2007;17(1):61-6. Epub Jun. 19, 2006.;;Osti et al., Hyaluronic acid increases tendon derived cell viability and collagen type I expression in vitro: Comparative study of four different Hyaluronic acid preparations by molecular weight. BMC Musculoskelet Disord. Oct. 6, 2015;16:284. doi: 10.1186/s12891-0150735-7.;;Paoloni et al., Topical nitric oxide application in the treatment of chronic extensor tendinosis at the elbow: a randomized, double-blinded, placebo-controlled clinical trial. Am J Sports Med. Nov.-Dec. 2003;31(6):915-20.;;Sims et al., Non-surgical treatment of lateral epicondylitis: a systematic review of randomized controlled trials. Hand (N Y). Dec. 2014;9(4):419-46. doi: 10.1007/s11552-014-9642-x.;;Walrod et al., Lateral Epicondylitis Treatment & Management: Treatment Options, Acute Phase, Recovery Phase. Medscape. Oct. 30, 2018:1-18. Retrieved from the Internet: https://emedicine.medscape.com/article/996969-treatment on Jul. 18, 2019.;;Young, Novel Collagen Scores Well in Tendinopathy Test. Orthopedics—This Week. Feb. 15, 2016. Retrieved from the Internet: http://ryortho.com/breaking/novel-collagen-scores-well-in-tendinopathy-test/ on Jul. 18, 2019. 2 pages.;;PCT/US2017/029635, Nov. 8, 2018, International Preliminary Report on Patentability.",ACTIVE
94,CN,A,CN 109562204 A,103-346-135-637-74X,2019-04-02,2019,CN 201780039442 A,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and a vascular necrosis",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/103-346-135-637-74X,Patent Application,no,1,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,DISCONTINUED
95,CA,A1,CA 3021764 A1,108-159-504-498-983,2017-11-02,2017,CA 3021764 A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/108-159-504-498-983,Patent Application,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,ACTIVE
96,TW,A,TW 201739457 A,174-697-271-790-992,2017-11-16,2017,TW 106114071 A,2017-04-27,US 201662328396 P;;US 201662367377 P,2016-04-27,Use of composition for preparing drug for treating injured tendon in animal or ahuman and kit,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/174-697-271-790-992,Patent of Addition,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/70;;A61K31/726;;A61K31/728;;A61K35/12;;A61L27/18;;A61L27/20;;A61L27/22;;A61L27/24;;A61P19/04,,0,0,,,,ACTIVE
97,CA,C,CA 3021764 C,056-941-758-291-507,2021-01-19,2021,CA 3021764 A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION VIA INTRA-OSTEOTENDINOUS INJECTION,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication and are formulated for administration via intra-osteotendinous injection.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/056-941-758-291-507,Granted Patent,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,ACTIVE
98,EP,C0,EP 3448394 C0,115-068-498-271-52X,2023-09-13,2023,EP 17723815 A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/115-068-498-271-52X,Unknown,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,ACTIVE
99,TW,A,TW 201739461 A,100-440-026-279-05X,2017-11-16,2017,TW 106114049 A,2017-04-27,US 201662328313 P,2016-04-27,Injectable biomaterial and making method and use thereof and kit,"The present disclosure relates to an injectable biomaterial and making method and use thereof and a kit. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and avascular necrosis.",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/100-440-026-279-05X,Patent of Addition,no,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61K33/42;;A61K9/00;;A61K31/715;;A61L27/12;;A61L27/14;;A61L27/20;;A61P19/02,,0,0,,,,ACTIVE
100,EP,B1,EP 3448394 B1,037-980-296-888-765,2023-09-13,2023,EP 17723815 A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/037-980-296-888-765,Granted Patent,yes,3,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,2,0,,,"PETRELLA ROBERT J ET AL: ""Management of Tennis Elbow with sodium hyaluronate periarticular injections"", SPORTS MEDICINE, ARTHROSCOPY, REHABILITATION, THERAPY & TECHNOLOGY, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. 1, 2 February 2010 (2010-02-02), page 4, XP021070550, ISSN: 1758-2555;;YOSHIDA MAMORU ET AL: ""Therapeutic effects of high molecular weight hyaluronan injections for tendinopathy in a rat model"", JOURNAL OF ORTHOPAEDIC SCIENCE, SPRINGER VERLAG. TOKYO, JP, vol. 20, no. 1, 25 September 2014 (2014-09-25), pages 186-195, XP035431765, ISSN: 0949-2658, DOI: 10.1007/S00776-014-0650-Z [retrieved on 2014-09-25]",ACTIVE
101,US,B2,US 10413632 B2,094-757-077-820-301,2019-09-17,2019,US 201815982686 A,2018-05-17,US 201815982686 A;;US 201715670284 A;;US 201615149986 A;;US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-07-16),https://lens.org/094-757-077-820-301,Granted Patent,yes,69,0,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/06;;A61K6/083;;A61K6/838;;A61K6/884;;A61L24/02;;A61L24/04,,30,18,038-399-707-220-522;;058-009-416-650-791;;081-991-165-119-818;;142-308-826-149-38X;;002-974-894-406-198;;174-928-735-004-634;;065-082-320-859-616;;044-329-228-978-129;;024-150-338-971-192;;069-164-232-245-440;;116-522-166-790-802;;038-941-767-748-705;;017-684-871-981-930;;015-989-772-543-489;;017-281-044-576-345;;036-529-121-020-291;;021-926-143-771-429;;008-779-797-892-977,12866105;;10.1002/anie.200351244;;15520369;;10.1073/pnas.0407218101;;pmc528737;;10.1016/j.biomaterials.2006.09.028;;17034844;;10458268;;10.1016/s8756-3282(99)00127-1;;10.2136/sssaj2005.0158;;10.1016/s1381-5148(98)00054-6;;10.1002/1097-4628(20000919)77:12<2711::aid-app190>3.0.co;2-t;;10.1016/j.biomaterials.2005.10.023;;16313954;;10.1016/s0142-9612(02)00370-8;;12485798;;10.1021/bc060200l;;17226966;;17079046;;10.1016/j.jconrel.2006.09.009;;10.1016/s0142-9612(96)00082-8;;9003891;;10.1039/b309487a;;14594315;;10.1007/978-1-4020-4728-2_4;;14963178;;10.1097/01.rvi.0000109394.74740.56;;pmc7976525;;15313726;;10.1016/j.biomaterials.2007.01.037;;17367850;;16081184;;10.1016/j.jconrel.2005.06.022,"U.S. Appl. No. 12/200,918, filed Aug. 28, 2008;;U.S. Appl. No. 14/461,138, filed Aug. 15, 2014.;;U.S. Appl. No. 15/149,986, filed May 9, 2016.;;U.S. Appl. No. 15/670,284, filed Aug. 7, 2014.;;“Standard Specification for Acrylic Bone Cement,” Annual Book of ASTM Standards; Medical Devices, F 451-99a: 56-62 (1999).;;3M ESPE, “Z100™ MP Brochure,” (1-5) Retrieved from the internet on Jul. 28, 2005 from www.matweb.com/search/SpecifiedMaterialPrint.asp?bassnum= PMMM02.;;Anderson et al., “Semi-Automated Synthesis and Screening of a Large Library of Degradable Cationic Polymers for Gene Delivery,” Angew. Chem. Int. Ed., 42: 3153-3158 (2003).;;Anderson et al., “A polymer library approach to suicide gene therapy for cancer,” Proceedings of the National Academy of Sciences of the United States of America, 101(45): 16028-16033 (Nov. 1, 2004).;;Arote et al., “A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier,” Biomaterials, 28: 735-744 (2007).;;Brown, “Solubilities of Phosphates and Other Sparingly Soluble Compounds,” Environmental Phosphorus Handbook, (Griffith et al., eds.), 203-239 (John Wiley & Sons, New York, NY, 1973).;;Burton et al., Huntsman Corporation Brochure, 1-105 (Apr. 27, 2005).;;Deramond et al., “Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty,” Bone, 25(2 Supplemental): 17S-21S (Aug. 1999).;;Farenhorst, “Importance of Soil Organic Matter Fractions in Soil-Landscape and Regional Assessments of Pesticide Sorption and Leaching in Soil,” Soil Sci, Soc. Am. J. 70: 1005-1012 (May-Jun. 2006).;;International Search Report with respect to PCT/US2008/074700, dated Jun. 8, 2011.;;Jagur-Grodzinski et al., “Biomedical application of functional polymers,” Reactive & Functional Polymers, 39: 99-138 (1999).;;Jean et al., “Polyurethane Acrylate/Epoxy-Amine Acrylate Hybrid Polymer Networks,” J. Applied Polymer Science, 77: 2711-2717 (2000).;;Kim et al., “Highly effective and slow-biodegradable network-type cationic gene delivery polymer: Small library-like approach synthesis and characterization,” Biomaterials, 27: 2292-2301 (2006).;;Kincaid, “Epoxy Polyacrylate Hybrids . . . A Continuing Study,” Resolution Performance Products LLC tech paper, 1-15 (Nov. 2001).;;Kweon et al., “A novel degradable polycaprolactone networks for tissue engineering,” Biomaterials, 24: 801-808 (2003).;;Lin et al., “Novel Bioreducible Poly(amido amine)s for Highly Efficient Gene Delivery,” Bioconjugate Chemistry, 18 (1): 138-145 (Jan./Feb. 2007).;;Lin et al., “Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: Synthesis and in vitro gene transfer properties,” Journal of Controlled Release, 116 (2): 130-137 (Nov. 28, 2006).;;Liso et al., “Analysis of the leaching and toxicity of new amine activators for the curing of acrylic bone cements and composites,” Biomaterials, 18(1): 15-20 (1997).;;Liu et al., “Novel poly(amino ester)s obtained from Michael addition polymerizations of trifunctional amine monomers with diacrylates: safe and efficient DNA carriers,” Chemistry Communication, (20): 2630-26301 (Oct. 21, 2003).;;Loffredo et al., “The Role of Humic Substances in the Fate of Anthropogenic Organic Pollutants in Soil with Emphasis on Endocrine Disruptor Compounds,” Soil and Water Pollution Monitoring, Protection and Remediation, 3(23): 69-92 (2006).;;Nussbaum et al., “The Chemistry of Acrylic Bone Cements and Implications for Clinical Use in Image-guided Therapy,” J. Vasc. Interv. Radiol. 15(2): 121-126 (Feb. 2004).;;Pressly, “Complications Related to the Use of Bone Cement and Bone Void Fillers in Treating Compression Fractures of the Spine”, FDA Public Health Web Notification, 1-3 (May 7, 2004).;;Provenzano et al., “Bone Cements: Review of Their Physiochemical and Biochemical Properties in Percutaneous Vertebroplasty,” American Journal of Neuroradiology, 25(7): 1286-1290 (Aug. 2004).;;Serbetci et al., “Mechanical and Thermal Properties of Hydroxyapatite—Impregnated Bone Cement,” Turk. J. Med. Sci., 30: 543-549 (2000).;;Srinivasachari et al., “Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy ,” Biomaterials, 28: 2885-2898 (2007).;;Zhong et al., “A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s,” Journal of Controlled Release, 109 (1-3): 317-329 (Dec. 5. 2005).",ACTIVE
102,US,A1,US 2016/0250376 A1,026-397-303-187-522,2016-09-01,2016,US 201615149986 A,2016-05-09,US 201615149986 A;;US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY INC (2010-10-29),https://lens.org/026-397-303-187-522,Patent Application,yes,1,2,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/06;;A61K6/083;;A61K6/838;;A61K6/884;;A61L24/02,,0,0,,,,INACTIVE
103,US,A1,US 2017/0326271 A1,173-022-819-349-130,2017-11-16,2017,US 201715497577 A,2017-04-26,US 201715497577 A;;US 201662367377 P;;US 201662328396 P,2016-04-27,METHODS AND COMPOSITIONS FOR TREATING TENDON DEGENERATION,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,ANIKA THERAPEUTICS INC (2017-05-24),https://lens.org/173-022-819-349-130,Patent Application,yes,1,1,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61L27/20;;A61L27/38;;A61L27/50,,2,0,,,"Pereira et al. Chapter 6 Hyaluronic Acid. Advances in Experimental Medicine and Biology 1059, J. M. Oliveira et al. (eds.), Osteochondral Tissue Engineering, Springer International Publishing AG, part of Springer Nature 2018. https://doi.org/10.1007/978-3-319-76735-2_6 (Year: 2018);;Glossary of medical education terms, Institute of International Medical Education. http://www.iime.org/glossary.htm Accessed in March 2013. (Year: 2013)",ACTIVE
104,US,B2,US 9993576 B2,018-673-651-587-256,2018-06-12,2018,US 201715670284 A,2017-08-07,US 201715670284 A;;US 201615149986 A;;US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-07-16),https://lens.org/018-673-651-587-256,Granted Patent,yes,66,3,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/06;;A61K6/083;;A61K6/838;;A61K6/884;;A61L24/02;;A61L24/04,,29,18,038-399-707-220-522;;058-009-416-650-791;;081-991-165-119-818;;142-308-826-149-38X;;002-974-894-406-198;;174-928-735-004-634;;065-082-320-859-616;;044-329-228-978-129;;024-150-338-971-192;;069-164-232-245-440;;116-522-166-790-802;;038-941-767-748-705;;017-684-871-981-930;;015-989-772-543-489;;017-281-044-576-345;;036-529-121-020-291;;021-926-143-771-429;;008-779-797-892-977,12866105;;10.1002/anie.200351244;;15520369;;10.1073/pnas.0407218101;;pmc528737;;10.1016/j.biomaterials.2006.09.028;;17034844;;10458268;;10.1016/s8756-3282(99)00127-1;;10.2136/sssaj2005.0158;;10.1016/s1381-5148(98)00054-6;;10.1002/1097-4628(20000919)77:12<2711::aid-app190>3.0.co;2-t;;10.1016/j.biomaterials.2005.10.023;;16313954;;10.1016/s0142-9612(02)00370-8;;12485798;;10.1021/bc060200l;;17226966;;17079046;;10.1016/j.jconrel.2006.09.009;;10.1016/s0142-9612(96)00082-8;;9003891;;10.1039/b309487a;;14594315;;10.1007/978-1-4020-4728-2_4;;14963178;;10.1097/01.rvi.0000109394.74740.56;;pmc7976525;;15313726;;10.1016/j.biomaterials.2007.01.037;;17367850;;16081184;;10.1016/j.jconrel.2005.06.022,"U.S. Appl. No. 12/200,918, filed Aug. 28, 2008.;;U.S. Appl. No. 14/461,138, filed Aug. 15, 2014.;;U.S. Appl. No. 15/149,986, filed May 9, 2016.;;“Standard Specification for Acrylic Bone Cement,” Annual Book of ASTM Standards; Medical Devices, F 451-99a: 56-62 (1999).;;3M ESPE, “Z100™ MP Brochure,” (1-5) Retrieved from the Internet on Jul. 28, 2005 from www.matweb.com/search/SpecifiedMaterialPrint.asp?bassnum= PMMM02.;;Anderson et al., “Semi-Automated Synthesis and Screening of a Large Library of Degradable Cationic Polymers for Gene Delivery,” Angew. Chem. Int. Ed., 42: 3153-3158 (2003).;;Anderson et al., “A polymer library approach to suicide gene therapy for cancer,” Proceedings of the National Academy of Sciences of the United State of America, 101(45):16028-16033 (Nov. 1, 2004).;;Arote et al., “A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier,” Biomaterials, 28: 735-744 (2007).;;Brown, “Solubilities of Phosphates and Other Sparingly Soluble Compounds,” Environmental Phosphorus Handbook, (Griffith et al., eds.), 203-239 (John Wiley & Sons, New York, NY, 1973).;;Burton et al., Huntsman Corporation Brochure. 1-105 (Apr. 27, 2005).;;Deramond et al., “Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty,” Bone, 25(2 Supplemental): 17S-21S (Aug. 1999).;;Farenhorst, “Importance of Soil Organic Matter Fractions in Soil-Landscape and Regional Assessments of Pesticide Sorption and Leaching in Soil,” Soil Sci. Soc. Am. J. 70: 1005-1012 (May-Jun. 2006).;;International Search Report with respect to PCT/US2008/074700, (dated Jun. 8, 2011).;;Jagur-Grodzinski et al., “Biomedical application of functional polymers,” Reactive & Functional Polymers, 39: 99-138 (1999).;;Jean et al., “Polyurethane Acrylate/Epoxy-Amine Acrylate Hybrid Polymer Networks,” J. Applied Polymer Science, 77: 2711-2717 (2000).;;Kim et al., “Highly effective and slow-biodegradable network-type cationic gene delivery polymer: Small library-like aproach synthesis and characterization,” Biomaterials, 27: 2292-2301 (2006).;;Kincaid, “Epoxy Polyacrylate Hybrids . . . A Continuing Study,” Resolution Performance Products LLC tech paper, 1-15 (Nov. 2001).;;Kweon et al., “A novel degradable polycaprolactone networks for tissue engineering,” Biomaterials, 24: 801-808 (2003).;;Lin et al., “Novel Bioreducible Poly(amido amine)s for Highly Efficient Gene Delivery,” Bioconjugate Chemistry, 18 (1): 138-145 (Jan./Feb. 2007).;;Lin et al., “Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: Synthesis and in vitro gene transfer properties,” Journal of Controlled Release, 116 (2): 130-137 (Nov. 28, 2006).;;Liso et al., “Analysis of the leaching and toxicity of new amine activators for the curing of acrylic bone cements and composites,” Biomaterials, 18(1): 15-20 (1997).;;Liu et al., “Novel poly(amino ester)s obtained from Michael addition polymerizations of trifunctional amine monomers with diacrylates: safe and efficient DNA carriers,” Chemistry Communication, (20): 2630-26301 (Oct. 21, 2003).;;Loffredo et al., “The Role of Humic Substances in the Fate of Anthropogenic Organic Pollutants in Soil with Emphasis on Endocrine Disruptor Compounds,” Soil and Water Pollution Monitoring, Protection and Remediation, 3(23): 69-92 (2006).;;Nussbaum et al., “The Chemistry of Acrylic Bone Cements and Implications for Clinical Use in Image-guided Therapy,” J. Vasc. Interv. Radiol. 15(2): 121-126 (Feb. 2004).;;Pressly, “Complications Related to the Use of Bone Cement and Bone Void Fillers in Treating Compression Fractures of the Spine”, FDA Public Health Web Notification, 1-3 (May 7, 2004).;;Provenzano et al., “Bone Cements: Review of Their Physiochemical and Biochemical Properties in Percutaneous Vertebroplasty,” American Journal of Neuroradiology, 25(7): 1286-1290 (Aug. 2004).;;Serbetci et al., “Mechanical and Thermal Properties of Hydroxyapatite-Impregnated Bone Cement,” Turk. J. Med. Sci., 30: 543-549 (2000).;;Srinivasachari et al., “Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy” Biomaterials, 28: 2885-2898 (2007).;;Zhong et al., “A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s,” Journal of Controlled Release, 109 (1-3): 317-329 (Dec. 5, 2005).",ACTIVE
105,TW,B,TW I755392 B,075-767-518-007-720,2022-02-21,2022,TW 106114071 A,2017-04-27,US 201662328396 P;;US 201662367377 P,2016-04-27,Use of composition for preparing drug for treating injured tendon in animal or human and kit,,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/075-767-518-007-720,Granted Patent,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,,,1,1,058-881-378-633-983,pmc4033484;;10.1155/2014/783632;;24895610,"Michele Abate et al,“The use of hyaluronic acid after tendon surgery and in tendinopathies”, BioMed Research International, 2014, Volume 2014, Article ID 783632, pages 1-6.",ACTIVE
106,MX,A,MX 2018012964 A,097-740-916-151-961,2019-06-10,2019,MX 2018012964 A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION.,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,EDWARD S AHN;;COLIN D WHITE;;SEKONI DAOUDA NOEL,,https://lens.org/097-740-916-151-961,Patent Application,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,ACTIVE
107,AU,A1,AU 2017/257956 A1,017-012-097-811-657,2018-11-15,2018,AU 2017/257956 A,2017-04-26,US 201662367377 P;;US 201662328396 P;;US 2017/0029635 W,2016-04-27,Compositions for use in treating tendon degeneration,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/017-012-097-811-657,Patent Application,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,ACTIVE
108,TW,B,TW I756221 B,037-572-996-893-896,2022-03-01,2022,TW 106114049 A,2017-04-27,US 201662328313 P,2016-04-27,Injectable biomaterial and makingmethod and use thereof and kit,,ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/037-572-996-893-896,Granted Patent,no,1,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,,,0,0,,,,ACTIVE
109,MX,A,MX 2018012965 A,032-705-061-519-545,2019-06-06,2019,MX 2018012965 A,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE.,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and a vascular necrosis.",ANIKA THERAPEUTICS INC,EDWARD S AHN;;CHIA-EN LIN;;COLIN D WHITE,,https://lens.org/032-705-061-519-545,Patent Application,no,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,PENDING
110,WO,A1,WO 2017/189733 A1,069-484-486-116-932,2017-11-02,2017,US 2017/0029651 W,2017-04-26,US 201662328313 P,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and a vascular necrosis",ANIKA THERAPEUTICS INC;;AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/069-484-486-116-932,Patent Application,yes,3,2,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,26,15,050-805-324-699-893;;079-917-155-143-075;;006-837-341-882-455;;044-676-914-321-692;;009-826-017-364-520;;137-899-486-143-649;;089-498-557-882-208;;067-853-870-646-274;;006-435-398-739-076;;021-069-836-946-558;;012-323-936-818-339;;036-529-943-767-423;;001-369-179-409-216;;066-428-476-761-414;;071-886-453-351-761,10.1179/1743676111y.0000000019;;23365809;;11774307;;10.1002/jbm.1263;;10.1007/s11999-015-4311-0;;pmc4457753;;25917421;;10.3390/ma10040334;;28772697;;pmc5506916;;19027947;;10.1016/j.biomaterials.2008.10.053;;2277045;;10.1016/0021-9290(90)90003-l;;10.1002/jor.1100020106;;6491796;;10.1002/jor.1100120506;;7931780;;10.1902/jop.2008.070038;;18251643;;10.1039/b811953h;;10.1080/0014013032000121660;;14668173;;28793687;;pmc5458904;;10.3390/ma8115430;;pmc4336550;;10.1002/acr.20632;;22588746;;10.1186/1471-2474-9-137;;pmc2575212;;18844988,"S AHMADZADEH-ASL ET AL: ""Preparation and characterisation of calcium phosphate-hyaluronic acid nanocomposite bone cement"", ADVANCES IN APPLIED CERAMICS: STRUCTURAL, FUNCTIONAL ANDBIOCERAMICS, vol. 110, no. 6, 1 August 2011 (2011-08-01), GB, pages 340 - 345, XP055393882, ISSN: 1743-6753, DOI: 10.1179/1743676111Y.0000000019;;ARTHRITIS FOUNDATION: WHAT IS OSTEOARTHRITIS, 12 April 2017 (2017-04-12), Retrieved from the Internet <URL:http://www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php>;;SHARKEY, P. F. ET AL., AM. J. ORTHOP. (BELLE MEAD NJ, vol. 41, no. 9, 2012, pages 413 - 17;;HISATOME, T. ET AL., J. BIOMED. MATER. RES., vol. 59, no. 3, 2002, pages 490 - 98;;CHATTERJEE, D. ET AL., CLIN. ORTHOP. RELAT. RES., vol. 473, no. 7, 2015, pages 2334 - 42;;TOFIGHI, A. ET AL., J. BIOMIMETICS BIOMAT. TISSUE ENG'G, vol. 2, 2009, pages 39 - 28;;FARR, J.; COHEN, S. B., OPER. TECH. SPORTS MED., vol. 21, no. 2, 2013, pages 138 - 43;;ELIAZ, N.; METOKI, N., MATERIALS, vol. 10, 2017, pages 334;;PEK, Y. S. ET AL., BIOMAT., vol. 30, 2009, pages 822 - 28;;AHMADZADEH-ASL, S. ET AL., ADV. APPLIED CERAMICS, vol. 110, no. 6, 2011, pages 340 - 45;;NORIAN® SRS9 TIABIA PLATEAU FRACTURES, SYNTHES®, 24 April 2017 (2017-04-24), Retrieved from the Internet <URL:http://www.rch.org.au/uploadedFiles/Main/Content/ortho/Norian_SRS_Tibia_plateau_fractur es.pdf>;;CHOI, K. ET AL., J. BIOMECH., vol. 23, no. 11, 1990, pages 1103 - 13;;BROWN, T. D.; VRAHAS, M. S. J., ORTHOPED. RES., vol. 2, no. 1, 1984, pages 32 - 38;;MENTE, P. L.; LEWIS, J. L. J., ORTHOPED. RES., vol. 12, no. 5, 1994, pages 637 - 47;;WEBB, P.: ""An introduction to the physical characterization of materials by mercury intrusion porosimetry with emphasis on reduction and presentation of experimental data"", 2001, MICROMERITICS INSTRUMENT CORP.;;NEIVA, R. F. ET AL., J. PERIODONTOL., vol. 79, no. 2, 2008, pages 291 - 99;;ASTM C414-03 AT 7.2, 8.2, 2012;;ASTM F1185-03, 2014;;ISO 13175-3, 2012;;BOHNER, M. ET AL., J. MATER. CHEM., vol. 18, 2008, pages 5669 - 75;;DIDOMENICO, A.; NUSSBAUM, M. A., ERGONOMICS, vol. 46, no. 15, 2003, pages 1531 - 1548;;SHEIKH, Z. ET AL., MATERIALS, vol. 8, 2015, pages 7913 - 25;;BONE-CEMENT DELIVERY SYSTEM (P-SYSTEM), 20 April 2017 (2017-04-20), Retrieved from the Internet <URL:http://www.medmix.ch/portfolio-item/bone-cement-delivery-system-p-system>;;COLLINS, N. J. ET AL., ARTHRITIS CARE RES. (HOBOKEN), vol. 63, no. 011, 2011, pages 208 - 228;;PATEL, P. S. D. ET AL., BMC MUSCULOSKELETAL DISORDERS, vol. 9, 2008, pages 137;;TRANSWEL1® PERMEABLE SUPPORTS SELECTION AND USE GUIDE, 24 April 2017 (2017-04-24), Retrieved from the Internet <URL:http://csmedia2.corning.com/LifeSciences/Media/pdt/transwell _ guide. pelf>",PENDING
111,CN,A,CN 109562124 A,093-628-174-676-594,2019-04-02,2019,CN 201780039455 A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,COMPOSITIONS FOR USE IN TREATING TENDON DEGENERATION,Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/093-628-174-676-594,Patent Application,no,3,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61P19/00,,0,0,,,,DISCONTINUED
112,US,A1,US 2017/0333594 A1,117-333-614-097-23X,2017-11-23,2017,US 201715670284 A,2017-08-07,US 201715670284 A;;US 201615149986 A;;US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-07-16),https://lens.org/117-333-614-097-23X,Patent Application,yes,0,1,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61L24/06;;A61K6/083;;A61K6/838;;A61K6/884;;A61L24/02;;A61L24/04,,0,0,,,,ACTIVE
113,US,A1,US 2021/0275720 A1,160-471-079-279-203,2021-09-09,2021,US 202017070183 A,2020-10-14,US 202017070183 A;;US 201715497720 A;;US 201662328313 P,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (“OA”), rheumatoid arthritis, and avascular necrosis.",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,ANIKA THERAPEUTICS INC (2017-05-24),https://lens.org/160-471-079-279-203,Patent Application,yes,1,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/20;;A61B17/34;;A61B17/88;;A61L24/00;;A61L27/02;;A61L27/12;;A61L27/46;;A61L27/50;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,PENDING
114,EP,A1,EP 3448447 A1,166-125-119-031-728,2019-03-06,2019,EP 17722590 A,2017-04-26,US 201662328313 P;;US 2017/0029651 W,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE,,ANIKA THERAPEUTICS INC;;AHN EDWARD S;;LIN CHIA EN;;WHITE COLIN D,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,"ANIKA THERAPEUTICS, INC. (2019-10-09)",https://lens.org/166-125-119-031-728,Patent Application,yes,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,ACTIVE
115,US,B2,US 9757493 B2,021-664-845-940-226,2017-09-12,2017,US 201615149986 A,2016-05-09,US 201615149986 A;;US 201414461138 A;;US 20091808 A;;US 96846207 P,2007-08-28,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation.",PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;SCHLOSSBERG BRIAN M,PIONEER SURGICAL TECHNOLOGY INC (2010-10-29),https://lens.org/021-664-845-940-226,Granted Patent,yes,63,4,16,16,0,A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/06;;A61L24/04;;A61K6/838;;A61K6/884;;A61K6/887;;A61L24/02;;A61L24/046;;A61L2430/02;;A61L2300/112;;A61L2300/412;;A61L2400/06;;A61L2400/12;;A61L2430/12,A61K6/083;;A61K6/838;;A61K6/884;;A61L24/02;;A61L24/04;;A61L24/06,,28,18,038-399-707-220-522;;058-009-416-650-791;;081-991-165-119-818;;142-308-826-149-38X;;002-974-894-406-198;;174-928-735-004-634;;065-082-320-859-616;;044-329-228-978-129;;024-150-338-971-192;;069-164-232-245-440;;116-522-166-790-802;;038-941-767-748-705;;017-684-871-981-930;;015-989-772-543-489;;017-281-044-576-345;;036-529-121-020-291;;021-926-143-771-429;;008-779-797-892-977,12866105;;10.1002/anie.200351244;;15520369;;10.1073/pnas.0407218101;;pmc528737;;10.1016/j.biomaterials.2006.09.028;;17034844;;10458268;;10.1016/s8756-3282(99)00127-1;;10.2136/sssaj2005.0158;;10.1016/s1381-5148(98)00054-6;;10.1002/1097-4628(20000919)77:12<2711::aid-app190>3.0.co;2-t;;10.1016/j.biomaterials.2005.10.023;;16313954;;10.1016/s0142-9612(02)00370-8;;12485798;;10.1021/bc060200l;;17226966;;17079046;;10.1016/j.jconrel.2006.09.009;;10.1016/s0142-9612(96)00082-8;;9003891;;10.1039/b309487a;;14594315;;10.1007/978-1-4020-4728-2_4;;14963178;;10.1097/01.rvi.0000109394.74740.56;;pmc7976525;;15313726;;10.1016/j.biomaterials.2007.01.037;;17367850;;16081184;;10.1016/j.jconrel.2005.06.022,"U.S. Appl. No. 12/200,918, filed Aug. 28, 2008.;;U.S. Appl. No. 14/461,138, filed Aug. 15, 2014.;;“Standard Specification for Acrylic Bone Cement,” Annual Book of ASTM Standards; Medical Devices, F 451-99a: 56-62 (1999).;;3M ESPE, “Z100™ MP Brochure,” (1-5) Retrieved from the internet on Jul. 28, 2005 from www.matweb.com/search/SpecifiedMaterialPrint.asp?bassnum=PMMM02.;;Anderson et al., “Semi-Automated Synthesis and Screening of a Large Library of Degradable Cationic Polymers for Gene Delivery,” Angew. Chem. Int. Ed., 42: 3153-3158 (2003).;;Anderson et al., “A polymer library approach to suicide gene therapy for cancer,” Proceedings of the National Academy of Sciences of the United States of America, 101(45): 16028-16033 (Nov. 1, 2004).;;Arote et al., “A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier,” Biomaterials, 28: 735-744 (2007).;;Brown, “Solubilities of Phosphates and Other Sparingly Soluble Compounds,” Environmental Phosphorus Handbook, (Griffith et al., eds.), 203-239 (John Wiley & Sons, New York, NY, 1973).;;Burton et al., Huntsman Corporation Brochure, 1-105 (Apr. 27, 2005).;;Deramond et al., “Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty” Bone, 25(2 Supplemental): 17S-21S (Aug. 1999).;;Farenhorst, “Importance of Soil Organic Matter Fractions in Soil-Landscape and Regional Assessments of Pesticide Sorption and Leaching in Soil,” Soil Sci. Soc. Am. J. 70: 1005-1012 (May-Jun. 2006).;;International Search Report with respect to PCT/US2008/074700 (Jun. 8, 2011).;;Jagur-Grodzinski et al., “Biomedical application of functional polymers,” Reactive & Functional Polymers, 39: 99-138 (1999).;;Jean et al., “Polyurethane Acrylate/Epoxy-Amine Acrylate Hybrid Polymer Networks,” J. Applied Polymer Science, 77: 2711-2717 (2000).;;Kim et al., “Highly effective and slow-biodegradable network-type cationic gene delivery polymer: Small library-like approach synthesis and characterization,” Biomaterials, 27: 2292-2301 (2006).;;Kincaid, “Epoxy Polyacrylate Hybrids . . . A Continuing Study,” Resolution Performance Products LLC tech paper, 1-15 (Nov. 2001).;;Kweon et al., “A novel degradable polycaprolactone networks for tissue engineering,” Biomaterials, 24: 801-808 (2003).;;Lin et al., “Novel Bioreducible Poly(amido amine)s for Highly Efficient Gene Delivery,” Bioconjugate Chemistry, 18 (1): 138-145 (Jan./Feb. 2007).;;Lin et al., “Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: Synthesis and in vitro gene transfer properties,” Journal of Controlled Release, 116 (2): 130-137 (Nov. 28, 2006).;;Liso et al., “Analysis of the leaching and toxicity of new amine activators for the curing of acrylic bone cements and composites,” Biomaterials, 18(1): 15-20 (1997).;;Liu et al., “Novel poly(amino ester)s obtained from Michael addition polymerizations of trifunctional amine monomers with diacrylates: safe and efficient DNA carriers,” Chemistry Communication, (20): 2630-26301 (Oct. 21, 2003).;;Loffredo et al., “The Role of Humic Substances in the Fate of Anthropogenic Organic Pollutants in Soil with Emphasis on Endocrine Disruptor Compounds,” Soil and Water Pollution Monitoring, Protection and Remediation, 3(23): 69-92 (2006).;;Nussbaum et al., “The Chemistry of Acrylic Bone Cements and Implications for Clinical Use in Image-guided Therapy,” J. Vasc. Interv. Radiol. 15(2): 121-126 (Feb. 2004).;;Pressly, “Complications Related to the Use of Bone Cement and Bone Void Fillers in Treating Compression Fractures of the Spine”, FDA Public Health Web Notification, 1-3 (May 7, 2004).;;Provenzano et al., “Bone Cements: Review of Their Physiochemical and Biochemical Properties in Percutaneous Vertebroplasty,” American Journal of Neuroradiology, 25(7): 1286-1290 (Aug. 2004).;;Serbetci et al., “Mechanical and Thermal Properties of Hydroxyapatite-Impregnated Bone Cement,” Turk. J. Med. Sci., 30: 543-549 (2000).;;Srinivasachari et al., “Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy,” Biomaterials, 28: 2885-2898 (2007).;;Zhong et al., “A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s,” Journal of Controlled Release, 109 (1-3): 317-329 (Dec. 5, 2005).",INACTIVE
116,KR,A,KR 20190009303 A,175-469-710-742-24X,2019-01-28,2019,KR 20187033872 A,2017-04-26,US 201662328396 P;;US 201662367377 P;;US 2017/0029635 W,2016-04-27,건 퇴행의 치료에 사용하기 위한 조성물,본원에는 동물 또는 인간에서 손상된 건을 치료하기 위한 주사 가능한 조성물 및 방법이 개시되어 있다. 그 주사 가능한 조성물은 골건 수분공급 및 윤활을 증가시키기 위한 유효량의 탄수화물을 포함한다.,ANIKA THERAPEUTICS INC,WHITE COLIN D;;AHN EDWARD S;;NOEL SEKONI DAOUDA,,https://lens.org/175-469-710-742-24X,Patent Application,no,0,0,27,27,0,A61K31/715;;A61P19/00;;A61P19/04;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/10;;A61L27/386;;A61K31/715;;A61P19/04;;A61K9/0019;;A61K9/06;;A61K31/715;;A61K38/39;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2430/10;;A61L2400/06;;A61K31/715;;A61L27/20;;A61L27/386;;A61L27/50;;A61L2400/06;;A61L2430/10,A61K31/715;;A61K9/00;;A61K9/06;;A61K38/39;;A61L27/20;;A61L27/38;;A61L27/50;;A61P19/04,,0,0,,,,DISCONTINUED
117,MX,A,MX 2022013092 A,014-561-800-152-562,2023-01-16,2023,MX 2022013092 A,2018-10-23,US 201662328313 P,2016-04-27,METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATE BONE.,"The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (""OA""), rheumatoid arthritis, and a vascular necrosis.",ANIKA THERAPEUTICS INC,AHN EDWARD S;;LIN CHIA-EN;;WHITE COLIN D,,https://lens.org/014-561-800-152-562,Patent Application,no,0,0,24,24,0,A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L2400/06;;A61L2430/02;;A61P19/02;;A61P19/08;;A61B17/3468;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61L24/0031;;A61L24/0036;;A61L24/0042;;A61L24/0084;;A61L27/12;;A61L27/20;;A61L27/46;;A61L27/52;;A61L27/56;;A61L27/58;;A61B2017/00893;;A61B2017/8838;;A61L2400/06;;A61L2430/02;;A61L24/0036;;A61L24/0042;;A61L24/0031;;A61L27/46;;A61L27/52;;A61L27/56;;A61L24/0084;;A61L27/58;;A61B17/3472;;A61B17/8816;;A61B17/8825;;A61B17/8833;;A61B2017/00893;;A61B2017/8838;;A61L27/025;;A61L27/12;;A61L27/20;;A61L27/50;;A61L2400/06;;A61L2430/02,A61L27/46;;A61L24/00;;A61L27/52;;A61L27/56;;A61L27/58,,0,0,,,,PENDING
118,EP,A3,EP 0423761 A3,000-177-361-078-449,1992-08-05,1992,EP 90119918 A,1990-10-17,US 42286489 A,1989-10-17,APPARATUS AND METHOD FOR PARTICLE REMOVAL BY FORCED FLUID CONVECTION,"An apparatus and method for removing contaminant particles from a surface, such as a semiconductor wafer (12), using the effect of a phase change of a condensate fluid, from liquid to solid form, on the adhesion force between a contaminant particle and a surface. Contaminant particles (172) are removed from a surface by wetting the particles with a thin film (20) of a removal fluid of a type that exhibits a volume expansion during a liquid to solid phase change, and then freezing the removal fluid to cause such expansion . Frozen material (21) including contaminant particles (172) is then removed from the surface by melting and throw-off of frozen material. Steam may be used for both the removal fluid and for melting the frozen material.  ","APPLIED MATERIALS, INC.","LORIMER, D'ARCY;;LIU, BENJAMIN Y.H.;;BAKER, EDWARD;;AHN, KANG HO",,https://lens.org/000-177-361-078-449,Search Report,yes,3,0,4,4,0,B08B5/00;;B08B7/0014;;B08B7/0064;;H01L21/02043;;H01L21/02052;;H01L21/67051,B08B7/00;;H01L21/00;;H01L21/304;;H01L21/306,,4,0,,,"PATENT ABSTRACTS OF JAPAN vol. 9, no. 225 (E-342)(1948) 11 September 1985 & JP-A-60 083 333 ( FUJITSU );;PATENT ABSTRACTS OF JAPAN vol. 7, no. 21 (E-155)(1166) 27 January 1983 & JP-A-57 178 328 ( HITACHI );;PATENT ABSTRACTS OF JAPAN vol. 7, no. 255 (E-210)12 November 1983 & JP-A-58 141 527 ( HITACHI );;PATENT ABSTRACTS OF JAPAN vol. 1, no. 1 (E-371)7 January 1986 & JP-A-60 165 727 ( TOSHIBA )",DISCONTINUED
119,EP,A1,EP 2182447 A1,008-785-308-109-373,2010-05-05,2010,EP 09174899 A,2009-11-03,KR 20080108474 A,2008-11-03,Real-time semantic annotation system and the method of creating ontology documents on the fly from natural language string entered by user,"Disclosed herein are a real-time semantic annotation system and a method of converting user-entered natural language strings into semantically-readable knowledge structure documents using the system in real time. The real-time semantic annotation system includes a natural language character string input device for enabling a user to enter natural language character strings, a character string pattern triplet-mapping table for storing natural language character string patterns and their corresponding triplets, a triplet extraction device for converting the entered natural language character strings into triplets by analyzing and processing the entered natural language character strings using the pattern-triplet mapping table, an alternative word recommendation device for providing notification that a user should enter an alternative word, and a machine-readable document generation device for generating machine-readable documents from the triplets using a semantically-readable knowledge structure.",CHOI KEY-SUN;;AHN JINHYUN;;BYUN EDWARD KANGSUP,JUNG JASON J;;CHOI KEY-SUN;;AHN JINHYUN;;BYUN EDWARD KANGSUP,,https://lens.org/008-785-308-109-373,Patent Application,yes,0,4,4,4,0,G06F16/367;;G06F40/169;;G06F40/30;;G06F16/367;;G06F40/169;;G06F40/30,G06F17/24;;G06F17/27;;G06F17/30;;G06F40/00;;G06F40/191,,10,3,012-837-358-654-034;;068-358-114-651-842;;005-739-856-722-842,10.1109/wiiat.2008.229;;10.1109/wetice.2006.46;;10.1016/j.websem.2007.11.003,"JINHYUN AHN ET AL: ""Interleaving Ontology Mapping for Online Semantic Annotation on Semantic Wiki"", WEB INTELLIGENCE AND INTELLIGENT AGENT TECHNOLOGY, 2008 IEEE/WIC/ACM INTERNATIONAL CONFERENCE ON, IEEE, PISCATAWAY, NJ, USA, 9 December 2008 (2008-12-09), pages 25 - 28, XP031403117, ISBN: 978-0-7695-3496-1;;EYAL OREN: ""SemperWiki: a semantic personal Wiki"", PROC OF 1ST WS ON THE SEMANTIC DESKTOP, November 2005 (2005-11-01), Galway, Ireland, XP002564803, Retrieved from the Internet <URL:http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.61.6422&rep=rep1&type=pdf> [retrieved on 20100122];;TOBIAS KUHN: ""AceWiki: A Natural and Expressive Semantic Wiki"", SEMANTIC WEB USER INTERACTION AT CHI 2008: EXPLORING HCI CHALLENGES, 5 April 2008 (2008-04-05), Florence, Italy, XP002564804, Retrieved from the Internet <URL:http://attempto.ifi.uzh.ch/site/pubs/papers/kuhn08acewiki.pdf> [retrieved on 20100122];;KARSTEN DELLO, ELENA PASLARU BONTAS SIMPERL, AND ROBERT TOLKSDORF: ""Creating and using Semantic Web information with Makna"", FIRST WORKSHOP ON SEMANTIC WIKIS: FROM WIKI TO SEMANTICS, 12 June 2006 (2006-06-12), Budva (Montenegro), XP002564805, Retrieved from the Internet <URL:http://stoc.ag-nbi.de/papers/semwiki06paper.pdf> [retrieved on 20100122];;SEBASTIAN SCHAFFERT: ""IkeWiki: A Semantic Wiki for Collaborative Knowledge Management"", ENABLING TECHNOLOGIES: INFRASTRUCTURE FOR COLLABORATIVE ENTERPRISES, 2 006. WETICE '06. 15TH IEEE INTERNATIONAL WORKSHOPS ON, IEEE, PI, 1 June 2006 (2006-06-01), pages 388 - 396, XP031044592, ISBN: 978-0-7695-2623-2;;HACÈNE CHERFI, OLIVIER CORBY, CATHERINE FARON-ZUCKER, KHALED KHELIF, M. T. NGUYEN: ""Semantic Annotation of Texts with RDF Graph Contexts"", SUPPLEMENTARY PROCEEDINGS OF THE 16TH INTERNATIONAL CONFERENCE ON CONCEPTUAL STRUCTURES, ICCS 2008, 7 July 2008 (2008-07-07) - 11 July 2008 (2008-07-11), toulouse, France, XP002564806, Retrieved from the Internet <URL:http://www.inria.fr/sophia/members/Hacene.Cherfi/resources/publis/iccs08.pdf> [retrieved on 20100122];;BUFFA ET AL: ""SweetWiki: A semantic wiki"", WEB SEMANTICS: SCIENCE, SERVICES AND AGENTS ON THE WORLD WIDE WEB, ELSEVIER, vol. 6, no. 1, 17 November 2007 (2007-11-17), pages 84 - 97, XP022495554, ISSN: 1570-8268;;J. HEFLIN; J. HENDLER; S. LUKE: ""Technical Report CS-TR-4078"", 1999, DEPT. OF COMPUTER SCIENCE, article ""Shoe: A knowledge representation language for internet applications"";;B. JUNG ET AL.: ""Annotizer: User-friendly www annotation system for collaboration in research and education environments"", THE IASTED INTERNATIONAL CONFERENCE ON WEB TECHNOLOGIES, APPLICATIONS AND SERVICES, WTAS 2006, 2006;;M. BACKHAUS; J. KELSO: ""16th International World Wide Web Conference (www2007)"", vol. 273, 8 May 2007, article ""Proceedings of the workshop on social and collaborative construction of structured knowledge""",DISCONTINUED
120,US,B1,US 11776193 B1,029-228-745-363-038,2023-10-03,2023,US 202117215115 A,2021-03-29,US 202117215115 A;;US 202063016809 P,2020-04-28,Granular motion control for a virtual agent,"Various implementations disclosed herein include devices, systems, and methods for granular motion control for a virtual agent. In various implementations, a device includes a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, a method includes obtaining an action for a virtual agent. In some implementations, the action is associated with a plurality of time frames. In some implementations, the method includes, for a first time frame of the plurality of time frames, determining respective confidence scores for a plurality of granular motions that advance the virtual agent towards completion of the action. In some implementations, the method includes selecting a subset of the plurality of granular motions based on the respective confidence scores.",APPLE INC,SIVAPURAPU SIVA CHANDRA MOULI;;MANGLIK AASHI;;AHN EDWARD S;;DRUMMOND MARK,APPLE INC (2021-03-15),https://lens.org/029-228-745-363-038,Granted Patent,yes,3,0,2,2,0,G06T13/40;;G06T13/80;;G06T7/251;;G06T2207/20084;;G06T2207/30241;;G06T2207/20081;;G06T13/40,G06T13/80;;G06T7/246;;G06T13/40,,1,1,058-861-580-909-957,10.1145/2501988.2502045,"Anderson, Fraser, et al. “YouMove: enhancing movement training with an augmented reality mirror.” 2013, Proceedings of the 26th annual ACM symposium on User interface software and technology. 2013, pp. 311-320 (Year: 2013).",ACTIVE
121,WO,A3,WO 2007/019461 A3,157-843-516-899-766,2007-05-10,2007,US 2006/0030764 W,2006-08-08,US 70647305 P,2005-08-08,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA INC;;LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,,https://lens.org/157-843-516-899-766,Search Report,yes,4,0,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K6/00;;A61K6/884;;A61K6/891;;A61L24/04,,0,0,,,,PENDING
122,DE,D1,DE 602006018023 D1,101-302-954-177-284,2010-12-16,2010,DE 602006018023 T,2006-08-08,US 70647305 P;;US 2006/0030764 W,2005-08-08,ZEMENTPRODUKTE SOWIE VERFAHREN ZU DEREN HERSTELLUNG UND VERWENDUNG,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA INC,LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,,https://lens.org/101-302-954-177-284,Granted Patent,no,0,0,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K6/00;;A61K6/884;;A61K6/891;;A61L24/04,,0,0,,,,ACTIVE
123,EP,A2,EP 1922052 A2,173-835-109-411-348,2008-05-21,2008,EP 06800903 A,2006-08-08,US 2006/0030764 W;;US 70647305 P,2005-08-08,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA INC,LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,,https://lens.org/173-835-109-411-348,Patent Application,yes,0,0,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K6/00;;A61K6/884;;A61K6/891;;A61L24/04,,0,0,,,,ACTIVE
124,US,A1,US 2007/0032568 A1,055-896-777-199-531,2007-02-08,2007,US 50079806 A,2006-08-08,US 50079806 A;;US 70647305 P,2005-08-08,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA,LIN JUCHUI R;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;ANGSTROM ACQUISITION CORP. II (2007-10-23);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;ANGSTROM MEDICA (2007-07-11);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/055-896-777-199-531,Patent Application,yes,78,44,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K6/884;;A61K6/891,523/116,0,0,,,,ACTIVE
125,US,B2,US 8795382 B2,100-159-169-399-169,2014-08-05,2014,US 98246110 A,2010-12-30,US 98246110 A;;US 50079806 A;;US 70647305 P,2005-08-08,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J;;PIONEER SURGICAL TECH INC,LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;ANGSTROM ACQUISITION CORP. II (2007-10-23);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;ANGSTROM MEDICA INC (2007-07-11);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/100-159-169-399-169,Granted Patent,yes,95,12,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61F2/30;;A61F2/00;;A61K6/083;;A61K6/884;;A61K6/891,623/23.62;;523/115,43,33,038-399-707-220-522;;058-009-416-650-791;;081-991-165-119-818;;142-308-826-149-38X;;174-928-735-004-634;;065-082-320-859-616;;044-329-228-978-129;;036-948-967-031-441;;024-150-338-971-192;;069-164-232-245-440;;116-522-166-790-802;;038-941-767-748-705;;017-684-871-981-930;;005-113-567-209-888;;017-281-044-576-345;;036-529-121-020-291;;021-926-143-771-429;;008-779-797-892-977;;057-769-884-836-269;;001-928-408-711-426;;047-525-991-478-010;;062-062-006-463-093;;020-228-114-596-196;;011-108-069-111-184;;124-910-358-027-435;;024-995-820-148-06X;;039-525-577-645-530;;053-299-705-514-215;;019-679-658-136-208;;005-870-893-758-776;;115-389-168-993-367;;025-009-938-664-640;;023-093-143-345-189,12866105;;10.1002/anie.200351244;;15520369;;10.1073/pnas.0407218101;;pmc528737;;10.1016/j.biomaterials.2006.09.028;;17034844;;10458268;;10.1016/s8756-3282(99)00127-1;;10.1016/s1381-5148(98)00054-6;;10.1002/1097-4628(20000919)77:12<2711::aid-app190>3.0.co;2-t;;10.1016/j.biomaterials.2005.10.023;;16313954;;10.1016/s0142-9612(03)00044-9;;12699652;;10.1016/s0142-9612(02)00370-8;;12485798;;10.1021/bc060200l;;17226966;;17079046;;10.1016/j.jconrel.2006.09.009;;10.1016/s0142-9612(96)00082-8;;9003891;;10.1039/b309487a;;14594315;;16564082;;10.1016/j.biomaterials.2006.03.007;;14963178;;10.1097/01.rvi.0000109394.74740.56;;pmc7976525;;15313726;;10.1016/j.biomaterials.2007.01.037;;17367850;;16081184;;10.1016/j.jconrel.2005.06.022;;10.1302/0301-620x.51b3.540;;5820800;;14554075;;10.1016/s0300-5712(03)00115-5;;18628196;;10.1016/s1543-2912(13)60044-2;;15672244;;pmc3454663;;10.1007/s00586-004-0822-1;;21359976;;10.1007/s00256-011-1114-6;;22523935;;12711518;;10.1016/s0142-9612(03)00086-3;;10.36076/ppj.2012/15/223;;22622906;;pmc3325397;;10.1007/s00586-012-2221-3;;22411037;;10.1088/0957-4484/18/47/475104;;10.1016/j.spinee.2011.07.027;;21889417;;10.1111/j.1601-1546.2005.00197.x;;10.1002/jbmr.5650020617;;3455637;;pmc2904930;;10.3390/ijms11062523;;20640166;;pmc3179283;;20564249;;10.1002/jbmr.164,"American Society for Testing and Materials, ""Standard Specification for Acrylic Bone Cement,"" Annual Book of ASTM Standards; Medical Devices, F 451-99a: 56-62 (1999).;;3M ESPE, ""Z100(TM) MP Brochure,"" (1-5) Retrieved from the Internet on Jul. 28, 2005 from www.matweb.com/search/SpecifiedMaterialPrint.asp?bassnum= PMMM02.;;Anderson et al., ""Semi-Automated Synthesis and Screening of a Large Library of Degradable Cationic Polymers for Gene Delivery,"" Angew. Chem. Int. Ed., 42: 3153-3158 (2003).;;Anderson et al., ""A polymer library approach to suicide gene therapy for cancer,"" Proceedings of the National Academy of Sciences of the United States of America, 101(45):16028-16033 (Nov. 1, 2004).;;Arote et al., ""A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier,"" Biomaterials, 28: 735-744 (2007).;;Brown, ""Solubilities of Phosphates and Other Sparingly Soluble Compounds,"" Environmental Phosphorus Handbook, (Griffith et al., eds.), 203-239 (John Wiley & Sons, Inc. New York, NY, 1973).;;Burton et al., ""Epoxy Formulations Using Jeffamine® Polyetheramines,"" Huntsman Corporation Brochure, 1-105 (Apr. 27, 2005).;;Deramond et al., ""Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty,"" Bone, 25(2 Supplement): 17S-21S, (Aug. 1999).;;European Patent Office, Examination Report in European Patent Application No. 06 800 903.4 (Sep. 17, 2009).;;Jagur-Grodzinski et al., ""Biomedical application of functional polymers,"" Reactive & Functional Polymers, 39: 99-138 (1999).;;Jean et al., ""Polyurethane Acrylate/Epoxy-Amine Acrylate Hybrid Polymer Networks,"" J. Applied Polymer Science, 77: 2711-2717 (2000).;;Kim et al., ""Highly effective and slow-biodegradable network-type cationic gene delivery polymer: Small library-like approach synthesis and characterization,"" Biomaterials, 27: 2292-2301 (2006).;;Kincaid, ""Epoxy Polyacrylate Hybrids . . . A Continuing Study,"" Resolution Performance Products LLC tech paper, 1-15 (Nov. 2001).;;Kokubo et al., ""Novel bioactive materials with different mechanical properties,"" Biomaterials, 24(13): 2161-2175 (2003).;;Kweon et al., ""A novel degradable polycaprolactone networks for tissue engineering,"" Biomaterials, 24: 801-808 (2003).;;Lin et al., ""Novel Bioreducible Poly(amido amine)s for Highly Efficient Gene Delivery,"" Bioconjugate Chemistry, 18 (1): 138-145 (Jan./Feb. 2007).;;Lin et al., ""Linear poly(amido amine)s with secondary and tertiary amino groups and variable amounts of disulfide linkages: Synthesis and in vitro gene transfer properties,"" Journal of Controlled Release, 116 (2): 130-137 (Nov. 28, 2006).;;Liso et al., ""Analysis of the Leaching and Toxicity of New Amine Activators for the Curing of Acrylic Bone Cements and Composites,"" Biomaterials, 18(1): 15-20 (Jan. 1997).;;Liu et al., ""Novel poly(amino ester)s obtained from Michael addition polymerizations of trifunctional amine monomers with diacrylates: safe and efficient DNA carriers,"" Chemistry Communication, (20): 2630-26301 (Oct. 21, 2003).;;Liu et al., ""Bioactivity and cytocompatibility of zirconia (ZrO2) films fabricated by cathodic arc deposition,"" Biomaterials, 27: 3904-3911 (2006).;;Nussbaum et al., ""The Chemistry of Acrylic Bone Cements and Implications for Clinical Use in Image-guided Therapy,"" J. Vascular and Interventional Radiology., 15(2): 121-126 (Feb. 2004).;;Pressly, ""Complications Related to the Use of Bone Cement and Bone Void Fillers in Treating Compression Fractures of the Spine"", FDA Public Health Web Notification, 1-3 (May 7, 2004).;;Provenzano et al., ""Bone Cements: Review of Their Physiochemical and Biochemical Properties in Percutaneous Vertebroplasty,"" Am. J. Neuroradiol., 25: 1286-1290 (Aug. 2004).;;Serbetci et al. ""Mechanical and Thermal Properties of Hydroxyapatite-Impregnated Bone Cement,"" Turk J. Med. Sci., 30: 543-549 (2000).;;Srinivasachari et al., ""Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy,"" Biomaterials, 28: 2885-2898 (2007).;;Zhong et al., ""A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s,"" Journal of Controlled Release, 109 (1-3): 317-329 (Dec. 5, 2005).;;European Patent Office, International Search Report dated Feb. 20, 2007, in PCT/US2006/030764.;;Amstutz et al., ""The Structure of the Vertebral Spongiosa,"" The Journal of Bone and Joint Surgery, 51B(3): 540-550 (Aug. 1969).;;Arrais et al., ""Occluding effect of dentifrices on dentinal tubules,"" Journal of Dentistry, 31: 577-584 (2003).;;Baroud, A Brief Update on the Biomechanisms Underlying Cement Injection and Leakage in Vertebroplasty, Supportive Cancer Therapy, 2(2): 105-108 (Jan. 2005).;;Baroud et al., ""A new cannula to ease cement injection during vertebroplasty,"" Eur. Spine J., 14: 474-479 (2005).;;Basile et al., ""Vertebroplasty in multiple myeloma with osteolysis or fracture of the posterior vertebral wall. Usefulness of a delayed cement injection,"" Skeletal Radiol, 40: 913-919 (2011).;;Bastian et al., ""Complications related to cement leakage in sacroplasty,"" Acta Orthopaedica Belgica, 7891): 100-105 (2012).;;Bohner et al., ""Theoretical and experimental model to describe the injection of a polymethylmethacrylate cement into a porous structure,"" Biomaterials, 24: 2721-2730 (2003).;;Georgy, ""Feasibility, Safety and Cement Leakage in Vertebroplasty of Osteoporotic and Malignant Compression Fractures Using Ultra-Viscous Cement and Hydraulic Delivery System,"" Pain Physician, 15: 223-228 (May/Jun. 2012).;;Kubinek et al., ""Examination of dentin surface using AFM and SEM,"" Modern Research and Educational Topics in Microscopy, (Eds. Méndez-Vilas and Diaz), 593-598 (2007).;;La Maida et al., ""Cement leakage: safety of minimally invasive surgical techniques in the treatment of multiple myeloma vertebral lesions,"" Eur. Spine J., 21(Suppl. 1): S61-S68 (2012).;;Liu et al., ""Filling in dentinal tubules,"" Nanotechnology, 18: 1-6 (2007).;;Nieuwenhuijse et al., ""Cement leakage in percutaneous vertebroplasty for osteoporotic vertebral compression fractures: identification of risk factors,"" The Spine Journal, 1-10 (2011).;;Ørstavik, ""Materials used for root canal obturation: Technical, biological and clinical testing,"" Endodontic Topics, 12: 25-38 (2005).;;Parfitt et al., ""Bone Histomorphometry: Standardization of Nomenclature, Symbols, and Units, Report of the ASBMR Histomorphometry Nomenclature Committee,"" Journal of Bone and Mineral Research, 2(6): 595-610 (1987).;;Sharma et al., ""Nanocharacterization in Dentistry,"" Int. J. Mol. Sci., 11: 2523-2545 (2010).;;Wegrzyn et al., ""Role of Trabecular Microarchitecture and Its Heterogeneity Parameters in the Mechanical Behavior of Ex Vivo Human L3 Vertebrae,"" Journal of Bone and Mineral Research, 25(11): 2324-2331 (Nov. 2010).",ACTIVE
126,EP,B1,EP 1922052 B1,044-406-082-664-851,2010-11-03,2010,EP 06800903 A,2006-08-08,US 2006/0030764 W;;US 70647305 P,2005-08-08,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA INC,LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,,https://lens.org/044-406-082-664-851,Granted Patent,yes,4,0,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K6/00;;A61K6/884;;A61K6/891;;A61L24/04,,0,0,,,,ACTIVE
127,US,B2,US 7947759 B2,002-412-565-555-833,2011-05-24,2011,US 50079806 A,2006-08-08,US 50079806 A;;US 70647305 P,2005-08-08,Cement products and methods of making and using the same,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA,LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;ANGSTROM ACQUISITION CORP. II (2007-10-23);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;ANGSTROM MEDICA (2007-07-11);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/002-412-565-555-833,Granted Patent,yes,81,16,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K6/884;;A61K6/891;;C08G59/68;;C09K3/00,523/116;;522/25;;106/35,26,17,005-113-567-209-888;;142-308-826-149-38X;;038-941-767-748-705;;036-529-121-020-291;;038-399-707-220-522;;058-009-416-650-791;;081-991-165-119-818;;174-928-735-004-634;;065-082-320-859-616;;044-329-228-978-129;;024-150-338-971-192;;116-522-166-790-802;;069-164-232-245-440;;017-281-044-576-345;;021-926-143-771-429;;008-779-797-892-977;;036-948-967-031-441,16564082;;10.1016/j.biomaterials.2006.03.007;;10458268;;10.1016/s8756-3282(99)00127-1;;10.1016/s0142-9612(96)00082-8;;9003891;;pmc7976525;;15313726;;12866105;;10.1002/anie.200351244;;15520369;;10.1073/pnas.0407218101;;pmc528737;;10.1016/j.biomaterials.2006.09.028;;17034844;;10.1016/s1381-5148(98)00054-6;;10.1002/1097-4628(20000919)77:12<2711::aid-app190>3.0.co;2-t;;10.1016/j.biomaterials.2005.10.023;;16313954;;10.1016/s0142-9612(02)00370-8;;12485798;;17079046;;10.1016/j.jconrel.2006.09.009;;10.1021/bc060200l;;17226966;;14963178;;10.1097/01.rvi.0000109394.74740.56;;10.1016/j.biomaterials.2007.01.037;;17367850;;16081184;;10.1016/j.jconrel.2005.06.022;;10.1016/s0142-9612(03)00044-9;;12699652,"Liu et al. Biomaterials 27, 2006, 3904-3911.;;""Standard Specification for Acrylic Bone Cement,"" Annual Book of ASTM Standards; Medical Devices, F 451-99a: 56-62 (1999).;;Brown, ""Solubilities of Phosphates and Other Sparingly Soluble Compounds,"" Environmental Phosphorus Handbook, (Griffith et al., eds.), 203-239 (John Wiley & Sons, Inc. New York, NY, 1973).;;Deramond et al., ""Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty,"" Bone, 25(2 Supplement): 17S-21S, (Aug. 1999).;;Liso et al., ""Analysis of the Leaching and Toxicity of New Amine Activators for the Curing of Acrylic Bone Cements and Composites,"" Biomaterials, 18(1): 15-20 (Jan. 1997).;;Provenzano et al., ""Bone Cements: Review of Their Physiochemical and Biochemical Properties in Percutaneous Vertebroplasty,"" Am. J. Neuroradiol., 25: 1286-1290 (Aug. 2004).;;Serbetci et al. ""Mechanical and Thermal Properties of Hydroxyapatite-Impregnated Bone Cement,"" Turk J. Med. Sci., 30: 543-549 (2000).;;3M ESPE, ""Z100(TM) MP Brochure,"" (1-5) Retrieved from the internet on Jul. 28, 2005 from www.matweb.com/search/SpecifiedMaterialPrint.asp?bassnum= PMMM02.;;Anderson et al., Angew. Chem. Int. Ed., 42: 3153-3158 (2003).;;Anderson et al., Proceedings of the National Academy of Sciences of the United States of America, 101(45):16028-16033 (Nov. 1, 2004).;;Arote et al., Biomaterials, 28: 735-744 (2007).;;Burton et al Huntsman Corporation Brochure, 1-105 (Apr. 27, 2005).;;Jagur-Grodzinski et al., Reactive & Functional Polymers, 39: 99-138 (1999).;;Jean et al., J. Applied Polymer Science, 77: 2711-2717 (2000).;;Kim et al. Biomaterials, 27: 2292-2301 (2006).;;Kincaid, ""Epoxy Polyacrylate Hybrids . . . A Continuing Study,"" Resolution Performance Products LLC tech paper, 1-15 (Nov. 2001).;;Kweon et al., Biomaterials, 24: 801-808 (2003).;;Lin et al., Journal of Controlled Release, 116 (2): 130-137 (Nov. 28, 2006).;;Lin et al., Bioconjugate Chemistry, 18 (1): 138-145 (Jan./Feb. 2007).;;Liu et al., Chemistry Communication, (20): 2630-26301 (Oct. 21, 2003).;;Nussbaum et al., J. Vascular and Interventional Radiology., 15: 121-126 (2004).;;Pressly, ""Complications Related to the Use of Bone Cement and Bone Void Fillers in Treating Compression Fractures of the Spine"", FDA Public Health Web Notification, 1-3 (May 7, 2004).;;Srinivasachari et al., Biomaterials, 28: 2885-2898 (2007).;;Zhong et al Journal of Controlled Release, 109 (1-3): 317-329 (Dec. 5, 2005).;;European Patent Office, Examination Report in European Patent Application No. 06 800 903.4 (Sep. 17, 2009).;;Kokubo et al., ""Novel Bioactive Materials with Different Mechanical Properties,"" Biomaterials, vol. 24, No. 13, pp. 2161-2175 (2003) Kyoto, Japan.",ACTIVE
128,US,A1,US 2024/0020905 A1,161-662-182-075-426,2024-01-18,2024,US 202318237625 A,2023-08-24,US 202318237625 A;;US 202117215115 A;;US 202063016809 P,2020-04-28,GRANULAR MOTION CONTROL FOR A VIRTUAL AGENT,"Various implementations disclosed herein include devices, systems, and methods for granular motion control for a virtual agent. In various implementations, a device includes a non-transitory memory and one or more processors coupled with the non-transitory memory. In some implementations, a method includes obtaining an action for a virtual agent. In some implementations, the action is associated with a plurality of time frames. In some implementations, the method includes, for a first time frame of the plurality of time frames, determining respective confidence scores for a plurality of granular motions that advance the virtual agent towards completion of the action. In some implementations, the method includes selecting a subset of the plurality of granular motions based on the respective confidence scores.",APPLE INC,SIVAPURAPU SIVA CHANDRA MOULI;;MANGLIK AASHI;;AHN EDWARD S;;DRUMMOND MARK,,https://lens.org/161-662-182-075-426,Patent Application,yes,0,0,2,2,0,G06T13/40;;G06T13/80;;G06T7/251;;G06T2207/20084;;G06T2207/30241;;G06T2207/20081;;G06T13/40,G06T13/80;;G06T7/246;;G06T13/40,,0,0,,,,PENDING
129,US,B1,US 10749729 B1,193-397-243-871-116,2020-08-18,2020,US 201916424328 A,2019-05-28,US 201916424328 A,2019-05-28,System and method for automatic gain control adaptation,"A circuit includes an AGC adaptation circuit configured to receive a first signal generated based on an AGC output signal from an AGC circuit. The AGC circuit applies an AGC gain to an AGC input signal to generate the AGC output signal. The AGC adaptation circuit determines an observed value of the first signal, and determines a AGC adaptation step size based on the observed value and a predetermined target value associated with the first signal. The AGC adaptation circuit provides a second signal to adjust the AGC gain of the AGC circuit using the AGC adaptation step size.",XILINX INC,WONG ALAN C;;AHN HONG SIK;;LEE EDWARD;;BORRELLI CHRISTOPHER J,XILINX INC (2019-05-20),https://lens.org/193-397-243-871-116,Granted Patent,yes,10,0,1,1,0,H04L25/03057;;H04L27/3809;;H03G3/3036;;H03G3/3036;;H03G3/3052;;H03G5/16;;H04B1/16;;H04B1/16;;H04L25/03057;;H04L25/03114;;H04L25/03885,H04L27/12;;H03G3/30;;H04B1/16;;H04B1/20;;H04L25/03;;H04L27/38,,0,0,,,,ACTIVE
130,WO,A2,WO 2007/019461 A2,036-660-412-171-747,2007-02-15,2007,US 2006/0030764 W,2006-08-08,US 70647305 P,2005-08-08,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA INC;;LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,,https://lens.org/036-660-412-171-747,Patent Application,yes,0,9,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K6/884;;A61K6/891,,0,0,,,,PENDING
131,US,B1,US 11430170 B1,023-222-530-774-328,2022-08-30,2022,US 202117173480 A,2021-02-11,US 202117173480 A;;US 202062982284 P,2020-02-27,Controlling joints using learned torques,"A method includes obtaining video data including a representation of a first plurality of motions of a real-world entity. The method includes determining, from the video data, a plurality of estimated torque values using a motion controller. The plurality of estimated torque values is associated with a plurality of real-world joints corresponding to the first plurality of motions. The method includes generating a second plurality of motions of a virtual agent by providing the plurality of estimated torque values to a corresponding plurality of virtual joints of the virtual agent. Movement of the virtual agent is controllable by the plurality of virtual joints, corresponding to the plurality of real-world joints of the real-world entity. The method includes, responsive to a determination that a comparison between the first plurality of motions and the second plurality of motions does not satisfy a performance metric, changing an operational value of the motion controller.",APPLE INC,SIVAPURAPU SIVA CHANDRA MOULI;;AHN EDWARD S;;DRUMMOND MARK;;MANGLIK AASHI,APPLE INC (2020-12-16),https://lens.org/023-222-530-774-328,Granted Patent,yes,3,0,1,1,0,G06T7/246;;G06T2207/20084;;G06T2207/30196;;G06T13/40;;G06T7/248;;G06T2207/30196;;G06T2207/10016;;G06T2207/20084;;G06T7/70,G06T13/40;;G06T7/246;;G06T7/70,,4,3,034-588-626-103-663;;167-126-201-799-366;;065-756-096-721-994,10.1007/978-3-030-01270-0_45;;10.1007/978-3-030-01249-6_37;;19261287;;10.1016/j.jbiomech.2009.01.033,"“Barrett et al., Humanoid Robots Learning to Walk Faster: From the Real World to Simulation and Back” (Year: 2013).;;“Yuan et al., 3D Ego-pose Estimation Via Imitation Learning” (Year: 2018).;;“Marcard et al., Recovering Accurate 3D Human Pose in the Wild Using IMUs and a Moving Camera” (Year: 2018).;;“Liu et al., Lower Extremity Joint Torque Predicted by using Artificial Neural Network During Vertical Jump” (Year: 2009).",ACTIVE
132,US,A1,US 2011/0097420 A1,190-860-515-945-311,2011-04-28,2011,US 98246110 A,2010-12-30,US 98246110 A;;US 50079806 A;;US 70647305 P,2005-08-08,CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME,"Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component comprising a polymerizable resin comprising ethylenic unsaturated double bond, a second component comprising a compound comprising more than one type of amine selected from the group consisting of primary amines, secondary amines, tertiary amines and quaternary amines, and, optionally, the cement product includes a bioactive component to promote bone formation.",ANGSTROM MEDICA,LIN JUCHUI RAY;;AHN EDWARD S;;YUAN HANSEN;;MRAZ PAUL J,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;ANGSTROM ACQUISITION CORP. II (2007-10-23);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;ANGSTROM MEDICA INC (2007-07-11);;PIONEER SURGICAL TECHNOLOGY INC (2013-08-28),https://lens.org/190-860-515-945-311,Patent Application,yes,92,6,10,10,0,A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887;;A61P19/08;;A61P19/10;;A61L24/0089;;A61L24/046;;A61K6/891;;A61K6/887,A61K31/78;;A61K6/884;;A61K6/891;;A61K9/14;;A61P19/08;;A61P19/10,424/501;;424/78.31,0,0,,,,ACTIVE
133,EP,A4,EP 2214680 A4,113-437-745-169-943,2010-12-29,2010,EP 08842941 A,2008-10-24,US 2008/0012126 W;;US 99607907 P,2007-10-26,PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID,,REXAHN PHARMACEUTICALS INC,LEE YOUNG BOK;;KIM DEOG JOONG;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/113-437-745-169-943,Search Report,no,4,0,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/424,,1,0,,,See also references of WO 2009055038A1,DISCONTINUED
134,CN,A,CN 101918004 A,023-119-536-483-112,2010-12-15,2010,CN 200880122463 A,2008-10-24,US 2008/0012126 W;;US 99607907 P,2007-10-26,Pharmaceutical formulation of clavulanic acid,"The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or ClavitesseTM, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.",REXAHN PHARMACEUTICALS INC,YOUNG-BOK LEE;;DEOG-JOONG KIM;;CHANG-HO AHN;;CARL SCHOLTZ EDWARD,,https://lens.org/023-119-536-483-112,Patent Application,no,4,1,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/70,,0,0,,,,DISCONTINUED
135,KR,A,KR 20100101574 A,172-725-725-841-436,2010-09-17,2010,KR 20107011374 A,2008-10-24,US 99607907 P,2007-10-26,PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID,,REXAHN PHARMACEUTICALS INC,LEE YOUNG BOK;;KIM DEOG JOONG;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/172-725-725-841-436,Patent Application,no,0,1,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K9/22;;A61K47/38,,0,0,,,,DISCONTINUED
136,AU,A1,AU 2008/317315 A1,072-001-305-996-715,2009-04-30,2009,AU 2008/317315 A,2008-10-24,US 99607907 P;;US 2008/0012126 W,2007-10-26,Pharmaceutical formulation of clavulanic acid,,REXAHN PHARMACEUTICALS INC,LEE YOUNG BOK;;KIM DEOG JOONG;;SCHOLTZ EDWARD CARL;;AHN CHANG HO,,https://lens.org/072-001-305-996-715,Patent Application,no,0,0,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/70,,0,0,,,,DISCONTINUED
137,EP,A2,EP 0423761 A2,183-422-771-548-020,1991-04-24,1991,EP 90119918 A,1990-10-17,US 42286489 A,1989-10-17,Apparatus and method for particle removal by forced fluid convection.,"An apparatus and method for removing contaminant particles from a surface, such as a semiconductor wafer (12), using the effect of a phase change of a condensate fluid, from liquid to solid form, on the adhesion force between a contaminant particle and a surface. Contaminant particles (172) are removed from a surface by wetting the particles with a thin film (20) of a removal fluid of a type that exhibits a volume expansion during a liquid to solid phase change, and then freezing the removal fluid to cause such expansion . Frozen material (21) including contaminant particles (172) is then removed from the surface by melting and throw-off of frozen material. Steam may be used for both the removal fluid and for melting the frozen material.  ",APPLIED MATERIALS INC,LORIMER D ARCY;;LIU BENJAMIN Y H;;BAKER EDWARD;;AHN KANG HO,,https://lens.org/183-422-771-548-020,Patent Application,yes,0,30,4,4,0,B08B5/00;;B08B7/0014;;B08B7/0064;;H01L21/02043;;H01L21/02052;;H01L21/67051,B08B7/00;;H01L21/00;;H01L21/304;;H01L21/306,,0,0,,,,DISCONTINUED
138,US,A1,US 2009/0270358 A1,125-234-715-752-535,2009-10-29,2009,US 25806208 A,2008-10-24,US 25806208 A;;US 99607907 P,2007-10-26,PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID,"The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or Clavitesse™, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.",REXAHN PHARMACEUTICALS INC,LEE YOUNG B;;KIM DEOG J;;AHN CHANG H;;SCHOLTZ EDWARD C,REXAHN PHARMACEUTICALS INC (2008-11-20),https://lens.org/125-234-715-752-535,Patent Application,yes,16,3,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/424,514/210.06,0,0,,,,DISCONTINUED
139,WO,A1,WO 2009/055038 A1,185-178-593-541-643,2009-04-30,2009,US 2008/0012126 W,2008-10-24,US 99607907 P,2007-10-26,PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID,"The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or ClavitesseTM, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.",REXAHN PHARMACEUTICALS INC;;LEE YOUNG BOK;;KIM DEOG JOONG;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,LEE YOUNG BOK;;KIM DEOG JOONG;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/185-178-593-541-643,Patent Application,yes,13,3,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/70,,7,6,060-145-575-505-338;;021-879-641-857-023;;011-503-160-667-407;;112-448-114-243-702;;002-981-317-725-805;;048-696-035-191-653,10.7164/antibiotics.29.668;;950324;;10.1128/aac.11.5.852;;879738;;pmc352086;;3820567;;2827899;;10.1038/nature03180;;15635412;;10.1016/0378-4347(91)80446-j;;1839793,"BROWN ET AL., J ANTIBIOT, vol. 29, 1976, pages 668 - 669;;READING; COLE, ANTIMICROB AGENTS CHEMOTHER, vol. 11, 1977, pages 852 - 857;;KOYU ET AL., JPN J ANTIBIOT., vol. 39, 1986, pages 2831 - 2862;;YAMABE ET AL., CHEMIOTERAPIA, vol. 6, 1987, pages 337 - 40;;NATURE, vol. 433, 2005, pages 73 - 77;;CHU S-Y ET AL.: ""Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high performance liquid chromatography with electrochemical detection"", J. CHROMATOGRAPHY, vol. 571, 1991, pages 199 - 208;;See also references of EP 2214680A4",PENDING
140,BR,A2,BR PI0818702 A2,124-775-766-806-041,2015-04-22,2015,BR PI0818702 A,2008-10-24,US 99607907 P;;US 2008/0012126 W,2007-10-26,Formulação farmacêutica de ácido clavulânico,,REXAHN PHARMACEUTICALS INC,LEE YOUNG BOK;;KIM DEOG JOONG;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/124-775-766-806-041,Patent Application,no,0,0,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/70,,0,0,,,,DISCONTINUED
141,CA,A1,CA 2703224 A1,061-165-531-260-708,2009-04-30,2009,CA 2703224 A,2008-10-24,US 99607907 P;;US 2008/0012126 W,2007-10-26,PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID,"The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or ClavitesseTM, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.",REXAHN PHARMACEUTICALS INC,LEE YOUNG BOK;;KIM DEOG JOONG;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/061-165-531-260-708,Patent Application,no,0,0,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/424;;A61J3/02;;A61K9/16;;A61K9/19,,0,0,,,,DISCONTINUED
142,EP,A1,EP 2214680 A1,160-473-557-901-394,2010-08-11,2010,EP 08842941 A,2008-10-24,US 2008/0012126 W;;US 99607907 P,2007-10-26,PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID,,REXAHN PHARMACEUTICALS INC,LEE YOUNG BOK;;KIM DEOG JOONG;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/160-473-557-901-394,Patent Application,yes,0,1,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/424,,0,0,,,,DISCONTINUED
143,MX,A,MX 2010004556 A,170-059-222-512-222,2010-07-01,2010,MX 2010004556 A,2008-10-24,US 99607907 P;;US 2008/0012126 W,2007-10-26,PHARMACEUTICAL FORMULATION OF CLAVULANIC ACID.,"The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as potassium clavulanate or ClavitesseTM, preferably in an immediate-release solid dosage form or an extended-release solid dosage form. Also provided are methods for making and using such immediate-release and stabilized compositions or extended-release and stabilized compositions.",REXAHN PHARMACEUTICALS INC,LEE YOUNG BOK;;KIM DEOG JOONG;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/170-059-222-512-222,Patent Application,no,0,0,12,12,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K31/424;;A61K31/70;;A61K31/70;;A61K9/1694;;A61K9/2054;;A61K9/205;;A61K31/424;;A61K9/2027,A61K31/70,,0,0,,,,DISCONTINUED
144,TW,A,TW 200848791 A,057-868-813-108-145,2008-12-16,2008,TW 97104679 A,2008-02-05,US 67224307 A,2007-02-07,Two dimensional light control film,"According to the invention, a light control film has a first matrix section comprising a polymer material which is at least partially opaque and has a film-like shape. Within this film are a plurality of second sections, which are of a pillar type, and are formed completely through a thickness direction of the film. In a second embodiment of the invention, a light control film has a first matrix section comprising a polymer material and having a film-like shape. Within this film are a plurality of second sections, which are at least partially opaque and are of a pillar type formed completely through a thickness direction of the film.",3M INNOVATIVE PROPERTIES CO,LEE JONG-SEO;;AHN YONG-CHAN;;VOGEL-MARTIN MARGARET MARY;;GAIDES GARY EDWARD,,https://lens.org/057-868-813-108-145,Patent of Addition,no,0,2,3,3,0,G02B5/003;;G02B5/003;;G02B6/04;;G02B6/04,G02B5/00;;C08J5/18;;G02B1/04;;G02F1/1335,,0,0,,,,PENDING
145,US,A,US 5739950 A,175-041-317-272-336,1998-04-14,1998,US 41115789 A,1989-09-01,US 41115789 A,1989-09-01,Broadband protector for photodetectors,"A trilaminar semiconductor device is placed at an intermediate focus is an optical instrument having a sensitive photodetector. The layers of the device are successively in the form of a two-photon absorber, a sacrificial layer, and a multiple quantum well. The composition of the semiconductor is varied in the layers to achieve the desired bandgap and function.","WOOD; GARY L.;;CLARK, III; WILLIAM W.;;AHN; BYONG H.;;SHARP; EDWARD J.",WOOD GARY L;;CLARK III WILLIAM W;;AHN BYONG H;;SHARP EDWARD J,UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SECRETARY OF THE ARMY (1989-08-28),https://lens.org/175-041-317-272-336,Granted Patent,yes,6,1,1,1,0,G02B5/20;;G02B5/20,G02B5/20,359/359;;359/885,0,0,,,,EXPIRED
146,EP,A1,EP 2424498 A1,074-369-731-999-386,2012-03-07,2012,EP 10717387 A,2010-04-29,US 2010/0032983 W;;US 17384109 P,2009-04-29,CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS,,REXAHN PHARMACEUTICALS INC,HUH YOUNGBUHM;;KIM DEOG JOONG;;LEE YOUNG BOK;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/074-369-731-999-386,Patent Application,yes,1,0,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K9/00;;A61K9/08;;A61K9/14;;A61K9/19;;A61K9/20;;A61K9/48;;A61K31/397;;A61K31/424;;A61P25/16;;A61P25/28,,0,0,,,,DISCONTINUED
147,AU,A1,AU 2010/242948 A1,165-010-583-869-368,2011-11-24,2011,AU 2010/242948 A,2010-04-29,US 17384109 P;;US 2010/0032983 W,2009-04-29,Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders,"The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.",REXAHN PHARMACEUTICALS INC,JOONG KIM DEOG;;BOK LEE YOUNG;;HO AHN CHANG;;CARL SCHOLTZ EDWARD;;YOUNGBUHM HUH,,https://lens.org/165-010-583-869-368,Patent Application,no,0,0,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K9/00;;A61K9/08;;A61K9/14;;A61K9/19;;A61K9/20;;A61K9/48;;A61K31/397;;A61K31/424;;A61P25/16;;A61P25/28,,0,0,,,,DISCONTINUED
148,WO,A1,WO 2010/127125 A1,060-933-421-376-198,2010-11-04,2010,US 2010/0032983 W,2010-04-29,US 17384109 P,2009-04-29,CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS,"The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.",REXAHN PHARMACEUTICALS INC;;KIM DEOG JOONG;;LEE YOUNG BOK;;AHN CHANG HO;;SCHOLTZ EDWARD CARL;;HUH YOUNGBUHM,KIM DEOG JOONG;;LEE YOUNG BOK;;AHN CHANG HO;;SCHOLTZ EDWARD CARL;;HUH YOUNGBUHM,,https://lens.org/060-933-421-376-198,Patent Application,no,4,2,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K9/08;;A61K9/00;;A61K9/14;;A61K9/19;;A61K9/20;;A61K9/48;;A61K31/397;;A61K31/424;;A61P25/16;;A61P25/28,,5,4,060-145-575-505-338;;021-879-641-857-023;;002-981-317-725-805;;048-696-035-191-653,10.7164/antibiotics.29.668;;950324;;10.1128/aac.11.5.852;;879738;;pmc352086;;10.1038/nature03180;;15635412;;10.1016/0378-4347(91)80446-j;;1839793,"BROWN ET AL., J ANTIBIOT, vol. 29, 1976, pages 668 - 669;;READING; COLE, ANTIMICROB AGENTS CHEMOTHER, vol. 11, 1977, pages 852 - 857;;NATURE, vol. 433, 2005, pages 73 - 77;;CHU S-Y ET AL.: ""Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high performance liquid chromatography with electrochemical detection"", J. CHROMATOGRAPHY, vol. 571, 1991, pages 199 - 208, XP002036824, DOI: doi:10.1016/0378-4347(91)80446-J;;See also references of EP 2424498A1",PENDING
149,CN,A,CN 102413814 A,147-380-138-014-316,2012-04-11,2012,CN 201080018447 A,2010-04-29,US 2010/0032983 W;;US 17384109 P,2009-04-29,Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders,"The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.",REXAHN PHARMACEUTICALS INC,JOONG KIM DEOG;;BOK LEE YOUNG;;HO AHN CHANG;;CARL SCHOLTZ EDWARD;;YOUNGBUHM HUH,,https://lens.org/147-380-138-014-316,Patent Application,no,3,0,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K9/00;;A61K9/08;;A61K9/14;;A61K9/19;;A61K9/20;;A61K9/48;;A61K31/397;;A61K31/424;;A61P25/16;;A61P25/28,,0,0,,,,DISCONTINUED
150,CN,A,CN 116670733 A,077-320-962-465-658,2023-08-29,2023,CN 202180080708 A,2021-12-02,US 202063120705 P;;US 2021/0061515 W,2020-12-02,Virtual immersive physical digital system and method for distributing physical consumer products,"Virtual immersive physical digital systems and methods for dispensing physical consumer products are described. In various aspects, such systems and methods include receiving, by one or more processors, a first selection corresponding to a selected virtual product from an input controller of a pedestal, the selected virtual product selected from one or more virtual rendered products rendered on a virtual immersive GUI. Based on the first selection, first virtual immersive graphical content is presented on a display screen that includes an image frame depicting the selected virtual product. A second selection corresponding to the selected virtual product is received from the input controller such that second virtual immersive graphical content is presented on the display screen. The second virtual immersive graphical content includes an image frame depicting a selected virtual product that is virtually assigned or provided. The entity distributor distributes an entity product corresponding to the selected virtual product in a location accessible to the user.",PROCTER & GAMBLE,AHN KHEE SONG Q;;JUNG GEORGE Y H;;FAN SHUFEN;;TRUONG EDWARD W Q,,https://lens.org/077-320-962-465-658,Patent Application,no,0,0,4,4,0,G07F11/10;;G06Q30/0643;;G07F9/023;;G07F11/165;;G06F3/011;;G06F3/0482;;G06Q20/18;;G06Q30/0237;;G06Q30/0643;;G06T19/006;;G06T2200/24,G07F11/10,,0,0,,,,PENDING
151,BR,A2,BR PI1013901 A2,110-330-904-040-516,2019-09-24,2019,BR PI1013901 A,2010-04-29,US 2010/0032983 W;;US 17384109 P,2009-04-29,formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos,,REXAHN PHARMACEUTICALS INC,CHANG HO AHN;;DEOG JOONG KIM;;EDWARD CARL SCHOLTZ;;YOUNG BOK LEE;;YOUNGBUHM HUH,,https://lens.org/110-330-904-040-516,Patent Application,no,0,0,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K9/08;;A61K9/00;;A61K9/14;;A61K9/19;;A61K9/20;;A61K9/48;;A61K31/397;;A61K31/424;;A61P25/16;;A61P25/28,,0,0,,,,DISCONTINUED
152,US,B1,US 11430308 B1,136-965-978-107-501,2022-08-30,2022,US 202117242856 A,2021-04-28,US 202117242856 A;;US 202063030090 P,2020-05-26,Multi-motion generator,"A method includes obtaining, by a motion generator that has been trained to generate torque values for a plurality of joints of a rig associated with a target, a set of parameters associated with a target motion. The method includes, in response to the target motion being a first type of motion, generating a first set of torque values for the plurality of joints based on the set of parameters and a set of previous poses of the target. The method includes, in response to the target motion being a second type of motion, generating a second set of torque values for the plurality of joints based on the set of parameters and the set of previous poses of the target. The method includes triggering a movement of the target in accordance with the first set of torque values or the second set of torque values.",APPLE INC,ZHANG JIAN;;SIVAPURAPU SIVA CHANDRA MOULI;;MANGLIK AASHI;;SAINI AMRITPAL SINGH;;AHN EDWARD S,APPLE INC (2021-04-22),https://lens.org/136-965-978-107-501,Granted Patent,yes,3,3,1,1,0,G08B6/00;;G06T13/40;;G08B6/00,H04B3/36;;G08B6/00,,0,0,,,,ACTIVE
153,MX,A,MX 2011011459 A,168-318-095-098-496,2011-11-18,2011,MX 2011011459 A,2010-04-29,US 17384109 P;;US 2010/0032983 W,2009-04-29,CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS.,"The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.",REXAHN PHARMACEUTICALS INC,LEE YOUNG BOK;;KIM DEOG JOONG;;SCHOLTZ EDWARD CARL;;HUH YOUNGBUHM;;CHANG HO AHN,,https://lens.org/168-318-095-098-496,Patent Application,no,0,0,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K9/00;;A61K9/08;;A61K9/14;;A61K9/19;;A61K9/20;;A61K9/48;;A61K31/397;;A61K31/424;;A61P25/16;;A61P25/28,,0,0,,,,PENDING
154,US,S,US D0502320 S,073-664-192-903-044,2005-03-01,2005,US 16099202 F,2002-05-17,US 16099202 F;;US 14317601 F;;US 14317701 F;;US 87803601 F,2001-06-08,Electric toothbrush head,,COLGATE PALMOLIVE CO,FATTORI JOSEPH EDWARD;;JANSSEN GERARDUS W H;;GATZEMEYER JOHN J;;ELIAV EYAL;;AHN KYOUNGEUN,ECCO DESIGN INC (2002-06-11);;COLGATE-PALMOLIVE COMPANY (2002-06-07),https://lens.org/073-664-192-903-044,Design Right,yes,8,1,2,14,0,,,D 4101,0,0,,,,EXPIRED
155,US,A1,US 2010/0255099 A1,019-406-597-230-941,2010-10-07,2010,US 77030410 A,2010-04-29,US 77030410 A;;US 25806208 A;;US 99607907 P;;US 17384109 P,2007-10-26,CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS,"The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.",REXAHN PHARMACEUTICALS INC,KIM DEOG J;;LEE YOUNG B;;AHN CHANG H;;SCHOLTZ EDWARD C;;HUH YOUNGBUHM,REXAHN PHARMACEUTICALS INC (2010-05-25),https://lens.org/019-406-597-230-941,Patent Application,yes,57,10,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K31/424;;A61K9/14;;A61P25/16;;A61P25/28,424/487;;514/210.06;;424/488,0,0,,,,DISCONTINUED
156,IT,B,IT 1273420 B,073-859-810-716-570,1997-07-08,1997,IT MI940645 A,1994-04-06,IT MI940645 A,1994-04-06,"COMPOSTI METALLOCENICI, PROCEDIMENTO PER LA PREPARAZIONE E LORO UTILIZZO IN CATALIZZATORI PER LA POLIMERIZZAZIONE DELLE OLEFINE",,SPHERILENE SRL,BISHOP EDWARD;;JONES ROBERT;;RAMAN KRISHNA;;DANG VU AHN;;YU LIN-CHEN;;RESCONI LUIGI,,https://lens.org/073-859-810-716-570,Granted Patent,no,0,0,20,20,0,C07C2/862;;C07C49/643;;C07C49/675;;C07F17/00;;C08F4/65912;;C08F4/65922;;C08F4/65927;;C08F10/00;;C08F110/02;;C08F110/06;;C08F210/16;;Y10S526/943;;C07F7/0805;;C07F17/00;;C08F10/00;;C07F17/00;;C08F4/65912;;C08F4/65927;;C07C2/862;;C07C49/643;;C08F4/65922;;C07C49/675;;C08F210/16;;C08F110/06;;C08F110/02;;Y10S526/943;;C07F7/0805,C07B61/00;;B01J31/22;;C07C1/207;;C07C2/86;;C07C13/54;;C07C13/547;;C07C13/567;;C07C45/46;;C07C49/643;;C07C49/675;;C07F7/08;;C07F17/00;;C08F4/622;;C08F4/64;;C08F4/642;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F110/02;;C08F110/06;;C08F210/16,,0,0,,,,EXPIRED
157,IT,A0,IT MI940645 A0,124-902-594-397-972,1994-04-06,1994,IT MI940645 A,1994-04-06,IT MI940645 A,1994-04-06,"COMPOSTI METALLOCENICI, PROCEDIMENTO PER LA PREPARAZIONE E LORO UTILIZZO IN CATALIZZATORI PER LA POLIMERIZZAZIONE DELLE OLEFINE",,SPHERILENE SRL,BISHOP EDWARD;;JONES ROBERT;;RAMAN KRISHNA;;DANG VU AHN;;YU LIN-CHEN;;RESCONI LUIGI,,https://lens.org/124-902-594-397-972,Patent Application,no,0,0,20,20,0,C07C2/862;;C07C49/643;;C07C49/675;;C07F17/00;;C08F4/65912;;C08F4/65922;;C08F4/65927;;C08F10/00;;C08F110/02;;C08F110/06;;C08F210/16;;Y10S526/943;;C07F7/0805;;C07F17/00;;C08F10/00;;C07F17/00;;C08F4/65912;;C08F4/65927;;C07C2/862;;C07C49/643;;C08F4/65922;;C07C49/675;;C08F210/16;;C08F110/06;;C08F110/02;;Y10S526/943;;C07F7/0805,B01J31/22;;C07B61/00;;C07C1/207;;C07C2/86;;C07C13/54;;C07C13/547;;C07C13/567;;C07C45/46;;C07C49/643;;C07C49/675;;C07F7/08;;C07F17/00;;C08F4/622;;C08F4/64;;C08F4/642;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F110/02;;C08F110/06;;C08F210/16,,0,0,,,,EXPIRED
158,CA,A1,CA 2758029 A1,094-853-863-657-134,2011-11-04,2011,CA 2758029 A,2010-04-29,US 17384109 P;;US 2010/0032983 W,2009-04-29,CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS,"The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.",REXAHN PHARMACEUTICALS INC,KIM DEOG JOONG;;LEE YOUNG BOK;;AHN CHANG HO;;SCHOLTZ EDWARD CARL;;HUH YOUNGBUHM,,https://lens.org/094-853-863-657-134,Patent Application,no,0,0,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K9/08;;A61K9/00;;A61K9/14;;A61K9/19;;A61K9/20;;A61K9/48;;A61K31/397;;A61K31/424;;A61P25/16;;A61P25/28,,0,0,,,,DISCONTINUED
159,BR,A,BR 9601346 A,187-283-458-696-367,1998-01-13,1998,BR 9601346 A,1996-04-12,US 42228495 A,1995-04-14,Composição de monômero estabilizado mistura estabilizadora e processo para inibição da polimeração prematura de um monômero,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,CIBA GEIGY AG,EVANS SAMUEL;;GANDE MATTHEW EDWARD;;NESVADBA PETER;;AHN VOLKER HARTMUT VON;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/187-283-458-696-367,Patent Application,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,EXPIRED
160,DE,T2,DE 69609110 T2,036-153-725-878-560,2001-03-22,2001,DE 69609110 T,1996-04-02,US 42228595 A,1995-04-14,7-Substituierte Chinonmethide als Inhibitor für ungesättigte Monomere,,CIBA SC HOLDING AG,NESVADBA DR;;EVANS DR;;GANDE MATTHEW EDWARD;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,"CIBA HOLDING INC., BASEL, CH (2008-10-16)",https://lens.org/036-153-725-878-560,Granted Patent,no,0,2,14,14,0,C07B63/04;;C07C7/20;;C07C45/512;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C59/80;;C07C69/007;;C07C69/738;;C07C205/45;;C07C255/31;;C07F9/3826;;C07F9/4015;;C07C2601/14;;C07C46/00;;C07C59/80;;C07C7/20;;C07C45/512;;C07F9/4015;;C07F9/3826;;C07C69/738;;C07C205/45;;C07C255/31;;C07C49/753;;C07C69/007;;C07B63/04;;C07C49/647;;C07C49/747;;C07C49/683;;C07C2601/14,C07D295/16;;C07B63/04;;C07C7/20;;C07C15/46;;C07C45/51;;C07C49/603;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C49/798;;C07C59/80;;C07C59/82;;C07C67/62;;C07C69/007;;C07C69/145;;C07C69/24;;C07C69/54;;C07C69/738;;C07C69/78;;C07C205/45;;C07C235/78;;C07C255/31;;C07C255/40;;C07F9/38;;C07F9/40;;C08F2/38;;C08F2/40;;C08K5/00;;C09K15/08;;C09K15/24;;C09K15/32,,0,0,,,,EXPIRED
161,ES,T3,ES 2186734 T3,042-885-272-008-757,2003-05-16,2003,ES 95941477 T,1995-11-27,US 36310494 A,1994-12-22,QUINAZOLINAS COMO INHIBIDORES DE LA ENZIMA DE CONVERSION DE LA ENDOTELINA.,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNGHYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE,,https://lens.org/042-885-272-008-757,Granted Patent,no,0,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/94;;C07D239/74;;C07D401/12;;C07D403/12;;C07D453/02,,0,0,,,,EXPIRED
162,TW,B,TW 332811 B,109-516-893-259-618,1998-06-01,1998,TW 85104714 A,1996-04-20,US 42228595 A,1995-04-14,"Composition and process for reducing premature polymerization of unsaturated monomers during manufacturing process,by incorporating an effective amount of a 7-aryl quinone methide compound","A stabilizing monomer composition includes: (a) Ethyl unsaturated monomers or mixtures of monomers (b) Compound of formula (I): R1 and R2 are independantly alkyl between 4 and 18 carbon atoms, epoxyalkyl with 5~12 carbon atoms and benzylalkyl with 7~15 C atoms and R3 is -CN, COOH, COOR4, COR5, OCOR6,-CONR7R8 or PO(OR9)2, R4 is alkyl with 1~8 C atoms, epoxyalkyl or benzyl with 5~12 C atoms. R5 is alkyl with 1~18 C atoms. Aromatic with 6~10 C atoms.",CIBA SC HOLDING AG,PETER NESVADBA;;SAMUEL EVANS;;MATTHEW EDWARD GANDE;;VOLKER HARTMUT VON AHN;;ROLAND ARTHUR EDWIN WINTER,,https://lens.org/109-516-893-259-618,Granted Patent,no,0,0,14,14,0,C07B63/04;;C07C7/20;;C07C45/512;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C59/80;;C07C69/007;;C07C69/738;;C07C205/45;;C07C255/31;;C07F9/3826;;C07F9/4015;;C07C2601/14;;C07C46/00;;C07C59/80;;C07C7/20;;C07C45/512;;C07F9/4015;;C07F9/3826;;C07C69/738;;C07C205/45;;C07C255/31;;C07C49/753;;C07C69/007;;C07B63/04;;C07C49/647;;C07C49/747;;C07C49/683;;C07C2601/14,C07D295/16;;C07C15/46;;C07C45/51;;C07C49/603;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C49/798;;C07C59/80;;C07C59/82;;C07C69/007;;C07C69/145;;C07C69/24;;C07C69/54;;C07C69/738;;C07C69/78;;C07C205/45;;C07C235/78;;C07C255/31;;C07C255/40;;C07F9/38;;C07F9/40;;C08F2/38;;C08F2/40;;C08K5/00;;C09K15/08;;C09K15/24;;C09K15/32,,0,0,,,,EXPIRED
163,KR,A,KR 20120012823 A,141-572-376-399-82X,2012-02-10,2012,KR 20117028280 A,2010-04-29,US 17384109 P;;US 2010/0032983 W,2009-04-29,CLAVULANATE FORMULATION FOR NEUROPROTECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS,,REXAHN PHARMACEUTICALS INC,HUH YOUNG BUHM;;KIM DEOG JOONG;;LEE YOUNG BOK;;AHN CHANG HO;;SCHOLTZ EDWARD CARL,,https://lens.org/141-572-376-399-82X,Patent Application,no,0,0,11,11,0,A61K9/1694;;A61K9/2027;;A61K9/205;;A61K9/2054;;A61K9/2095;;A61K9/2846;;A61K31/424;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/28;;A61P43/00;;A61K31/397;;A61K31/424;;A61K9/20;;A61K9/48;;A61K9/1694;;A61K9/2846;;A61K9/205;;A61K9/2054;;A61K9/2027;;A61K9/2095;;A61K31/424,A61K31/397;;A61K9/20;;A61K9/48;;A61K31/424,,0,0,,,,DISCONTINUED
164,US,A1,US 2023/0169711 A1,155-776-959-069-120,2023-06-01,2023,US 202318102177 A,2023-01-27,US 202318102177 A;;US 202117557273 A;;US 202163134381 P,2021-01-06,Method and Device for Generating a Blended Animation,"In one implementation, a method for generating a blended animation. The method includes: obtaining a motion input vector for a current time period; generating a motion output vector and pose information for the current time period based on the motion input vector; selecting an animated motion from a bank of animated motions for the current time period that matches the pose information within a threshold tolerance value; obtaining a blending coefficients vector for the current time period; generating a blended animation for the current time period by blending the motion output vector with the animated motion based on the blending coefficients vector; and generating a reward signal for the blended animation for the current time period.",APPLE INC,MAHASSENI BEHROOZ;;MANGLIK AASHI;;DRUMMOND MARK;;AHN EDWARD S;;BUDHRAM SHAUN;;SIVAPURAPU SIVA CHANDRA MOULI,,https://lens.org/155-776-959-069-120,Patent Application,yes,0,0,3,3,0,G06F3/011;;G06N3/0442;;G06N3/0464;;G06N3/08;;G06N20/10;;G06N20/20;;G06N5/01;;G06T13/40;;G06T19/006;;G06N3/04,G06T13/40;;G06N3/04;;G06T19/00,,1,1,084-820-415-611-622,10.1145/3359566.3360052,"Sprenger et al., “Natural Posture Blending Using Deep Neural Networks”, ACM, 2019. (Year: 2019)",ACTIVE
165,CA,C,CA 2174060 C,028-640-186-332-806,2009-08-11,2009,CA 2174060 A,1996-04-12,US 42228495 A,1995-04-14,INHIBITION OF UNSATURATED MONOMERS WITH 7-ARYL QUINONE METHIDES,Ethylenically unsaturated monomers are protected from premature polymerizati on during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,CIBA GEIGY AG,EVANS SAMUEL;;GANDE MATTHEW EDWARD;;NESVADBA PETER;;WINTER ROLAND ARTHUR EDWIN;;VON AHN VOLKER HARTMUT,,https://lens.org/028-640-186-332-806,Granted Patent,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C09K15/08;;C07B63/04;;C07C7/20;;C07C15/46;;C07C49/683;;C07C49/747;;C07C49/753;;C07C51/50;;C07C57/075;;C07C67/62;;C07C69/15;;C07C69/54;;C07C205/45;;C07C225/22;;C07C231/22;;C07C233/09;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,EXPIRED
166,CA,A1,CA 2174061 A1,183-149-844-137-691,1996-10-15,1996,CA 2174061 A,1996-04-12,US 42228595 A,1995-04-14,7-SUBSTITUTED QUINONE METHIDES AS INHIBITORS FOR UNSATURATEDMONOMERS,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-substituted quinone methide compound.,CIBA GEIGY AG,NESVADBA PETER;;EVANS SAMUEL;;GANDE MATTHEW EDWARD;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/183-149-844-137-691,Patent Application,no,0,0,14,14,0,C07B63/04;;C07C7/20;;C07C45/512;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C59/80;;C07C69/007;;C07C69/738;;C07C205/45;;C07C255/31;;C07F9/3826;;C07F9/4015;;C07C2601/14;;C07C46/00;;C07C59/80;;C07C7/20;;C07C45/512;;C07F9/4015;;C07F9/3826;;C07C69/738;;C07C205/45;;C07C255/31;;C07C49/753;;C07C69/007;;C07B63/04;;C07C49/647;;C07C49/747;;C07C49/683;;C07C2601/14,C07D295/16;;C07B63/04;;C07C7/20;;C07C15/46;;C07C45/51;;C07C49/603;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C49/798;;C07C59/80;;C07C59/82;;C07C67/62;;C07C69/007;;C07C69/145;;C07C69/24;;C07C69/54;;C07C69/738;;C07C69/78;;C07C205/45;;C07C235/78;;C07C255/31;;C07C255/40;;C07F9/38;;C07F9/40;;C08F2/38;;C08F2/40;;C08K5/00;;C09K15/08;;C09K15/24;;C09K15/32,,0,0,,,,EXPIRED
167,CA,C,CA 2174061 C,193-435-953-148-293,2009-01-20,2009,CA 2174061 A,1996-04-12,US 42228595 A,1995-04-14,7-SUBSTITUTED QUINONE METHIDES AS INHIBITORS FOR UNSATURATEDMONOMERS,"Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-substituted quinone methide compound of formula I: (see formula I) wherein R1 and R2 are independently alkyl of 4 to 18 carbon atoms, cycloalkyl of 5 to 12 carbon atoms or phenylalkyl of 7 to 15 carbon atoms, and R3 is -CN, -COOH, - COOR4 ,- COR5,- OCOR6,- CONR7R8 or -PO(OR9)2 where R4 is alkyl of 1 to 18 carbon atoms, cycloalkyl of 5 to 12 carbon atoms, phenyl or benzyl, R5 is alkyl of 1 to 18 carbon atoms, aryl of 6 to 10 carbon atoms or said aryl substituted by one or two alkyl of 1 to 4 carbon atoms or by hydroxyl, R6 is alkyl of 1 to 18 carbon atoms, aryl of 6 to 10 carbon atoms or said aryl substituted by one or two alkyl of 1 to 4 carbon atoms or by hydroxyl, R7 and R8 are independently hydrogen, alkyl of 1 to 18 carbon atoms or said alkyl substituted by alkylamino of 1 to 4 carbon atoms, by dialkylamino of 2 to 8 carbon atoms or by hydroxyl; benzyl, aryl of 6 to 10 carbon atoms or said aryl substituted by alkyl of 1 to 4 carbon atoms, by alkylamino of 1 to 4 carbon atoms, by dialkylamino of 2 to 8 carbon atoms, by phenylamino or by hydroxyl, or -NR7R8 is morpholino, piperidino or pyrrolidino, andR9 is hydrogen or alkyl of 1 to 18 carbon atoms.",,NESVADBA PETER;;EVANS SAMUEL;;GANDE MATTHEW EDWARD;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/193-435-953-148-293,Granted Patent,no,0,0,14,14,0,C07B63/04;;C07C7/20;;C07C45/512;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C59/80;;C07C69/007;;C07C69/738;;C07C205/45;;C07C255/31;;C07F9/3826;;C07F9/4015;;C07C2601/14;;C07C46/00;;C07C59/80;;C07C7/20;;C07C45/512;;C07F9/4015;;C07F9/3826;;C07C69/738;;C07C205/45;;C07C255/31;;C07C49/753;;C07C69/007;;C07B63/04;;C07C49/647;;C07C49/747;;C07C49/683;;C07C2601/14,C07C69/78;;C07D295/16;;C07B63/04;;C07C7/20;;C07C15/46;;C07C45/51;;C07C49/603;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C49/798;;C07C57/26;;C07C59/80;;C07C59/82;;C07C67/62;;C07C69/007;;C07C69/14;;C07C69/145;;C07C69/24;;C07C69/54;;C07C69/738;;C07C205/45;;C07C235/78;;C07C255/31;;C07C255/40;;C07D295/185;;C07F9/38;;C07F9/40;;C08F2/38;;C08F2/40;;C08K5/00;;C09K15/08;;C09K15/24;;C09K15/32,,0,0,,,,EXPIRED
168,US,B1,US 11593982 B1,065-414-883-057-99X,2023-02-28,2023,US 202117557273 A,2021-12-21,US 202117557273 A;;US 202163134381 P,2021-01-06,Method and device for generating a blended animation,"In one implementation, a method for generating a blended animation. The method includes: obtaining a motion input vector for a current time period; generating a motion output vector and pose information for the current time period based on the motion input vector; selecting an animated motion from a bank of animated motions for the current time period that matches the pose information within a threshold tolerance value; obtaining a blending coefficients vector for the current time period; generating a blended animation for the current time period by blending the motion output vector with the animated motion based on the blending coefficients vector; and generating a reward signal for the blended animation for the current time period.",APPLE INC,MAHASSENI BEHROOZ;;MANGLIK AASHI;;DRUMMOND MARK;;AHN EDWARD S;;BUDHRAM SHAUN;;SIVAPURAPU SIVA CHANDRA MOULI,APPLE INC (2021-12-15),https://lens.org/065-414-883-057-99X,Granted Patent,yes,2,0,3,3,0,G06F3/011;;G06N3/0442;;G06N3/0464;;G06N3/08;;G06N20/10;;G06N20/20;;G06N5/01;;G06T13/40;;G06T19/006;;G06N3/04,G06T19/00;;G06N3/04;;G06T13/40,,3,2,155-523-269-051-50X;;053-565-015-295-798,10.1145/1276377.1276384;;10.1145/1015706.1015753,"Zhao Wang, “Motion Capture Data Processing, Retrieval and Recognition,” Doctoral Dissertation, Bournemouth University, 2018, pp. 1-204.;;Seih Cooper et al., “Active Learning for Real-Time Motion Controllers,” ACM Transactions on Graphics (TOG) 26.3 (2007): pp. 1-7.;;Matthew Stone Rutgers et al., “Speaking with Hands: Creating Animated Conversational Characters from Recordings of Human Performance,” ACM Transactions on Graphics (TOG) 23.3 (2004): pp. 506-513.",ACTIVE
169,US,B1,US 11797889 B1,160-308-257-189-105,2023-10-24,2023,US 202117557288 A,2021-12-21,US 202117557288 A;;US 202163139898 P,2021-01-21,Method and device for modeling a behavior with synthetic training data,"In one implementation, a method for modeling a behavior with synthetic training data. The method includes: obtaining source content that includes an entity performing one or more actions within an environment; generating a first environment characterization vector characterizing the environment; generating a first set of behavioral trajectories associated with the one or more actions of the entity based on the source content and the first characterization vector for the environment; generating a second environment characterization vector for the environment by perturbing the first environment characterization vector; generating a second set of behavioral trajectories associated with one or more potential actions of the entity based on the source content and the second characterization vector for the environment; and training a behavior model for a virtual agent based on the first and second sets of behavioral trajectories in order to imitate the entity.",APPLE INC,AHN EDWARD S;;SIVAPURAPU SIVA CHANDRA MOULI;;DRUMMOND MARK;;MANGLIK AASHI;;BUDHRAM SHAUN;;MAHASSENI BEHROOZ,APPLE INC (2021-12-15),https://lens.org/160-308-257-189-105,Granted Patent,yes,6,0,1,1,0,G06N3/006;;G06N3/092;;G06N3/0442;;G06N3/0464;;G06N20/10;;G06N5/01;;G06F3/011;;G06V40/20;;G06V10/82;;G06V10/7747;;G06T13/00;;G06T17/00;;G06F3/012;;G06T17/00;;G06N20/00,G06N20/00;;G06T17/00,,3,2,005-708-199-059-064;;183-883-663-289-342,10.3389/frobt.2020.00047;;pmc7806025;;33501215;;10.1109/ivs.2019.8814238,"Judith Butepage et al., “Imitating by Generating: Deep Generative Models for Imitation of Interactive Tasks,” Frontiers in Robotics and AI 7 (2020): 47, pp. 1-17.;;Jonathan Ho et al., “Generative Adversarial Imitation Learning,” Advances in neural information processing systems 29 (2016): pp. 4565-4573.;;Wenwen Si et al., “AGen: Adaptable Generative Prediction Networks for Autonomous Driving,” 2019 IEEE Intelligent Vehicles Symposium (IV). IEEE, 2019, pp. 1-6.",ACTIVE
170,CA,A1,CA 2174060 A1,037-669-330-563-293,1996-10-15,1996,CA 2174060 A,1996-04-12,US 42228495 A,1995-04-14,INHIBITION OF UNSATURATED MONOMERS WITH 7-ARYL QUINONE METHIDES,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,CIBA GEIGY AG,EVANS SAMUEL;;GANDE MATTHEW EDWARD;;NESVADBA PETER;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/037-669-330-563-293,Patent Application,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,EXPIRED
171,CZ,B6,CZ 296467 B6,040-971-075-167-335,2006-03-15,2006,CZ 106896 A,1996-04-12,US 42228495 A,1995-04-14,"Stabilized monomeric composition, stabilizer mixture and inhibition method of premature polymerization of ethylenically unsaturated monomer",Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,ONDEO NALCO ENERGY SERVICES,EVANS SAMUEL;;GANDE MATTHEW EDWARD;;NESVADBA PETER;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/040-971-075-167-335,Granted Patent,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07B63/04;;C07D333/22;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,EXPIRED
172,US,B2,US 11776192 B2,087-414-355-678-942,2023-10-03,2023,US 202318102177 A,2023-01-27,US 202318102177 A;;US 202117557273 A;;US 202163134381 P,2021-01-06,Method and device for generating a blended animation,"In one implementation, a method for generating a blended animation. The method includes: obtaining a motion input vector for a current time period; generating a motion output vector and pose information for the current time period based on the motion input vector; selecting an animated motion from a bank of animated motions for the current time period that matches the pose information within a threshold tolerance value; obtaining a blending coefficients vector for the current time period; generating a blended animation for the current time period by blending the motion output vector with the animated motion based on the blending coefficients vector; and generating a reward signal for the blended animation for the current time period.",APPLE INC,MAHASSENI BEHROOZ;;MANGLIK AASHI;;DRUMMOND MARK;;AHN EDWARD S;;BUDHRAM SHAUN;;SIVAPURAPU SIVA CHANDRA MOULI,,https://lens.org/087-414-355-678-942,Granted Patent,yes,2,0,3,3,0,G06F3/011;;G06N3/0442;;G06N3/0464;;G06N3/08;;G06N20/10;;G06N20/20;;G06N5/01;;G06T13/40;;G06T19/006;;G06N3/04,G06T13/40;;G06N3/04;;G06T19/00,,4,3,084-820-415-611-622;;155-523-269-051-50X;;053-565-015-295-798,10.1145/3359566.3360052;;10.1145/1276377.1276384;;10.1145/1015706.1015753,"Sprenger et al., “Natural Posture Blending Using Deep Neural Networks”, ACM, 2019. (Year: 2019).;;Zhao Wang, “Motion Capture Data Processing, Retrieval and Recognition,” Doctoral Dissertation, Bournemouth University, 2018, pp. 1-204.;;Seth Cooper et al., “Active Learning for Real-Time Motion Controllers,” ACM Transactions on Graphics (TOG) 26.3 (2007): pp. 1-7.;;Matthew Stone Rutgers et al., “Speaking with Hands: Creating Animated Conversational Characters from Recordings of Human Performance,” ACM Transactions on Graphics (TOG) 23.3 (2004): pp. 506-513.",ACTIVE
173,DE,D1,DE 69622910 D1,102-902-945-176-357,2002-09-19,2002,DE 69622910 T,1996-04-09,US 42228495 A,1995-04-14,Inhibition von ungesättigten Monomeren mit 7-Arylchinonmethiden,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,ONDEO NALCO ENERGY SERV LP,EVANS DR;;GANDE MATTHEW EDWARD;;NESVADBA DR;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/102-902-945-176-357,Granted Patent,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,EXPIRED
174,DE,T2,DE 69622910 T2,101-438-387-606-443,2003-05-08,2003,DE 69622910 T,1996-04-09,US 42228495 A,1995-04-14,Inhibition von ungesättigten Monomeren mit 7-Arylchinonmethiden,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,ONDEO NALCO ENERGY SERV LP,EVANS DR;;GANDE MATTHEW EDWARD;;NESVADBA DR;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/101-438-387-606-443,Granted Patent,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,EXPIRED
175,DE,D1,DE 69609110 D1,144-469-246-734-670,2000-08-10,2000,DE 69609110 T,1996-04-02,US 42228595 A,1995-04-14,7-Substituierte Chinonmethide als Inhibitor für ungesättigte Monomere,,CIBA SC HOLDING AG,NESVADBA DR;;EVANS DR;;GANDE MATTHEW EDWARD;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,"CIBA HOLDING INC., BASEL, CH (2008-10-16)",https://lens.org/144-469-246-734-670,Granted Patent,no,0,0,14,14,0,C07B63/04;;C07C7/20;;C07C45/512;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C59/80;;C07C69/007;;C07C69/738;;C07C205/45;;C07C255/31;;C07F9/3826;;C07F9/4015;;C07C2601/14;;C07C46/00;;C07C59/80;;C07C7/20;;C07C45/512;;C07F9/4015;;C07F9/3826;;C07C69/738;;C07C205/45;;C07C255/31;;C07C49/753;;C07C69/007;;C07B63/04;;C07C49/647;;C07C49/747;;C07C49/683;;C07C2601/14,C07D295/16;;C07B63/04;;C07C7/20;;C07C15/46;;C07C45/51;;C07C49/603;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C49/798;;C07C59/80;;C07C59/82;;C07C67/62;;C07C69/007;;C07C69/145;;C07C69/24;;C07C69/54;;C07C69/738;;C07C69/78;;C07C205/45;;C07C235/78;;C07C255/31;;C07C255/40;;C07F9/38;;C07F9/40;;C08F2/38;;C08F2/40;;C08K5/00;;C09K15/08;;C09K15/24;;C09K15/32,,0,0,,,,EXPIRED
176,IT,A1,IT MI940645 A1,195-888-578-649-620,1995-10-06,1995,IT MI940645 A,1994-04-06,IT MI940645 A,1994-04-06,"COMPOSTI METALLOCENICI, PROCEDIMENTO PER LA PREPARAZIONE E LORO UTILIZZO IN CATALIZZATORI PER LA POLIMERIZZAZIONE DELLE OLEFINE",,SPHERILENE SRL,BISHOP C EDWARD;;DANG VU AHN;;JONES ROBERT L;;RAMAN KRISHNA;;RESCONI LUIGI;;YU LIN-CHEN,,https://lens.org/195-888-578-649-620,Patent Application,no,0,0,20,20,0,C07C2/862;;C07C49/643;;C07C49/675;;C07F17/00;;C08F4/65912;;C08F4/65922;;C08F4/65927;;C08F10/00;;C08F110/02;;C08F110/06;;C08F210/16;;Y10S526/943;;C07F7/0805;;C07F17/00;;C08F10/00;;C07F17/00;;C08F4/65912;;C08F4/65927;;C07C2/862;;C07C49/643;;C08F4/65922;;C07C49/675;;C08F210/16;;C08F110/06;;C08F110/02;;Y10S526/943;;C07F7/0805,C07B61/00;;B01J31/22;;C07C/;;C07C1/207;;C07C2/86;;C07C13/54;;C07C13/547;;C07C13/567;;C07C45/46;;C07C49/643;;C07C49/675;;C07F7/08;;C07F17/00;;C08F4/622;;C08F4/64;;C08F4/642;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F110/02;;C08F110/06;;C08F210/16,,0,0,,,,EXPIRED
177,EP,B1,EP 0737659 B1,145-530-225-412-548,2000-07-05,2000,EP 96810206 A,1996-04-02,US 42228595 A,1995-04-14,7-Substituted quinone methides as inhibitors for unsaturated monomers,,CIBA SC HOLDING AG,NESVADBA PETER DR;;EVANS SAMUEL DR;;GANDE MATTHEW EDWARD;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,CIBA SC HOLDING AG (1997-01-15);;CIBA SPECIALTY CHEMICALS HOLDING INC. (1997-03-12),https://lens.org/145-530-225-412-548,Granted Patent,yes,1,3,14,14,0,C07B63/04;;C07C7/20;;C07C45/512;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C59/80;;C07C69/007;;C07C69/738;;C07C205/45;;C07C255/31;;C07F9/3826;;C07F9/4015;;C07C2601/14;;C07C46/00;;C07C59/80;;C07C7/20;;C07C45/512;;C07F9/4015;;C07F9/3826;;C07C69/738;;C07C205/45;;C07C255/31;;C07C49/753;;C07C69/007;;C07B63/04;;C07C49/647;;C07C49/747;;C07C49/683;;C07C2601/14,C07B63/04;;C07C7/20;;C07C15/46;;C07C45/51;;C07C49/603;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C49/798;;C07D295/16;;C07C59/80;;C07C59/82;;C07C67/62;;C07C69/007;;C07C69/145;;C07C69/24;;C07C69/54;;C07C69/738;;C07C69/78;;C07C205/45;;C07C235/78;;C07C255/31;;C07C255/40;;C07F9/38;;C07F9/40;;C08F2/38;;C08F2/40;;C08K5/00;;C09K15/08;;C09K15/24;;C09K15/32,,1,0,,,"AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 30, 1977, pages 2565-2569, XP000572553 F. R. HEWGILL ET AL: ""3,5-Di-t-butyl-4-hydroxyphenylglycine: a potential spin label""",EXPIRED
178,CA,A1,CA 2860227 A1,046-493-979-345-194,2013-06-27,2013,CA 2860227 A,2012-12-20,US 201161579820 P;;US 2012/0071002 W,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECHNOLOGY,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,,https://lens.org/046-493-979-345-194,Patent Application,no,0,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/48;;C08L89/00,,0,0,,,,ACTIVE
179,EP,A1,EP 0737660 A1,096-278-126-808-46X,1996-10-16,1996,EP 96810217 A,1996-04-09,US 42228495 A,1995-04-14,Inhibition of unsaturated monomers with 7-aryl quinone methides,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,CIBA GEIGY AG,EVANS SAMUEL DR;;GANDE MATTHEW EDWARD;;NESVADBA PETER DR;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,"CIBA SC HOLDING AG (1997-01-15);;NALCO/EXXON ENERGY CHEMICALS, L.P. (2000-06-21);;ONDEO NALCO ENERGY SERVICES, L.P. (2001-10-31);;CIBA SPECIALTY CHEMICALS HOLDING INC. (1997-03-12)",https://lens.org/096-278-126-808-46X,Patent Application,yes,1,17,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,1,0,,,"CHEMICAL ABSTRACTS, vol. 90, no. 23, 4 June 1979, Columbus, Ohio, US; abstract no. 186075q, N. ZOLOTOVA: ""Reactivity of methylenequinones as inhibitors of the liquid-phase oxidation of hydrocarbons"" page 589; column 1; XP002005559",EXPIRED
180,MX,B,MX 352601 B,038-119-661-229-206,2017-11-30,2017,MX 2014007705 A,2012-12-20,US 201161579820 P;;US 2012/0071002 W,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH.","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECH,FRANCIS VINCENT LAMBERTI;;RONALD STEWART HILL;;ADAM MACMILLAN;;EDWARD AHN;;BRIAN SCHLOSSBERG;;STEPHEN CAPISTRON;;WILLIAM H LLOYD,,https://lens.org/038-119-661-229-206,Granted Patent,no,0,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/34;;C08L89/00,,0,0,,,,ACTIVE
181,AT,T1,AT E222224 T1,049-514-411-812-019,2002-08-15,2002,AT 96810217 T,1996-04-09,US 42228495 A,1995-04-14,INHIBITION VON UNGESÄTTIGTEN MONOMEREN MIT 7- ARYLCHINONMETHIDEN,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,ONDEO NALCO ENERGY SERV LP,EVANS SAMUEL DR;;GANDE MATTHEW EDWARD;;NESVADBA PETER DR;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/049-514-411-812-019,Granted Patent,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,PENDING
182,US,B2,US 8940317 B2,100-423-144-535-742,2015-01-27,2015,US 201213722237 A,2012-12-20,US 201213722237 A;;US 201161579820 P,2011-12-23,"Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECHNOLOGY,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-03-02),https://lens.org/100-423-144-535-742,Granted Patent,yes,47,3,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61F2/28;;A61L27/22;;A61L27/40;;A61L27/48;;C08L89/00,424/426,10,9,008-205-203-749-506;;008-205-203-749-506;;005-089-741-481-100;;016-265-697-674-181;;079-458-745-329-822;;086-180-176-359-801;;064-227-787-307-477;;071-558-017-678-001;;009-910-178-925-159,17617489;;10.1016/j.jconrel.2007.05.023;;17617489;;10.1016/j.jconrel.2007.05.023;;10.1016/s0969-806x(98)00324-7;;10.1021/bi00489a001;;2271534;;10.1016/s0142-9612(03)00340-5;;12922147;;10.1016/s0169-409x(01)00239-3;;11755703;;9549620;;10.1002/(sici)1097-4636(199805)40:2<257::aid-jbm10>3.0.co;2-j;;10822487;;10.1002/adfm.200400325,"Chen et al., ""Novel Glycidyl Methacrylated Dextran (Dex-GMA)/Gelatin Hdrogel Scaffolds Containing Microspheres Loaded with Bone Morphogenetic Proteins: Formulation and Characteristics,"" Journal of Controlled Release, 2011, pp. 81-90, vol. 121.;;Chen et al., ""Periodontal Regeneration Using Novel Glycidyl Methacrylated Dextran (Dex-GMA)/Gelatin Scaffolds Containing Microspheres Loaded with Bone Morphogenetic Proteins,"" Journal of Controlled Release, 2007, pp. 81-90, vol. 121.;;Aso et al., ""Thermally Controlled Protein Release from Gelatin-Dextran Hydrogels,"" Radiation Physics and Chemistry, 1999, pp. 179-183, vol. 55.;;Wells, ""Additivity of Mutational Effects in Proteins,"" Biochemistry, 1990, pp. 8509-8517, vol. 29, No. 37.;;Drury et al. ""Hydrogels for Tissue Engineering: Scaffold Design Variables and Applications,"" Biomaterials, 2003, pp. 4337-4351, vol. 24.;;Hoffman, ""Hydrogels for Biomedical Applications,"" Advanced Drug Delivery, 2002, pp. 3-12, vol. 43.;;Jennings, ""Effect of Formulation on Lyophilization, Part 1"" IVD Technology, 1997, pp. 1-6. http://www.ivdtechnology.com/print/1212.;;Liu et al., ""Covalent Bonding of PMMA, PBMA, and poly(HEMA) to Hydroxyapatite Particles,"" J. Biomed Mater Res, 1998, pp. 257-263, vol. 40.;;Noro et al., ""Biochemical Behavior of Hydroxyapatite as Bone Substitute Material in a Loaded Implant Model, On the Suface Strain Measurement and the Maximum Compression Strength Determination of Material Crash"" Biomedical Materials and Engineering, 1999, pp. 319-324, vol. 9.;;Zhang et al., ""Inverted-Colloidal-Crystal Hydrogel Matrices as Three-Dimensional Cell Scaffolds,"" Advanced Functional Materials, 2005, pp. 725-731, vol. 15, No. 5.",ACTIVE
183,WO,A2,WO 2013/096650 A2,142-226-215-306-893,2013-06-27,2013,US 2012/0071002 W,2012-12-20,US 201161579820 P,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECHNOLOGY,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,,https://lens.org/142-226-215-306-893,Patent Application,no,18,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/48,,1,0,,,"DEAN ET AL.: ""Affinity Chromatography: A Practical Approach"", 1985, IRL PRESS",PENDING
184,US,B2,US 9370608 B2,099-964-104-239-816,2016-06-21,2016,US 201414568339 A,2014-12-12,US 201414568339 A;;US 201213722237 A;;US 201161579820 P,2011-12-23,"Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECHNOLOGY;;RTI SURGICAL INC,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-03-02),https://lens.org/099-964-104-239-816,Granted Patent,yes,46,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61F2/28;;A61K9/00;;A61L27/22;;A61L27/40;;A61L27/46;;A61L27/48;;A61L27/54;;A61L27/56;;A61L27/58;;C08L89/00,,10,9,005-089-741-481-100;;028-521-400-115-297;;008-205-203-749-506;;079-458-745-329-822;;086-180-176-359-801;;064-227-787-307-477;;071-558-017-678-001;;016-265-697-674-181;;009-910-178-925-159,10.1016/s0969-806x(98)00324-7;;17250921;;10.1016/j.jconrel.2006.11.016;;17617489;;10.1016/j.jconrel.2007.05.023;;10.1016/s0142-9612(03)00340-5;;12922147;;10.1016/s0169-409x(01)00239-3;;11755703;;9549620;;10.1002/(sici)1097-4636(199805)40:2<257::aid-jbm10>3.0.co;2-j;;10822487;;10.1021/bi00489a001;;2271534;;10.1002/adfm.200400325,"Aso et al., ""Thermally Controlled Protein Release From Geltain-Dextran Hydrogels,"" Radiation Physics and Chemistry, 1999, pp. 179-183, vol. 55.;;Chen et al., ""Novel Glycidyl Methacrylated Dextran (Dex-GMA)/Gelatin Hdrogel Scaffolds Containing Microspheres Loaded with Bone Morphogenetic Proteins: Formulation and Characteristics,"" Journal of Controlled Release, 2011, pp. 65-77, vol. 118.;;Chen et al., ""Periodontal Regeneration Using Novel Glycidyl Methacrylated Dextran (Dex-GMA)/Gelatin Scaffolds Containing Microspheres Loaded with Bone Morphogenetic Proteins,"" Journal of Controlled Release, 2007, pp. 81-90, vol. 121.;;Drury et al. ""Hydrogels for Tissue Engineering: Scaffold Design Variables and Applications,"" Biomaterials, 2003, pp. 4337-4351, vol. 24.;;Hoffman, ""Hydrogels for Biomedical Applications,"" Advanced Drug Delivery, 2002, pp. 3-12, vol. 43.;;Jennings, ""Effect of Formulation on Lyophilization, Part 1"" IVD Technology, 1997, pp. 1-6. http://www.ivdtechnology.com/print/1212.;;Liu et al., ""Covalent Bonding of PMMA, PBMA, and poly(HEMA) to Hydroxyapatite Particles,"" J. Biomed Mater Res, 1998, pp. 257-263, vol. 40.;;Noro et al., ""Biochemical Behavior of Hydroxyapatite as Bone Substitute Material in a Loaded Implant Model, on the Suface Strain Measurement and the Maximum Compression Strength Determination of Material Crash"" Biomedical Materials and Engineering, 1999, pp. 319-324, vol. 9.;;Wells, ""Additivity of Mutational Effects in Proteins,"" Biochemistry, 1990, pp. 8509-8517, vol. 29, No. 37.;;Zhang et al., ""Inverted-Colloidal-Crystal Hydrogel Matrices as Three-Dimensional Cell Scaffolds,"" Advanced Functional Materials, 2005, pp. 725-731, vol. 15, No. 5.",ACTIVE
185,ES,T3,ES 2559467 T3,148-157-751-413-942,2016-02-12,2016,ES 12813670 T,2012-12-20,US 201161579820 P;;US 2012/0071002 W,2011-12-23,"Matriz continua con partículas osteoconductoras dispersadas en la misma, procedimiento de formación, y su uso para regenerar el hueso con la misma","Una composición que comprende: una matriz continua formada por un polipéptido reticulado con un segundo polímero que comprende un polisacárido; y partículas de un material poroso, osteoconductor dispersadas en la matriz continua; en la que los poros del material osteoconductor tienen un polipéptido adsorbido en los mismos.",PIONEER SURGICAL TECH INC,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,,https://lens.org/148-157-751-413-942,Granted Patent,no,0,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/34;;C08L89/00,,0,0,,,,ACTIVE
186,MX,A,MX 2014007705 A,156-754-706-245-789,2015-03-05,2015,MX 2014007705 A,2012-12-20,US 201161579820 P;;US 2012/0071002 W,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH.","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECHNOLOGY,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,,https://lens.org/156-754-706-245-789,Patent Application,no,0,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/34;;C08L89/00,,0,0,,,,ACTIVE
187,US,A1,US 2013/0195928 A1,053-297-549-311-379,2013-08-01,2013,US 201213722237 A,2012-12-20,US 201213722237 A;;US 201161579820 P,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECHNOLOGY;;PIONEER SURGICAL TECHNOLOGY,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-03-02),https://lens.org/053-297-549-311-379,Patent Application,yes,1,4,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/48,424/400;;514/773;;424/577;;424/602,0,0,,,,ACTIVE
188,WO,A3,WO 2013/096650 A3,123-102-738-079-526,2013-09-26,2013,US 2012/0071002 W,2012-12-20,US 201161579820 P,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECHNOLOGY,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,,https://lens.org/123-102-738-079-526,Search Report,yes,1,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,C08L89/00;;A61L27/34,,2,2,028-521-400-115-297;;008-205-203-749-506,17250921;;10.1016/j.jconrel.2006.11.016;;17617489;;10.1016/j.jconrel.2007.05.023,"CHEN ET AL: ""Novel glycidyl methacrylated dextran (Dex-GMA)/gelatin hydrogel scaffolds containing microspheres loaded with bone morphogenetic proteins: Formulation and characteristics"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 118, no. 1, 24 February 2007 (2007-02-24), pages 65 - 77, XP005903634, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2006.11.016;;CHEN ET AL: ""Periodontal regeneration using novel glycidyl methacrylated dextran (Dex-GMA)/gelatin scaffolds containing microspheres loaded with bone morphogenetic proteins"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 121, no. 1-2, 31 July 2007 (2007-07-31), pages 81 - 90, XP022179909, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2007.05.023",PENDING
189,CZ,A3,CZ 106896 A3,003-698-825-046-414,1996-11-13,1996,CZ 106896 A,1996-04-12,US 42228495 A,1995-04-14,"STABILIZED MONOMERIC COMPOSITION, STABILIZER MIXTURE AND INHIBITION METHOD OF PREMATURE POLYMERIZATION OF ETHYLENICALLY UNSATURATED MONOMER",Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,CIBA GEIGY AG,EVANS SAMUEL DR;;GANDE MATTHEW EDWARD;;NESVADBA PETER DR;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/003-698-825-046-414,Patent Application,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,EXPIRED
190,US,A1,US 2015/0098998 A1,181-163-036-629-506,2015-04-09,2015,US 201414568339 A,2014-12-12,US 201414568339 A;;US 201213722237 A;;US 201161579820 P,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECHNOLOGY,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,PIONEER SURGICAL TECHNOLOGY NEWCO INC (2023-06-14);;XTANT MEDICAL HOLDINGS INC (2023-08-10);;PIONEER SURGICAL TECHNOLOGY INC (2012-03-02),https://lens.org/181-163-036-629-506,Patent Application,yes,0,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/46;;A61L27/56,424/489;;424/602,0,0,,,,ACTIVE
191,CA,C,CA 2860227 C,174-599-214-520-284,2020-03-24,2020,CA 2860227 A,2012-12-20,US 201161579820 P;;US 2012/0071002 W,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH","The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.",PIONEER SURGICAL TECH,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,,https://lens.org/174-599-214-520-284,Granted Patent,no,0,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/48;;C08L89/00,,0,0,,,,ACTIVE
192,ES,T3,ES 2181861 T3,101-105-966-629-02X,2003-03-01,2003,ES 96810217 T,1996-04-09,US 42228495 A,1995-04-14,INHIBIDORES DE MONOMEROS INSATURADOS CON METANUROS DE 7-ARILQUINONA.,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,ONDEO NALCO ENERGY SERV LP,EVANS SAMUEL DR;;GANDE MATTHEW EDWARD;;NESVADBA PETER DR;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,,https://lens.org/101-105-966-629-02X,Granted Patent,no,0,0,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07B63/04;;C07C7/20;;C07C49/683;;C07D333/22;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,0,0,,,,EXPIRED
193,EP,B1,EP 0737660 B1,196-247-701-887-533,2002-08-14,2002,EP 96810217 A,1996-04-09,US 42228495 A,1995-04-14,Inhibition of unsaturated monomers with 7-aryl quinone methides,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-aryl quinone methide compound.,ONDEO NALCO ENERGY SERV LP,EVANS SAMUEL DR;;GANDE MATTHEW EDWARD;;NESVADBA PETER DR;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,"CIBA SC HOLDING AG (1997-01-15);;NALCO/EXXON ENERGY CHEMICALS, L.P. (2000-06-21);;ONDEO NALCO ENERGY SERVICES, L.P. (2001-10-31);;CIBA SPECIALTY CHEMICALS HOLDING INC. (1997-03-12)",https://lens.org/196-247-701-887-533,Granted Patent,yes,1,4,19,19,0,C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07C2601/16;;C07C46/00;;C07C255/56;;C07C67/62;;C07C49/753;;C07B63/04;;C07C205/45;;C07C7/20;;C07C49/683;;C07C225/22;;C07C49/747;;C07C2601/16,C07D333/22;;C07B63/04;;C07C7/20;;C07C49/683;;C07C49/747;;C07C49/753;;C07C67/62;;C07C205/45;;C07C225/22;;C07C255/56;;C07D207/333;;C07D211/94;;C07D307/46;;C07D401/04;;C07D401/14;;C08F2/38;;C08F4/00,,1,0,,,"CHEMICAL ABSTRACTS, vol. 90, no. 23, 4 June 1979 Columbus, Ohio, US; abstract no. 186075q, N. ZOLOTOVA: ""Reactivity of methylenequinones as inhibitors of the liquid-phase oxidation of hydrocarbons"" page 589; column 1; XP002005559 & KINET. KATAL., vol. 20, no. 1, 1979, pages 48-55, & ""Chemical Abstracts Tenth Collective Index, Chemical Substances, Benzene, ethen - Benzeneethanimine"" , CHEMICAL ABSTRACTS SERVICE",EXPIRED
194,EP,A1,EP 0737659 A1,186-618-939-903-932,1996-10-16,1996,EP 96810206 A,1996-04-02,US 42228595 A,1995-04-14,7-Substituted quinone methides as inhibitors for unsaturated monomers,Ethylenically unsaturated monomers are protected from premature polymerization during manufacture and storage by the incorporation therein of an effective stabilizing amount of a 7-substituted quinone methide compound.,CIBA GEIGY AG,NESVADBA PETER DR;;EVANS SAMUEL DR;;GANDE MATTHEW EDWARD;;VON AHN VOLKER HARTMUT;;WINTER ROLAND ARTHUR EDWIN,CIBA SC HOLDING AG (1997-01-15);;CIBA SPECIALTY CHEMICALS HOLDING INC. (1997-03-12),https://lens.org/186-618-939-903-932,Patent Application,yes,1,8,14,14,0,C07B63/04;;C07C7/20;;C07C45/512;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C59/80;;C07C69/007;;C07C69/738;;C07C205/45;;C07C255/31;;C07F9/3826;;C07F9/4015;;C07C2601/14;;C07C46/00;;C07C59/80;;C07C7/20;;C07C45/512;;C07F9/4015;;C07F9/3826;;C07C69/738;;C07C205/45;;C07C255/31;;C07C49/753;;C07C69/007;;C07B63/04;;C07C49/647;;C07C49/747;;C07C49/683;;C07C2601/14,C07B63/04;;C07C7/20;;C07C15/46;;C07C45/51;;C07C49/603;;C07C49/647;;C07C49/683;;C07C49/747;;C07C49/753;;C07C49/798;;C07D295/16;;C07C59/80;;C07C59/82;;C07C67/62;;C07C69/007;;C07C69/145;;C07C69/24;;C07C69/54;;C07C69/738;;C07C69/78;;C07C205/45;;C07C235/78;;C07C255/31;;C07C255/40;;C07F9/38;;C07F9/40;;C08F2/38;;C08F2/40;;C08K5/00;;C09K15/08;;C09K15/24;;C09K15/32,,1,1,002-741-006-863-079,10.1071/ch9772565,"F. R. HEWGILL ET AL: ""3,5-Di-t-butyl-4-hydroxyphenylglycine: a potential spin label"", AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 30, 1977, pages 2565 - 2569, XP000572553",EXPIRED
195,EP,A2,EP 2793963 A2,016-504-601-213-299,2014-10-29,2014,EP 12813670 A,2012-12-20,US 201161579820 P;;US 2012/0071002 W,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH",,PIONEER SURGICAL TECH INC,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,,https://lens.org/016-504-601-213-299,Patent Application,yes,0,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/34;;C08L89/00,,0,0,,,,ACTIVE
196,EP,B1,EP 2793963 B1,165-235-807-791-780,2015-11-18,2015,EP 12813670 A,2012-12-20,US 201161579820 P;;US 2012/0071002 W,2011-12-23,"CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH",,PIONEER SURGICAL TECH INC,LAMBERTI FRANCIS VINCENT;;HILL RONALD STEWART;;MACMILLAN ADAM;;AHN EDWARD;;SCHLOSSBERG BRIAN;;CAPISTRON STEPHEN;;LLOYD WILLIAM H,,https://lens.org/165-235-807-791-780,Granted Patent,yes,1,0,13,13,0,C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61L27/54;;A61L27/58;;C08L89/00;;A61L27/22;;A61L27/40;;A61L2400/06;;A61L2430/02;;A61L27/48;;A61L27/46;;A61L27/56;;A61L2300/112,A61L27/34;;C08L89/00,,2,0,,,"CHEN ET AL: ""Novel glycidyl methacrylated dextran (Dex-GMA)/gelatin hydrogel scaffolds containing microspheres loaded with bone morphogenetic proteins: Formulation and characteristics"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 118, no. 1, 24 February 2007 (2007-02-24), pages 65-77, XP005903634, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2006.11.016;;CHEN ET AL: ""Periodontal regeneration using novel glycidyl methacrylated dextran (Dex-GMA)/gelatin scaffolds containing microspheres loaded with bone morphogenetic proteins"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 121, no. 1-2, 31 July 2007 (2007-07-31), pages 81-90, XP022179909, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2007.05.023",ACTIVE
197,MX,A,MX 9704040 A,047-885-794-586-986,1997-09-30,1997,MX 9704040 A,1995-11-27,US 36310494 A;;US 9515366 W,1994-12-22,QUINAZOLINES AS INHIBITORS OF ENDOTHELIN CONVERTING ENZYME.,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNHGYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN EDWARD;;LEE CHITASE;;LEONARD DANIELE M;;NIKAM SHAM SHRIBHAR;;WERBEL LESLIE MORTON,,https://lens.org/047-885-794-586-986,Patent Application,no,0,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/74;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,0,0,,,,EXPIRED
198,WO,A1,WO 2013/106241 A1,012-212-788-017-465,2013-07-18,2013,US 2013/0020210 W,2013-01-04,US 201261584556 P;;US 201261623704 P,2012-01-09,ILLUMINATED DISPLAY DEVICE CASE COMPRISING AN INTEGRATED OPTICAL FILM,Cases and case kits suitable for receiving an illuminated display device such as a tablet are described. The cases comprise a (e.g. light-collimating) optical film integrated with the case. The illuminated display device is intended to be operated while contained within (rather than being removed from) the case. The illuminated display surface can be viewed through the (e.g. light-collimating) optical film when an illuminated display device is provided within the case.,3M INNOVATIVE PROPERTIES CO;;SNYDER THOMAS M;;TOY MICHELLE L;;KIM JEONG-WAN;;AHN YONGCHAN;;OH YOU-JUNG;;WEAVER EDWARD L II,SNYDER THOMAS M;;TOY MICHELLE L;;KIM JEONG-WAN;;AHN YONGCHAN;;OH YOU-JUNG;;WEAVER EDWARD L II,,https://lens.org/012-212-788-017-465,Patent Application,yes,5,7,5,5,0,G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G06F1/182;;G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G02B27/30;;G06F1/182,G02B6/00;;G02B27/30,,1,0,,,See also references of EP 2802929A4,PENDING
199,WO,A2,WO 2004/030763 A2,010-448-505-164-894,2004-04-15,2004,US 0330255 W,2003-09-26,US 26095502 A,2002-09-30,NONWOVEN LOOP MATERIAL AND PROCESS AND PRODUCTS RELATING THERETO,"The present invention provedes nonwoven fiber materials, and methods for making the same, useful for loop materials in hook and loop mechanical attachment systems, the nonwoven materials having crimped monocomponent fibers having substantially circular cross sections, and the webs may further contain uncrimped fibers. The invention also provides disposable articles comprising nonwoven loop materials including disposable personal care absorbent articles such as diapers, feminine care sanitary napkins, and adult incontinence articles, and disposable protective articles such as surgical drapes and gowns and other protective apparel.",KIMBERLY CLARK CO,AHN JUNGYEUL;;BOLIAN II CHARLES EDWARD;;CHIN JEASEUNG;;FORBES BRIAN STEPHEN;;JUNG SOOGYUNG;;KIM BYUNGSOO;;LEE JINHEE;;NING XIN;;YOU KUEYOUNG,,https://lens.org/010-448-505-164-894,Patent Application,yes,0,5,12,12,0,A44B18/0011;;D04H3/00;;D04H11/00;;A61F13/627;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;A61P1/00;;A61L15/16;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;D04H3/00;;A44B18/0011;;D04H11/00;;A61F13/627,A44B18/00;;A61L15/16;;A61F13/62;;A61P1/00;;D04H3/00;;D04H11/00,,0,0,,,,PENDING
200,US,A1,US 2015/0043084 A1,180-600-023-572-279,2015-02-12,2015,US 201314342808 A,2013-01-04,US 201314342808 A;;US 201261584556 P;;US 201261623704 P;;US 2013/0020210 W,2012-01-09,ILLUMINATED DISPLAY DEVICE CASE COMPRISING AN INTEGRATED OPTICAL FILM,for receiving an illuminated display device such as a tablet are described. The cases comprise a (e.g. light-collimating) optical film integrated with the case. The illuminated display device is intended to be operated while contained within (rather than being removed from) the case. The illuminated display surface can be viewed through the (e.g. light-collimating) optical film when an illuminated display device is provided within the case.,3M INNOVATIVE PROPERTIES CO,SNYDER THOMAS M;;TOY MICHELLE L;;KIM JEONG-WAN;;AHN YONGCHAN;;OH YOU-JUNG;;WEAVER II EDWARD L;;BISEK PATRICK E,3M INNOVATIVE PROPERTIES COMPANY (2013-07-26),https://lens.org/180-600-023-572-279,Patent Application,yes,2,5,5,5,0,G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G06F1/182;;G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G02B27/30;;G06F1/182,G06F1/18;;G02B27/30,359/641,0,0,,,,DISCONTINUED
201,EP,A1,EP 2802929 A1,062-824-770-406-244,2014-11-19,2014,EP 13735605 A,2013-01-04,US 201261584556 P;;US 201261623704 P;;US 2013/0020210 W,2012-01-09,ILLUMINATED DISPLAY DEVICE CASE COMPRISING AN INTEGRATED OPTICAL FILM,,3M INNOVATIVE PROPERTIES CO,SNYDER THOMAS M;;TOY MICHELLE L;;KIM JEONG-WAN;;AHN YONGCHAN;;OH YOU-JUNG;;WEAVER EDWARD L II;;BISEK PATRICK E,,https://lens.org/062-824-770-406-244,Patent Application,yes,0,0,5,5,0,G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G06F1/182;;G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G02B27/30;;G06F1/182,G06F1/16;;F21V8/00,,0,0,,,,DISCONTINUED
202,WO,A3,WO 2004/030763 A3,110-772-232-110-70X,2004-07-01,2004,US 0330255 W,2003-09-26,US 26095502 A,2002-09-30,NONWOVEN LOOP MATERIAL AND PROCESS AND PRODUCTS RELATING THERETO,"The present invention provedes nonwoven fiber materials, and methods for making the same, useful for loop materials in hook and loop mechanical attachment systems, the nonwoven materials having crimped monocomponent fibers having substantially circular cross sections, and the webs may further contain uncrimped fibers. The invention also provides disposable articles comprising nonwoven loop materials including disposable personal care absorbent articles such as diapers, feminine care sanitary napkins, and adult incontinence articles, and disposable protective articles such as surgical drapes and gowns and other protective apparel.",KIMBERLY CLARK CO,AHN JUNGYEUL;;BOLIAN II CHARLES EDWARD;;CHIN JEASEUNG;;FORBES BRIAN STEPHEN;;JUNG SOOGYUNG;;KIM BYUNGSOO;;LEE JINHEE;;NING XIN;;YOU KUEYOUNG,,https://lens.org/110-772-232-110-70X,Search Report,yes,5,0,12,12,0,A44B18/0011;;D04H3/00;;D04H11/00;;A61F13/627;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;A61P1/00;;A61L15/16;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;D04H3/00;;A44B18/0011;;D04H11/00;;A61F13/627,A44B18/00;;A61F13/62;;A61P1/00;;D04H3/00;;A61L15/16;;D04H11/00,,0,0,,,,PENDING
203,DE,D1,DE 69116422 D1,067-414-392-021-397,1996-02-29,1996,DE 69116422 T,1991-02-08,US 52640390 A,1990-05-18,Supraleitendes Mehrschichtkeramiksubstrat,,IBM,AHN BYUNG TAE;;BEYERS ROBERT BRUCE;;COOPER EMANUEL ISRAEL;;GIESS EDWARD AUGUST;;O'SULLIVAN EUGENE JOHN;;ROLDAN JUDITH MARIE;;ROMANKIW LUBOMYR TARAS,,https://lens.org/067-414-392-021-397,Granted Patent,no,0,0,6,6,0,H01L21/4867;;H01L23/15;;H01L23/49888;;Y10S428/93;;Y10S505/704;;Y10S428/901;;Y10S505/701;;Y10S505/703;;H01L2924/0002;;Y10T428/24917;;Y10T428/31678;;H10N60/0661;;Y10T428/24917;;Y10T428/31678;;H01L23/49888;;H01L21/4867;;H01L23/15;;Y10S428/901;;Y10S505/701;;Y10S505/703;;Y10S505/704;;Y10S428/93;;H01L2924/0002;;H10N60/0661,C01G1/00;;C01G29/00;;C04B35/00;;C04B35/45;;H01B12/06;;H01B13/00;;H01L21/48;;H01L23/15;;H01L23/498;;H01L39/02;;H01L39/24,,0,0,,,,EXPIRED
204,EP,B1,EP 0456963 B1,001-161-323-888-395,1996-01-17,1996,EP 91101732 A,1991-02-08,US 52640390 A,1990-05-18,Superconducting multilayer ceramic substrate,,IBM,AHN BYUNG TAE;;BEYERS ROBERT BRUCE;;COOPER EMANUEL ISRAEL;;GIESS EDWARD AUGUST;;O'SULLIVAN EUGENE JOHN;;ROLDAN JUDITH MARIE;;ROMANKIW LUBOMYR TARAS,"GLOBALFOUNDRIES INC., KY (2016-05-12);;GLOBALFOUNDRIES INC., GB (2016-08-29)",https://lens.org/001-161-323-888-395,Granted Patent,yes,1,1,6,6,0,H01L21/4867;;H01L23/15;;H01L23/49888;;Y10S428/93;;Y10S505/704;;Y10S428/901;;Y10S505/701;;Y10S505/703;;H01L2924/0002;;Y10T428/24917;;Y10T428/31678;;H10N60/0661;;Y10T428/24917;;Y10T428/31678;;H01L23/49888;;H01L21/4867;;H01L23/15;;Y10S428/901;;Y10S505/701;;Y10S505/703;;Y10S505/704;;Y10S428/93;;H01L2924/0002;;H10N60/0661,C01G1/00;;C01G29/00;;C04B35/00;;C04B35/45;;H01B12/06;;H01B13/00;;H01L21/48;;H01L23/15;;H01L23/498;;H01L39/02;;H01L39/24,,3,0,,,"JAPANESE JOURNAL OF APPLIED PHYSICS, LETTERS, vol. 28, no. 6, June 1989, TOKYO, JP, pages 984-986; M. YOSHIMOTO et al.: ""Preparation of a Bi-Sr-Ca-Cu-O high Tc superconductor by the reaction of a Cu-free precursor with Cu plate"";;JAPANESE JOURNAL OF APPLIED PHYSICS, LETTERS, vol. 26, no. 7, July 1987, TOKYO, JP, pages 1172-1173; H. KUMAKURA et al.: ""Ba-Y-Cu-O superconducting tape prepared by surface diffusion process"";;PATENT ABSTRACTS OF JAPAN vol. 013, no. 496 (E-843) 09 November 89, & JP-A- 01 199454",EXPIRED
205,AU,A1,AU 2003/276942 A1,110-400-611-061-330,2004-04-23,2004,AU 2003/276942 A,2003-09-26,US 26095502 A;;US 0330255 W,2002-09-30,NONWOVEN LOOP MATERIAL AND PROCESS AND PRODUCTS RELATING THERETO,,KIMBERLY CLARK CO,AHN JUNGYEUL;;BOLIAN II CHARLES EDWARD;;CHIN JEASEUNG;;FORBES BRIAN STEPHEN;;JUNG SOOGYUNG;;KIM BYUNGSOO;;LEE JINHEE;;NING XIN;;YOU KUEYOUNG,,https://lens.org/110-400-611-061-330,Patent Application,no,0,0,12,12,0,A44B18/0011;;D04H3/00;;D04H11/00;;A61F13/627;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;A61P1/00;;A61L15/16;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;D04H3/00;;A44B18/0011;;D04H11/00;;A61F13/627,A61L15/16;;A44B18/00;;A61F13/62;;A61P1/00;;D04H3/00;;D04H11/00,,0,0,,,,DISCONTINUED
206,CN,A,CN 1681462 A,097-481-710-189-733,2005-10-12,2005,CN 03822031 A,2003-09-26,US 26095502 A,2002-09-30,Nonwoven loop material and process and products relating thereto,,KIMBERLY CLARK CO,JUNGYEUL AHN;;EDWARD BOLIAN II CHARLES;;JEASEUNG CHIN;;STEPHEN FORBES BRIAN;;SOOGYUNG JUNG;;BYUNGSOO KIM;;JINHEE LEE;;XIN NING;;KUEYOUNG YOU,,https://lens.org/097-481-710-189-733,Patent Application,no,0,0,12,12,0,A44B18/0011;;D04H3/00;;D04H11/00;;A61F13/627;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;A61P1/00;;A61L15/16;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;D04H3/00;;A44B18/0011;;D04H11/00;;A61F13/627,A61L15/16;;A44B18/00;;A61F13/62;;A61P1/00;;D04H3/00;;D04H11/00,,0,0,,,,DISCONTINUED
207,AU,A8,AU 2003/276942 A8,132-588-768-372-685,2004-04-23,2004,AU 2003/276942 A,2003-09-26,US 26095502 A;;US 0330255 W,2002-09-30,Nonwoven loop material and process and products relating thereto,,KIMBERLY CLARK CO,KIM BYUNGSOO;;YOU KUEYOUNG;;NING XIN;;BOLIAN II CHARLES EDWARD;;FORBES BRIAN STEPHEN;;JUNG SOOGYUNG;;LEE JINHEE;;CHIN JEASEUNG;;AHN JUNGYEUL,,https://lens.org/132-588-768-372-685,Patent Application,no,0,0,12,12,0,A44B18/0011;;D04H3/00;;D04H11/00;;A61F13/627;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;A61P1/00;;A61L15/16;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;D04H3/00;;A44B18/0011;;D04H11/00;;A61F13/627,A61L15/16;;A44B18/00;;A61F13/62;;A61P1/00;;D04H3/00;;D04H11/00,,0,0,,,,DISCONTINUED
208,US,A,US 5834405 A,135-355-327-962-120,1998-11-10,1998,US 83970792 A,1992-02-24,US 83970792 A;;US 52640390 A,1990-05-18,Superconducting multilayer ceramic substrate,"A superconducting multilayer ceramic substrate is disclosed, prepared by firing a laminate of at least two polymer bonded cast sheets of a ceramic dielectric oxide powder, at least one sheet of which has a metallization pattern provided thereon, to thereby form a superconducting oxide reaction layer at the interface between the sintered ceramic material and the embedded metallic conductor lines of the metallization pattern.",IBM,AHN BYUNG TAE;;BEYERS ROBERT BRUCE;;COOPER EMANUEL ISRAEL;;GIESS EDWARD AUGUST;;O'SULLIVAN EUGENE JOHN;;ROLDAN JUDITH MARIE;;ROMANKIW LUBOMYR TARAS,GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/135-355-327-962-120,Granted Patent,yes,15,5,6,6,0,H01L21/4867;;H01L23/15;;H01L23/49888;;Y10S428/93;;Y10S505/704;;Y10S428/901;;Y10S505/701;;Y10S505/703;;H01L2924/0002;;Y10T428/24917;;Y10T428/31678;;H10N60/0661;;Y10T428/24917;;Y10T428/31678;;H01L23/49888;;H01L21/4867;;H01L23/15;;Y10S428/901;;Y10S505/701;;Y10S505/703;;Y10S505/704;;Y10S428/93;;H01L2924/0002;;H10N60/0661,C01G1/00;;C01G29/00;;C04B35/00;;C04B35/45;;H01B12/06;;H01B13/00;;H01L21/48;;H01L23/15;;H01L23/498;;H01L39/02;;H01L39/24,505/236;;505/237;;505/238;;505/220;;505/230;;505/232;;505/701;;505/703;;505/704;;428/701;;428/702;;428/209;;428/457;;428/901;;428/930,22,10,002-548-917-616-859;;031-711-280-762-355;;098-156-933-189-930;;013-010-650-234-281;;116-407-918-765-447;;054-110-108-009-856;;058-349-006-115-738;;040-724-407-364-848;;032-761-523-748-403;;137-668-674-195-704,10.1143/jjap.28.l984;;10.1126/science.259.5101.1550;;17733017;;10.1038/scientificamerican1292-24;;10.1103/physrevb.36.226;;9942040;;10.1038/337345a0;;10.1016/0921-4534(90)90338-f;;10.1021/ed064p480;;10.1103/physrevlett.62.1197;;10039601;;10.1063/1.98472;;10.1143/jjap.26.l1172,"Japanese Journal Appl. Phys., vol. 27, No. 7, Jul. 1988, pp. L1261 L1270 Weng et al.;;Japanese Journal of Applied Physics, Letters vol. 28, No. 6, Jun. 1989, Tokyo JP pp. 984 986; M. Yoshimoto et al: Preparation of a Bi Sr Ca Cu O high T c superconductor by the reaction of a Cu free precursor with Cu plate .;;Patent Abstracts of Japan, vol. 013, No. 496, (E 843) 09 Nov. 89, & JP A 01 199454 (Fujitsu) 10 Aug. 1989.;;Paths to Higher Temperature Superconductors, Science vol. 259, 12 Mar. 1993, pp. 1550 1551.;;Theoretical Resistance Scientific American Dec. 1992, pp. 24 25.;;Doss, Engineers Guide to High T Superconductivity, Wiley & Sons, 1989 pp. 105 108.;;Tarascon et al Oxygen and Rare Earth Doping of the 90K Superconducting Perovskite YBa 2 Cu 3 O 7 x Physical Review B , vol. 36, No. 1, pp. 226 234 (Jul. 1987).;;Arima et al, Extended Family of New Bi 2222 Superconducting Cuprates Bi 2 Sr 2 (RE 1 x Ce x ) 2 Cu 2 O 10 y , Physica C , vol. 168, pp. 79 84 (1990).;;Tokura et al A Superconducting Copper Oxide Compound With Electrons as the Charge Carriers Nature , vol. 337, No. 26, pp. 345 347 (Jan. 1989).;;Ishida et al, Critical Temperature Control of Bi 2 Sr 2 CuO x By Quenching , Physica C , vol. 167, pp. 258 262 (1990).;;Derek W. Smith, An Acidity Scale for Binary Oxides:, Journal of Chemical Education , vol. 64, No., 6 pp. 480 481 (Jun. 1987).;;Tatsumi et al, Jpn. J. Appl. Phys., vol. 31, Part 2, No. 4A, pp. 392 395 (Apr. 1992).;;Saito et al, High T c Superconducting Properties In (Y 1 x Tl x )Ba 2 Cu 3 O 7 y , Y(Ba 1 x K x ) 2 Cu 3 O 7 y and YBa 2 (Cu 1 x Mg x ) 3 O 7 y , Physica B , vol. 148, pp. 336 338 (1987).;;Fuertes et al, Oxygen Excess and Superconductivity at 45 K in La 2 CaCu 2 O 6 y , Physica C , vol. 170 pp. 153 160 (1990).;;Takagi et al, Superconductivity Produced by Electron Doping in CuO 2 Layered Compounds , Physical Review Letters , vol. 62, No. 10, pp. 1197 1200 (Mar. 1989).;;Zandbergen et al, The Effect of the Oxygen Content in Pb 2 SrLaCu 2 O 6 and Pb 2 Ba 2 YCU 3 O 8 on the Structural and Superconducting Properties , Physica C , vol. 166, pp. 502 512 (1990).;;Veal et al, Superconductivity in YBa 2 x Sr x Cu 3 O 7 , Appl. Phys. Lett., vol. 51, No. 4, pp. 279 281 (Jul. 1987).;;Dalichaouch et al, Superconducting and Normal State Properties of Y 1 x M x Ba 2 Cu 3 O 7 (M Pr, Na) , Solid State Communication , vol. 65, No. 9, pp. 1001 1006 (1988).;;CA 114:15684 x.;;CA 114:53754 c.;;CA 114:175913 z.;;Japanese Journal of Applied Physics, vol. 26, No. 7 (Jul. 1987), pp. L1172 L1173 (Kumakura et al), entitled Ba Y Cu O Superconducting Tape Prepared by Surface Diffusion Process .",EXPIRED
209,EP,A4,EP 2802929 A4,059-642-128-271-244,2015-07-15,2015,EP 13735605 A,2013-01-04,US 201261584556 P;;US 201261623704 P;;US 2013/0020210 W,2012-01-09,ILLUMINATED DISPLAY DEVICE CASE COMPRISING AN INTEGRATED OPTICAL FILM,,3M INNOVATIVE PROPERTIES CO,SNYDER THOMAS M;;TOY MICHELLE L;;KIM JEONG-WAN;;AHN YONGCHAN;;OH YOU-JUNG;;WEAVER EDWARD L II;;BISEK PATRICK E,,https://lens.org/059-642-128-271-244,Search Report,no,5,0,5,5,0,G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G06F1/182;;G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G02B27/30;;G06F1/182,G06F1/16;;F21V8/00,,1,0,,,See also references of WO 2013106241A1,DISCONTINUED
210,EP,A1,EP 0456963 A1,080-520-758-393-495,1991-11-21,1991,EP 91101732 A,1991-02-08,US 52640390 A,1990-05-18,Superconducting multilayer ceramic substrate.,"A superconducting multilayer ceramic substrate is disclosed, prepared by firing a laminate of at least two polymer bonded cast sheets of a ceramic dielectric oxide powder, at least one sheet of which has a metallization pattern provided thereon, to thereby form a superconducting oxide reaction layer at the interface between the sintered ceramic material and the embedded metallic conductor lines of the metallization pattern.",IBM,AHN BYUNG TAE;;BEYERS ROBERT BRUCE;;COOPER EMANUEL ISRAEL;;GIESS EDWARD AUGUST;;O'SULLIVAN EUGENE JOHN;;ROLDAN JUDITH MARIE;;ROMANKIW LUBOMYR TARAS,"GLOBALFOUNDRIES INC., KY (2016-05-12);;GLOBALFOUNDRIES INC., GB (2016-08-29)",https://lens.org/080-520-758-393-495,Patent Application,yes,1,0,6,6,0,H01L21/4867;;H01L23/15;;H01L23/49888;;Y10S428/93;;Y10S505/704;;Y10S428/901;;Y10S505/701;;Y10S505/703;;H01L2924/0002;;Y10T428/24917;;Y10T428/31678;;H10N60/0661;;Y10T428/24917;;Y10T428/31678;;H01L23/49888;;H01L21/4867;;H01L23/15;;Y10S428/901;;Y10S505/701;;Y10S505/703;;Y10S505/704;;Y10S428/93;;H01L2924/0002;;H10N60/0661,C01G1/00;;C01G29/00;;C04B35/00;;C04B35/45;;H01B12/06;;H01B13/00;;H01L21/48;;H01L23/15;;H01L23/498;;H01L39/02;;H01L39/24,,3,1,002-548-917-616-859,10.1143/jjap.28.l984,"JAPANESE JOURNAL OF APPLIED PHYSICS.LETTERS vol. 28, no. 6, June 1989, TOKYO JP pages 984 - 986; M. YOSHIMOTO ET AL: ""Preparation of a Bi-Sr-Ca-Cu-O high Tc superconductor by the reaction of a Cu-free precursor with Cu plate"";;JAPANESE JOURNAL OF APPLIED PHYSICS.LETTERS vol. 26, no. 7, July 1987, TOKYO JP pages 1172 - 1173; H. KUMAKURA ET AL: ""Ba-Y-Cu-O superconducting tape prepared by surface diffusion process"";;PATENT ABSTRACTS OF JAPAN vol. 013, no. 496 (E-843) 09 November 89, & JP-A-01 199454 (FUJITSU) 10 August 1989,",EXPIRED
211,BR,A,BR 0314386 A,031-643-662-676-645,2005-07-19,2005,BR 0314386 A,2003-09-26,US 26095502 A;;US 0330255 W,2002-09-30,Material não-tecido em laço e processos para fabricação dos mesmos,"""MATERIAL NãO-TECIDO EM LAçO E PROCESSOS PARA FABRICAçãO DOS MESMOS"". A presente invenção proporciona materiais em fibra não-tecidos e métodos para a fabricação dos mesmos, úteis para materiais em laço em sistemas de fixação mecânica em gancho e laço. Os materiais não-tecidos tendo fibras de monocomponente encrespadas tendo seções transversais substancialmente circulares e as tramas podem ainda conter fibras não encrespadas. A invenção também proporciona artigos descartáveis compreendendo materiais em laço não-tecidos incluindo artigos absorventes descartáveis para cuidados pessoais, tais como fraldas, absorventes sanitários femininos e artigos para incontinência em adultos e artigos protetores descartáveis, tais como cortinas e aventais cirúrgicos e outro vestuário protetor.",KIMBERLY CLARK CO,AHN JUNG YEUL;;BOLIAN CHARLES EDWARD II;;CHIN JEASEUNG;;FORBES BRIAN STEPHEN;;JUNG SOOGYUNG;;KIM BYUNGSOO;;LEE JINHEE;;NING XIN;;YOU KUEYOUNG,,https://lens.org/031-643-662-676-645,Patent Application,no,0,0,12,12,0,A44B18/0011;;D04H3/00;;D04H11/00;;A61F13/627;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;A61P1/00;;A61L15/16;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;D04H3/00;;A44B18/0011;;D04H11/00;;A61F13/627,A61L15/16;;A44B18/00;;A61F13/62;;A61P1/00;;D04H3/00;;D04H11/00,,0,0,,,,DISCONTINUED
212,US,A,US 5658902 A,139-783-874-815-193,1997-08-19,1997,US 36310494 A,1994-12-22,US 36310494 A,1994-12-22,Quinazolines as inhibitors of endothelin converting enzyme,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNGHYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE;;LEONARD DANIELE;;NIKAM SHAM;;WERBEL LESLIE MORTON,WARNER-LAMBERT COMPANY (1995-02-22),https://lens.org/139-783-874-815-193,Granted Patent,yes,22,16,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/74;;C07D239/91;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,514/234.8;;514/259;;514/254;;514/255;;514/228.2;;514/212;;544/293;;544/116;;544/284;;544/238;;544/357;;544/296;;544/62;;540/600;;540/582,9,2,060-775-331-629-365;;086-668-487-573-839,10.1071/ch9850467;;10.1021/jm00212a010;;137981,"Takase, Y. et al. Chemical Abstract Services, CA 119:203427 (1993).;;Patterson, S.E., et al., J. Heterocycl. Chem (Jul. 1992), 29(4) 703 6.;;Browns, D.J., et al., Aust. J. Chem. (1985), 38(3), 467 74.;;Genther, C.S., et al., J. Med. Chem. (1977), 20(2), 237 43.;;PCT International Search Report, PCT/US 95/15366, Jun. 1996.;;Chemical Abstracts, vol. 93, No. 21, 1980, abstract No. 204585z.;;Chemical Abstracts, vol. 90, No. 5, 1979, abstract No. 198861f.;;Chemical Abstracts, vol. 83, No. 28, 1975, abstract No. 58869v.;;Sandoz, AG Derwent Abstract No. 76 72258x (1976).",EXPIRED
213,US,A,US 5773444 A,012-212-681-464-521,1998-06-30,1998,US 83717697 A,1997-04-14,US 83717697 A;;US 36310494 A,1994-12-22,Quinazolines as inhibitors of endothelin converting enzyme,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNGHYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE;;LEONARD DANIELE;;NIKAM SHAM;;WERBEL LESLIE MORTON,,https://lens.org/012-212-681-464-521,Granted Patent,yes,21,5,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,A61K31/505;;A61K31/517;;A61P43/00;;C07D239/74;;C07D239/90;;C07D239/91;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,514/260;;514/259;;514/234.8;;514/255;;514/228.2,8,2,060-775-331-629-365;;086-668-487-573-839,10.1071/ch9850467;;10.1021/jm00212a010;;137981,"PCT International Search Report, PCT/US 95/15366.;;Chemical Abstracts, vol. 93, No. 21, 1980, abstract No. 204585z.;;Chemical Abstracts, vol. 90, No. 5, 1979, abstract No. 198861f.;;Chemical Abstracts, vol. 83, No. 28, 1975, abstract No. 58869v.;;Sandoz, AG Derwent Abstract No. 76 72258X (1976).;;Patterson, S.E., et al., J. Heterocycl. Chem (1992), 29(4) 703 6.;;Brown, D.J., et al., Aust. J. Chem . (1985), 38(3), 467 74.;;Genther, C.S., et al., J. Med. Chem . (1977), 20(2), 237 43.",EXPIRED
214,CN,A,CN 104081258 A,094-984-539-455-135,2014-10-01,2014,CN 201380004405 A,2013-01-04,US 2013/0020210 W;;US 201261584556 P;;US 201261623704 P,2012-01-09,Illuminated display device case comprising integrated optical film,Cases and case kits suitable for receiving an illuminated display device such as a tablet are described. The cases comprise a (e.g. light-collimating) optical film integrated with the case. The illuminated display device is intended to be operated while contained within (rather than being removed from) the case. The illuminated display surface can be viewed through the (e.g. light-collimating) optical film when an illuminated display device is provided within the case.,3M INNOVATIVE PROPERTIES CO,SNYDER THOMAS M;;TOY MICHELLE L;;KIM JEONG-WAN;;AHN YONG-CHAN;;OH YOU-JUNG;;WEAVER EDWARD L II;;PATRICK E BISEK,,https://lens.org/094-984-539-455-135,Patent Application,no,5,1,5,5,0,G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G06F1/182;;G02B6/0053;;G06F1/1609;;G06F1/1628;;G06F2200/1633;;G02B27/30;;G06F1/182,G02B27/30;;G02B6/00,,0,0,,,,DISCONTINUED
215,US,A1,US 2004/0063369 A1,099-985-193-012-72X,2004-04-01,2004,US 26095502 A,2002-09-30,US 26095502 A,2002-09-30,Nonwoven loop material and process and products relating thereto,"
   The present invention provides nonwoven fiber materials, and methods for making the same, useful for loop materials in hook and loop mechanical attachment systems, the nonwoven materials having crimped monocomponent fibers having substantially circular cross sections, and the webs may further contain uncrimped fibers. The invention also provides disposable articles comprising nonwoven loop materials including disposable personal care absorbent articles such as diapers, feminine care sanitary napkins, and adult incontinence articles, and disposable protective articles such as surgical drapes and gowns and other protective apparel. 
",AHN JUNG YEUL;;BOLIAN CHARLES EDWARD;;CHIN JEASEUNG;;FORBES BRIAN STEPHEN;;JUNG SOOGYUNG;;KIM BYUNGSOO;;LEE JIN HEE;;NING XIN;;YOU JUEYOUNG,AHN JUNG YEUL;;BOLIAN CHARLES EDWARD;;CHIN JEASEUNG;;FORBES BRIAN STEPHEN;;JUNG SOOGYUNG;;KIM BYUNGSOO;;LEE JIN HEE;;NING XIN;;YOU JUEYOUNG,KIMBERLY-CLARK WORLDWIDE INC (2003-09-22),https://lens.org/099-985-193-012-72X,Patent Application,yes,39,19,12,12,0,A44B18/0011;;D04H3/00;;D04H11/00;;A61F13/627;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;A61P1/00;;A61L15/16;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;D04H3/00;;A44B18/0011;;D04H11/00;;A61F13/627,A44B18/00;;A61F13/62;;A61L15/16;;A61P1/00;;D04H3/00;;D04H11/00,442/327;;442/352;;428/85;;428/92,0,0,,,,DISCONTINUED
216,WO,A1,WO 1996/019474 A1,040-247-186-835-394,1996-06-27,1996,US 9515366 W,1995-11-27,US 36310494 A,1994-12-22,QUINAZOLINES AS INHIBITORS OF ENDOTHELIN CONVERTING ENZYME,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNGHYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE;;LEONARD DANIELE;;NIKAM SHAM SHRIBHAR;;WERBEL LESLIE MORTON,,https://lens.org/040-247-186-835-394,Patent Application,yes,5,5,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/74;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,5,1,086-668-487-573-839,10.1021/jm00212a010;;137981,"CHEMICAL ABSTRACTS, vol. 93, no. 21, Columbus, Ohio, US; abstract no. 204585z, ZHIKHAVERA,G. ET AL.: ""SYNTHESIS AND ANTILEISHMANIASIS ACTIVITY OF SUBST. 2-STYRYLQUINAZOLINES."" page 684; column 2;;CHEMICAL ABSTRACTS, vol. 90, no. 5, Columbus, Ohio, US; abstract no. 198861f, page 167; column 1;;CHEMICAL ABSTRACTS, vol. 83, no. 28, Columbus, Ohio, US; abstract no. 58869v, page 511; column 2;;STEVEN E. PATTERSON: ""NEW SYNTHESIS OF N-SUBSTIT.-2-ALKYL(OR ARYL)QUINAZOLIN-4-AMINES"", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 29, no. 4, PROVO US, pages 703 - 706;;CLARA GENTHER ET AL.: ""ANTIFOLATE STUDIES."", JOURNAL OF MEDICINAL CHEMISTRY, vol. 20, no. 2, WASHINGTON US, pages 237 - 243",PATENTED
217,WO,A1,WO 2022/117567 A1,176-028-113-430-291,2022-06-09,2022,EP 2021083575 W,2021-11-30,US 202063120232 P,2020-12-02,BIOABSORBABLE TEXTILES AND METHODS FOR JOINT FUNCTION RESTORATION,"A bioabsorbable textile for the restoration of the joint function whereas the joint is affected by partial thickness tears, small to medium full-thickness tears, large to massive full-thickness tears, acute and chronic/degenerative tears. The bioabsorbable textile may comprise polymeric yarns interconnected to form a weave or knitted configuration, wherein said bioabsorbable textile provides a combined mechanical and biological augmentation in the target joint tissue. The bioabsorbable textile may beimplanted in combination with fixation tools during open, mini-open or arthroscopic repair/augmentation procedures of joint tissue tears.",ANIKA THERAPEUTICS S R L,AGNELLO STEFANO;;AHN EDWARD;;CENTOLA MATTEO;;EK STEVEN W;;KENNEDY STEPHEN J;;MANNARINO MATTHEW M;;MARCHETTO ELVIRA;;PURI SONALI;;RICHARD ROBERT;;SIMONCIONI SARA,,https://lens.org/176-028-113-430-291,Patent Application,yes,7,0,3,3,0,A61L27/46;;A61L27/446;;A61L27/58;;A61L27/3834;;A61L27/386;;A61L2430/10;;A61L27/56;;A61L27/20;;A61F2/30;;A61F2002/30062;;A61F2210/0004;;A61L27/20;;A61L27/32;;A61L27/58;;D02G3/448;;D03D1/00;;D03D19/00;;D10B2331/04;;D10B2401/12;;D10B2509/00,A61L27/38;;A61L27/20;;A61L27/44;;A61L27/46;;A61L27/56;;A61L27/58;;B32B5/00;;B32B27/00,,33,33,040-513-699-406-797;;046-410-717-713-878;;063-078-407-495-611;;001-171-006-486-340;;041-016-121-433-982;;066-383-177-912-888;;011-898-698-467-780;;017-230-522-625-755;;062-993-796-903-457;;098-821-581-556-262;;042-149-563-374-663;;010-278-434-298-801;;017-477-373-659-963;;011-748-683-120-748;;062-980-707-787-480;;039-331-671-894-028;;013-708-278-839-616;;086-795-048-341-026;;004-606-999-499-638;;061-044-259-495-354;;057-740-201-415-352;;010-175-183-995-095;;070-925-258-367-218;;024-375-303-768-861;;061-152-429-687-235;;054-737-259-081-336;;022-283-228-200-019;;034-935-066-048-662;;018-351-761-562-672;;063-078-407-495-611;;015-918-904-707-513;;056-514-744-350-725;;022-559-514-544-255,15789422;;10.1002/jbm.a.30261;;19249964;;10.1089/ten.tec.2008.0569;;10.32098/mltj.03.2013.17;;pmc3838334;;24367785;;20580140;;10.1016/j.clinbiomech.2010.05.010;;21976447;;10.1002/jbm.a.33179;;10.1016/j.arthro.2005.12.021;;16651164;;10.1016/j.jse.2005.09.017;;16679227;;9442325;;10.1016/s0749-8063(97)90006-2;;10.1016/j.biomaterials.2011.08.035;;pmc3947519;;21880362;;10.1586/17434440.6.1.61;;19105781;;14668510;;10.2106/00004623-200312000-00018;;19411465;;pmc2674245;;10.2106/jbjs.h.00775;;10.1177/0363546504272689;;16000663;;14960664;;10.2106/00004623-200402000-00002;;27614271;;pmc5154820;;10.1016/j.jmbbm.2016.08.034;;8804277;;10.1097/00003086-199609000-00010;;10.1016/j.biomaterials.2011.11.066;;22177622;;pmc3279298;;10.1016/j.joca.2007.03.017;;pmc2034527;;17507255;;8541777;;20047971;;10.1093/bmb/ldp051;;10.14227/dt180311p15;;24403741;;10.1016/j.jor.2013.01.008;;pmc3768248;;pmc2809655;;10.1089/ten.tea.2008.0014;;18788982;;pmc4380768;;10.1007/s10439-015-1263-1;;25650098;;10.22203/ecm.v031a08;;26815643;;10.1016/j.jse.2017.06.035;;28865966;;26665095;;10.1177/2325967115587495;;pmc4622366;;10.1016/j.csm.2012.07.001;;23040548;;22818988;;10.1016/j.biomaterials.2012.07.002;;10.32098/mltj.03.2013.17;;pmc3838334;;24367785;;10.1016/j.jse.2009.04.006;;19540777;;25750610;;10.1002/adfm.201400828;;pmc4349415;;22244070;;10.1016/j.jse.2011.11.016;;pmc3260004,"CRISTINO S. ET AL: ""Analysis of mesenchymal stem cells grown on a three-dimensional HYAFF 11 -based prototype ligament scaffold : Analysis of Mesenchymal Stem Cells"", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, vol. 73A, no. 3, 23 March 2005 (2005-03-23), US, pages 275 - 283, XP055895130, ISSN: 1549-3296, DOI: 10.1002/jbm.a.30261;;GRIGOLO BRUNELLA ET AL: ""Osteoarthritis treated with mesenchymal stem cells on hyaluronan-based scaffold in rabbit"", TISSUE ENGINEERING. PART C, METHODS DEC 2008, MARY ANN LIEBERT, INC. PUBLISHERS, US, vol. 15, no. 4, 10 December 2009 (2009-12-10), pages 647 - 658, XP002603369, ISSN: 1937-3384, [retrieved on 20090427], DOI: 10.1089/TEN.TEC.2008.0569;;VAN KAMPEN ET AL., MUSCLES, LIGAMENTS AND TENDONS JOURNAL, 2013;;AURORA AGATICA JEDEN BOGERT AJMCCARRON JADERWIN KA: ""An analytical model for rotator cuff repairs"", CLIN BIOMECH, vol. 25, 2010, pages 751 - 758, XP027197526;;AURORA AMESIHA MTAN CDWALKER ESAHOO SIANNOTTI JPMCCARRON JADERWIN KA: ""Mechanical characterization and biocompatibility of a novel reinforced fascia patch for rotator cuff repair"", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A, vol. 99A, 2011, pages 221 - 230;;BARBER FAHERBERT MACOONS DA: ""Tendon Augmentation Grafts: Biomechanical Failure Loads and Failure Patterns"", ARTHROSCOPY: THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, vol. 22, 2006, pages 534 - 538, XP005405593, DOI: 10.1016/j.arthro.2005.12.021;;BISHOP JKLEPPS SLO IKBIRD JGLADSTONE JNFLATOW EL: ""Cuff integrity after arthroscopic versus open rotator cuff repair: a prospective study"", J SHOULDER ELBOW SURG, vol. 15, 2006, pages 290 - 299, XP005416903, DOI: 10.1016/j.jse.2005.09.017;;BURKHART SSDIAZ PAGAN LWIRTH MAAHANASIOU KA: ""Cyclic loading of anchor-based rotator cuff repairs: Confirmation of the tension overload phenomenon and comparison of suture anchor fixation with transosseous fixation"", ARTHROSCOPY, vol. 13, 1997, pages 720 - 724;;CALIARI SRRAMIREZ MAHARLEY B: ""The development of collagen-GAG scaffold-membrane composites for tendon tissue engineering"", BIOMATERIALS, vol. 32, no. 34, 2011, pages 8990 - 8998, XP028300016, DOI: 10.1016/j.biomaterials.2011.08.035;;CHEN JXU JWANG AZHENG M: ""Scaffolds for tendon and ligament repair: review of the efficacy of commercial products"", EXPERT REV MED DEVICES, vol. 6, 2009, pages 61 - 73;;COLEMAN SHFEALY SEHTESHAMI JRMACGILLIVRAY JDALTCHEK DWWARREN RFTURNER AS: ""Chronic rotator cuff injury and repair model in sheep"", J BONE JOINT SURG AM., vol. 85, no. 12, pages 2391 - 402;;DERWIN KACODSI MJMILKS RABAKER ARMCCARRON JAIANNOTTI JP: ""Rotator cuff repair augmentation in a canine model with use of a woven poly-L-lactide device"", JOURNAL OF BONE AND JOINT SURGERY A, vol. 91, 2009, pages 1159 - 1171;;FUNAKOSHI TMAJIMA TIWASAKI NSUENAGA NSAWAGUCHI NSHIMODE KMINAMI AHARADA KNISHIMURA S: ""Application of Tissue Engineering Techniques for Rotator Cuff Regeneration Using a Chitosan-Based Hyaluronan Hybrid Fiber Scaffold"", THE AMERICAN JOURNAL OF SPORTS MEDICINE, vol. 33, 2005, pages 8;;GALATZ LMBALL CMTEEFEY SAMIDDLETON WDYAMAGUCHI K: ""The outcome and repair integrity of completely arthroscopically repaired large and massive rotator cuff tears"", J BONE JOINT SURG AM, vol. 86-a, 2004, pages 219 - 224;;GRIER WKIYOHA EMHARLEY B: ""The influence of pore size and stiffness on tenocyte bioactivity and transcriptomic stability in collagen-GAG scaffolds"", J MECH BEHAV BIOMED MATER, vol. 65, 2017, pages 295 - 305, XP029839603, DOI: 10.1016/j.jmbbm.2016.08.034;;HUGHES REAN KN: ""Force analysis of rotator cuff muscles"", CLIN ORTHOP RELAT RES, vol. 330, 1996, pages 75 - 83;;KISHORE VBULLOCK WSUN XVAN DYKE WSAKKUS O: ""Tenogenic differentiation of human MSCs induced by the topography of electrochemically aligned collagen threads"", BIOMATERIALS, vol. 33, no. 7, 2012, pages 2137 - 2144, XP028442462, DOI: 10.1016/j.biomaterials.2011.11.066;;KRAUS VBSTABLER TVKONG SYVARJU GMCDANIEL G: ""Measurement of synovial fluid volume using urea"", OSTEOARTHRITIS CARTILAGE, vol. 15, no. 1 0, October 2007 (2007-10-01), pages 1217 - 20;;LEHMAN CCUOMO FKUMMER FJZUCKERMAN JD: ""The incidence of full thickness rotator cuff tears in a large cadaveric population"", BULL HOSP JT DIS, vol. 54, 1995, pages 30 - 31;;LONGO UGLAMBERTI AMAFFULLI NDENARO V: ""Tendon augmentation grafts: a systematic review"", BR MED BULL, vol. 94, 2010, pages 165, XP055875066, DOI: 10.1093/bmb/ldp051;;MARQUES MRCLOEBENBERG RALMUKAINZI M: ""Simulated Biological Fluids with Possible Application in Dissolution Testing"", DISSOLUTION TECHNOLOGIES, 2011;;MINAGAWA HYAMAMOTO NABE HFUKUDA MSEKI NKIKUCHI KKIJIMA HITOI E: ""Prevalence of symptomatic and asymptomatic rotator cuff tears in the general population: From mass-screening in one village"", J ORTHOP., vol. 10, no. 1, 2013, pages 8 - 12;;MOFFAT KLKWEI ASSPALAZZI JPDOTY SBLEVINE WNLU HH: ""Novel nanofiber-based scaffold for rotator cuff repair and augmentation"", TISSUE ENG PART A, vol. 15, no. 1, 2009, pages 115 - 126;;RATCLIFFE ABUTLER DLDYMENT NACAGLE PJ, JR.PROCTOR CSRATCLIFFE SSFLATOW, E.L.: ""Scaffolds for tendon and ligament repair and regeneration"", ANN BIOMED ENG, vol. 43, 2015, pages 819, XP035475362, DOI: 10.1007/s10439-015-1263-1;;SMITH RDJCARR ADAKIN SSNELLING SYAPP CHAKIMI O: ""The response of tenocytes to commercial scaffolds used for rotator cuff repair"", EUR CELL MATER, vol. 30, 2016, pages 107;;SMITH RDJZARGAR NBROWN CP ET AL.: ""Characterizing the macro and micro mechanical properties of scaffolds for rotator cuff repair"", J SHOULDER ELBOW SURG., vol. 26, 2017, pages 2038 - 46, XP085228157, DOI: 10.1016/j.jse.2017.06.035;;THANGARAJAH TPENDEGRASS CJSHAHBAZI SLAMBERT SALEXANDER SBLUNN GW: ""Augmentation of rotator cuff repair with soft tissue scaffolds"", THE ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE, vol. 3, no. 6, 2015;;TASHJIAN, RZ: ""Epidemiology, natural history, and indications for treatment of rotator cuff tears"", CLIN SPORTS MED, vol. 31, no. 4, 2012, pages 5 89 - 604;;TONG WYSHEN WYEUNG CWZHAO YCHENG SHCHU PKCHAN DCHAN GCCHEUNG KMYEUNG KW ET AL.: ""Functional replication of the tendon tissue microenvironment by a bioimprinted substrate and the support of tenocytic differentiation of mesenchymal stem cells"", BIOMATERIALS, vol. 33, no. 31, 2012, pages 7686 - 98;;VAN KAMPEN CARNOCZKY SPARKS P ET AL.: ""Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep"", MUSCLES LIGAMENTS TENDONS J., vol. 3, no. 3, 2013, pages 229 - 235;;YAMAMOTO ATAKAGISHI KOSAWA TYANAGAWA TNAKAJIMA DSHITARA HKOBAYASHI T: ""Prevalence and risk factors of a rotator cuff tear in the general population"", J SHOULDER ELBOW SURG, vol. 19, 2010, pages 116 - 120, XP026803639;;YOUNESI MISLAM AKISHORE VANDERSON JMAKKUS O: ""Tenogenic Induction of Human MSCs by Anisotropically Aligned Collagen Biotextiles"", ADV FUNCT MATER., vol. 24, no. 36, 2014, pages 5762 - 5770;;ZHANG XBOGDANOWICZ DERISKEN CLEE NMLU HH: ""Biomimetic Scaffold Design for Functional and Integrative Tendon Repair"", J SHOULDER ELBOW SURG, vol. 21, no. 2, 2012, pages 266 - 277, XP028439312, DOI: 10.1016/j.jse.2011.11.016",PENDING
218,US,A1,US 2022/0168105 A1,024-267-382-328-873,2022-06-02,2022,US 202117456901 A,2021-11-30,US 202117456901 A;;US 202063120232 P,2020-12-02,BIOABSORBABLE TEXTILES AND METHODS FOR JOINT FUNCTION RESTORATION,"A bioabsorbable textile for the restoration of the joint function whereas the joint is affected by partial thickness tears, small to medium full-thickness tears, large to massive full-thickness tears, acute and chronic/degenerative tears. The bioabsorbable textile may comprise polymeric yarns interconnected to form a weave or knitted configuration, wherein said bioabsorbable textile provides a combined mechanical and biological augmentation in the target joint tissue. The bioabsorbable textile may be implanted in combination with fixation tools during open, mini-open or arthroscopic repair/augmentation procedures of joint tissue tears.",ANIKA THERAPEUTICS S R L,AGNELLO STEFANO;;AHN EDWARD;;CENTOLA MATTEO;;EK STEVEN W;;KENNEDY STEPHEN J;;MANNARINO MATTHEW M;;MARCHETTO ELVIRA;;PURI SONALI;;RICHARD ROBERT;;SIMONCIONI SARA,ANIKA THERAPEUTICS S.R.L (2021-12-01),https://lens.org/024-267-382-328-873,Patent Application,yes,0,0,3,3,0,A61L27/46;;A61L27/446;;A61L27/58;;A61L27/3834;;A61L27/386;;A61L2430/10;;A61L27/56;;A61L27/20;;A61F2/30;;A61F2002/30062;;A61F2210/0004;;A61L27/20;;A61L27/32;;A61L27/58;;D02G3/448;;D03D1/00;;D03D19/00;;D10B2331/04;;D10B2401/12;;D10B2509/00,A61F2/30;;A61L27/20;;A61L27/32;;A61L27/58;;D02G3/44;;D03D1/00;;D03D19/00,,0,0,,,,PENDING
219,EP,A1,EP 4255517 A1,199-234-463-410-006,2023-10-11,2023,EP 21827197 A,2021-11-30,US 202063120232 P;;EP 2021083575 W,2020-12-02,BIOABSORBABLE TEXTILES AND METHODS FOR JOINT FUNCTION RESTORATION,,ANIKA THERAPEUTICS INC,AGNELLO STEFANO;;AHN EDWARD;;CENTOLA MATTEO;;EK STEVEN W;;KENNEDY STEPHEN J;;MANNARINO MATTHEW M;;MARCHETTO ELVIRA;;PURI SONALI;;RICHARD ROBERT;;SIMONCIONI SARA,,https://lens.org/199-234-463-410-006,Patent Application,yes,0,0,3,3,0,A61L27/46;;A61L27/446;;A61L27/58;;A61L27/3834;;A61L27/386;;A61L2430/10;;A61L27/56;;A61L27/20;;A61F2/30;;A61F2002/30062;;A61F2210/0004;;A61L27/20;;A61L27/32;;A61L27/58;;D02G3/448;;D03D1/00;;D03D19/00;;D10B2331/04;;D10B2401/12;;D10B2509/00,A61L27/38;;A61L27/20;;A61L27/44;;A61L27/46;;A61L27/56;;A61L27/58;;B32B5/00;;B32B27/00,,0,0,,,,PENDING
220,PT,E,PT 799221 E,042-796-442-915-962,2003-03-31,2003,PT 95941477 T,1995-11-27,US 36310494 A,1994-12-22,QUINAZOLINAS COMO INIBIDORES DA ENZIMA DE CONVERSAO DE ENDOTELINA,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,DOHERTY ANNETTE MARIAN;;AHN KYUNGHYE;;CHENG XUE-MIN;;ELS EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE;;LEONARD DANIELE M;;NIKAM SHAM SHRIBHAR;;WERBEL LESLIE MORTON,,https://lens.org/042-796-442-915-962,Granted Patent,no,0,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/74;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,0,0,,,,EXPIRED
221,DK,T3,DK 0799221 T3,017-959-957-583-490,2003-02-24,2003,DK 95941477 T,1995-11-27,US 36310494 A;;US 9515366 W,1994-12-22,Quinazoliner som inhibitorer af endothelin converting enzym,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,WERBEL LESLIE MORTON;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;CHENG XUE-MIN;;KORNBERG BRIAN;;LEE CHITASE;;NIKAM SHAM SHRIBHAR;;AHN KYUNGHYE;;LEONARD DANIELE M,,https://lens.org/017-959-957-583-490,Granted Patent,no,0,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,C07D239/74;;A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,0,0,,,,EXPIRED
222,AT,T1,AT E226951 T1,152-882-285-340-235,2002-11-15,2002,AT 95941477 T,1995-11-27,US 36310494 A;;US 9515366 W,1994-12-22,CHINAZOLINEN ALS INHIBITOREN DES ENDOTHELIN KONVERTIERENDEN ENZYME,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNGHYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE;;LEONARD DANIELE M;;NIKAM SHAM SHRIBHAR;;WERBEL LESLIE MORTON,,https://lens.org/152-882-285-340-235,Granted Patent,no,0,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,C07D239/74;;A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,0,0,,,,DISCONTINUED
223,EP,B1,EP 0799221 B1,003-999-640-257-839,2002-10-30,2002,EP 95941477 A,1995-11-27,US 9515366 W;;US 36310494 A,1994-12-22,QUINAZOLINES AS INHIBITORS OF ENDOTHELIN CONVERTING ENZYME,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNGHYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE;;LEONARD DANIELE M;;NIKAM SHAM SHRIBHAR;;WERBEL LESLIE MORTON,,https://lens.org/003-999-640-257-839,Granted Patent,yes,5,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,C07D239/74;;A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,5,0,,,"CHEMICAL ABSTRACTS, vol. 93, no. 21, 1980 Columbus, Ohio, US; abstract no. 204585z, ZHIKHAVERA,G. ET AL. 'SYNTHESIS AND ANTILEISHMANIASIS ACTIVITY OF SUBST. 2-STYRYLQUINAZOLINES.' page 684; column 2; & KHIM.-PHARM. ZH., vol. 14, no. 6, 1980 RUSS., pages 40-43,;;CHEMICAL ABSTRACTS, vol. 90, no. 5, 1979 Columbus, Ohio, US; abstract no. 198861f, page 167; column 1; & JP,A,07 902 327 (NAKAGAMI,K. ET AL.) 9 January 1979;;CHEMICAL ABSTRACTS, vol. 83, no. 28, 1975 Columbus, Ohio, US; abstract no. 58869v, page 511; column 2; & SU,A,466 233 (ALL UNION SCI.-RES. CHEM.-PHARM. INSTIT.) 5 April 1975;;JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 29, no. 4, July 1992 PROVO US, pages 703-706, STEVEN E. PATTERSON 'NEW SYNTHESIS OF N-SUBSTIT.-2-ALKYL(OR ARYL)QUINAZOLIN-4-AMINES';;JOURNAL OF MEDICINAL CHEMISTRY, vol. 20, no. 2, 1977 WASHINGTON US, pages 237-243, CLARA GENTHER ET AL. 'ANTIFOLATE STUDIES.'",EXPIRED
224,SI,T1,SI 0799221 T1,059-623-901-356-306,2003-02-28,2003,SI 9530621 T,1995-11-27,EP 95941477 A;;US 9515366 W;;US 36310494 A,1994-12-22,QUINAZOLINES AS INHIBITORS OF ENDOTHELIN CONVERTING ENZYME,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNGHYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE;;LEONARD DANIELE M;;NIKAM SHAM SHRIBHAR;;WERBEL LESLIE MORTON,,https://lens.org/059-623-901-356-306,Granted Patent,no,0,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/74;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,0,0,,,,EXPIRED
225,CA,A1,CA 2206046 A1,013-721-067-090-98X,1996-06-27,1996,CA 2206046 A,1995-11-27,US 36310494 A,1994-12-22,QUINAZOLINES AS INHIBITORS OF ENDOTHELIN CONVERTING ENZYME,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,ELSLAGER EDWARD FAITH;;LEE CHITASE;;WERBEL LESLIE MORTON;;LEONARD DANIELE M;;KORNBERG BRIAN;;CHENG XUE-MIN;;NIKAM SHAM SHRIBHAR;;DOHERTY ANNETTE MARIAN;;AHN KYUNGHYE,,https://lens.org/013-721-067-090-98X,Patent Application,no,0,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,C07D239/74;;A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,0,0,,,,DISCONTINUED
226,EP,A1,EP 0799221 A1,145-236-800-325-057,1997-10-08,1997,EP 95941477 A,1995-11-27,US 9515366 W;;US 36310494 A,1994-12-22,QUINAZOLINES AS INHIBITORS OF ENDOTHELIN CONVERTING ENZYME,"Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.",WARNER LAMBERT CO,AHN KYUNGHYE;;CHENG XUE-MIN;;DOHERTY ANNETTE MARIAN;;ELSLAGER EDWARD FAITH;;KORNBERG BRIAN;;LEE CHITASE;;LEONARD DANIELE M;;NIKAM SHAM SHRIBHAR;;WERBEL LESLIE MORTON,,https://lens.org/145-236-800-325-057,Patent Application,yes,0,0,15,15,0,C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02;;A61P43/00;;C07D401/12;;C07D453/02;;C07D239/94;;C07D403/12,C07D239/74;;A61K31/505;;A61K31/517;;A61P43/00;;C07D239/90;;C07D239/91;;C07D239/94;;C07D401/12;;C07D403/12;;C07D453/02,,0,0,,,,EXPIRED
227,KR,A,KR 20040028564 A,186-237-991-675-181,2004-04-03,2004,KR 20030067289 A,2003-09-29,US 26095502 A,2002-09-30,NON-WOVEN LOOP MATERIAL HAVING DISCONTINUOUS NON-BONDED AREA DEFINED BY CONTINUOUS BONDED AREA AND PROCESS AND PRODUCTS RELATING THERETO,"PURPOSE: A non-woven loop material and a process and a product relating thereto are provided to be useful in a mechanical attachment system such as a hook and loop mechanical attachment system. CONSTITUTION: The non-woven loop material(4) comprises unicomponent fibers which have a substantially circular section and are crimped helically, and has a first and a second planes. The non-woven loop material(4) comprises a plurality of discontinuous non-bonded area(8) defined by a substantially continuous bonded area(6), wherein the discontinuous non-bonded area(8) is about 85 to 50% of the second plane area of the non-woven material. The unicomponent fibers comprise a thermoplastic polymer selected from the group consisting of polyolefins and copolymers thereof.",KIMBERLY CLARK CO,AHN JUNG YEUL;;BOLIAN CHARLES EDWARD;;CHIN JEA SEUNG;;FORBES BRIAN STEPHEN;;JUNG SOO GYUNG;;KIM BYUNG SOO;;LEE JIN HEE;;NING XIN;;YOU KUE YOUNG,,https://lens.org/186-237-991-675-181,Patent Application,no,0,0,12,12,0,A44B18/0011;;D04H3/00;;D04H11/00;;A61F13/627;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;A61P1/00;;A61L15/16;;Y10T442/627;;Y10T442/60;;Y10T428/23957;;D04H3/00;;A44B18/0011;;D04H11/00;;A61F13/627,A61L15/16;;A44B18/00;;A61F13/62;;A61P1/00;;D04H3/00;;D04H11/00,,0,0,,,,DISCONTINUED
228,CN,A,CN 115840519 A,039-856-760-010-900,2023-03-24,2023,CN 202210984916 A,2022-08-17,US 202163246631 P,2021-09-21,Method and system for composing and executing scene,"The invention relates to a method and a system for composing and executing a scene. In one implementation, a method of displaying content is performed at a device that includes a display, one or more processors, and a non-transitory memory. The method includes scanning a first physical environment to detect a first physical object in the first physical environment and a second physical object in the first physical environment, where the first physical object conforms to at least one first object criterion and the second physical object conforms to at least one second object criterion. The method includes displaying a virtual object moving along a first path from a first physical object to a second physical object in association with a first physical environment. The method includes scanning the second physical environment to detect a third physical object in the second physical environment and a fourth physical object in the second physical environment, where the third physical object conforms to the at least one first object criterion and the fourth physical object conforms to the at least one second object criterion. The method includes displaying, in association with a second physical environment, a virtual object moving along a second path from a third physical object to a fourth physical object, wherein the second path is different from the first path.",APPLE INC,DRUMMOND MARK;;MANGLIK ARMIN;;MAHASENI BABAK;;MORGAN BRIAN;;FENG DAN;;KOVACS DANIEL L;;AHN EDWARD S;;GUTTENSON MICHAEL;;QIAO MU;;GAMBOA NATHAN J;;JOTWANI PRASHANT;;BUDRUM SHANE;;SIVAPURAPU SUBRAHMANYAM CHANDRA MOHAN,,https://lens.org/039-856-760-010-900,Patent Application,no,0,0,2,2,0,G06T19/006;;G06T2200/24;;G06T2219/004;;G06F3/011;;G06V20/20;;G06F3/04815;;G09B25/08;;G06T19/006;;G06T2200/24;;G06T2219/004;;G06T19/003,G06F3/04817;;G06F3/04883,,0,0,,,,PENDING
229,US,A1,US 2023/0089049 A1,078-627-298-202-309,2023-03-23,2023,US 202217853557 A,2022-06-29,US 202217853557 A;;US 202163246631 P,2021-09-21,Methods and Systems for Composing and Executing a Scene,"In one implementation, a method of displaying content is performed at a device including a display, one or more processors, and non-transitory memory. The method includes scanning a first physical environment to detect a first physical object in the first physical environment and a second physical object in the first physical environment, wherein the first physical object meets at least one first object criterion and the second physical object meets at least one second object criterion. The method includes displaying, in association with the first physical environment, a virtual object moving along a first path from the first physical object to the second physical object. The method includes scanning a second physical environment to detect a third physical object in the second physical environment and a fourth physical object in the second physical environment, wherein the third physical object meets the at least one first object criterion and the fourth physical object meets the at least one second object criterion. The method includes displaying, in association with the second physical environment, the virtual object moving along a second path from the third physical object to the fourth physical object, wherein the second path is different than the first path.",APPLE INC,DRUMMOND MARK E;;KOVACS DANIEL L;;BUDHRAM SHAUN D;;AHN EDWARD;;MAHASSENI BEHROOZ;;MANGLIK AASHI;;JOTWANI PAYAL;;QIAO MU;;MORGAN BO;;GAMBOA NOAH;;GUTENSOHN MICHAEL J;;FENG DAN;;SIVAPURAPU SIVA CHANDRA MOULI,APPLE INC (2022-06-13),https://lens.org/078-627-298-202-309,Patent Application,yes,0,0,2,2,0,G06T19/006;;G06T2200/24;;G06T2219/004;;G06F3/011;;G06V20/20;;G06F3/04815;;G09B25/08;;G06T19/006;;G06T2200/24;;G06T2219/004;;G06T19/003,G06T19/00,,0,0,,,,PENDING
230,US,A1,US 2023/0350536 A1,159-882-803-268-03X,2023-11-02,2023,US 202318113020 A,2023-02-22,US 202318113020 A;;US 2021/0044256 W;;US 202163142248 P;;US 202063070008 P,2020-08-25,DISPLAYING AN ENVIRONMENT FROM A SELECTED POINT-OF-VIEW,"Various implementations disclosed herein include devices, systems, and methods for selecting a point-of-view (POV) for displaying an environment. In some implementations, a device includes a display, one or more processors, and a non-transitory memory. In some implementations, a method includes obtaining a request to display a graphical environment. The graphical environment is associated with a set of saliency values corresponding to respective portions of the graphical environment. A POV for displaying the graphical environment is selected based on the set of saliency values. The graphical environment is displayed from the selected POV on the display.",APPLE INC,FENG DAN;;MANGLIK AASHI;;O'HERN ADAM M;;MORGAN BO;;PEEBLER BRADLEY W;;KOVACS DANIEL L;;AHN EDWARD;;MOLL JAMES;;DRUMMOND MARK E;;CHUA MICHELLE;;QIAO MU;;GAMBOA NOAH;;JOTWANI PAYAL;;SIVAPURAPU SIVA CHANDRA MOULI,,https://lens.org/159-882-803-268-03X,Patent Application,yes,0,0,2,2,0,G06F3/167;;G06F3/04815;;G06F3/011;;G06F3/017;;A63F13/5255;;A63F13/213;;A63F13/215;;A63F13/217;;A63F13/424;;A63F13/428;;G06F3/017;;G06F3/04815;;G06T17/00;;G10L15/22;;G10L2015/223,G06F3/04815;;G06F3/01;;G06T17/00;;G10L15/22,,0,0,,,,PENDING
